B?

Gu
h?

950
U1r|Dn
?n?u
?n?u ?nu ?44

Acetycyste
ne
9 p' dynamcs /
effcacy
untuuMu
acetycytene tutt
tt:ulunlt|tu
antdote u1
paracetamo overdose
uuMu acetycystene lt W
140 mg/kg un:MLMuuuM
70 mg/kg n 4 tlL1 uu
17 dose
Drug
Informaton
Handbook 11
edton, 2003 -
2004, p.35

Acycovr 7 ADR/sde
effect
WtulMtn0M
acycovr Lun 10 u
:LWnMMtvlL
WtulMtu acycovr Lun
10 u t1uuLn metabosm
WuMt|wu1|nnuu ( sma
amount ) un:utn1tnn:
1lLLWnMn1uu1Mt
uMnWtuLt:M|tulWMtL
nu M1LnMMMLW
enzyme u1Mtu1M|u1
Drug
Informaton
Handbook 11
edton, 2003 -
2004

Adrenane 11 compatbty/
Stabty
nLnWnL adrenane
ntnn:nu 0.9 %
NSS un: 5% D/W lM
vlL
nLnWnLlM1ntnn:nu
0.9 % NSS un: 5% D/W
Handbook on
Inectabe drug
, 11 edton ,
p.494

Acoho 4 pregnancy/nu
rsng
tLnunnunn
LnnnL1:LWnM
nluvu1M1WD
unnunMulu Pregnancy
Category D t1unnun:L
Wnlv|nMWLWMtnM|un
" Feta Acoho Syndrome"
W lvnL1WMtnM wMun
tn1 n|u|MtlMWMtnM
M1uuvu1LWDlLW
tt:uunnun t1ML
unvuMu1 Amercan
counc on scence and
heath vu1LWDlLWlMt
unnun|nu 30 m Mu
Drugs n
Pregnancy and
Lactaton 2
edton ,2002 ,
p. 510-516/e

Amodpne 7 ADR/sde
effect
WtulMtu
amodpne unL
ntntL vutL
MtL unt
nltuM1nnlv
|nMWn|vnulMvlL
nnntWuuLn wtu1u
n|nM face edema n
amodpne t1lut
2000-2003 wtWtuuu 3
u ulu:Mtu:lt 2 u
un::lt 1 u un:wt
u1un|nM edema
perorbta ( MtL ) uu 2
u lMu:MtWLu:|tuu
u:ltun::lt
1.
Spontaneous
report of ADR
t 2000 , 2001
, 2002 2. A
Practca
Guode to
pharmacovga
nce vu 117 -
120

Amoxcn 9 p' dynamcs /

effcacy
uwun1ltu
Amoxcn ( 250 ) 1*
3 pc , Augmentn (
375 ) 1*3 pc ,
Roxthromycn (150 )
1*2 pc lLtlt
uM1nnLnulM
vlL
Augmentn |tuuWtWnL
|t gram - postve , gram -
negatve uMlLWtWnL
atypca pathogen |tu
Mycopasma , Chamyda
spp. t1 Roxthromycn LWnM
|tM1nn M1uu1nLnlvlM
|wnLnMM|t1|Muvul
The sanford
gude to
antmcroba
therapy ,2005

Amphoterc
n B
7 ADR/sde
effect
nLnuntuv
Thrombophebts n
nltu Amphotercn
B lMu1lt1
nLnuntuv
Throbophebts n
AmphotercnB lMlMuu sow
nfuson , nfuse uWu1
centra ne , lt sma bone
neede , rotate sde of
nfuson , use of dute
souton ( < 0.1 mg/ m ) ,
addton of 500 - 1000 U of
heparn / ter of souton
1. AHFS , Drug
Informaton ,
2004 , p. 524
2. |nn
t:tLtn
1u|DntnL
Wnun W1 6 /
2546

Amphoterc
n B
11 compatbty/
Stabty
Amphotercn B
nLnWnLnt NSS lM
vlL
lLnLnWnL Amphotercn B
nt NSS lM |u1n:lvu
MnM:nu

Amphoterc
n B
11 compatbty/
Stabty
Amphotercn B
vn1nWnLun nLn
|ntllMuu|l
nLn|ntnvDLv1lMuu
24 tlL1 un:nLn|ntlu
M|uulMuu 1 ntMv

Ampcn 11 compatbty/
Stabty
Ampcn vn1nWnL
unnLn|ntllMuu
|l
Ampcn vn1nWnLunW
ltDulu 1 tlL1
|nn
t:ntnltu

Cefazon 3 Pharmacokne
tcs
luWtulMtu
Cefazon :v1n
haemodayss lL
tu:nnnMn
lMvlL
Cefazon nLnnn dayze
lMt:Ln 20 - 50 % M1uu1
Wlvuvn1n
hemodayss vlv
suppement dose 0.5 - 1 nL
vn1n dayss
1.Drug
Informaton
Handbook 8
edton 2.
Drug
Prescrbng n
rena - faure
4 edton

Cefdnr 11 other WtulMt hepatts B

vaccne Lun 2 |uL
uMWtuM1tt:u
u Cefdnr lvM1
|nun0M vaccne lu
|uL 3 nlt un
t:0M vaccne
lu dose 3 lM|Ll
hepatts B vaccne |tu
vaccne tuMMMu t1nLn
0MlMlu:v1lMtu
cefdnr lMulLM1|nun0M
nlt
DWt|Dnt
nLWnun ,
tn ( |nn
t:ntn
|uunnu )
Wn:|DntWnM

Lvunun1un
uWu ,2542

Cefprome 9 p' dynamcs /

effcacy
M1ntuuMu
Cefprom ltlun
nLWtu Pneumona
uuMu1u Cefprome lt
nLlWMM|t1|Muvul
nun1 |tu D:tMn|nt W
1 - 2 g IV n 12 tlL1 t1
M1LnttuuMuluWtuL
n1uu1lMtnw1
|u1nuLnutn1lM
|tuvnn
uttt:|Lu
DUE u1u
Cefprome

Ceftraxone 11 compatbty/
Stabty
Ceftraxone vn1n
WnLunnLn|ntl
lMuu|l
nLn|ntnvDLv1lMuu
24 tlL1 un:nLn|ntlu
M|uulMuu 3 u

Cndamcn 4 pregnancy/nu
rsng
Cndamcn n .
nLnlvluWtulvuL
tMlMvlL
Cndamcn nLnutn1
uuLlM|nnuuun:|Wuwt
u1u:u1n|tu|nM
nLMlMtu
Cndamcn Lnt
Gentamcn M1uu1Wltu
u1:LM:1un:MMMLn
u1nu1lnntM
Drug Therapy
n Pregnancy

Coxacn 7 ADR/sde
effect
Wtultu Coxacn
n. unLnuuu
vun vullLn
|tun|vMnnuwu
lMvlL
nuwulMuLn uuuvun
vtun:vullLn |tu
nuwuutt Anaphyatc
shock uMu1lnMLWLn
t:|Lun|nMuu|tu
n|vMnnuwu Coxacn
ltu1vlL
WLnltu
0ttnLtn ,
2545

Damcron
MR
6 formuaton u Damcron MR
nLnut1W1lMvlL
u Damcron MR lLuu:ulv
ut1W1 |u1nu|tututt
Modfed reease tabet
1.WLunvt
wutn 2547
2. |nn
nntu

Dcoxacn 9 p' dynamcs /

effcacy
Dcoxacn ltluuuM
|l un:uMnM1nu
Coxacn u1l
uuMltu1u Dcoxacn
W |MnLuvunM < 40 kg lt
uuM 12.5 - 25 LnnnLM
nlnnLMu ut1lvn 6 tlL1
, |Mnun:WlvuLuvun > 40
kg ltuuM 125 - 250 LnnnL
n 6 tlL1 lMuu1 2 tuML
nu1|Dntu|vLunuun:
nLnltuunulM |wu1uM
uuMnltuu1 dcoxacn
:Mn coxacn t:Ln
W1vu1|uu ( ltun: 4 W1
n 6 tlL1|vLunu) |u1n
ntt:uuluuuM|nu
:Mtulu|nMu1
Drug
Informaton
handbook 11
edton , 2003 -
2004

Dcoxacn 9 p' dynamcs /

effcacy
uwun1u
Dcoxacn uuM 500
mg tt:u 2 * 4
ac untuuM
ulvn1|nultvlL
uuMu dcoxacn luWtu
LuvunMLnn 40 kg W
250 - 500 mg bd - qd M1uu
uuMun11n1|nult W
consut uwunW1
Drug
Informaton
handbook 11
edton , 2003 -
2004

Dantn n. 11 compatbty/
Stabty
Dantn n. nLn
WnLntnn:nulMlM
t1
nLnWnLnt 0.9 % NSS un:
Rnger lM uMlLnLnWnLnt
5% un: 10 % Dextrose
water lM |u1n:lv
MnM:nu un:|LWnLunWlt
u lLWutM|uu|w:lv
uMnM:nulM
Pocket Gude
of Inectabe
drugs

Dtazem 4 p' dynamcs /

effcacy
untuuM|LMu
u1u Dtazem
Angna Pectors : uuMu
|LMu W 120-180 mg once
day ( maxmum dose : 480
mg/ day ) Hypertenson :
uuMu|LMu W 180-240
mg/day
Drug
Informaton
Handbook 11
edton, 2005
p.482

Ethroxne 9 p' dynamcs /

effcacy
Wtu|Mnu 15 u
nLnltu Ethroxne
uuM 1*1 OD lMvlL
uuMu Ethroxn Lut1ltlu
nnLlW Hypothyrodsm
(Cretnsm ) t1nltulu|Mn
uu uuMult:uuntuvun
un:u u1|Mn lMu|Mnu 15
u WltuuuM 10 -15 mcg /
kg/u (u Etroxn 1 tab Lu
Levothyroxne 0.1 mg v
100 mcg ) M1uu1Wt
uvunMu1|MnnuWunv
uuMu|vL:nL
Drug
Informaton
Handbook ,
2003 - 2004,
p.820

Ephredne 6 formuaton nLnlt 3 %

ephredne nasa spray
vuMWWtulMvlL
Ephredne nasa spray 3 %
|tu|DntMtu1l1wutn t1
LnuWnLu1 Ephredne un:
Stere water un:lLLWn|nu
utt systemc lu1nu un:
|tunlt|wv1Wnnnnu
|0w: M1uu1nLnltvuM
WWtulM

Erythromyc
n
9 p' dynamcs /
effcacy
M1n|tnuuuu1
Wtun Erythromycn
lt|tu Roxthromycn
:M1lt dose |l
un:uMnM1nuu1l
luuMn:t1u
uuMu Erythromycn lu|Mn
W 30 - 50 mg/kg/day ut1lv
n 6 - 8 tlL1 un:uuMulu
WlvuW 250-500 mg n 6 -
12 tlL1 nuuuMu
Roxthromycn lunun
|nMun:lu|Mn ltuuM 2.5 - 5
mg/kg un: 2 W1 un:uuMu
ltluWlvu W 150 mg un:
2 W1
Drug
Informaton
Handbook , 11
th edton
,2003-4 ,
p.1000

Erythromyc
n
9 p' dynamcs /
effcacy
WtuLt:M|tulW
heart un:uwu
Pencn :lt
erythromycn |w
t1nunuwu M1lt
uuMu|l
nlt erythromycn |tu
denta premed surgery n
erythromycn |tut|nn
ethysuccnate :ltuuM 800
mg uMn|tut|nn stearate
:lt 1 gm lMutt:unu
vMnn 2 tlL1 un:vn1n
uun 6 tlL1 lvtt:un
W1lMunMuuMun1W1vu1u1
dose un
www.askrx.net

Esomepraz
oe
4 pregnancy /
nurse
Nexum tabet
nLnltluvu1lvuL
tMlMvlL
u1lLwtnWnLluWu
esomeprazoe nnutn1
uuLvlL u1lnML wt
u1u omeprazoe t1|tu
unnL|MununLnutn
1uuLlM 1lLuu:ulvlt
luvu1lvuLtM
AHFS , Drug
Informaton ,
2004 , p.2832

Ferrous
sufate
9 p' dynamcs /
effcacy
untuuMu
ferrous sufate lu|Mn
u 5 ut uvun 18
kg lunnLD:uM
uM|vnn
lu|MnLD:uMuM|vnn :lv
eementa on luuuM 3 - 6
mg/kg/day lMuut1lvun: 2 -
3 W1 ( Fer-n-so 0.6 m
t:ntMu ferrous sufate 75
mg t1:lvuM|vnn 15 mg)
AHFS drug
nformaton,
2004

Fonc acd 9 p' dynamcs /

effcacy
untuuMu
fonc acd lt
t1nunnMlun:Mn
nu Pyrmethamne
un: Sufadazne
u Pyrmethamne un:
Sufadazne |tuultnL
D:nL1n|ntn|t
Toxopasma ond t1
Wnu1|Wu1u1u1 2 tuMuW
nMlun:Mn nvtnltnL
luD:MM|t:u:|0utwnu :
lt fonc acd uuM 10 mg/u
Lnt sufadazne 1- 2 g n
6 tlL1 Lnt
Pyrmethamne uuM 100 -
200 mg lMutt:uu1uu
6 ntMv nunlt|wt1nu
nnnt|tut :lt fonc acd
uuM 10 mg / u tt:u
uu1n
nLWtulW
|Mn, n:1
nunnu ,
2545

Furosemde 11 compatbty/
Stabty
Furosemde n.
nLnWnLnt
nn:nulMlMt1
nLnWnL furosemde n. nt
0.9 % NSS, nn:nu
Dextrose water un: Rnger
actate souton lM
Handbook of
Inectabe
drugs, 11
edton, 2001

G-6-PD 8 Toxcty/
Posonng
ulMt1lLWltlu
Wtu|tu G-6-PD
G-6-PD |tu|ultLulu
1nuun:lu|tn|LM|nMuM1
lMuLvut1nulLlvltMu
u1|tn|LM|nMuM1nnnu t1
vnuM|ultLM1nn:lv
|LM|nMuM1uMnlM1u t1u
Wvnn|nu1luWtu|tulWu
W unnL sufa (Bactrm),
Prmaqun ,Phenazopyrdne ,
Vtamn C ( hgh dose ) ,
Asprn |tuMu
Textbook of
adverse drug
reacton , 4 th
edton,1991,
p.650

Gentamcn 4 pregnancy/nu
rsng
WtulvuLtM nLn
lv gentamcn n. lM
vlL
Gentamcn |tuuMuntwlu
nnL amnogycosde nLn
utn1uuLlM|nnuu (
sma amount ) u1lnML
|Wuwtu1u:u1n
|tu|nMluLMlMtu
gentamcn Lnt
Cndamycn un:nM1nn
lMvult|LvuMu M1uu1W
ltu1:LM:1un:MMML
nu1nu1lnntM
Drug
Informaton
Handbook 11
edton , 2003 -
2004 p. 646

Gentamcn 7 ADR/sde
effect
gentamcn n.
nLnlv|nMwLM
lMlMt:Lnnu
vn1nlMtu ( Wtu
lMtuuuM 240 mg
unnL amnogycosde
nLnlv|nM acute rena
faure lMun: 10 - 30 u1
Wtultu lMuwtnnMn1u1
Mnn1u1|vn
1.nttn1
|DntnLlu
WtulWlM
2. www.eb-
onne.com

Gycery
Trntrate
4 pregnancy/nu
rsng
WtulMtu
Ntrogycerne n. |L
uu uunLnlvuL
tMlMvlL
lLwtuLn Ntrogycerne
Lnutn1uuLvlL
u1lnMLuLWW1tM
t:Ln 1-4 u un:Wtu
lMtuM1uM|Lu M1uu1
Drug
Informaton
Handbook 11
edton , 2003 -
2004 p. 1009-

Haoperdo 7 ADR/sde
effect
WtuLn
extrapyramda
symptom nnltu
Haoperdo nLn
unlulMu1l
nunluD: Extrapyramda
symptoms nLnlMlMu
ltu Antchonergc tuM
antparknson lMultu
Dphenhydramne n. 50 mg
1. Drugs facts
and
comparson
2002 2.
AHFS drug

Hepatts B
vaccne
13 other Wtu0M hepatts B
vaccne Lun 7 u
un:M1n0M vaccne
luvMlvu :M1|u
t1nu
nLn0M vaccne luvMlvu
lM|nu lMulLM1|u:u:|nlu
n0M
Genera
Recommendat
ons on
Immunzaton,
MMWR , Vo.

Humun - N 11 compatbty/
Stabty
Humun - N vn1n
|tMlt nLn|ntlMuu
|l
u nsun nLn|ntluM|uu
lMuu 1 |Mu
Drug
Informaton
Handbook 11
edton, 2003 -
2004

Hydergne
FAS
10 Therapeutc
use
Hydergne FAS
nLnlt|wLWLlu
|MnlMvlL
nnntWuuLnu1lLwtn
u Hydergne FAS Llt|w
|wLWLlu|Mn
CCIS ;
Mcromedex
Heathcare
seres , 1974 -
2004

Hyoscne 4 pregnancy/nu
rsng
u Hyoscne nLnlt
luvu1M1WD 7 |Mu
lMvlL
Hyoscne M|tuulunnL
Pregnancy category C t1u1
lLwtuLnnltuluvu1L
WD M1uuWltuu|LLWL
|tu|uu
Drug
Informaton
Handbook 11
edton, 2003 -
2004

Ibuprofen 4 pregnancy /
nurse
Ibuprofen nLnltlu
vu1lvuLtMlMvlL
Ibuprofen nLnWu1uuL
lMuMwtlutLnuu 1Wlt
MuWL:LM:1
Drugs
Informaton
Handbook 11
th edton .

Insun 6 formuaton untnLnlt

Insun Muuu
Insun Lspro lMvlL
Insun spro |tututt
Insun nnu| t1nLn
lt Reguar Insun uulM
|u1n|tu Insun tuMn
nu||tunuuM:LWL
uMnM1nuluu1u1 onset un:
Duraton W Lspro nsun :L
onset 0.5 - 1 tlL1 un:L
Duraton u 8 - 12 tlL1
nu Reguar nsun :L onset
0.25 tlL1 un:L Duraton
u 6 - 8 tlL1
Drugsfacts and
comparson ,
2005

Irbesartan 7 ADR/sde
effect
uwun1ltu
Irbesartan uuM 600
mg lvntWtu un
t:LWnMWtu
u1lt1
uuM|LMuu1u Irbesartan
W 150 mg un:W1 un:
nLn|wLuuMulMn1 300
mg un:W1 lMun|wLuuM
uLnn 300 mg vut1
dose u n|tuun: 2 W1 n
lLLWnlvWnnnL
|tnuuutn1ltn|ML
AHFS : Drug
Informaton ,
2004

Isonazd 6 formuaton uwun1 Isonazd lu

Wtu|Mn 30 mg /u :
nLn|MuL|tuuu
lMvlL un:|ntllM
uunu
lul1wutnn1unL Isonazd
uuM 100 mg tabet uu:u
lvtMun:WnLntu 60 m Mu
1 |LM lMutt:uun:W1
W1n: 20 m t1ntMWnL 1
W1:LtLnnlt 3u lL
uu:ulvtMWnLutLnLn
|u1nulMun1un:WLu
1W|ntulluM|uu un:lL
WWnLnt suspendng
|u1nlvuMnM:nu
AHFS : Drug
Informaton ,
2004 : p. 544 -
560

Ketoconazo
e
4 pregnancy /
nurse
nLnltu
Ketoconazoe |wnL
Vagna canddass
luWtuM1WD 6 |Mu
lMvlL
u Ketoconazoe Mulu
pregnancy category C uM
u1lnML nltuuluWtu
LuWD 6 |Mu lLlMlv
|nMWLWMtnMMnluWD
Drug
Informaton
handbook 11
edton , 2003 -
2004

Lncomycn 9 p' dynamcs /

effcacy
WtunLnlMtu
Lncomycn utt IM
uuM 600 mg un: 2
W1lMvlL ( tnM0M
un:W1 )
nLn0MlMlu more severe
nfecton
AHFS : Drug
Informaton ,
2004 : p. 477

Mefenamc
acd
4 pregnancy /
nurse
Mefenamc acd
nLnltluvu1lvuL
tMlMvlL
Mefenamc acd lv|nM
toxcty of mefenamc acd
1Wvnn|nu1ltlt Nsad u
uu |tu Ibuprofen ,
Dcofenac
Drugs
Informaton
Handbook 11
th edton .

Meropenam 9 p' dynamcs /

effcacy
Meropenam un:
Tenam LWnnLtM
uMnM1nuu1lluu1
u1uuMltun:
WnnLtMu1u|Lltlu
Wtu|MnLu 7 |Mu
meropenem ltlul1wutn
LuuM 1 g nu Tenem |tuu
WnL:v1 Impenem un:
Castatn t1uuMu
Meropenem ltlu|Mnu 7
|Mu W 20 - 40 mg/kg n 8
tlL1 ( maxmum dose W 2
g n 8 tlL1 ) nu Tenem
uuMultW 15 - 25 mg / kg
/ dose n 6 tlL1 ( non-CNS
nfecton )
Drugsfacts and
comparson ,
2005 , p 828 -
831

Meropenam 9 p' dynamcs /

effcacy
uwun1u Meropenem
lMulL:t|nltlu
n drp t1tnMuwu
:n1 drp lMult|n 3
tlL1 unt:lt
|n drp |tuu1u
lMvlL
lMutnM Meropenem nLn
lvlMlMuu nfuse IV t1lt|n
lunlvuLnn 15 - 30 u
AHFS : Drug
Informaton ,
2004

Metrondaz
oe
4 pregnancy /
nurse
Metrondazoe tabet
nLnltluvu1lvuL
tMlMvlL
Metrondazoe nLnWulM
1uuL 1lLuu:ulvlt
:v1lvuLtM
Drugs
Informaton
Handbook 11
th edton .

Metrondaz
oe
10 Therapeutc
use
untnLnlt
Metrondazoe 400
mg 4 tab utt snge
dose lunnL T.
vagnas lMvlL
uu:ulvlt metrondazoe 2 g
snge dose v 500 mg u
n: 2 W1 MMMnu 7 u (
nvtnltuluvu1M1WD
uu:ulvlt Cotrmazoe
vagna tabet uulut1lM
Lnun )
1.AHFS Drug
Informaton,
2004 2.
MlWMM|t ,
nLWLlWMM
|tuv1t:|W
lu |nL 2

Morphne 9 p' dynamcs /

effcacy
nunWnMuvun 3
kg vnM1nltu
t|ntMvn1
nWMM :ltu
morphne v
fentany n. lMvlL
nt|ntMvn1n
WMMlMult morphne M1lt
WL:LM:1n1|u1nu|un
nL1lvnMnvullM
lMu|0w:lu|Mnun|nMn
nMu:t u1lnMuu:u
uuM IV nfuson ltlLW|nu
0.015 - 0.02 mg/kg/hr un:
|W:1nvulu1lnntM
nu fentany necton u1lL
tn1WLtnMDuun:
t:nuDwlunnLlu|Mn
uuun 2 t
Drug
Informaton
handbook 11
edton , 2003 -
2004

Morphne 7 ADR/sde
effect
Morphne lv|nMWu
uwuttlMlMt1 LM
n|nM|tu|l un:L
WnM:tt1|Mu
vulvlL
Morhne lv|nMWuuwutt
rash LnnM lMuwtu1un
|nM rash 19 u 1n1LW
WuuwuttWu ( Prurts ) 14
u unnuwtLn|nM
respratory depresson 2 u
Spontaneous
report of
adverse drug
reacton , 2002

Morphne 9 p' dynamcs /

effcacy
Antdote u1
morphne W:l M1
ltuuM|l un:L
nnlnnnnuu1l
Antdote u1 morphne W
naoxone nnu|tu pure
opod antagonst lMu|ult
uu1tun:uu morphne
receptor lMuuuMu1
naoxone ltnLD:lMt
opod |nuuuM W 0.4 - 2 mg
IV un:nLnlvtlMn 2-3
u nunlt|wnMnnM
t:nnunn1nunnL
opod ltuuM 100 mcg - 200
mcg ( 1.5 - 3 mcg/kg ) t1
uuMu naoxone Lltlu
l1wutnn1un W 400
mcg/m , 1 m
Drug
Informaton
Hanbook , 11
th edton
p.974 - 975

Nfedpne
SR
9 p' dynamcs /
effcacy
Wtultu Nfedpne
SR uwuM1n
|tnuuulvWtu|tu
Amodpne :M1lt
uuMu|l
uuMu Nfedpne SR W
20-40 mg bd nuuuMu
Amodpne W 5 - 10 mg /day
t1ntt:uu Nfedpne
SR un: 2 W1 lvWtu
nLtt:uulM un:lv
WnnnLlLM|W nu
Amodpne tt:u|wu1u
n:W1 LWnlvnLnWtWL
WLMulnvMlMu1nL|nL
MnMu un:lLlv|nM refex
tachycarda
www.kkh.go.th/
pharmacy/phne
ws.htm.

Norfoxacn 4 pregnancy/nu
rsng
Norfoxacn nLnlv
luvu1lvuLtMlM
vlL
lLt norfoxacn utn
1uuLvlL uM|Llvu
uuM 200 mg 1tn|wu1W1
|MulLwtLunnutn1
uuL uMnlvuluuuMn1uu
vlvuvnu dose |tultlM
u:nnutn1uuL un:
|nMWnulLw1t:n1WM
nlM |tu arthropathy ,
phototoxcty 1lLuu:ulvlt
luvu1lvuLtM
1.Drug
Informaton
Handbook 10
edton, 2002 -
2003 2.
|nnnntu

Norfoxacn 4 pregnancy /
nurse
untu
Norfoxacn nLnlt
luvu1M1WD 7 |Mu
lMvlL
nlt Norfoxacn lu:v1
M1WDlLwtLWL|nu1M
nluWD uL:LuLn
u1ulv|nMWLWMtnM
u1MulunMMn1|Lltlu
uuMn1 1M1:LM:1nlt
lut1 frst trmester
Drug
Informaton
Handbook 10
edton, 2002 -
2003

Omeprazoe 6 formuaton Omeprazoe nLn

feed lMvlL
Omeprazoe uuM 20 mg
capsue |tuuulututt
nnu|uu t1|tututtlL
WtM uMn|tuM1lvu
tuttu1 NG tube nLn
lvlM lMu|tM capsue nun
WnLntu
ntvu1
nu NG tube

Omeprazoe 4 pregnancy/nu
rsng
WtuM1WD 2 |Mu
un:lMtu
omeprazoe unt
:LWnMnM1WD
vlL
Omeprazoe Mulu
Pregnancy Category C
vLun1 LnWnLnltulu
nMMn1un:wtWnulLw1
t:n1WMMu uMu1lLL
nWnLtM|uluLuLu M1uu
nltu omeprazoeluvu1
M1WDW|tut|ut
t:lutu:lMtLnnWn|nu
:|nMuuvlL u1lnML
Wvnn|nu1nlt omprazoe
lut1 3 |Muunu1n
M1WDv|tnuultltuMu
tnMDuLnn |tu
Rantdne ( Mulu
Drug
Informaton
Handbook 11
edton, 2003 -
2004,p.1029 -
1030

Omeprazoe 11 compatbty/
Stabty
Omeprazoe n.
nLnWnLnt
nn:nulMlMt1
Omeprazoe n. nLnWnL
ntnn:nu NaC 0.9 % , 5%
Dextrose water 5 m lun
reconsttute t1u
reconsttute un nLn
Dute |tunn:nu 100 m
lMultnn:nu|Munu
Handbook on
Inectabe drug
, 11 edton ,
p.1359

OMVI 11 compatbty/
Stabty
OMVI LunWnL
u1l
OMVI WnLlMu unn:nunM
2 WnLn1lunM 1 ( W1uv1)
nn:nuWnLun:ultWnL
ntnn:nulv1vnM|nM
|nnnntu

Pencn 9 p' dynamcs /

effcacy
uwun10M Benzathne
Pencn G 1.2 MU
utt IM |tuM1Ln
test nuvlL un:L
untvuu1l
lunnu Wtu|Wutt:uu
Pencn V un:lL|WuLt:M
uwu lL|tuM1 test
nvtutvuutt IM lv
n:nuu 1.2 MU ntunnu 3.6
m
uu1n
tvu0M|w
nMWL|nu1

Pethdne 7 ADR/sde
effect
M1n|tut|utWn
MunlLw1t:n1W
u1 Pethdne un:
tramo Mn|nM
nWnuln |uulu
|Mn|utnWMMML
tons un:nnMn
vulluWlvu
lu|Mnu 4 - 7 t |utn
WMMML tons wt
pethdne nLn:1tn
tMlMMn tramo nun
u1|Wu1 W Wnuln |uu
wtlLuMnM1nu nunnM
nvul wt tramo nMn
vuluun pethdne un:
morphne
www.pumed.co
m

Phenobarbt
a
4 pregnancy/nu
rsng
Phenobarbta nLn
ltluvu1M1WDlM
vlL nlLlMnLn
ltuMlMuulMt1
nltuMuntnlu:v1
M1WD lv|nMWL
WMtnMMnluWD uM
u1lnMLnltu:v1
M1WD:|nMWn|nuuun:
tnulv|nMntn:v1M1WD
M1uulunnWtunLn
WtWLntnlMMuunutn
tt:uuunun:wtLn
M1WDluDuvn1 nlL|tuM1
|tnuutuMvuuMu1u
tt:uu uMlvtt
:u:|nlunlvu lMu
|tnuu|tutt:uuun: 2 -
4 W1 |wnM:Mtu1u
1.Drug
Informaton
Handbook 11
edton, 2003 -
2004, 2.AHFS
Drug
Informaton,
2004

Phenobarbt
a
9 p' dynamcs /
effcacy
untnLnlt
uMlMuu
Phenobarbta n. lu
Wtu|MnlMt1 un:M1
ltluuuM|l
nLnlt Phenyton n. uu
lM lMuuuMult W Loadng
dose ltuuM 15 - 20 mg/kg ,
Inta dose ltuuM 5
mg/kg/day n 2 dvded dose ,
6 mo. - 3 yr ltuuM 8 - 10
mg/kg/day , 4 - 6 yr ltuuM
7.5 - 9 mg/kg/day , 7 - 9 yr
ltuuM 7 - 8 mg/kg/day , 10
- 16 yr ltuuM 6 - 7
mg/kg/day
Drug
Informaton
Handbook 11
edton, 2003 -
2004, p.1102

Prednsoon
e
4 pregnancy/nu
rsng
WtulvuLtM nLn
ltu Prednsoone lM
vlL
nnWnLvu1lvuLtM 6
u wt|Ltt:u
Prednsoone 10 - 80 mg/day
wt:Mtu prednsoone lu
|nMu1LMLWL|uLuu
t:Ln 5 - 25 % t1Wu
nt|Mn:lMtu1uuLlu
tLnuu uMnLM
|tuM1lMtuluuuMn1uu
uu:ulvLMlvuLtMvn1
tt:uultunu1uu 4
tlL1
Drugs n
Pregnancy and
Lactaton 6
edton , 2002 ,
p. 1152

Propythour
ac
4 pregnancy/nu
rsng
WtulvuLtM nLn
lvu propythourac
un: Lugo souton lM
vlL
Lugo souton t:ntMu
Iodne un: potassum
chorde WL|uLuuL 130
mg/m t1 Ioddes |tu
n|vMlv|nM abnorma
thyrod functon v goter n
neonate lM nu
propythourac nLnutn
lM1uuL t1M1:LM:1n
ltluvu1lvuLtM u1lnML
lLuu:ulvltuM1nn:v1
lvuLtM
1.Drug
Informaton
Handbook ,
2005, p.1304
2.AHFS ,
Drug
Informaton,
2004,p.3096

Pseudoephe
drne
7 ADR/sde
effect
untn
u1|Wu1u1u
Pseudoephedrne
nu1|Wu1u1u
Pseudoephedrne lMun v
l|MuWM1v: tw|Mu| 11
tL tMv Wnuln |uu
u|wnu
Drug
Informaton
Handbook 11
edton, 2003 -
2004, p.1179

Roxthromy
cn
7 ADR/sde
effect
Wtultu
Roxthromycn Lun
2 u unLWuWu un:
|nM|nMM uwun1 off
ultun 4 u uM
Wtuu1LnWuu
un:u1L|nM|nMM
uwun1nuWtuuwu
Roxthromycn un
t|WuLu1un
|nM ADR M1nnvlL
nnntWu lLwtu1un
|nM|nM|nMMluWtuuwuu
uMwtu1un|nMnlL
w1t:n1W W |nM
gastrontestna reacton ,
nausea , vomttng ,
abdomna pan , darrhoea
un: aergc skn reacton
1.Spontaneous
report of
adverse drug
reacton ,2002,
p.191 - 193
2. Mms
Annua 16 th
edton ,2004,
p.730

Sabutamo 9 p' dynamcs /

effcacy
nwuu sabutamo
Lnt Beradua v
wunntnu lvWn
uMnM1nuvlL u1l
nnntWuuLn wtnlt
uwu Beradua t1|tuuWnL
u1 beta -2 agonst (
Fenotero ) LntnnL
antchonergc (Ipratropum)
lLlMuMnM1nnlt
Sabutamo |wu1M|Mu u1
LuunWu
Zebach R. et
a ,
Bronchodatoto
ry effect of
sabutamo ,
Ipratopum Br
nd ther
compatbty ,
Peadaty
Pumono ,
2001, Iune ,
31 (6) : 431 -5

Sandostatn 11 compatbty/
Stabty
Sandostatn nLn
WnLntnn:nu
dextrose lMvlL
nLnWnL sandostatn nt
nn:nu dextrose lM lMuu
:LWLW1M 24 tlL1 u1l
nML|u1n sandostatn L
WnMn|nM gucose
hemostass M1uu1WWnL
ntnn:nu norma sane
Lnnnn:nu dextrose
1.Handbook on
Inectabe
drugs , 11
edton , 2001,
p.980 - 981
2. |nn
nntu

spramycn 4 pregnancy/nu
rsng
u spramycn nLn
ltluvu1M1WDlM
vlL
nnltulu French un:
Europe n 15 t lLwtu1u
Wnu1|Wu1nnltu
spramycn MnluWD t1
LnltuulMlunn|tu
Drug n
Pregnancy and
Lactaton

streptomyc
n
9 p' dynamcs /
effcacy
u streptomycn
nLnlv1 v lM
vlL ( uwun1ltlu
Wtu HIV ) un:nlv
1 v. LuW:1
:lt1 un:LWnMn
nMwLMMtu1Wtu
vlL
tnM streptomycn :lv1 IM
|u1nMMtLlMMun:nLn
nMwL|nMnu uMnLnlv
1 v. lM lMult|n 30 - 60
ulunlvu |u1nulv
|nMwLMvlMnlMtulu
M|n1|nult un:uW
:1u1nlt streptomycn
:M1LnttuuMn1luWtu
lWlM uMlLM1ttuuMulu
WtulWMt M1uunlvuutt
v. 1lLu:LWnMnnMwL
MMtu1WtulW|Mn
1.Cnca
Pharmacy and
Therapeutcs ,
3 rd edton
,2003 ,
p.588,591
2. Drugs
Informaton
handbook , 11
th edton ,
2003 p. 1290

streptomyc
n
9 p' dynamcs /
effcacy
untuuMu
streptomycn ltlu
nnL TB
uuMu streptomycn lt
nL TB W WtuuvunM
> 50 kg uuMult W 1
g/day nuWtuuvunM <
50 kg uuMult W 0.75
g/day
|nnt:tL
tn|Dnt
nLWnunW1
6/2546 |1
tubercuoss

Swff 3 Pharmacokne
tcs
Swff L onset uu
|l
Swff t:ntMu monobasc
sodum phosphate 2.4 g un:
Dbasc sodum phosphate
0.9 g lMult|tuu:tuun:
|MuLnln|wnWMMvn1
nn1 lMuu:nnuDulu 2
-5 u un::u:|nlunn
nu 1 - 3 tlL1 lMu:u:|n
lunlvu:uuntuuMulv
t1uluMnuwuu1uwu
CCIS ;
Mcromedex
Heathcare
seres

Tetanus
toxod
4 pregnancy/nu
rsng
WtuM1WD nLn0M
Tetanus-Dpthera
toxod lMtnMDu
vlL
WtuM1WDnLn0M
Tetanus-Dpthera toxod lM
u1tnMDu
www.drspock.c
om

Tramo 9 p' dynamcs /

effcacy
Tramo n. nLnlv
utt IV lMvlL
nLnlvlM1utt IM,IV,SC
un: IV nfuson
|nn
t:ntnltu

Verorab 9 p' dynamcs /

effcacy
Wtu|WulMt verorab
dose 1 - 3 luu
21 ,24,28 n.W.2548
un:lLlM0MuMlu
dose 4 - 5 MLu
1 u.W. 48 WtulMu
uLuu uwun10M
verorab |wLn 2 dose
W1n: 1 M luu 1
u.W.48 un: 30 L.W. 49
lLtnnM1vlL
n0M vaccne vn1nLWnnM
nW|WulMt vaccne
Lnn 3 dose vML
DLWLnu > 0.5 IU/m |tuW
|WulMt vaccne Lnu nn
nLWnnMn uu:ulv0M
vaccne 1 - 2 W1 lMunlMt
vaccne W1nMuuun 6
|Mu :0M|wu1W1|Mu un:n
Lnn 6 |Mu :0M 2 W1 lu
u 0 , 3 lMu0M|unnL|u
MuuuMLMu v0M 0.1 -
0.2 m |uluWvu1 unuM
tuMu1 vaccne lMulLM10M
RIG M1uunuwun10M
WLWtu ,2548
, p. 108

verorab 9 p' dynamcs /

effcacy
vaccne verorab lu
dose 1 - 3 nLn
deayed n0Mnlt
lMnu
nLntnntWLWnM|Wnu
lM 1 - 2 u

verorab 9 p' dynamcs /

effcacy
Wtu|WulMt vaccne
Wt course Lun|L
5 tnu un:lMunuunM
uu untM1
|L0M vaccne lvL
1vLMvlL
vn|WulMt vaccne |uL
nMuuun 6 |Mu uu:u
lv0M|wu1 1 M uMnlMtn
0M vaccne W1nMuL
Lnn 6 |Mu :M10M
vaccne luu 0 , 3 nulu
nnu|WulMt vaccne W1
nMuLuuun 1uu:ulv
nnLlvL1vLM
Update n
Rabes Contro
and
Prophyaxs n
Thaand (
Symposum X ,
December
13 - 14 ,
2001

Vtamn B
compex
11 compatbty/
Stabty
Potassum chorde
n. nLnlvLnt
Vtamn B compex
n. un: 5% D/N/2 lM
vlL
nLnlvLnulM Handbook of
Inectabe
drugs, 11
edton, 2001:
p. 1079 - 1084
B?
Gu
h?

950
U1r|Dn
?n?u
?n?u ?nu

Acetycyste
ne
4 pregnancy/nu
rsng
nLnltu
acetycystene un:
Benadry luvu1
M1WD 4 |Mu lMvlL
u acetycystene un:
benadry Mulu pregnancy
category B t1uLnnWnL
lunMMn1 wtlLnlv|nM
WLtnMMMu un:u1lLL
u1uWLWMtnMlMluLuLu
1u:ltu12 tuMlMu1
tnMDu

Acetycyste
ne
9 p' dynamcs /
effcacy
uwun1
acetycystene tutt
u0M |wunwLnu
Paracetamo lMulv
Acetycystene uu
3 dose uM functon
MtlLMuu unt
nn1ltu dose 4 :
LWnu1l
u Paracetamo uuM 10 G
:lvMtnnnuDulu 12
tlL1 t1nlt Acetycystene
|tu Antdote u1 Paracetamo
uu :lvu 3 dose uMnnu
WtulMt Paracetamo
|tu:u:|nuu|nultnu:
lMtnnL M1uuW consut
uwunW1|wM|uunnL
Mlt

Acycovr 11 compatbty/
Stabty
untWLW1M
u1u Acycovr
necton 1tutt
nn:nuun:W1uv1
lututtW1uv1vn1nWnLnt
stere water for necton
un u:LWLW1M 12 tlL1
nvDLv1 vnn|nu1n|ntu
luM|uu|u1nlvu
MnM:nu un:1tuMnn:nu
un:W1uv1|L|1Mu NSS
v D5W un :LWLW1M 24
tlL1nvDLv1 lLW|nt
uluM|uu

Acycovr ,
Coxacn
,
Dexametha
sone ,
Rantdne
11 Compatbty/
Stabty
u Acycovr ,
Coxacn ,
Dexamethasone ,
Rantdne nLn
drp lu|nu|MunulM
vlL
u Acycovr , Rantdne un:
Dexamethasone nLn drp
wLnulM lMulvuWu1 Y-
ste nu Coxacn lLLuLn
11n1 |u1nlLLtutt
uuluM1t:|W u1lnML
Coxacn lv|nMn rrtate
lM1u1uu:ulvuunlvLnt
uMu

Adrenane 8 Toxcty/Poso
nng
WtulMt Adrenane
n. luuuM 1: 10 un:
WtuLuuM pup lvu
uu unt|tuWn
n Adrenane vlL
nlMt Adrenane |nuuuM
lv pup LuuMlvu
WMtnMlM t1Wtuuu|tu
WnnnlMtu|nuuuM

Amkacn 11 compatbty/
Stabty
Amkacn |L|MuL
|tuuvuMM:LWL
W1Mu1l
|L|ntluM|uu:LWLW1M 7
u uMn|ntunM|uu:LWL
W1M 24 tlL1

Amphetam
ne
13 other unt Antdote
u1u Amphetamne
Antdote u1 Amphetamne
W Propanoo n. lMuwLu1
Amphetamne :lv|nM
n Snus tachycarda v
Ventrcuar arrythyma
nvtWtuLn stabe
unwnlv Propanoo tuM
tt:u ( w. n1unlLL
tuttu0M )

Atropne 9 p' dynamcs /

effcacy
untuuMu1u
Atrpne un: 2-PAM lu
n|tu Antdote u1
uLuLn1
uuMu1u Atrpne lun|tu
Antdote u1uLuLn1W 1-2
mg v v m lMulvtlMlu
|n 20-30 u un:1lLwt
n1 muscarnc nu
2-PAM :ltuuM 1-2 g lMu
WnLnt 0.9%NSS 100 m t1:
lvulMuu nfuson un:lt|n
lunlvu 15-30 u nu
dose nMlt lvvn1n dose
un 1 tlL1 nn musce
weakness lLMuu

Benzathne
Pencn G
11 compatbty/
Stabty
uwun10M Benzathne
Pencn G 1.2 MU
utt IM lLtLu
|MuLu1l
|MuLlMun:nuu 1.2 MU lu
unnu 3.6 m

Cacum
guconate
6 formuaton 10% Cacun
guconate L
eementa cacum n
mg
10% Cacum guconate lu
l1wutnn1un LuuM 10 m
t1t:ntMu cacum
guconate 1 g un:L
eementa cacum 90 mg

Ceftraxone 11 compatbty/
Stabty
Ceftraxone vn1n
reconsttuted Mu
SWFI nLn|ntllM
uunu
vn1n reconsttuted uL
WLW1M 3 unvDLv1
un: 10 u|L|ntluM|uu

Chopromaz
ne
10 Therapeutc
use
nLltu
Chopromazne
tutttt:u lu
nnLnn:nlM
vlL
nLnlt Chopromazne
tutttt:ulunnL
nn:nlM lMultuuuM
25-50 mg un: 3 - 4 W1

Cndamyc
n
11 compatbty/
Stabty
untntvu
un:WLW1Mu1u
cndamycn
u Cndamycn LWLu1 150
mg/m tLMt 4 m
tvulMu|1ulvlMWL
|uLuu 600 mg/50 m Mu
D5W v NSS lt|nlunlv
u 30 u un:n:nuLWLW1
M 24 tlL1nvDLv1

Dazepam 4 pregnancy/nu
rsng
uwun1 Dazepam lv
WtuM1WD uMu
M1nnMulu
Category D unt
:L transquzer M
lMt1nLnltlu
vu1M1WDlMu1
tnMDu
unnL Mnor transquzer
lMun aprazoam ,
Chodazepoxde ,
Conazepam , Dazepam ,
Lorazepam |Wuwtu1u
lulMLn 1 lv|nM
orofaca cefts un: cardac
maformatons uMlunWnL
MLnntlLwtu1uM1nn
nulMLn 3 vlu:v1
nWnM lv|nM foppy
nfant un: neonata
wthdrawa syndrome u1l
nMLltunnLulMluWtu
LD: severe un: debtatng

Dazepam 9 p' dynamcs /

effcacy
Antdote u1
Dazepam W:l un:
Luntvuu1l
Antdote u1 Dazepam W
Fumazen LtnW
Anexate Lutvu W uuM
|LMu 0.2 mg v bous vn
WtulLMtnu1Mu|Llv
W1un nLnlvtlMluuuM
0.3 mg v bous Dulu 1 u
lMu tota dose lL|nu 3 mg

Dmenhydr
nate
7 ADR/sde
effect
untu
Dmenhydrnate
nLnlv|nMnuw
uutt fxed drug
erupton lMvlL un:
nnLn:u1nuwu|tu
u1l
nnLn:u1 fxed drug erupton
:Lt1nnL uttM|u :u:
un|L:LnuM1M MLM1
nn1u1Wu|tunuM1Wnv
nL1 nWtuLnuwLn
M1nn1u1Wu|tuMLunlM
lMuwtu1unuwuuttu
luWtultu
Dmenhydrnate :MtWL
u:|tuutt certan 6 kp ,
probabe 29 u , Possbe 3
u un: unkey 1 u (
u1u spontaneous report of
adverse drug reacton 2003 )

Dopamne 11 compatbty/
Stabty
M1nWnL Dopamne
nt Dextrose souton
LWL|uLuu 12 %
lMvlL
lMutnM Dopamne uuM
200-400 mg :WnLnt D5W
vnu|unulMlutLM
200-500 m unM1
Dopamne nLnWnL|unu
lMntnn:nu Dextrose
M1uu1u:WnLntnn:nu
dextrose LWL|uLuun1uulM
8
DTP
vaccne
2 Avaabty unttnWu1
DTP vaccne lut:|W
lu un: DTP vaccne
ut1n|tunt:|D
un:t:|DlMlv|nM
nlulMuunM
vaccne DTP L 2 tuM W tuM
|ML|tnnun:tuMlLL|tnn lMu
vaccne tuMlLL|tnn:lv
|nMnlulMuun un:t
nWu1 vaccne DTP tuMlL
L|tnn W Aceuvax
TM
,
Acelluvax ( DTPa ) , TripAcel
(DTPa) , nfanrix ( DTPa) ,
Boostrix ( dTpa )

rythromyc
n
10 Therapeutc
use
untnLnlt
uMlMuu
rythromycn 1 G
tt:utlL1 19 ,
18 , 9 nunWMM
coorecta Lnt
Neomycn sufate 1 G
lMt1
nntWuuLnlLwtLn
uu:ulvltutt:uMu
uM:uu:u second ne lun
nL W Cefoxtn 2 G v |L
|LMLu v Cefazon 1-2 G
v Lnt metrondazoe 0.5 G
v lunt1nunMM|tnu
nWMM Coorecta

thambuto 3 P'Knetc uwun1 thabuto lu

uuM 7.5/kg/day lu
WtulMu ( CrC =
43.7 ) untM1
ttnMuuMuvlL
lMultuuMu1u
thambuto W 15-25
mg/kg/day nunttuuM
uluWtuLW GFR = 10-50
m/mn ttlMulvun 24
- 36 tlL1 uMt1MlL
uu:ulvttuuMuluWtu
LW GFR 10 - 50 m / mn
unM1WtuuulL
|tuM1lMtnttuuMu
uMu1lnMLuuMuWtu
lMtM|nult

FBC 8 Toxcty/Poso
nng
WtuM1WDtt:u
u FBC 34 |LM un
t:LuMu
vlL u1l ( Wtu
uvun 60 kg )
FBC t:ntMu Fe fumarate
200 mg , Vtamn B1 2 mg ,
Vtamn B2 2 mg , Vtamn
B 12 5 mg , VtamnC 20 mg
, Nacn 10 mg , Foc acd
100 mcg , Ca phosphate
trbasc 100 mg t1Wtu
lMtwLuu1lMvnlMt
eementa ron |nun 60
mg/kg t1LnunM1W
shock , coma , sezure , GI
beedng, v metaboc
acdoss (Fe fumarate 200
mg L eementa ron = 66 mg
) WtuuulMtu FBC 34

Foctafenn
e
7 ADR/sde
effect
untu
Foctafenne ,
Orphenadrne un:
torcoxb MlMlv
|nMnlLw1t:n1W
lMulv|nMnM
tLlMLnnM
nntWuuLnnWuuMMML
nulLw1t:n1Wnnlt
WnMDnvnuDwu1n:1
nunnu wt Foctafenne
nLnlv|nMnlLw1
t:n1WlM W eye
abnormaty , eye rrtaton ,
eye pan , eyed oedema
un: oedema perorbta nu
Orphenadrne un:
torcoxb lLwtu1un
|nMnulLw1t:n1WMM

Foctafenn
e
7 ADR/sde
effect
Foctafenne nLn
lv|nMnWnuln
|uulMvlL
nWL Spontaneous report
of adverse drug reacton t
2003 u1WuuMMMLnu
lLw1t:n1WnnltWnMDnv
nuDw nun1uWn:nLn
vun:u n:1
nunnuwt Foctafenne
nLnlv|nMn|uu
:MtWLu:|tuuttu:lt
3 u un::Mt:lt 1 u

Fuer's
earth
9 p' dynamcs /
effcacy
untuuMu1u
Fuer's earth lunlt
|tu Antdote
uuMu1u Fuer's earth W
lvuuuM 30 % w/v
suspenson tLn 200-500
m n 2 tlL1 |tuuu 3
dose lMulvLnt 5% W/V
magnesum sufate v
manto

Gabapentn 7 ADR/sde
effect
Wtutt:uu
Gabapentn unL
nuuu1Ln
unt|nMnu
M1nnvlL
nnntWuuLn wt
Gabapentn nLnlv|nM
nulLw1t:n1WM:tt
neuromuscuar un: skeeta
lMt1W wtn myaga lM
t:Ln 2% u1lnMLuu:u
lvWtuwtuwu|wvn|vM
nW1vu1nM1nn|nM
nn|vMulMnvlL

H.pyor 10 Therapeutc
use
unt:ltulM
nL H.pyor lMt1
lLltu Carthromycn
nMnL H.pyor nLWL
uwu:tt1|Muvuv1
t:|Wluuu:u un:|tunM
ulLlt Carthromycn W
nMM1u Lansoprazoe v
Omeprazoe v Rantdne
+ Amoxcn +
Metrondazoe Wtuuw
Pencn lvlt Tetracycne
uu lMuuuMuuu:u W
Lansoprazoe 30 mg bd v
Omeprazoe 20 mg bd v
Rantdne 400 mg bd ,
Amoxcn 1,000 mg bd v
Tetracycn 500 mg qd ,

Hepatts 8 Toxcty/Poso
nng
Wtu TB LD:|nu1
Mn|nMMtn|nt
nM1nn|nMnu
MlMlMt1 un:Lun
unluu1l
pt. |nMD:Mtn|ntuttlL
uu1lvvuMunuuu u
WnnMvuu1MttnMv
WnlL|nu 3 |u1WtnM un:
lvMn1ltun:uuu uM:lL
lt RMP Lnt PZ n n
WtuLD:Mtn|ntuu1lv
vuMunuuu uMnM1nlt
unLnlWM lvlt
Streptomycn , thambuto
un: Ofoxacn nWtuLW
ver functon test WMtnMlL
|nu 3 | lvltnM
2HR/7HR uMnWtuLW
ver functon test WMtnM|nu

Hepatts B
vaccne
7 ADR/sde
effect
nlv Hepatts B
vaccne lutWWnlL
tMu|1LDL
MuuvlL :|nM
uMuvlL u1l
nlv vaccne HBV v HBIG
lunnLDLMuuuun lL
lv|nMuMuuM:lv
nu|tn1|nuWL|tu

Hydraazne 8 Toxcty/Poso
nng
Wtu|Mn|tu SL
nLnlMtu
Hydraazne lMvlL
nltu Hydraazne
|vuuulv|nM SL luWtulM
uu:ulvvuMulunnlvWn +
ANA ( Antnucear antbody )
vWtunMunt v
rana functon nMn1 un:lM
uuMuLnn 200 mg/day
nvtWtuuu|tu SL u
unuML admt Munu
un:WnM ANA |tu negatve
un:WtulMtu Hydraazne
Luuun M1uu1lLlM|tuu
vLltu1Wtuuu un:nlt
unMWLMu hydraazne n
|tuM|nnluWtulMu

Indapamde 8 formuaton Indapamde vLt

nW Natrx
nLnut1W1|LMulM
vlL
Indapamde v Natrx |tu
uvLut1 tM |Wu vlv
|LMuuMnlMu|MMuM

Indnavr /
Rtonavr
4 pregnancy/nu
rsng
Wtu HIV M1WDun:
uwu Nevrapne un:
faverenze nLnlt
u Indnavr un:
Rtonavr lMvlL
u Saqunavr - soft geatn
capsue ( Fostaras )/
Rtonavr t1|tuunnL
protease nhbtor nltlu
uuM 800/100 mg bd lu
WtuM1WD :Mtulun:un
|nM:|wu1wMnnnu
vltluuuM 1000/100 n
lM nu Indnavr lLuu:ulv
ltluWtuM1WD |u1nlv
:Mt brubn n1uu t1lt
n:Mulv|nMD: physoogc
hyperbrubn |wLuulM
unnuuuMu1 booster
ndnavr |vL:nLluWtu

Isonazd ,
Rfampcn
,
Pyraznam
de ,
thambuto
4 pregnancy/nu
rsng
WtuM1WD 4 |Mu
nLntu TB nM
HRZ lMvlL
u Isonazd , Rfampcn ,
Pyraznamde Mulu
category C nu thambuto
Mulu Category B t1nlt
unLnlWluvu1M1WD L
2 nM W 1. 2 HR/7 HR +
Vtamn B 6 25 mg/day ( ATS
) 2. 2HRZ/4HR + Vtamn
B 6 25 mg/day ( WHO )
M1uunltnMu1 WHO n
nLnltulM

Itraconazo
e
10 Therapeutc
use
u Itraconazoe |tu
frst ne drug lun
nL Oropharyngea
canddass vlL
Itraconazoe |tu Second ne
drug lunnL
Oropharyngea canddass
lMultuluuuM 200 mg/day
tt:uuMMMnu 10-14
u nuult|tu frst ne
drug W Cotrmazoe L ( 10
mg ) un: 5 W1 v
Ketoconazoe (200 mg ) un:
2 W1

Ketoconazo
e /
Nevrapne
5 Interacton uwun1ltu
Nevrapne Lntu
Ketoconazoe un
tLWL|vL:nL
vlL un:vn|tnuuu
|tu Fuconazoe :
|nMtnu:v1u
vlLu1l
Ketoconazoe |LlvLnt
Nevrapne wt
Ketoconazoe :LW AUC
nMn1 63 % un:lv:Mtu
Nevrapne n1uu 15-30 % 1
lLuu:ulvltLnu nu
Fuconazoe |LlvLnt
Nevrapne wt:LWn|wL
Cmax , Cmn un: AUC u1
Nevrapne t:Ln 50 %
M1uu1M1:LM:1lunlt
Lnu nvtWtuuu
uu:ulv|tnuu|tuutuMu
nnu|0w: |tu
Cotrmazoe tuMLuu

Meropenem 11 compatbty/
Stabty
Meropenem nLn
WnLntnn:nulMlM
t1|LM1n drp u
lvunWtu
Meropenem nLnWnLlMnt
5%dextrose un: 0.9% NSS
uMWLW1Mvn1WnL:uMnM1
nuW |LWnLnt 5%dextrose
:LWLW1M 3 tlL1 un:|L
WnLnt 0.9% NSS :LWLW1
M 8 tlL1 15-25 1W
|tn|tun

Meropenem 11 compatbty/
Stabty
u0M meropenem
vn1n|tMlt :nLn
|ntullMuu|l
|LWnLnt :LWLW1M
tlL1nvDLv1un: tlL1
|L|ntluM|uu nWnLnt $$
:LWLW1M tlL1
nvDLv1un: tlL1|L
|ntluM|uu

Methypred
nsoone
9 p' dynamcs /
effcacy
untuntv
u
Methyprednsoone (
uwun10Mulv|Mnlu
uuM 500 mg )
nLnlvuutt v nfuson
lMunn:nultlMW D5W
vnlvuluuuM|nt 15
mg/kg v 1 g Wlt|n
lvuuun 1 tlL1

Metrondaz
oe
4 pregnancy/nu
rsng
u Metrondazoe
nLnltluvu1M1WD
4 |MulMvlL
Metrondazoe Mulu
Pregnancy category B t1L
unvuMlv|tu
contrandcaton lut1lM
Lnunu1nM1WD uM
nLnltlMlut1lMLn 2
un: 3 M1uuWtuM1WD 4
|Mu MululMLn2 1
nLnltuulM

Ondansetro
n
10 Therapeutc
use
uwun1ltu
Ondansetron 1 amp v
prn luWtu severe
emess untL
WL|vL:nLvlL
u1l ( WtulMtu
|WLttMLt:Ln 1
Mu )
Ondansetron Lut1ltlun
nLvt1nun|uu
|nuu1ntnnt:n
Serotonn ( 5-HT) t1Ltt
nWulv|nMnWnuln
|uulMu|0w:luWtulMt
u|WLttM , 1nttMv
vn1nnWMM t1nlvu
Ondansetron :uu:ulv|tu
uttM1|nun:un:uu1lLL
uLnnutnuun1nlMt:lutu
u1u:uluWtuLn
Wnuln|uulM|nMuuun

Ondansetro
n
11 compatbty/
Stabty
Ondansetron nLn
WnLntnn:nulMlM
t1
Ondansetron nLnlvlMuu
v lMlMulLM1 dute lt|n
lvu 2-5 u uMnM1n
dute nLn|1lMnt D5W
v NSS 50-100 m un:lt
|nlunlvuuu 15-30 u

Phenyton 9 p' dynamcs /

effcacy
uwun1 phenyton 8
cap stat MLMu 300
mg hs wutnlv
Wtutt:uu stat
dose Mu 15.00 u.
lLtM1nuun
W1|Ll
uuMu mantanence dose
:lvnW1lLW|n 12
tlL1vn1n|Lu dose un (
oadng dose )

Phenyton 11 compatbty/
Stabty
Phenyton n.
vn1nWnLun nLn
|ntullMuu|l
|L|1unWltu lLW
utM|uu |w::lvu
MnM:nu

Pregnancy
test
13 other unt acoho
un:uMlMt1
lvWnnM1WDWMwnM
uLWnlvnMD:
M1WD|tu fase postve
lMun Antparknson drugs ,
Antconvusant ,
Phenothazne nutuu
LWnlMun D: thyrotoxcoss,
hematura , protenema ,
manopause un: soap :LWn
lun nterfere reacton lM
nu acoho lLwtLuLn
tnn1WnlvnMn
M1WDWMwnM

Pyrdoxn (
vtamn B6
)
9 p' dynamcs /
effcacy
untuuMu1u
Vtamn B 6 ltlun
t1nuluWtulMtu
TB
uuMu1 Vtamn 6 lun
t1nun|nM neurts n
Isonazd W 25-100 mg/day
nuuuMltlunnLW
100-200 mg/ day

TAT vaccne 9 p' dynamcs /

effcacy
untuuMu1 TAT
lu|Mnuuun 2 t
nn Tetanus prophyaxs :
lvMLuvunM|Mn W < 30
kg. lvuuM 1500 unt , |Mn
un:WlvuuvunM > 30 kg.
lvuuM 3000 - 5000 unt
lMulvlM1utt v. un: sc.
nunn treatment 1|Mnun:
WlvulvuuM 50,000 -
100,000 unt lMuut1nuvu1
lvutt v. |vnlvutt m
nunnLnun|nMMM
|ttM:un uu:ulv0M TAT
10,000 - 20,000 unt 1 v.

Tetanus
toxod
11 compatbty/
stabty
Tetanus toxod tuM
mutpe dose vn1n
|tMltW1un:|ntl
lMuu|l
lMultuu:ulv|ntllMuu
24 tlL1 lMu|nt 2-8
4
C

Tramado 4 pregnancy/nu
rsng
uwun1ltu Tramado
1 cap prn v n 8
tlL1 |wnLn
tMWL:lL|nulu
WtuM1WD 7 ntMv
untLWL
|vL:nLvlL
u Tramado Mulu
pregnancy category C t1u
nLnWunlM lLuu:ulvlt
:v1nWnMvlt|tu
t:lu:v1M1WD
|u1nlv|nM physca
dependence un:nuLn
post marketng survance
wtlv|nM neona
sezure , fata death un:
stbrth vnltu|tut:
un:vn|tuM1ltuu uu:u
lvltlu:u:nu |LLn
|uu

Vancomcn 11 compatbty/
Stabty
Vancomcn |L|MuL
|tuuvuMM:LWL
Mu1l
|L|ntluM|uu:LWLW1M 14
u uMn|ntunM|uu:LWL
W1M 24 tlL1

Vancomyc
n
9 p' dynamcs /
effcacy
M1lvu Vancomycn
luM||l|wnM
n|nM Red man
syndrome
nlv Vancomycn lMuu
nfuson M1lt|nu1uu 60
u WL|uLuu 5 mg/m
vn|nM red man syndrome
tt rate lunlvu|tu 1
1/2 - 2 tlL1un:|wL duton
voume

Verorab 9 p' dynamcs /

effcacy
Wtu|WulMtu
verorab Lun 3 dose
utt d M1n|tnuu
Lltulvuutt m
:Luttnlvu
u1l
WtulMtuLun 3 dose
lMuu d luu 0 ,3,7 nLn
|tnuuLlvulMuu m lu
dose 4 un: 5 luu 14 un:
30 uunlvuutt d luu
14 un: 90 lMuuuMulvW
0.5 m
qs
1. Drugs
Informaton
Handbook
Interatona
2. AHFS drug
nformaton,
2004
Departent of
Medca
Seences ,
Mnstry of
Pubc Heath ,
TP nformaton
on Antdote ,
p.17
WLnltu
nvttWnn
nunnu ,
2549,p.135-
153
WLuu1n
tvu0M|w
nMWL|nu1
nnL1u|Dnt
nL
l1wutnn1un
Drug
Informaton
Handbook
Internatona ,
13 edton
,2005-2006 ,
p.555-558
1.Drug
Informaton
Handbook
WLnltu
nvttWnn
nunnu 2549
, p.265-291
Departent of
Medca
Seences ,
Mnstry of
Pubc Heath ,
TP nformaton
on Antdote ,
p.21 ,72
uu1n
tvu0M|w
nMWL|nu1
1.Drug
Informaton
Handbook
Internatona ,
p.259 -260
WLuu1n
tvu0M|w
nMWL|nu1
nnL1u|Dnt
nL
l1wutnn1un
WLuu1n
tvu0M|w
nMWL|nu1
nnL1u|Dnt
nL
l1wutnn1un
WLnltu
nvttWnn
nunnu ,
2549,p.92-93
WLnltu
nvttWnn
nunnu 2549
, p.287
Spontaneous
report of
adverse drug
reacton t
2003 Wuu
MMMLnu
lLw1t:n1W
nnlt
WnMDnvnuDw
u. 2.WL
MMMLnlL
w1t:n1WWL
WMtnM1
:ttWvu1
0ttttt1
WLuu1n
tvu0M|w
nMWL|nu1
nnL1u|Dnt
nL
l1wutnn1un
Wtuun:lWMM
|tt1nulM
MuWtu
1.
Antmcroba
prophyaxs n
surgery (M
|DntttM)
2.nt1nun
MM|t(MlW
MM|t 2)
1.Drug
Prescrbng n
rena faure . 4
edton , p.56
2. |nn
nt:tL|t1
ttMn 1u
|DntnLWnun
W1 6/2546
vu Trends n
Infectous
dsease. lMu .
tn nuunLtM
1. WLnltu
nvttWnn
nunnu ,
2549,p.265-
291 2.
Drug
Informaton
Handbook
Spontaneous
report of
adverse drug
reacton , 2001
,2002
Spontaneous
report of
adverse drug
reacton t
2003 Wuu
MMMLnu
lLw1t:n1W
nnlt
WnMDnvnuDw
u.
Departent of
Medca
Seences ,
Mnstry of
Pubc Heath ,
TP nformaton
on Antdote ,
p.55
Drug
Informaton
Handbook
Internatona ,
13 edton , p
726-727
Advance n
Pharmaceutca
care and
Pharmacothera
peutcs , 2549
, p.221
vdence -
Based Cnca
Practce
Gudene ,
2548 , p.370-
371
nLWLnL
uwuuv1
t:|Wlu ,
Wtuun:lWMM
|tt1nulM
MuWtu ,
p.47-59
1.AHFS Drugs
Informaton
2004 , p. 1667
2.Drug
Informaton
Handbook , 11
edton
WLnltu
nvttWnn
nunnu ,
2549,p.155-
167
MvLuu|Mu
n.w. 48
lW1nWutM
lvwuL|wnn
uutnM|Mn
( MTCT-Pus )
|nn
t:ntn
t:tL|t1
ttMn1u
|DntnLWnun
W15/2548
vu|1
Tubercuoss
lMuutn
nuunLtM
uu1nMun
nLnMM|t
HIV un:Wtu
lW|Mn|Mnun:
Wlvulut:|W
lu t w.W. 2545
|nn
t:ntn
t:tL|t1
ttMn1u
|DntnLWnun
W15/2548
vu|1
Antretrovra
therapy n
adut lMu
utn
nuunLtM
1.Handbook on
Inectabe
drug 11
edton , p
835-841
2.|nnnnt
u meropenem
WLnltu
nvttWnn
nunnu ,
2549,p.135-
153
Drug
Informaton
Handbook
Internatona ,
2003-2004 ,
p.914-916
1.Drug
Informaton
Handbook
Internatona
,11 edton ,
p.922-924 2.
Drugs n
Pregnancy and
actaton , 6
edton , p.920-
927
1.Drug
Informaton
Handbook
Internatona ,
2003-2004 ,
p.1171 2.
Textbook of
Pharmacothera
py , Nausea
and vomttng ,
p.94-110
Drug
Informaton
Handbook
Internatona
,13 edton ,
2005 -2006 ,
p.1173
Drug
Informaton
Handbook
Internatona ,
2003-2004 ,
p.1102-1106
WLuu1n
tvu0M|w
nMWL|nu1
nnL1u|Dnt
nL
l1wutnn1un
Drug
Informaton
Handbook
Internatona ,
13 edton
,2005-2006 ,
p.1353
Drug
Informaton
Handbook
Internatona
|nnnntu
1. AHFS , Drug
Informaton ,
2004 , p. 2067
1.Drug
Informaton
Handbook
Drug
Informaton
Handbook
Internatona
,13 edton ,
2005 -2006 ,
p.1625
nuLw Wuu ,
WDLM tnv
nuMu , lW
wLnuut , p
8-9
B?
Gu
h?
95
0
U1r|Dn
?n?u
?n?u ?nu ?44

Tetanus
toxod
9 P'dynamcs/
effcacy
Wtu|Wu0M vaccne
Tetanus toxod Wt 1
course ( |uLnMu
|Mu L.u.2544 ) ML
LtMuWnMM|t
tM:unlM un
tWtuM1lMt
vaccne tvlL
u1l
nnuWtu|WulMt vaccne
LWt course un t1 vaccne
|uLnMuWtulMtWu
Lunt:Ln 5 t uMMuu
WtuLtMuWn|nMnMM
|ttM:un M1uuWtuW
lMt vaccne utt booster t
nW1 ( lMult vaccne
t1nutM:un:M10Mtn
10 t )
Wtuulu
uWunn1
|nLDLWLnu
lWu1
n:1
nunnu

Mk of
Magnesa
( MOM)
3 P'knetcs Wtu|tulWlM LW
creatnne cearance
10 m/ mn un
t:ltu:tu
M.O.M lMvlLun:
:ttnltulM
u1l
WtulWlM LW cearatnne
cearance 10 m/mn lMuu
luD:nMuu1lWlM ( end
stage rena dsease ; ESRD)
nlt M.O.M. 1|nu1Mn
tnw1u1nutnu1
magnesum 1lM |u1nlM
Ln1unMn1 1Wvnn|nu1
nltu:tuL magnesum
|tunut:nt lMu
|tnuultltu:tu Senokot
v Bsacody uu
uu |LL:
nnML ,
tt Lunu
Mnn , vLn
nun1u , n
|nuM tu
uDw ,
Pharmacother
apy M|Dnt
ttM ,2546 ,
p.339-342

Pencn ,
skn test
13 other Wtuuwu Pencn
uwun1ltu
Cephaosporn n.
untLun
skn test u1lun:
|tuM1vlL
uLn|1n skn test u1
unnL cephaosporn u1L
Wuu1nM lMuwtn|nn
WL|uLuu|vL:nL lL:Wu
|W1Wvu1un:nMnt|tu
tnnWuu1u|tnWtu
:uwu1 u1lnML
tuvunutnWn nnWn
nMnt|tunt |u1nlu
ttuu1lLLlW1n1lMv
metabote lMu1unnLu|tu
detergenc determnant t1
nLnn:Munn1 IgE
antbody 1lv|nMWnnt
n1lM un:u1lLLuLnuuuu
uM u1nuu,
uL luu
wnL , M1
t:|Mu|1
Adverse Drug
Reacton ,
2549 , p.71

Potassum
chorde
11 Compatbt
y/ Stabty
WtulMt 5% D/N/2
500 cc luM| 80
cc/hr tnWtuL
W K+ |nt 2.8 t1
MnWtnM uwu1
n1lvWnL Potassum
chorde 40 mEq lu
uMu|nnM1nn
untnLn
WnLlMvlL
ntvu potassum
chorde |Llv1 perphera
ne WLWL|uLuulL|nu 40
mEq/L un:M|lunlvu
lLW|n 10 mEq/hr
nvtWtuuunnlv
Potassum chorde 40 mEq
luu|nn 500 cc WL|uLuu:
|nt 80 mEq/L t1WL|uLuu
:|nunuu:ulun:
lvWtu|nu1Mn|nMvnM
|nMMn|ntlM
|nn1u
t:tLtn "
nMnu
LWL|nu1n1 "
lMu .L1n
t:wuuMu:

Propythour
ac (PTU)
7 ADR/Sde
effect
WtulMtu PTU lu
uuM 300 mg/day
un:LnWnuln
|uu lLt
nM1nn|nMn
nlMtutuMulM
vlL
PTU lv|nMnWnuln
|uulM u1lnMLn
M1nnlLltuvLltu1Wtu
un:M1wnn1tuu
lvWtu|nMnM1nn
t1luWtuuuWtuLD:u1
lWn:|w:vLMu t1
|tun|vMu1n|nMn
Wnuln|uulM
Drug
Informaton
Handbook 11
th edton ;
p.1175-176

Propythour
ac (PTU)
7 ADR/Sde
effect
WtulMtu PTU un
LnMtL un
t|WuLu1un
|nMnMtLnu
M1nnvlL
nnntWuuLn wtL
u1un|nM Oedema
perorbta ( |tMtL ) uu
2 u lu:MtWLu:|tu
u:lt ( possbe )
Spontaneous
Report of
Averse Drug
Racton
2002,2003.

Methydopa
,Levodopa,I
rbesartan
5 Interacton WtuLt:Mltu
snemet |wnL
n Parknson
MLWtulMtu
Irbesartan un:
Methydopa |wL|ML
un:vn1nltuWtu
Ln|uuWL: Lnu
unt|tuWn
nnltuLnu
vlL
nltu Levodopa Lnt
Methydopa lv|nM
Interacton lu:Mt
sgnfcance 5 lMuL onset
utt rapd , documentaton
utt possbe , un: severty
utt mnor nuu Irbesartan
|tuunnL Angotensn II -
receptor bocker (ARB) t1
Wnu1|Wu1u1unnLulv|nM
nu1|Wu1 W |uuWL:un:
hyperkaema 1|tultlM
n|uuWL:|nMnu
lunnL ARB
1. Tatro DS. ,
Drug
Interacton
Facts,2006 ,
p.1004 2.
M|DntttM
, 2546 , p.20

Tenem 11 Compatbt
y/ Stabty
Impenem nLn
WnLnt Lactate
Rnger 's Souton lM
vlL
n|nnnntu:t
Tenem |unulLlMnt actate
1lLWWnLuntuuL
actate |tunut:nt u1l
nMLnLntvu Tenem
lMuWu IV system t1nn1vuM
uu actate uuulM
1.LA. Trsse.
Handbook on
Inectabe
Drugs., 11th
edton.,2001.

2. |nnnnt
u Tenem

Ketoconazo
e,
Ibuprofen ,
Roxthromy
cn,
Norgesc
7 ADR/Sde
effect
WtulMtu
Ketoconazoe ,
Ibuprofen,
Roxthromycn un:
Norgesc unt
uMlMLu1u
lv|nMnuwuttM
tLun:WMLnlMt1
nnntWuuLn wt
Ibuprofen Lu1un|nM
nWMLn:Mt certan 1
u un:|nMnMtL:Mt
certan 10 u ,probabe 107
u , possbe 53 u nu
ketoconazoe wtnMtL
:Mt certan 1 u ,
probabe 2 u ,possbe 1
u u Roxthromycn wt
nMtL:Mt probabe 4
u un: possbe 1 u nuu
norgesc lLwtu1u|nM
nM1nn
WuuMMML
nlLw1
t:n1Wnn
ltWnMDnv
nuDw ,
Spontaneous
Report of
Adverse Drug
Reacton,
2003.

Ceebrex ,
Norfex ,
Idarac
7 ADR/Sde
effect
WtulMtu
Ceebrex un: Norfex
Lnvunn|tuuu
lLWu |ttn ML
uwun1 Idarac un:
Mydocam uMWtult
Idarac un: Norfex L
nvunn uMlLL
Wu untWtu
uwuvlL
nnntWu ceecoxb lv
|nM ADR 1 Dermatoogc
utt skn rash lM 2.2% nuu
Norfex lv|nMtnuv1 1 u
,mouth rrtaton 1 u un:
wtu1unuwuttWu nu
Idarac lLwtu1uuutM
lv|nMnM1nn uMwt
u1u|nMnuwuttWu
|tunu u1lnMLWtn
t:Mun:MMMLnltuu1
Wtuun:t:|Lun|nM ADR
nW1
1.Drug
Informaton
Handbook,
13th edton ,
2005

2.WuuMMML
nlLw1
t:n1Wnn
ltWnMDnv
nuDw ,
Spontaneous
Report of
Adverse Drug
Reacton,

Kayexaate 10 Therapeutc
use
nlt Kayexaate
nutt:uM1WnL
nt:l u1lun:L
ut1ltlunnL
D::l
Kayexaate v Sodum
poystyrene sufonate ltlu
nnLD:ltuMn|tuLlu
|nMn1 t1:wttuluWtulW
lM|1uuLu|nuW lv
nLnu t
Mu.
Advance n
Management
of

Nevrapne,
Phenyton
5 Interacton WtulMtuMuln
nM 1 t1Lnut:nt
u1 Nevrapne un:
lMtu Phenyton
LMu unt
u|nM DI MnuvlL
un:vnL DI M1unlu
u1l
Nevrapne |LltLnt
Phenyton u Phenyton
ltLWnlv:Mtu Nevrapne
nMn1 lMuu1n1M:
metabote Wu cytochrome
P450 unlulMunttuuM
u Nevrapne vltuMutn
lLWunnlnu
Drug
Informaton
Handbook
Internatona
2005-2006.

Omeprazoe
necton
11 Compatbt
y/ Stabty
Losec necton
nLnn:nuW1unt
nn:nulMlMt1
|u1n sovent uuM
10 m tLlvL
lLlM:t|tuM
n:nutuMlM
nLnn:nuW1u Losec lMnt
Sodum chorde 0.9% v
Dextrose 5% n water lM uM
1tL:uu:ulvltM
n:nuu1tLlvL|uu
1. Handbook
on Inectabe
drug., 11th
edton.

2. |nnnnt
u

Hydrocorts
one ,
Prednsoon
e,
Dexametha
sone
3 P'knetcs unt equvaent
dose :v1
Hydrocortsone ,
Prednsoone un:
Dexamethasone
:.4.47ti.4id App74imate
eq:ivaent d48e
Hydrocortsone
20 mg
Prednsoone
5 mg
Dexamethasone
0.75 mg
Drug Facts
and
Comparsons.
2002 page,
354

Tetanus
anttoxn
10 Therapeutc
use
untuuMu TAT
lu|Mnu 10 t u.u
26 kg nnlt|tu
Prophyaxs tetanus
|u1nuwulv 1500
U IM
uuMuu1 tetanus anttoxn
lu|Mnun:Wlvu:lvMLuvun
W chdren < 30 kg lv 1500
unt chdren and aduts
K 30 kg : 3000-5000 unts
Drug
Informaton
Handbook
Internatona
2005-2006.
page.1518.

Cephaospo
rn
2 Avaabty unt thrd
generaton
cephaosporn tuM
tt:ulu
l1wutnL:lt1
lul1wutnn1un thrd
generaton cephaosporn L
M|Mu W cefdnr vt
nW omncef
unu
l1wutn
n1un0tt
ttt1 2549

Magnesum
sufate
8 Toxcty/Pos
onng
WtulMt
magnesum sufate
IV drp unLnt
M unt|tu
WnnnlMt
magnesum vlL
|u1n Magnesum sufate L
WnnMn1uu1
neuromuscuar transmsson
1LWnM:ttnnL|ulv
|nMntv parayss lM
lMu|0w:WtuLlW
neuromuscuar dsease (|tu
myasthena gravs) vnuu
unLnutu1
neuromuscuar Lntn
lMtu magnesum sufate n
:u1lv|nMnM1nnlM
1uuu 1unLwuunt:Mt
Mg lu|nMMu1WMMML
:Mt Mg lu|nMLMu
AHFS, Drug
Informaton,
2004., Page
2142.

Vtrmx 11 Compatbt
y/ Stabty
unt vtrmx
nLnlv1 cut
down lMvlLun:
nLnlvLntu
Meropenem un:
Omeprazoe n lM
vlL
Vtrmx nLnlvlM11
Centra ne un: Perphera
ne un:uu:ulvuunlvLnt
uMu |u1n Vtrmx |tu
nvlv1vnM|nMM
un:Lnut:ntu1nv
vnutuM t1|nMtuvWL
lL|unuu1ulM
|nnnntu
Vtrmx

PCEC 10 Therapeutc
use
untnM10M
PCEC lututt IM
M1ltun m
lunn0M PCEC utt IM M1
lt vaccne 1 m
lWwLnuut.
nuLw Wuu
un:WDLM
tnvnuMu
tnun.
vu 8.

Enoxaparn 13 other untutvu

Cexane nnM1
ntvu Cexane
(Enoxaparn)
1. Wlvu cexane 1lM
Wvu1lMu0Mu|ulMWvu1
t|nWu1vu1Muu1u1
nMWult1u1vuvvn1
nlMlMun0Mnntnu:v1
Mutuun:u
2. W0MlMu
u1|uLluuuM10nntWvu1
t1nntM1uuMuuvuLLun:
utlMuWvu1:nnunuuL
MnM|nn0Mu
3. nu0MulLM1ln
w1nW
AHFS, Drug
Informaton,
2004.

Drug
Informaton
Handbook.

Esomepraz
oe
13 other WtulMtu1nu
u1lvv (NG
tube) lLtM1
tvu Nexum
u1l
Nexum v Esomeprazoe
|tuunnu|uunLn
ut1W1lMuMvLtM|LMuvn
|tuM1lvututtu1nu
vlvu|LMultutunnW
:LnuMnMu1|LMuwt
peets n:uluuun1lv
1nuvlM
ntvu
1nu
Nasogastrc
tube MlMu
nnL1u|Dnt
nL
l1wutn
n1un

PCEC, ERIG 10 Therapeutc

use
Wtu|WulMtn0M
vaccne PCEC un:
ERIG t1nuwLnuu
tWt WnLun|L
t 47 LW1ulMuuL
nMLlLtM1|L
0MlvLvlLun:vn
M1n0M ERIG Mu
M1|LlvLvlL
Wtu|WulMtWtulWwLnuu
ttuM|tnn|w:|nu1vlu|tM
wntnu (PCEC) Wt W
nLnu |LnLWnlWnW1un:
|tuM1lMtnnL nLn
lvnnLlMun0M|uLn:Mu
un:lL|tuM1lv RIG lMun
0M|unnL|u 1 dose v0M
|uluWvu1 1 M (tLnWtu
0.1 v 0.2 m) t|nvlvn
lMu0M 1 W1 (u 0) lunn
WtulMtWtu|uLnMu < 6
|Mu un:0M 2 W1 (u 0 un:
3) lunnWtulMtWtu|uL
nMu > 6 |Mu
u:w1L Mnv
|tu. Wtu
un:lWMM|t
t1nulMMu
Wtu.WnM
ltM|nWnM
un:Wn:
(tnun)
vu 171-189.

MAC 10 Therapeutc
use
untuu1n
nLlWMM|t0u
lnn
Mycobacterum
Avum Compex
(MAC) luWtu|Mn
Wlvu
nMultlunnL
dssemnated MAC un:t1nu
nnnt|tutlMu
mantenance therapy lt
MnMtM (un|ulunnWtu
lMtuMulnutt HAART
uDLWLnu|wLuu >100
ces/mm3 |tu|nuu (M1uM
6 |Mu) un:lMtnnL
MAC > 1 t uultlLLn
t1n1nMM|tnLn:vuM
nnL MAC lM) W
Carthromycn 500 mg un:
2 W1 v azthromycn 500
mg un: 1 W1 Lnt
uu1|t
tDtMnMun
nLlWMM|t
0ulnnlu
WtuMM|t
HIV/AIDS.
nunlW|Mn
nlWun:
lWMMM1
|wWnLwuu
nLWtWLlW
n:1
nunnu.
2547

Verapam 10 Therapeutc
use
uwun1ltu
Verapam n lun
nL SVT uMu
M1nnlLLlu
l1wutnnLnlt
ulMuulM
ultlunlv SVT nnt|tu
snus rhythm unn
verapam W
1. Adenosne
6-12 mg 0M|uvnM|nMM
| un:M1tlv ntravenous
fud MLvn1u1uu 20 m

2. Dtazem
15-30 mg 0M IV t (lLLlu
.w) 3. Dgoxn 0.25-0.5
mg 0M|uvnM|nMMuMlL
Wlt|tu frst ne of
treatment |w::nnuvn1
lvu 2 tlL1
1lu nnMu
w1L lu v
l|Mu|WM
1v:tuM
Supraventrcu
ar un: Atra
Futter. vu
150-237.

Dmenhydr
nate,
Loperamde
10 Therapeutc
use
untun
tt:uu uuMu
uW:1un:
uuu:ulun
tt:uu
Dmenhydrnate un:
Loperamde lu
Wn1u
Dmenhydrnate uuMult
W 50-100 mg v 1-2 |LMn
6 hr LuW:1un:Wuu:u
luntt:uuW u
lv11uu tnLnun:Wuv1
Wn1ulMMuLnn
tnM1WltuluuuMMnM
lvWnn1nM
Loperamde uuMuuu:u
nn1|Muuttwnu|LMu
uuMu 4 mg MLMu 2 mg
vn1nnu uuMulL|nuun:
16 mg uW:1un:uuu:u
W unM:ttt:n
nunn11lv11uuun:
wn 1WMu:
lu u The P
Book. wLw
W1 2 ,2547.
vu 33-36L
49-52.

Doxycycne 9 uwun1uu
Doxycycne (100)
1x2 pc lvWtu|Mn
u 1 t lMu|MuL|tu
uunvt|Mn un
tuuMu
M1nnLWL|vL:nL
vlL
nnntWuu1lLwtuLnWL
tnMDuu1nltu
Doxycycne luWtuLu <
18 t t1nltuuluWtuL
nwMunn1n:Mnun:wu
Wlut1W1vn1u1nM1WD
t1un|nM un:|MnLu < 8
t Wvnn|nu1nltuu
|u1nLWnlvnu1wu
WMtnMun:u1wtu1un|nM
eneme hypopasa nMu
AHFS Drug
Informaton.
2004.page
449,2624.

u TB 9 P'dynamcs/
effcacy
uwun1u TB nM A3
(H:300,
R:600,Z:2000,E:1200
) lMu HRE tlvnuL
|Munuuunu PZA
uunlvnu 1x4 pc lL
t|tu|w:|vMlM
unlWnM:uu:ulvnuW1
|Munuuu |wlvWtulLnL
nuuun:nMWnu1|Wu1u1u
|wWtuuuvntlunn
WtuLWnu1|Wu1nu |tu
Wnuln Lu1 :uu:ulvuun
nuu lMuuuMn:tuMlvnuW1
|Mu |tuu sonazd un:
rfampcn nuW1|MuMu|t
nuu PZA un: ethambuto
nunuuu t1nnuuW1|Mu
:lv:Mtulu|nMn1n
nuunnulvLt:nuDw
lunnLn1n uMlunn
Wtuuuuwulvuunnuu
|u tltM
n.nlWlu
Wlvu.MlW
MM|t 1.
nLWLlWMM
|tuv1t:|W
lu. wLwW1
1 MnWL
2548.683-719.

PCEC 10 Therapeutc
use
untunlv
Wtu PCEC t1nu
lWwLnuututtnu
nLWnlW
n0MWtut1nuMWwLnuu
tuttnunLWnlW (PCEC) lv
0MWtu 1 dose |unnL|u
v 0.1 m 0M|uluWvu1
t|nvlvnluu 0 , 7 un:
21 v 28 (n0MlLM1u
|nnuunuLtlM) |MnW
ltuuMu1Wtu|ntWlvu
u:w1L Mnv
|tu. Wtu
t1nuMWwL
nuut.nLWL
nLuwuuv1
t:|Wlu
2548. 171-
189.
9
Manto 11 Compatbt
y/ Stabty
uwun1 drp manto
8 cc uu 30-60 u
lLtnLn
dute ulMvlLun:
ltnu:l
Manto nLn|1lMnt
D5W lMuWL|uLuunMulL
W|nu 15% |u1nwt
WL|uLuuLnn 15%
manto MnM:nulM
nvDLM
www.globalrph.com/dil
m#MANNTOL

Cmetdne
n
7 ADR/Sde
effect
uwun10Mu
cmetdne IV push
wutn0Mulvnt
Wtuvn10MuwtL
uuM1ML|nu|nM
0MlLt|nMn
:l
ntvu cmetdne
necton lunnlv IM
nLnlvlMlMulLM1|1uM
lunnlv drect IV uu:ulv
0Mt >5 u lMu dute lv
lMWL|uLuuL 20 m lMu
|1nt 0.9%Nac lunn
WtuuuuuM1MLuut|n
|nu|nM|nMn 0Mu|
|nult v |1uuult
lv:Wu|W1|nu|nM
Lawrence A.
Trsse,
Handbook on
nectabe
drugs.11th
edton page
305.

Norfoxacn,

Metrondaz
oe
7 ADR/Sde
effect
|Mnu 6 |Mu vun
6.5 kg ltwtuwu
Wnun uwutn
|tutMLMun:tMlLL
MlMu Norfoxacn
(100) 3/4x3 pc un:
Metrondazoe (200)
1x2 pc uLt
Duvn1|MnlMuuM
unntnu1unt
:|tuuMuvlL
uuMu Norfoxacn uu:ulu
|Mn:1nnMM|t
shgea (tMlLLM) W 15-20
mg/kg/day uu 3-5 u nu
uuMu metrondazoe ltlu
nnLtMLM (amebass)
W 35-50 mg/kg/day uu 10
u uM Norfoxacn LuW
:1nltlu|Mn|u1nwt
u1un|nMun|nt
(arthropathy) lunMMn1
un:LtuvMnwMu
n:Mnu1|Mn 1Wltu|L
|tuun:lt|tu:u:|nnu
|LwnuuMu
1.Lacy CF et
a., Drug
Informaton
Handbook ,
13th edton
2005-2006.
2. uu |LL:
nnML.
Infectous
Darrhea. lu
Textbook of
Pharmacother
apy 2546.
111-125.

Vaccne 9 P'dynamcs/
effcacy
Vaccne t1nulW
lwuMutt0MLu
tvuu1l
Vaccne utt0M 1 dose L 0.5
m lvlu|MnuLnn 2 t uu
lt lt0M|unnL|u nLn
n:MulMn 2 t nu1Llnn
|nu1MnnLWn|tlMuWtuL
t:nuDwun: 64-72
WLWtu,
2548 :113-
117.

Cacum
guconate
n
9 P'dynamcs/
effcacy
Ca guconate n
nLn0M IV push lM
vlL
Ca guconate n nLn0M
utt drect IV lM lMulLM1|
1 lMulvluM| 0.5-2
m/mn nlvu||nult:
lv|nM hypotenson ,
arrhythma
1.|nnnnt
u 2.
WLuu1
ntvu
|wnMWL
|nu1
l1wutn
n1un

Ntrogycer
n n
13 other untuWnLu
NTG 1:10 WnL
u1l
NTG 1:10 vLuWLWnLu
1 mg Mnu 10 m lMun
unLnltWnLlMW NSS
v D5W lMulvlMWL|uLuu
lL|nu 400 mcg/m lMultuM
un v hard sod pastc |tu
poyethyene , poyoefn
vnn|nu1 PVC |u1nLWnMM
ttu
WLuLWL
|nu1n1 uLn
tWnn1
nuwuW
t|wWL
tnMDuWtu
l1wutn
n1un

Dynastat 11 Compatbt
y/ Stabty
nnlLLMn:nu
ntLu Dynastat
nLnn:nuntM
n:nu:llMt1
Mn:nunLnltn:nuW1
u dynastat nu0MlvWtulM
W 0.9%NSS, D5W ,
0.45%NSS LRS lMu|LWnLu
unWltlvvLMDuluW1|Mu
1.|nnnnt
u 2.
WLuu1
ntvu
|wnMWL
|nu1
l1wutn
n1un

Ceecoxb,
Idarac
10 Therapeutc
use
untL
nWnLnlt
ceecoxb Lnt
Idarac |wlv
WnnnLluMu
lMt1
nnntWuuLnwtlLL
1uuun:u1unltu
combne :v1 Idarac un:
NSAID Mu |u1n|wLWL
|nu1lun|nM gastrontestna
damage
www.askrx.net

Dopamne,
Amodarone
11 Compatbt
y/ Stabty
unt
Dopamne un:
Amodarone nLn
lvWtu1|nu|Munu
lMvlL
nnntWuuLnwtnLn
lvu Dopamne un:
Amodarone 1|nu|MunulM
|u1nlLwtuLnWLlL|u
nuu1u
WLuu1
ntvu0M
|wnMWL
|nu1.w. n1un
,2549. 4-5, 24.
8
Cprofoxac
n,
Metrondaz
oe,
Doxycycne
5 Interacton unt
Cprofoxacn ,
Metrondazoe un:
Doxycycne nLn
|nM DI nulMvlL
nnntWuuLnlLwtu1
3 tuM |nM drug nteracton nu
Drug
Interacton
Facts,2006.
9
Acycovr 9 P'dynamcs/
effcacy
untWtulW
Be's pusy lMtu
acycovr uu 4
|LM un: 5 W1 |tu
|n 7 u LWL
|vL:nLvlL

Terbutane 9 P'dynamcs/
effcacy
untuuMu
Terbutane lu|Mnu
1 |Mu
uuMu Terbutane lu|Mnu
< 12 t lvutt SC W
0.005-0.01 mg/kg/dose ,
maxmum 0.3 mg/dose n
15-20 u (3 dose)
Drug
Informaton
Handbook
,13th
edton.page
1513.

Cactonn 7 ADR/Sde
effect
unt
Cactonn (Caco) L
nu1|Wu1nu
un:uW:1:lt1
Caco v samon cactonn
n nu1|Wu1wtlM >
10% W Faca fushng ,
Wnuln, 1|nu, |tv un:
tLt|n0M
Drug
Informaton
Handbook
,13th
edton.page

Ceftraxone 11 Compatbt
y/ Stabty
uwun10Mu
ceftraxone 100 mg
utt IM lvWtu|Mn
untM1WnL
ntMn:nulMlu
tLn|l 1:L
WL|vL:nL
u ceftraxone utt IM
lv|nMnn|nt tMt|n0M
lM M1uu1uu:ulvWnLuuuM
250 mg M 1% docane 2 cc
uwun1 100 mg M1uuM1lt
nn:nu 1% docane 0.5 cc
1.WLuu1
ntvu0M
|wnMWL
|nu1.w n1un
,2549.
2.
|nnnntu

Smvastatn 9 P'dynamcs/
effcacy
M1ntlL
M1tt:uu
smvastatn luMu
|uuvnuuu
|u1nu smvastatn :L
peak pasma eve u 4
tlL1un::nMn1u1M|u
|vn|wu1 10% u1tLnn1nM
vn1ntt:uultun 12
tlL1 M1uunlvulut1Mu
|uuvnuuu:lv peak
eve u1uu|n|vL:nL
lunn1|W:v choestero
n1nMWt1|n |u1Wun1M 2
http://se-
ed.net/belotte/nacha/fre
quency.html

Ldocane
n
11 Compatbt
y/ Stabty
wutnuu
docane n lt|nt
luM|uut:Ln 3
tlL1lLt:
lvLtuvMWLW1
Mu1uvlL
Ldocane n tnM:LWLW1
MMnvDLv1lL|tuM1
|ntluM|uu nnntWuuLn
n1WLW1Mu1 docane n
LnWnLn1WLW1Mu1
docane |LWnLlu 5%DW
|ntluM|uu (4 C) un:
nvDLv1 (30 C) uu 30, 60
un: 120u wtlLLn
nu|nuu|nMuuun:uLWLW1
MMun1 120 unWnL
1nvDL 30 un: 4 C u1ln
ML Xyocane Topca lu
tutt spray, vscous qud,
ey |tututtlLuu:ulv
Am I Hosp
Pharm. 1981.

Nov;38(11):17
45-7.
uL luu
wnL.Dtu:
tuun:n
|ntnLu lu
WLnltu
nvttWnn
nunnu.
134-153.

Roxthromy
cn
10 Therapeutc
use
uwun1u
Roxthromycn (150)
2x2 luWtu otts
meda lLtlM
vlL
uuMulMultu1
Roxthromycn luWtuWlvu
W 300 mg/day lMulvutt
snge dose vut1lvun: 2
W1 LnWnLutt
mutcenter,RCT |tut|utu
Roxthromycn (Rx) un: 300
mg nt amoxy/cavuanc
(Amx) 875+125 mg un: 2
W1 luWtu ear-nose-throat
nfecton wtWtuMtnu1
MnnLM (82% lunnL Rx
un: 78% lunnL Amx) M1uu
uuMu Roxthromycn lu
uuM 600 mg/day u1lLwtn
I Chemother.
2001. Dec;
13(6):621-7.

Drug
nformaton
Handbook
13th
edton.page
1416.

Deparon 10 Therapeutc
use
u Deparon Wu:l
Lut1ltu1l
Deparon LtnLu1uW
Anagn nnulMunMn
tM n arthrts untMv
MIMs,2004.

Fentany 10 Therapeutc
use
untnLnlv
fentany luWtu|Mn
lMu1lt1
luut1lt sedatve/anagesa
nLnlvutt sow IV push
luuuM 1-4 mcg/kg/dose
nLntlMn 2-4 tlL1 n
M1nutt Contnuous
nLnlvlMlMulvuutt IV
bous luuuM|LMu 1-2
mcg/kg un:MLMu 0.5-1
mcg/kg/hr un:nLnWnLlM
ntnn:nu D5W v NSS
Pedratrc
dosage
handbook,
8th edton,
2001-
2002:422-423.

Dmenhydr
nate n
7 ADR/Sde
effect
uwun10Mu
dmenhyrnate IV
tnWtu|nM
ntLuM1t|n
0M lLt|nMn
:l
Dmenhydrnate tutt0M
nLnlvlMutt IM v IV
lMunlvutt IV uuMu 50 mg
u1 Dmenhydrnate :M1
|1nt 0.9%NSS 10 m un:
M1tvutu1uu 2 u
AHFS Drug
Informaton.
2004.page
2786.

Adrenane
nI
11 Compatbt
y/ Stabty
Adrenane n u
nnM|uuLu
vLMuu1l
u adrenane unn
M|uu:nvuMuvLMu|vn 1
t utnuunnM|uu
un:M1lL|nuuvLMu
nvuMtuvnMu
WLuLWL
|nu1n1 uLn
tWnn1
nuwuW
t|wWL
tnMDuWtu
l1wutn
n1un

Lactuose 10 Therapeutc
use
untuuMuu1
actuose ltluWtu
crrhoss Ln
hepatc
encephaopathy
uuMuu1 actuose tutt
tt:uW actuose 20-30
g (30-45 m) n 1-2 hr
nuunttuuMuluuM
n:ulMulvLnnuun: 2-3
W1 uMLWunMuuMun1
|tu 60-100 g (90-150 m) M
u
Recta admnstraton:
200 g (300 m) |1Mu
700 m (uv NSS) lvu1
vunlMuWu recta
baoon catheter un: retan
30-60 u n 4-6 hr
Drug
Informaton
Handbook
13th edton,
page 905.

Doxycycne 10 Therapeutc
use
untWtu|Mn
LD:|nu1Mn|tu
maara :nLnlt
u doxycycne lu
nnLlMvlLun:
LuMlMnt1
nLnltlMluWtu
uu
unLnltlunnL
Ln|u lMun choroqune,
qundne, prmaqune,
doxycycne tetracycne un:
cndamycn uMu
doxycycne LunMu1n
ltlu|MnuMn 8 t 1
|tnuuLlt cndamycn lMu
ltuluuuM 8-25 mg/kg/day
ut1lv 3-4 W1/u
1.Drug
Informaton
Handbook.13t
h
edton,2005-
2006.
2. Cnca
Handbook of
Pedratrc.3th
edton,2003.

Esomepraz
oe
7 ADR/Sde
effect
unt
Esomeprazoe tab
lv|nMnWnuln
tM1lMvlLun:
|nMuun%
Nexum v Esomeprazoe L
u1un|nM nausea un:
abdomna pan lM 4%
Drug
Informaton
Handbook.13t
h
edton,2005-
2006.page
581.

Potassum,
Sodum,Pho
sphate
13 other unt day
requrements u1
Potassum, Sodum,
un: Phosphate lu|Mn
u 1 t
Day eeectroyte
requrements lu
nfants/chdren W

Sodum 2-6 mEq/kg

Potassum 2-4 mEq/kg

Phosphate 0.5-1 mmo/kg
Pedratrc
dosage
handbook,
8th edton,
2001-
2002:1109.

Gpzde 3 P'knetcs unt gpzde

utn1lMun:Ln
ttuuMuu1l
Gpzde utn1 urne
60-80% lMu 91-97% ulut
metabotes nun 11% ut
n1 feces nttuuMu
u1 gpzde luWtuLD:
lMtnw1 W
ose for normal
renal function: .- mg q h
Adjustment for renal function
(GFR,ml/min) >
- <


Drug
Informaton
Handbook,
2005-2006
edton,P 750.

Drug
Prescrbng n
rena faure,
Dosng
Gudenes for
aduts ,forth
edton;83.

Castazo ,
Pentoxfy
ne
10 Therapeutc
use
Wtu|tu ntermttent
caudcaton ulL
tLuu
nLnltlunnL
nM1nnlMvlL
un|vun
Castazo un:
Pentoxfyne
D:ntMu|tuW1W
|n|MunvnM|nMuM1MMu
(ntermttant caudcaton)
nnntWuuLnwtult
lunnLD:M1nnult
lunnLD:M1nn W
costazo un: pentoxfyne
un:lLuu:uuu (Ln1
vasodators) lunnLD:
M1nn nn|tut|utn
lt castazo un:
pentoxfyne lunnL
ntermttant caudcaton
wt costazo Mn
pentoxfyne u1LuunWu
Mc
Cormack.Drug
Therapy
Decson
Makng
Gude.Page
31-32.
www.dms.mop
h.go.th/secton
3/315015.htm.

TB drug 10 Therapeutc
use
untun
desenstzaton u TB
luWtu TB/HIV
|u1nWtuuwu
INH, Rfampcn ,
Streptomycn
luWtu TB/HIV n
desenstzaton M1u1
:LM:1luWtunnLu|u1n
LWL|nu1n1:|nMtnu
uu1 nvt|WuWlun
desenstzaton W |LMu
uuMuuut:Ln 1/10 u1
uuMutnMun:1Wt 10 u
Management
of TB. n1n
lW nLWtWL
lWMMM.0tt
unlu wLwW1
1. w.W. 2544.

Foodpne 4 Pregnancy/n
ursng
unt
feodpne nLnlt
luvu1M1WDlMvlL
u feodpne |tuuMulu
Pregnancy cat.C 1WWu1
WnMun:Wn|nu:lMnnltu
Drug
Informaton
Handbook,200
6.
8
Monteukas
t
6 Formuaton unt
monteukast uuM 10
mg nLnWnLnt
suspendng agent
lvntWtulMvlL
un:u:LWLW1M
vlL u1l
Monteukast v Snguar L
nut:ntluMt|tu
hydroxypropy ceuose
actuose monohydrate,
Magnesum stearate un:
mcrocystane ceuose t1
nut:ntM1nnlvu|nM
WLtulM1u M1uunWnL
|tututtuu1lL|vL:nL
un:uM1nnM1|ntlvwuun1
un:WLtu 1lLuu:ulvWnL
lvntWtu uMnLWL|tu
1 lvWnL|1luMnu
|vL:nLun:tt:uu
www.rxlist.com
9
Theophyn
e
10 Therapeutc
use
unt:lt
Theophyne (200)
uuM 2*2 pc luWtu
|tu asthma un:L
uvunM 65 kg lM
vlL
uuMu Theophyne
steady state mantanance
dose W 900 mg/24 hr u1l
nMLuuMu|wLuulv
Wtu|nMwLnulM 1M1
uu:ulvWtutn|tu
wL|nMnu W Ln
Wnuln |uu tM1 uulL
vnt un:lnu t1nLn
M1nnuu:ulvWtunntlt
wtuwu
Drug
Informaton
Handbook ,
13 th edton
,p. 1525-1528

Bactrm 10 Therapeutc
use
untuuMu1u
Bactrm ltlun
nL PCP luWlvu
uuMu1u Bactrm ltlun
nL Pneumocystc W 15-20
mg u1 Trmethoprm /day
lMuut1lvn 6 - 8 tlL1
Drug
Informaton
Handbook ,
13 th edton
,p. 1480-1482

Maxfed^ 10 Therapeutc
use
Maxifed^ t:ntMu
Mu:lt1
Maxfed^ t:ntMu
Pseudoephedrne 80 mg un:
Guafenesn 780 mg
www.googe.c
om ,
www.mcramer
can.com/prod
uct

Phenyton 9 P'dynamcs/
effcacy
unt
phenyton utt
prompt un: extended
capsue nLnlv
utt|Munu W 3*1 hs
lMvlL nlLlM
untLWL
uMnM1nuu1l
nlvu phenyton ( extened
) utt 3*1 :LWnM1u1 C
max nt C mn Lnnnlv
uutt 1*3 (prompt) un:n
lvuutt 1*3 v 3*1 M1
Wu1n1 sde effect un:
compance u1Wtu nu
WnnnL:lLM1nuLn uM
t1nWnLwtnlv
prompt phenyton :lvW
Cmax u1un1nnlvulu
tuttu t1nlvututt
prompt ( lLlt extended ) lL
nLnlv|wu1 dose |Mulu 1
ulM 1:M1lvuutt 1*3
www.googe.c
om ,
www.pubmed.
com

Duxar 7 ADR/Sde
effect
untDuxar L
Wnu1|Wu1lvWtu
|nMnuulLvnt
lMvlL
u Duxar t:ntMuMu
nWu Ammtrne 30 mg un:
Ranbasne 10 mg nn
ntWuuLn wt Duxar
nLnlv|nMnlLw1
t:n1WlMutnunuuvntlM
MIMs annua
16 th
edton,2004.p
.230-231

Sucrafate 2 Avaabty unt

l1wutnn1un Lu
sucrafate vlL un:
LuuMn mg
l1wutnn1unL sucrafate
uuM 1000 mg ( 1G)
tutunu
l1wutn
n1un 0tt
ttt1 2549
t:t
tu
uwu
|0w:
1
gqq
j
gqq
j
eph
eph
eph
wut
n
|Dntn
eph
eph
eph
eph
uwu
|Dntn
uwu
wut
n
gqq
j
gqq
j
gqq
j
eph
eph
|Dntn
un
n
un
nu
eph
eph
eph
wut
n
|Dntn
t:t
tu
wut
n
wut
n
|Dntn
|Dntn
|Dntn
|Dntn
|Dntn
uwu
wut
n
wut
n
|Dntn
|Dntn
|Dntn
|Dntn
wut
n
wut
n
wut
n
|Dntn
eph
eph
eph
uwu
|Dntn
eph
eph
h?

950
U1r|Dn
?n?u
?n?u ?nu
1 Acetylcystein
e
7 ADR/side
effects
tu|nLlv|nM
anaphylactoid reaction
n Fluimucil inj lun
nLWtu Paracetamol
overdose L:lt1
Anaphylactoid reaction |tu
rash,flushing,chest
pain,tachycardia,fever,hypotension,a
ngioedema,broncospasm |tun
lLw1t:n1Wu1vu1u1ndrip
uut1|nMnn0Mu|uvnM
|nMMMuM||nultun:
tnun|nMu1uuntuuMu
M1uu1wtvn1nlv loading dose
unnunnWnLwtWtu
Lt:MDLuwlMun asthma,atopic
dermatitis,allergic rhinitis un:
allergic conjunctivitis |tu rish factor
vu1lv|nMtnu
anaphylactoid reaction n V lM
|wLuu
2 Actrapid 6 Formulation Wtu|WulMtu
Actrapid Lnw.L.
lMLwtuwuw.
n1unuMuM1nnlLL
luw.lLtnLn
lt Humulin-R uulM
vlL
Actrapid un:Humulin-R ulunnL
Regular nsulin uMLWLuMnM1
nulunuu1 Pharmakinetic M1u
Actrapid HM L onset 0-5 hr,Peak
1-3 hrun: Duration 8 hr nu
Humulin-R onset 0-5 hr,Peak 2-4 hr
un: Duration 6 hr t1:|vuLW
1|DntnuWnMlnn|Wu1nu1
nLnltuunulM
3 Alkaline
phosphatase
20 Others WtuLW alkaline
phosphatase nMn1
nLnutnWn1Wnun
lMu1lt1
Alkaline phosphatase |tu|ultL
wtlMlun:Mn Mt nun:wtlMlu
tLnn1lulMun:nln luWtu
|tu biliary canaliculi n
|ultLuWMtnM:|tuMtutn
D:lW|nuntn:MnvD:L
nnnuuWn|tuLnn:Mn lu
WtulWMt:Mt|ultLulu|nM
:n1uu |u1n1|MuuMMMu
nvtnutnWn1Wnunuu
nvtWnMn1wtlMluWLD:
hypophosphatemia,hypothyroidism
un: D:wlDtun
4 Antihypertens
ive agent
10 Therapeutic
use/Efficacy/ndi
cation
untultlu
nnLWLMulnvMn1
luWtuL Scr=2
nLnltuMlM|w
WLtnMDunLnlt
HCTZ lMvlL
nWunW CrCl luWtuuu
|nt 34 ml/min t1unMWLMu
nnL Diuretic |tu HCTZ lLM1tt
uuMu vnWtuLMnn1
10-50 ml/min unnnLvu1lLM1
ttuuMuW Calcium channel
blocker |u1nutn1lMuu
Mu1unnLuluw.W
Amlodipine 5,10 mg ,Felodipine
5,10 mg nuu|tvuWtu
tt:uuun:uW Metformin
uuwtWtuLW Scr 1.5 mg/dl
lu|wWtu|tuuvLltu1u
|u1nlv|nMD: lactic
acidosis un:luWtuuu Scr =2
mg/dl 1uu:ulv|tnuultltuM
u |tu Glipizide lMuWtuLW
CrCl 10-50 ml/min lvnMuuMun1
50%
5 Arthalgia 20 others Arthalgia LWLvLu
u1l
Arthalgia utn tMuM n
tMu
6 Augmentin
syrup
9 Dosage/Admini
stration
unt|Mnu 4
ut uvun 20 kg
uwun1lt Augmentin
syrup 1.5 tut un: 4
W1 untuuM
un1ltM1nnLWL
|vL:nLvlL
lL|vL:nL|u1n uuMu
Augmentin syrup uu:ulvltlu
|Mnu 2-6 t (13-21 kg)W 25/3.6
MKD (mild to moderate infection)
un: 45/6.4 MKD (serious nfection)
t1WunuuMun1nMMLuvun
u1WtuuuW 1,028 mg/day uM
uuMuuwun1|tu 1,368 mg/day
t1|tuuuMun1nuuMu
uu:ulvltMu
7 Azithromycin,
Cefuroxime
tablet
10 Therapeutic
use/
Efficacy/ndicati
on
Wtu|tuvn|ntlMtu
Cefuroxime tablet un:
Azithromycin LnulL
t|vL:nLvlL
|tnlWwtluWtuvn|nt
|0utwnu vn|tu|tutW|u
lMun S.pneumoniae un: 25-50 ,
H.nfluenzae un: 15-30 ,
M.catarrhalis un: 8-20 |tu
wtlM|tu S.pyogenes, Enteric
bagteria, S.aureus, P.aenginasea
t1u Azithromicin nWtWnL|tn
lWnWu un: Cefuroxime n
WtWnL|tnlWnWu|tunu
M1uuW|nnlt|wu1M|Mu
nvtuu1n|nnuMuntw
lunnLD:vtunn1n|nt
|0utwnulut:|WluW Day
0:Amoxycillin, Amoxycillin(High
dose 80-90 MKD), Azithromycin,
Clarithromycin Fail day3:Co-
amoxiclav(high-dose), Cefuroxime,
Cefdinir
8 Baclofen,
Tolperisone
7 ADR/Side effect unttt:u
u Baclofen un:
Tolperisone |tu
:u:|nvnu|Mu:
|nMnu1|Wu1:l
lMt1
Tolperison ltt|n
|nuntn|n1Mu1nnL|uun:
tuWnunnL|u vnlt|tu
|nuunu1|Wu1wtlM
W nnL|uuu1 Wnuln|uu
tnuv1 Wuv1 lLntu1 tM
WL: WLMulnvMM lM nu
Baclofen nu1|Wu1wtlM
W 11uu WLMulnvMM
u|wnu Mw Wnuln|uu
tMWL: un:uulLvnt
unnunlLw1t:n1Wwt
lMuuW nutnn:tu |t1tL
ntnu Mu|Mu tL|W t:nvnu
|tuMu
9 Band,PMNs 20 others untWLvLu
u1W band un:
PMNs wtnnM
u11v1ttMn
Band vLun1 Muu1|LM|nM
unntnMtnunLlun:un
|nM|nMuu|u1n nMM|t
L:|1|LM|nMuvnnu|nu
|nM nu PMNs vLun1 |LM|nM
utuMvu1W neutrophil
10 Cal-D-Vita 4 pregnancy/nursi
ng
unt CDV
nLnlvlMluvu1lv
uLtMvlL
CDV v Cal-D-Vita t:ntMu
Ca 600mg,vitamin D3 400 units M
1 |LM nnWnLnlt vitamin D
luvu1lvuLtM wtvitamin D
nnutn1uuLluuuuu
un: The Nation Academy of
Sciencer uu:ulvltluvu1lvuL
tMluuuM 400units un:nLn
lvluuuM low dose lMuMlLuu:u
lvluuuMn1 t1lunnuWtu
lMtun: 1|LM(Vitamin D 400
units) M1MLuu:u
11 Cefazolin 7 ADR/Side
effects
Wtuuwu cefazolin
lLtLlnn:
uwunnL Penicillin lM
vlL u1l
n|nMnuwulunnL Cephalosporin
ut1lM|tu 3 nn W
1. nn antigenic determinant W
Beta-lactam ring Wtuuw
Cephalosporin MlMMvu1 nLlnnn1
:uw Cephalosporin Mu Mun
M unnuuu1Llnnn1:uwunnL
Beta-lactam |tu Penicillin lM|tunu
2. nn antigenic determinant W side
chain u1 Cephalosporin Wtuuw
Cephalosporin MlMMvu1Llnn:
uwu Cephalosporin MuvunnL
Penicillin |0w:ML side chain
|vLunu|uu
3. nn antigenic determinant W
lW1n1u1u1lL|nnnWtu:uw
Cephalosporin |wu1M|Mu|uu
u1lnM uLn|Lluttuwt
nu|tu side chain u1
Cephalosporin |tu antigenic
determinant lMtuLnnnuu1
12 Ceftriaxone 7 ADR/Side effect untWtuL
t:Muwu Penicillin
:Llnnuwu
Ceftriaxone lMvlL
un:W|nu1ltltunnL
lMuu
WtuLt:Muwu Penicillin L
lnn:uwunnL Cephalosporin
|tu Ceftriaxone lMvn antigenic
determinant W beta-lactam ring t1
vnM1nvnn|nu1ltltunnL
Quinolone uu |tu Ciprofloxacin
13 Ceftriaxone,
Penicillin G
Sodium,
18 Alternative
medicine
WtulMtu PGS 2 mu
q6hr un: Ceftriaxone 2
gm OD vn1nuuLWu
uuuwu off Ceftriaxone
u1|MulLt
nLnltuMlMuu
un:vnuwu off PGS
Mu:ltMlMuulM
nLn|tnuunnLultltunnLu
|tu lt Ciprofloxacin inj. uu
Ceftriaxone |u1nLnuWtWnL
|tutW|unLntlM nuvn
uwuM1n off PGS lt
clindamycin inj. uulMlun
WtWnL|tutW|unLtnun:
anaerobe uMvnM1n|nn
Cephalosporin lv|nnltMlLL
Side chain |vLuntMLt:Muw
14 Clarinase 7 ADR/Side
effects
WtuLt:Muwu sulfa
nLnltu clarinase
lMvlL
Clarinase t:ntMuu Loratadine
un: Pseudoephedrine t1|tuu
lLL Sulfonamide |tunut:nt
1nLnltluWtuuwu sulfa lM
15 Cloxacillin,Di
cloxacillin
9 Dosage/Admini
stration
untu
Cloxacillin un:
Dicloxacillin LuuMu
ltuMnM1nuu1l
uuMltu1u Dicloxacillin W
|MnLuvunM < 40 kg ltuuM
12.5 - 25 LnnnLMnlnnLMu
ut1lvn 6 tlL1 , |Mnun:Wlvu
Luvun > 40 kg ltuuM 125 -
250 LnnnL n 6 tlL1 lMuu1
2 tuMLnu1|Dntu|vLunu
un:nLnltuunulM |wu1uM
uuMnltuu1 dicloxacillin :M
n cloxacillin t:LnW1vu1
|uu ( ltun: 4 W1n 6 tlL1
|vLunu) |u1nntt:u
uluuuM|nu :Mtulu|nM
u1 dicloxacillin :Lnn
16 Diazepam inj. 9,10 Dosage/Admini
stration,Therap
eutic use/
Efficacy/ndicati
on
untuu1lun
nLntnM|u1
(stetus epilepticus) un:
nWnLu Diazepam inj.
|wvuMlvWtu|w
t1nunMnM:nu
nnL SE |LMunlv
Diazepam V 10 mg lL|nu 2
mg/min vnu1lLvuMtnWu load
Phenytoin 20 mg/kg rate lL|nu 50
mg/min vnu1lLvuMtnlv V
Diazepam t v V Phenytoin
|wL|MLluuuM 5 mg/kg nvt
nlv Diazepam lMult:
uu:ulvutt V direct uMvn
|tuM1lvutt infusion M1:1
|1MnM:nu|u1nun:nuu
lMuu nn:nuuu:ulvltW
D5W, NSS 0.9% |1lu
Mnu > 1:40 v/v nuunu
:MnM:nu t1n|1WL
|uLuuu:LWLW1M 6 tlL1 un:
WL|uLuu >1:50 v/v :LWLW1
M 24 tlL1
17 Diclofenac
sodium inj.
9 Dosage/Admini
stration
Diclofenac sodium inj.
nLn0M V lMvlL
Diclofenac sodium inj. nLn0M V
lMlMuuuMuWlvW 1mg/kg
V push v slow V infuion nlt
Diclofenac sod.25mg/ml M nvt
lv V W|1lv|tu 5 mg/ml Mu
NSS nuun1lv V infusion t
|tu|nuun 10 u lMu
Loading dose 75 mg Mnuu1lv
5 mg/hr
18 Dimenhydrina
te inj.
9 Dosage/Admini
stration
Dimenhydrinate inj.
nLnWnLnt
nn:nu:lun:L
untvu1l
|u1nWtuuu|Wu
0Munnnunt
Dimenhydrinate inj. nLnlvlM1
M un: V un:vnlvutt V
nLnWnLnt 0.9%NSS uu 10
ml 0Muu 2 u
19 Dopamine inj. 11 Compatibility/St
ability
unt Dopamine
nLnlv1|nu|Munt
50% Glucose lMvlL
Dopamine lLLu1u|unu
lLlMnt 50 % Glucose M1uu1
nLnlv1|nu|MunulM
20 Dopamine
inj.,
Protamine inj.
11 Compatability,S
tability
untnLnlv
DoPAmine inj.nt
Protamine inj. unWtu
1nu|MunulM
vlL

DoPAmine lLnLnWnLnt
Acyclovir Amikacin, Amphotericin
B, Ampicillin, Furosemide,
Gentamicin, Heparin, ron,
Metronidazole, Nitropusside, PGS,
Sodium bicarbonate (v
nn:nuM1un ) M1uu
DoPAmine nLnlv1nu
|Mununt Protamine lM un:
Protamine LW pH 6-7 t1Lnu
|tunn11nLnlvLnulM
21 Drug use in
Mycoplasma
pneumonia
infection
10 Therapeutic
use/
Efficacy/ndicati
on
Wtu|Mnu 4 |MuL
t:Muwu Penicillin
un: admit Mu|1
Pneumonia uwu
M1nltunLn
WtWnL|t
Mycoplasma pneumonia
lutu0MlLt:
ltuMlM
nnLunLnWtWnL|t
Mycoplasma pneumonia lMWun
nL Fluoroquinolones lMun
Ciprofloxacin,Levofloxacin,Moxifloxa
cin |tuMu unnuu1nnL
Macrolides lMun
Erithromycin,Azithromycin,Clarithrom
ycin uMuLlututt0Mluw.:
|tuulunnL Fluoroquinolones t1
lMun Ciprofloxacin,Levofloxacin
t1uLnnltlu|M:Luu1nM
un:M1:1 ADR lu:tt
neuromuscular&skeletal lMun
arthralgia, arthritis, tendonitis uuM
uuu:uM1u u Ciprofloxacinlu
neonate :7-40 MKD ut1lvn12hr,
lu children: 20-30 MKD ut1lvn
12hr nuuLevofloxacinchildren:
5-10 MKDoselvn24hr uuMu
n1nMW 500 mg
22 dT vaccine 10 Therapeutic
use/Efficacy/ndi
cation
untnLnlt
dT v DT vaccine uu
Tetanus toxoid lMvlL
nLnlt dT uu Tetanus toxoid
lM |w: Tetanus toxoid
t:ntMu purified tetanus toxoid
lutLn 5-10 Lf/0.5 ml nu dT
t:ntMu purified tetanus toxoid
lutLn 5-10 Lf/0.5 mlun: purified
diphtheria toxoid 1-2 Lf/0.5 ml t1:
|vu dT un: TT LtLnpurified
tetanus toxoid M dose |nu
23
Duphalac

9 Dosage/Admini
stration
unt Duphalac

|LltluWlvu:M1lt
uuMu|lM un:L
onset u1u|tuu1l
Duphalac

v Lactulose LuuM
ultnvtn constipation lu
Wlvu W 15-30 ml/day nLn|wL
uuMulMn1 60 ml/day lMuut1lv
1-2 W1 (WL|uLuuu1u 10
g/15ml) :u:|nlunnnuu1
uW 24-48 tlL1nnu colon
lMun|wLu1 osmotic colon
24 Dynastat 7 ADR/Side effect WtuLt:Muwu sulfa
lMtu Dynastat wt
Wtu|nMWu lLt
WtuLt:Muw sulfa
:uw Dynastat vlL
Dynastat v Parecoxib :LnM
lW1n1|tu Sulfonamide derivative t1
lu|nnnntuLW|MuvLltlu
WtuLt:MuwulunnL sulfonamide
|w::LWL|nu1Mn|nMnlL
w1t:n1W1Wvu1uu1 u1lnM
LnWnLutt retrospective cohort |w
|W:vWLt:MnuwuMuntw
nnLsulfonamide LWL|nu1:uwuL
sulfonamide |tunut:ntlLltu
MuntwLnuu|wu1lM |L|utntW
lLLt:MuwuMuntwnnL
sulfonamide Lnu lMunWnLlu
nnLWLt:MuwuMuntwnnL
sulfonamide uu 969 Wu |tut|ut
ntnnLWuu 19,257 Wu lLL
t:MuwuMuntwnnLsulfonamide
WnnWnLwt Wtu 9.9% lunnLL
t:MuwuMuntwnnLsulfonamide
|nMnuwuu|LlMtulunnL
sulfonamide lLltuMuntw |ut
ntWtulLLt:MnuwuMuntw
nnLsulfonamide |nMnuwuu 1.6%
|LlMtunnLsulfonamide lLltu
Muntw
25 Esomeprazol
e inj.
11 Compatability,S
tability
untuNexium
inj. nLnWnLnt
nn:nulMlMt1un:L
unWnLuu1lun:
M1lvulMult|n
|lMun::M1lvutt
V direct v drip
Nexium inj. v Esomeprazole inj.
nLnltlM1utt V direct un:
drip (nfusion) lMunlvutt V
direct lvWnLuuuM 40 mg nt
0.9% NSS 5 ml lt|nu1uu 3
u nuutt V infusion lvWnLnt
0.9% NSS 100 ml lt|nuuu1
uu 10-30 u un:lLuu:ulv
WnLntnn:nuMu|u1nL
uLnlL|wu1wlu|1u1 stabiity
un: compatibility u1u
26 Fluconazole 10 Therapeutic
use/
Efficacy/ndicati
on
uwun1lt Fluconazole
luuuM 600 mg/day
luWtu HV |tu
cryptococcal meningitis
lMtu Amphotericin
B Wt 14 u un:lL
tuuMuM1nn
ltlMvlL
uuMulMultu1 Fluconazole
ltluWtu cryptococcal
meningitis W 400 mg/day |tu
|n 8 ntMv vn1nlMt
Amphotericin B 0.7-1.0 mg/kg/day
|tu:u:|nu1uu 2 ntMv
nvtnlv Fluconazole lu
uuM 600 mg/day lvM
nnM|tnulunuvn1Mn
uuMu 400 mg/day un:L
nWnL|tut|ut efficacy
:v1 Fluconazole luuuM 600
mg/day nt traconazole 600
mg/day |tu:u:|n 10 ntMv
luWtulMt Amphotericin B
|tu|n 2 ntMvLun wt
CSF sterilization rate u1
Fluconazole group un:
traconazole group |nt 100
un: 94% MLnMt (P= 0.26)
M1uunnWnLuuMuM1nn
1nLnltlM
27 Gentamicin
nj.
7 ADR/side
effects
untu
Gentamicin inj.lv|nM
WulMn|t|tuM
n Spontaneous Report of Averse
Drug Raction 2003 wt nLn
lv|nM rash lu:Mtu:lt 19
u,:lt 19 u un:lLu:lt
2 u un:n Druginformation
Handbook 2003-2004 wt
nLnlv|nM skin
itching,reddening of skin,rash lM
t:Ln 1-10%
28 Gentamicin
nj.
7 ADR/Side
effects
unt Gentamicin
nLnlv|nM rash
lMvlL un:L
|t|tuMn|nM|tu
u1l
Gentamicin nLnlv|nM n
lLw1t:n1Wlu:ttWvu1 lM1
utt Skin itching,reddening of skin
un: rash lMuwtMn|nM
t:Ln 1-10% u1WlMtuu
29 Gentamicin
nj.
11 compatibility/St
ability
unt Gentamicin
inj. |tMltun|vnlu
vial |ntlMnu
nnntWuuLnLWuu:un1
WLW1Mu1u Gentamicin inj.lu
nn multiple dose vial lv|ntu
wuun1un:vn1nltunu|vn
lv|ntluM|uuun:uLu 24 tlL1
30 Haemophlus
nfluenzae
type B
vaccine
10 Therapeutic
use
/Efficacy/ndicati
on
untun:|uM
u1uLnWtuutlu|1
u1uWlMtWtu
un:t1|n0M
Wtut1nulWMM|t|uvLnL1
n|ntn|t HB uu:ulv0Mlu
|Mnu 2 |Mu lMuuu|uLun:
t1|n0Muuuntu|L0M
un:tuMu1Wtult (Mun:|uM
ML|nn11)unnulL
|tuM10Mn:Mulu|MntnMuM
uu:ulv0Mn:MulunnL|nu1n
W1|Lu 18 |MulMuM1v1n
|uLnMuu1uu 2 |Mu
31 Hydralazine
inj.
11 compatibility/St
ability
Hydralazine inj.Lun
lvu1lun:WnLnt
nn:nu:l
Hydralazine inj.uu:ulvutt M
v V push t (uun 1 u )
lMulLM1|1(nnu|tu
nn:nu) un: monitor BP n 5
u nvtnlvuutt nfusion L
standard dilution W WL|uLuu
0-20 mg/50ml rate 30 u ,WL
|uLuu 21-40 mg/100 ml rate 30 u
, WL|uLuuLnn 40 mg/250 ml
rate 1 tlL1 lMunn:nu
|nnltW NSS lunn|tuutt
W1uv1 un:M1nlvutt V push
1M1|1uMu NSS v SW
32 Hydralazine
inj.,
Dihydralazine
inj.
9 Dosage/Admini
stration
unt
Hydralazine inj uMnM1
n Dihydralazine inj.
u1l lunltnM
WLMuunWtuun:
Hydralazine inj
nLnWnLntnn:nu
(solvent) tuMlMlMt1
Hydralazine un: Dihydralazine
Lut1ltlunnMWLMulnvM
|vLunu lMu Hydralazine LuuM
ultW 10-40 mg lMu|Llu
uuMM nu nuulvtlMn
3-6 tlL1ML|tu lMuuuMu
n1nMlL|nu 400 mg/day nu
Dihydralazine LuuMultW
6.25 mg lMu0Mt t:Ln 2
u un:lvtlM lMuv1nu
t:Ln 20-30 u nu
t:nuDwun:nu1|Wu1
wtlLuMnM1nununn:nu
nLnWnLnulMnt Hydralazine
W dextrose solution, Ringer's
lactate solution un: sodium
chloride solution
33 mipramine 4 pregnancy/nursi
ng
untnLnlv
mipramine luvu1lvuL
tMlMvlL
|u1nunLnlM1uuLlL
uu:ulvlt AAP(The American
Academy of Pediatrics) lvulu
:Mt concern
34 nfluenza
vaccine
9 Dosage/Admini
stration
unt|Mnu 2 t
nLnlMtWtuluvM
lvulMvlLun:L
unlvu1l
WtuluvMlvunLnlvlu|Mn
uLnn 6 |Muuult M1uu|Mn
u 2 t1nLnlvlM lMulvlu
uuM 0.5 ml uu 1-2 W1 |Mn
uuun 9 t W0Mn1|uLv1
nu 1 |Mu nvtn0MW1un
35 nsulatard
HM penfill
3,6 Pharmacokineti
cs/Formulation
unt nsulatard
HM Penfill nLnlt
Humulin N uulMvlL
nsulatard HM Penfill t:ntMu
Neutral sophan (NPH) nsulin
(Human monocomponent
recombinant DNA origin) Mulu
nnL ntermediate acting nsulin
|tu|Munt Humulin N lMuLW
Pharmacokinetic M1u Humulin N L
onset 1-2 hr,peak 6-12 hr un:
duration 18-24 hr nu nsulatard HM
onset 1.5 hr,Peak 4-12 hr un:
duration 24 hr :|vuuLW|Dnt
nuWnMlnn|Wu1nu1lt
uunulM
36 nsulin,Hepari
n,ventolin,Ber
aduol solution
11 compatibility/St
ability
unt:u:|n
vLMuu1u multiple
dose u1 nsulin,
Heparin,
ventolin,Beraduol solution
u|tu multiple dose u1w.
n1unnvuMuvLMuvn1n
|tMlt M1u nsulin 1 |Mu,Heparin
14 u, ventolin un: Beraduol
solution 1 |Mu
37 Leuprorelin
acetate
10 Therapeutic
use/
Efficacy/ndicati
on
untut1ltu1
u Leuprorelin acetate
3.75 mg injection |nu
|ulul1wutn
Leuprorelin acetate v Enantrone
Lut1ltM1u nLlW
Endometriosisn stage - V lt
nLn|u1nnnL|uLMnn
(uterine fibroid) |wnMuuMu1|u
1nnunWMM un:ltnL
lWL:|1MLnnvLn:u:nnnL
38 M.tussis 7 ADR/side
effects
untLu1u
n|nMnlLw1
t:n1Wnu M.tussis
t1vlL
nu1u Spontaneous report of
ADR 2003 wtu1un|nM
anaphylactic shock lu:Mtu:lt
1 u,|nM angioedima lu:Mtu:
lt 2 u un: |nM Face oedema lu
:Mt:lt 1 u t1:wt
M.tussis uL|tuunLut:tu
uMnLu1un|nMnlLw1
t:n1Wuu1lM
39 Magnesium
inj
11 compatibility/St
ability
untnLnWnL
Magnesium inj. nt
Aminoparen lMvlL
Magnesium sulfate |unulLlMnt
Sodium bicarbonate un: phosphate
t1 Aminoparen |tu nn:nuu1
amino acid LnuWnLu1|nn
Sodium M1uu1lLuu:ulvWnL
Lnuv|tnuultltnn:nu
amino acid lLLnuWnLu1
Sodium uu
40
Mobic

,Colch
icine
9 Dosage/Admini
stration
WtulMtu Mobic

un: Colchicine un
tuMlM
nLnvuMtt:u
lMvtt:u|0w:
|nLn|uu
u Mobic

v Meloxicam |tuu
t|ntM t1M1
tt:uvn1vu lMu
tt:u|LLntM nu
Colchicine :nMnn1nMlv
|nMntMtLun:n|nt1W
tt:uuMLuwun1un:1
n1uuwuuMwt|wMMMLM
nluW1Mlt
41 Morphine nj. 9 Dosage/Admini
stration
untLn chest
pain uwun1 morphine
sulfate uuM 3 mg V
unt:lvut
lM|Ll
uuMu morphine |Llvutt V n
LlvulMluuuM 2.5-5 mg n
3-4 tlL1 un:nLnlvutlMn
5 u vn|tu uMu1lnML
WLn monitor respiratory and
mental status un: bood pressure
lMunlvu:M1 dilute Mu SWF
v NSS 4-5 ml un:lt|nlun
lvu 3-5 u
42 Multivitamin
syr.
9 Dosage/Admini
stration
untuuMuu1
MTV syr. ltlu|Mnu
uun 1 t
Multivitamin syrup v Complevit
syrup Llul1wutnn1un uM
n: 5 ml t:ntMu vitamin A
1990 U , vitamin D 150 u, B1 1 mg,
B2 1 mg, B6 1 mg, B12 2.5 mcg,
Vitan E 7.5 mg, Vitamin C 35 mg,
Nicotinamide 10 mg , Calcium
pantothenate 5 mg un: folic acid
0.1 mg t1uuMuuu:ulu|Mn
u 1-6 t W 5 ml OD uMn
Lnn 6 t W 5-10 ml OD nvt
uuMuuu:ulu|Mnu uun
1 t :|tuutt MTV drop lMu
uMnM1nu|nnuuW |Mnuuu
n 1 t W 0.5 ml uMnLnn 1 t
W 1 ml OD
43 Mybacin 7 ADR/Side effect WtuLt:Muwu
Roxithromycin unL
W1un1nuuwu Mybacin
lLtMu
Neomycin Llu Mybacin
:LlnnuwuLnnL
lMvlL
Mybacin t:ntMu Neomycin
sulfate (equivalence to neomycin
base 2.5 mg),Bacitracin 100 unit,
Amylocain HCl 0.5 mg Mu
Neomycin Lluu Mybacin uu|tu
ulunnL Aminoglycoside Lnulu
nL|tutW|u Neomycin L
lnnuwuLnnLlMnt Framycetin,
Gentamycin, Kanamycin,
Paromonycin, Spectinomycin,
Streptomycin, Tobramycin nvt
nuwuLnnLnt Roxithromycin u1
lLwtuLn nnntWuuLn
|wL|MLwt Ln1unuw
Mybacin wtW pruritus,
maculo-papular rash, urticaria lM
44 Nifuroxazide 10 Therapeutic
use/
Efficacy/ndicati
on
Nifuroxazide |tu
antibiotic nnLlM
Nifuroxazide |tuunvtnL
n1|nu nnuutt broad
spectrum lLLn:tulunnL
lM |tuultlunnLt:|Wult
un:lLWuwtuLnnltuuLnun
45 Potassium
chloride,Sodi
um
bicarbonate
11 Compatibility/St
ability
untu0M
Potassium chloride un:
Sodium bicarbonate WnL
|unulMvlL
u 2 MunLnlvLnulMlMu
|tunWnL WL|uLuu
Potassium chloride 2.4 mEq/L lMu
ltnn:nu D5W wtuL
physical compatible 24 hr
46 Progynova 10 Therapeutic
use/
Efficacy/ndicati
on
Progynova |uLuu
premarin nLnltuu
nulMvlLu1l un:
LltuMnM1n
Cycloprogynova u1l
Progynova un: premarin LMu
ulLu|nlM|u lMu Progynova
:|tu estradiol valerate lMnwt
Wn|vn1 nu premarin W
conjugated equine estrogen lM
nnM un:LuuMnM1nulu|1
uuM nuttu un:n
u1|Wu1 (un:|uMluutttun
nlvuLnu) nu
Cycloprogynova t:ntMu 11
|LMnu W estradiol valerate 2 mg,
10 |LMnuMn W estradiol
valerate 2 mg,norgestrel 0.5 mg lMu
Progynova ltlunnMMLMnnun
nuCycloprogynova :ltlunn 47 Pseudoephed
rine
7 ADR/Side effect unt
Pseudoephedrine L
nlLw1t:n1W
lvvuuM1lMvlL
Pseudoephedrine LWnM:tt
vlun:vnM|nMW lvv
l|Mu| lnu lM lMuulv
WLMulnvM|wLuu u1lnMLL
u1uulv|nM hypotension
lM|tunu nnntWuuLnwt
nvuuM1 wtlM|LlMtu
luuuMn1un:nu1u
Spontaneous report of ADR t 2004
wtu1un|nMn flushing 1
u lu:Mt u:lt
48 RDW 20 Others unt RDW luW
Lab CBC uLn:l
nMutnWLvLu
u1l
RDW uLn RBC Distribution
width (RDW) t1:|tunM|t1
tLnlMuMnWLuMnM1u1
uuM|LM|nMuM1t1:tuu0u
D: anemia
49 RG 10 Therapeutic
use/
Efficacy/ndicati
on
untn0M RG
lunnlLnLn0M
wLntnlvWtulu
W1unlM nLn0Mlu
uMLlMvlL
nlv RG nvuMlvunWtu
vu1W1wLntnlvWtulu
uuMnvuMnlvuuMn1n
nvuM:LWnnMDLWLnu|nMuu
lMu|0w:luu 10-14 lunn
lLnLnlv RG luuunwL
ntnlvWtu Wwnlvlu
uMLuMlLWlvvn1u 7
u1nlvWtu|w::LWnlun
nMDLWLnu|nMuunnlvWtu
50 Roxithromyci
n
10 Therapeutic
use/
Efficacy/ndicati
on
unt
Roxithromycin Lltlu
nnWtuLMnuvlL
Roxithromycin nLnltlun
nLvu1lu|uL (Nongonococcal
urethritis) lMulvluuuM 150 mg
un:W1v uuM 300 mg un:
W1 |tu:u:|n 10 u t1Wvu1
MM|tvu1lu|uLnuLn:lLL
nuMnuuu:LnMnulM
51 Shohl's
solution
6,14 Formulation
,Contraindicatio
n/ Precaution
M1nuLn Shohl's
solution ltu1l
t:ntMu:lt1un:
lvunM1:1:l
Shohl's solution |tuM1ulu
tutttt:ultlunnL
D: metabolic acidosis utt|1
lLnLnunlun|vMlM
|tuM1lMM1tM|tu|wnL
:Mt pH lu|nMlvLWt:Ln
7.35 v:Mt HCO3 t:Ln 20
mmol/l 1u|wlv:Mtn1u
M1 u11nuuluMntnM
L1t1nun|nM osreopenia
u1n:Mnun:tulv|MnLn
|u|MtlMtnM lMu
l1wutnn1un:L 2 nMlMun
nM 1 Na 0.51 mEq/ml K
0.46 meq/ml HCO3
0.94 mEq/ml Citrate 0.93 mEq/ml
nM 2 Na 1.02 mEq/ml HCO3
0.94 mEq/ml Citrate 0.93
mEq/ml
lMu Chronic acidosis :wnlv
alkali 2 mE/kg/day un:|wLu
:Mt HCO3 tnM (22-23 mEq/l)
nlvuM1:1luWtuLD:
52 Tetanus
antitoxin
(TAT)
10 Therapeutic
use/
Efficacy/ndicati
on
Wtut:nttM|vML
tMuWnu lMtn0M
Tetanus toxiod (TT)lu
uun admit uwun1
TAT LMuuMwutn
nL0MlvntWtulMu
WuL|tu:u:|n 2 u
unt:LWn|nu
MWtuvlL un:
:u:|nlunlv TAT
lLW|nu:u:|n|l
nnntWulLwt:u:|n:t
ltM|ulunlv TAT uMnlv
TAT :LWnlvLnltnu TT
u1lLt:ttt:n lMun
:lv TAT vlLuunttMuWnu1
WtulMu:lvluuuWnlvu
nntnLnvlMWtuLuu|nu
10 t un:LtMuWnLuu|nu 24
tlL1 M1uuWtuuu1Wlvu
unWtuu|L|vuWn1uwu
lMu:u:|nWuL 2 u:u1
lLLWnn:tuu1MWtuun:
nlv TAT W|MuL adrenalin 0.1
ml lMu|wt1nunuwutt
anaphylaxis
53 Transamine
inj.
11 compatibility/St
ability
unt
Transamine inj. nLn
lvlMuu V push lM
vlLun:nLnWnL
ntnn:nuMlMlMt1
5%Transamine inj. L transamine
acid 250 mg/5 ml nLnlvlM1
V v M ratelL|nu 1 ml/min un:
nLnWnLntnn:nu D5W,
NSS, D10W un: RLS
54 Virkon 11 compatibility/St
ability
uuL|t Virkon
vn1nWnLun|ntllM
uu|l un:u1lL
WnLnLn|ntlMuu
|l un:nLnult
utlu|W1L tnn
tuMlMlMt1 lt|nlu
nutuu|l
uuL|t Virkon v Sodium
hypochlorite nWnLun|ntllMuu
7 u vnnnn:nu|tnuunn
uLw|tunn:nulnW|tnuu
uu|u1nt:nuDwu1uu
n1|nMlMnnu1nn:nu un:u1
lLWnLulutW1uv1nLn|ntlM
uu 3 t nLnultltnt|WL
|nu1MnMM|t:Mtnn1 |tu
tMlu lLnMnu |W1n1nn1
nuu1nvtlvv|vn
:u:|nltutuu 10-30 u uM
Lu|nuW LnunMnu nu
tnn|tunnu1wnnMnlLu
WLulvnL|tlMultuu
qs
1.vnnnMun
WtulMtu
|nuuuM lu
WLnltu
nvttWnn
nunnu
2.JRMS,2006.11(
2),108-110
MM,102
edition.2006.309
lnnnL
WnM .wLwW1
1.126-127
1.nttn1
|DntnLlu
WtulWlM
2.Drug
nformation
Handbook
nternational ,11
edition, p.894-896
Medical
Dictionary,2547
MM
annual.2006.p59
1.The Sanford
Guide to
antimicrobial
therapy,2005.p51
-53 2.M
lWMM|t1.
2548,149-162
1.http://www.phar
m.chula.ac.th

2. u The pill
book.2547,117-
120
nM1
v1ttMn.
2543.106-142
1.Drug in
Pregnancy and
Lactation.6th
edition,1485-
1489
2.www.uknicentra
l.nhs
M1t:|Mu|1
Adverse Drug
Reaction .2549.
60-61
M1t:|Mu|1
Adverse Drug
Reaction
.2549.57-94
1.The Sanford
Guide to
antimicrobial
therapy,2005.p51
-53 2.
|nnnt:tL
|1u1l..
|Ln1nuuwu
M1t:|Mu|1
Adverse Drug
Reaction
.2549.63-65
Drug nformation
handbook 11
edition , 2003 -
2004
1. Handbook of
njectable drugs,
11 edition, 2001:
p.402
2.Update in
Emergency
Medicine.2549.92
-104 3.WLn
tvu0M|w
nMWL|nu1 w.
n1un
1.WLntv
u0M|wnMWL
|nu1 w.n1un

2. CCS
1.Handbook of
njectable drugs,
11 edition, 2001:
p.420-432
Handbook of
njectable drugs,
11 edition, 2001:
p.447-455
1. Handbook of
njectable drugs,
11 edition, 2001:
p.1129
2.WL
ntvu0M
|wnMWL|nu1
w.n1un
1.The Sanford
Guide to
antimicrobial
therapy,2005.p51
-53
2.Pedriatric
dosage
Handbook.8 th
edition.2001-
2002.p586-587
WLWtu,2548 :
31.
Drug nformation
Handbook
nternational ,13
edition , 2005 -
2006 , p.1734
1.www.drug.phar
macy.psu.ac.th


2.www.cbh.moph.
go.th 3.M1
t:|Mu|1
Adverse Drug
Reaction
.2549.63-65
WLntv
u0M|wnMWL
|nu1 w.n1un
1. J Med Assoc
Thai. 2003.
April;86(4):293-8
2. uu1
ttMnMun
nLlWMM|u
0ulnnluWMM
|t|tl /|Mn .
2547.75-83
1.Drug
nformation
Handbook
nternational ,12
edition , 2003 -
2004
2.Spontaneous
Report of Averse
Drug Raction
2003.
Drug nformation
Handbook
nternational ,13
edition , 2005 -
2006 , p.742
http://members.tri
pad.com/dgholgat
e/sixteen.html
Wtuun:lWMM
|tt1nulM
MuWtu.
2548.83-90
Handbook of
njectable drugs,
11 edition, 2001:
p.694-697
1.Handbook of
njectable drugs,
11 edition, 2001:
p.694-697

2.www.pharmacy.
psu.ac.th
1.Drug
nformation
Handbook
nternational ,11
edition , p.725-
726 2.Drug in
pregnancy and
lactation,6th
edition.p693
WLWtu,vu 9
1.MMs.102nd
edition.2006.p309
-310 2. nMun
nLWtu
|tvuutt
1WL
1.uuttM
nvtn|nt
un:MunuM1
:1|tuw|WL
w.n1un
2.uLnn
tLnnLluu
ventolin un:
beraduol solution
uttwL|nu
u|u
l1wutnn1un
Spontaneous
Report of Averse
Drug Raction
2003.p143
WLuu1n
tvu0M|w
nMWL|nu1
nnL1u|Dnt
nL
l1wutnn1un
Drug nformation
Handbook
nternational ,13
edition , 2005 -
2006 , p.394-395
1. Drug
nformation
Handbook
nternational ,13
edition , 2005 -
2006 ,
p.1085-1086 2.
WLntv
u0M|wnMWL
|nu1 l1wutn
n1un
Pedriatric
Dose.2547.144-
145
1.http://dermnetnz
.org
2.Spontaneous
Report of Averse
Drug Raction
2001.
www.google.co.th
Handbook of
njectable drugs,
11 edition, 2001:
p. 1165 - 1177
1.Clinical
practice
condition |1
nMunnL
nMu1.w.
n1un
2.
|nnnntu
Progynova
3.
MMs.100th
edition. 2005
1. Drug
nformation
Handbook
nternational ,13
edition , 2005 -
2006
2.Spontaneous
report of adverse
drug reaction
,2004, p.182
www.google.co.th
Wtuun:lWMM
|tt1nulM
MuWtu.
2548.171-189.
1.MicromedexH
ealth care series
vol.127
exp.3/2006

2.www.thailabonli
ne.com
1. M|nnlM
lnMlu|Mn.
2548,221-239
2. tuv
wttulu|Mn
un:uu1n
MunnL.
2546,236-240
1.http://nonthaburi
.moph.go.th

2.http://thaigcd.dd
c.moph.go.th
WLuu1n
tvu0M|w
nMWL|nu1
w.n1un .
2549,64
1.www.si.mahidol.
ac.th
2.http://drug.phar
macy.ac.th
tu D
type
t:|DWnL WnL WMt
1 Acyclovir 10 Therapeutic
use/
Efficacy/ndicati
on
untu Acyclovir
Lut1lt:l un:M1
ttuuMuluWtulW
lMvlL (uwun1lt
utt oral)
Acyclovir Lut1ltlunnL
genital herpes simplex virus,herpes
labialis(Cold score),herpes zoster
(Shigles), HSV encephalitis,
Varicella-Zoster (chicken pox) lMu
nlvuutt oral :ttuuMu
luWtulWlM M1u ClCr 10-25
ml/min:800 mg q 4 hr n1 800 mg q 8
hr, ClCr <10 ml/min:200 mg q 4 hr
v 200 mg q 8 hr v 400 mg q
12 hr n1 200 mg q 12 hr v
lvluuuM 800 mg q 4 hr n1 800
mg q 12 hr
2 Adrenaline 7 ADR/ Side
effects
WtuLn
anaphylaxis uwun1
Adrenaline (1:1000) 0.5
ml M uMwutnlv
direct V unt:
|nMuMuntWtu
vlL un:vn10Mu
Wtutuuuuvun
Lnuu:|nuu1nt
0MuWM1vlL un:
Adrenaline Lnuuuu
vnMnLvlL
Adrenaline inj. (1:1000) ltlu case
anaphylaxis uuMultW 0.3-0.5
mg M tlMn 15-20 u nun
lv direct V uuMultW 0.1-0.25
mg nvt case ultuuMu M L
0M V lvuuMun1ltn
uu:u un:n0Mutt direct V u
:nnu|n M vn10Mu
Wtu1tuu1uuuvunu n
lv V u:ltvl|uu 1Ln:
lvuuluWtu cardiac arrest M1uu
case uW mornitor HR,BP Mu n
HR > 100 W1/u M1u1uwu
tMu un: adrenaline Lnu
lunuuuvnMnLnMu
3 Adrenaline 9 Dosage/
Administration
unt Adrenaline
L maximum dose |tu
|l |Llvutt V
infusion
nlv Adrenaline utt iv infusion
:M1|MuL adrenaline 1:1000 lv
lMWL|uLuu 8 v 4 mcg/ml (
dosage range 1-4 mcg/ml ) lMu
Mnlvu|LMuW 0.1 mcg/kg
/min u1lnMLlLWlvu|nu 5
mg/u
4 BCG vaccine 11 Compatibility/
Stability
BCG vaccine vn1WnL
nLn|ntlMuu|l
BCG vaccine WnLunlvltvLM
Dulu 8 tlL1 :v1nltlv|nt
lunvDL 2-8 1W|tn|tun lu
M|uuvn:Mnuuu1MnM|n
un:t1nulLlvnnun1 vL1l
lunvDLv1
5 Benzathine
benzylpenicilli
n
9 Dosage/
Administration
untuuMu
Benzathine
benzylpenicillin lun
nLWtu|tu Syphilis
WtuWlvu|tu Syphilis utt
|0utwnu:lt Benzathine
benzylpenicillin utt single dose
2,400,000 unit nulunnWtu
|tuLuun 1 t uuMult W
2,400,000 unit ntMvn:W1|tu
|n 3 ntMv
Ceftriaxone,
lidocain,
Theophylline
4 Pregnancy/
Nursing
WtuM1WD 5 |Mu
lMtu Theophylline
un:uwuM1n0M
Ceftriaxone+lidocain lv
WtulLtnLn
lvuM1nnlMvlL
Theophylline Mulu Pregnacy
category C t1nltluWtuM1WD
:M1wnn1WnlMtM
uMu:|nMuu t1WtulMt
Calcium,Vitamin B complex un:
Obimin AF LMu lMulL|nM Drug
nteraction nu
Ceftriaxone+Lidocain Mulu
Pregnancy category B nLnltlu
WtuM1WDlMu1tnMDu
7 Cephalexin 4 Pregnancy/
Nursing
Cephalexin v Keflex
nLnltlMluvu1
M1WD 7 |MuvlL
Cephalexin v Keflex Mulu
Pregnancy category B lLwt
teratogenic luvu un:luWu L
nWnLltu Cephalexin :v1
M1WDuu 4 Wu lLwtWnu1
ulu fetus un:lMMMMLnun
WnMuu 2 |Mu uu 2 u
wttnM
8 Clindamycin 9 Dosage/
Administration
Clindamycin inj. WL
|uLuu 00 mg/4 ml
nLnlvuutt direct
iv lMvlL
u Clindamycin lLnLnlv1
direct iv lM uMnLnlvlMlMuu
0M deep im un: infusion |uu
|u1nulv|nM phebitis lM
lMu|LlvulMuu deep im uuM
uM1lL|nu 00 mg nunlvlMu
u iv infusion :M1 dilute Mu
NSS, D5W un:WL|uLuuu1ulL
|nu 18 mg/ml lt:u:|nlunlv
u 10 - 0u un:M|lun
lvulL|nu 30 mg/min
9 Cloxacillin inj. 11 Compatibility/
Stability
Cloxacillin inj. vn1WnL
nLn|ntllMuu|l
Cloxacillin WnLnt NSS v D5W
LWLW1M 2 tlL1 nvDLv1
un: 24 tlL1|L|ntluM|uu
10 Cytarabine 9 Dosage/
Administration
u Cytarabine nLn
0MlMuu sc lMulLM1
dilute lMvlL (uuMu
lt 30 mg)
Cytarabine |tuulunnL
antimetabolite WL|uLuu low
dose (100-200 mg/m2 ) nLnlv
1 im, sc, iv lMlMulLM1 dilute
uMnltuWL|uLuun1 ( 1-3
g/m2) M1lvlMuu infusion lMu
dilute Mu D5W v NSS tLM
250 -1,000 ml un:lt|nlunlv
u 1-3 tlL1
11 Digoxin,Grise
ofulvin
5 nteraction untu Digoxin
un: Griseofuvin |nM drug
interaction nulMvlL
nnntWulLwtu Digoxin
un: Griseofuvin |nM drug
interaction nu
12 Doxazosin 7 ADR/ Side
Effects
Doxazosin nLnlv
|nMnuwuuttWulMn
|t|tuM
nnntWu wt'u Doxazosin L
lnnlv|nMnuwuuttWulM
1% un:|nM pruritis lM 1 %
13 dT vaccine 4 Pregnancy/
Nursing
uwun10M dT vaccine
0.5 ml M luvu1M1WD
,8 |Mu lLt
nLn0MlMvlL
dT vaccine t:ntMu purified
tetanus toxiod 5-10 Lf un: purified
diphtheria toxoid 1-2 Lf/0.5 ml Mu
lu Pregnancy category C uM
nLn0Mluvu1M1WDlM t1:
tut1nulWtM:unlunun
|nMlMM ttuWtulW
tM:unwtLn|tu|MnlMv
WtulL|WulMtWtuLnuv
lMtlLWt |tDLWLnunn
0MWtulv|MnlMvWlvuM
n:Mtt1nulWlM 1L
uuWM:u dT Lltuu TT lu
nt1nulWtM:unlu|MnlM
t:tn1lt un:vu1M1WD
14 Enoxaparin 3 Pharmacokineti
cs
unt Enoxaparin
Luuulu1nuuu
|l
Elimination half life u1u
Enoxaparin |Llvutt single dose
:u 4.5 tlL1 uMnlvutt
repeated dose :ut:Ln 7
tlL1
15 Erythopoietin 11 Compatibility/
Stability
unt
Erythopoietin nlLlM|nt
luM|uu:|ntlMuunu
nnntWuuLnwt Recormon
nLn|ntlunM|uulMuu 3 u
nu Hemax un: Eprex lLwt
uLnWLW1Mu1u|LlLlM|nt
luM|uu t1nD:tnM|ntluM|uu
Recormon :|ntlMuu 24 |Mu
nu Hemax un: Eprex :|ntlM
uu18 |Mu
1 Fluticasone
propionate
2 Availability u Fluticasone
propionate lu
l1wutnn1un Lt
nWu1l
u Fluticasone propionate lu
l1wutnn1un |tuuWnL
:v1 Fluticasone propionate un:
Salmeterol LtnW W Seretide
17 Furosemide,
Torsemide
10 Therapeutic
Use/ Efficacy/
ndication
unt furosemide
nt Torsemide LWL
uMnM1nuu1l
Furosemide un: Torsemide Mu
lunnLu Loop Diuretics t1Lu
uMnM1nu W Torsemide L
duration unun:LWLu1n1
n un:lv|nM hypokalemia uu
n Furosemide
18 Heparin 11 Compatibility/
Stability
unt Heparin L
uvn1WnLnu
Heparin nLnWnLlMnt D5W
un: NSS lMuvn1WnL:LWLW1M
1 unvDLv1 un:w.n1un
nvuMlvLuvn1n|tMlt 14 u
(muitiple dose)
19 Heparin 9 Dosage/
Administration
uwun1 Heparin drip
900 unit /hr M1nt
u|MuLunvtWtu
uu
u Heparin lul1wutnn1unL
uuM 5,000 unit/ml uwun1 900
unit/hr |w:0:uu:M1lt Heparin
(900/5,000)= 0.18 ml /hr , ratelu
nlvu Heparin uuM 900 unit W
18 ml/hr |w:0:uulu 18 ml :L
Hepain u 0.18 ml un:L NSS v
D5W u 17.82 ml t1nlt
nn:nu NSS v D5W tLM
100 ml n:M1lt Heparin ( 0.18*
100)/17.82 = 1 ml
20 sosorbide
mononitrate
9 Dosage/
Administration
unt Monolin
lLM1lvnu |n
09.00un: 15.00 u.
Monolin v sosorbide mononitrate
MulunnL Nitrate Lnuuuu
vnM|nMvl unnLuLtuvlu
|1 tolerance (uMu) L
uuu:ulunt1nun|nM
tolerance lMun lvuluuuMM,
nMWLnluntvu, |nnlt
short-acting nitrate, lvLt1vuMlt
u (Nitrate free-interval) , WnL
untvu|vL:nLluuMn:
dosage form nvtu Monolin 20
mg Luuu:uWlvun: 2 W1
v1nu 7 tlL1 lMuuL 2 v1
nLunluunMltlLMn 17
tlL1 |tu 08.00,14.00 u. v
09.00,15.00 u. nLnt1nu
tolerance un:L efficacy M
21 traconazole,
Omeprazole
5 nteraction untu
traconazole un:
Omeprazole |nM Drug
interaction nuvlL
un:Lununluu1l
u traconazole un:Omeprazole
|nM interaction nulMuL onset utt
rapid; severity utt modurate ;
documentation utt suspected lMu
Omeprazole LWnnMnvn1nMlu
n:|w:v 1LWnnMnuMn
Mu1 traconazole lvnMnMM
tLun:nMnuu1 traconazole 1
uu:ulvtt:uuv1nuu1
uu 2 tlL1
22 Kamilosan 2 Availability w.n1unL Kamilosan
wuWvlL |tuu ED
v NED
v1uLu Kamilosan M spray lt
wulut1tn |tuu NED
23 Ketoconazole
, Norfloxacin
4 Pregnancy/
Nursing
u Ketoconazole un:
Norfloxacin nLnut
n1uuLlMvlL
u Ketoconazole nLnutn
1uuLlM 1lLuu:ulvltlu
vu1lvuLtM nu Norfloxacin lL
LuLnunnutn1uuL
vlL 1lv:1nltuluvu1lv
uLtM
24 Levofloxacin 7 ADR/ Side
Effects
WtulMtu
Levofloxacin (500) un:
Lnvt|vuu L
||uu uuuvun
untn
M1nn|tunuwu
vlL
Levofloxacin |tuunnL
Fluoroquinolone t1wt ADR uu
LnW < 1% lMun anaphylactoid
reaction , acute renal failure,
arthalgia,bradycardia |tuMu t1
nWtu|tuuuM1t:|Lu
nLwuuntnWtulMtuvlL
un:vnWtulLnLnuM
nM1nnlM uu:ulvWtu
tnLuwu|wtt|tnuunlt
uun:|W:1nltuMlt
25 Levofloxacin 11 Compatibility/
Stability
unt
Levofloxacin vn1n|tM
lt nLn|ntlltlM
uu|l
Levofloxacin lututtu0M
vn1nWnLWL|uLuu 5 mg/ml
nLn|ntllMuu 72 tlL1
nvDLv1 un:n|ntluM|uu :
nLn|ntllMuu 14 u un:n
|ntlut1utuu1:nLn|ntllM
uu |Mu uM|LuLltun
vLunntltutuu1n un:vLu
ulMutnnlvu |w:lv
u|nLnDwlM
2 Levothyroxine 3 Pharmacokineti
cs
u Levothyroxine
nLnWu1uuLlM
vlL
u Levothyroxine nLnutn
1uuLlM M1uu1WltMuWL
:LM:1luvu1lvuLtM
27 Loratadine,
salbutamol
4 Pregnancy/
Nursing
WtuM1WD 2 |Mu
tt:uu
Clarityne,Ventolin lu1st
trimeter :|nMuMu
ntnluWDlMvlL
Loratadine Mulu Pregnancy
category B lLwt teratogenic lu
nMuMu1lLLuLnluWu n cohort
study lLwtnWnLluWuu1l
nMLnuLntLuWWnM
u1ulLwt teratogenic lunM
nu salbutamol Mulu Precnancy
categry C Lu1un|nM Adverse
event lu maternal & fetal t1uLlt
systemic salbutamol wt|nM
tachycardia, pulmonary edema un:
death u1lLLuLnuu:ulvlt
systemic beta-agonist Mu uML
uLnnlt nhaled-salbutamol lu
maternal & fetal lLLn
|tnuuutn1u1:ttlvn|uu|nM
u1LuunWuuMLuuluLn|nM
Hyperglycemia luuL w nt|nM
Hypoglycemia lunluWD
nvtuL|tu|tvuun:lt
salbutamol lun dosage form
unnuwtn|nM arrhymias un:
atrial flutter lu fetus lMnuLlt
high dose inhale salbutamol L
28 Meropenam,
Tienam
11 Compatibility/
Stability
u Meropenam un:
Tienam LWLW1M
vn1WnLu1l
u Meropenam LWLW1Mvn1
reconstitute (500mg/10ml) Mu
0.9% NSS 24 tlL1 un:|L Dilute
lvnn:nuLWL|uLuu 1-20
mg/ml :LWLW1M 48 tlL1 |L
|ntluM|uuun:W1M 8 tlL1|L
|ntnvDLv1 uMnlt
nn:nuu|tuMn:nu W
5%Glucose v D5S u:LWL
W1M 14 tlL1 |L|ntluM|uu un:
2 tlL1nvDLv1 nu
Tienam nLnWnLlM1nt NSS
un: Dextrose lMuu:LWLW1M
24 tlL1 |L|ntluM|uu un: 4
tlL1nvDLv1
29 Morphine
inj.,
Pethidine inj.
11 Compatibility/
Stability
Morphine inj., Pethidine
inj. |vnn|tMltL
uu1nM|uun
u1l lvnLn
ultltMlMun:uM|n
nvLMuu1u
nnntWuwtLnWnL
stability u1 morphine inj. wtL
Mut|nuu1lMun tuMu1
syringelt|ntu,WL|uLuuu1u
,nn:nult|1,nvDL|nt
nLu un:un1 wt|ntlMuu
14 u,30 u v ntMvt1t1
nuuMwMn1lu|1tLnMu
|Lult:u1lvnulunnLuM
LlMwMn1|1 Sterility t1L
WLnWuLnluu0M t1u0M
lMultvn1nWnLnLn|ntl
lMuu 24 tlL1 uL|1nt
SW,D5W v NSS lMnn:nuln
lLLnvn|vn1u |ntluM|uu
v 22 1W|tn|tun un:|ntlu
LM vnnn:nu|tnuu|tun|vn1
|uLn1uMnunM1u|nLnDw
unlLWltM uMnnntnL
ltu1tLWWnMlLuu:ulvuu
morphine un: pethidine inj. |tM
ltunLltM |u1nu1lLLuLn
|1 Sterility uLu:u1Lnulu
nnLnML
30 Nitrofuradone 7 ADR/ Side
Effects
lul1wutnn1un|Wu
wt case uwu
nitrofuradone vlL
u Nitrofuradone v Nitrofurazone
v Furacin |tu anti- infective lt
nLuWn burn skin grafting Lulu
tutt cream , ointment, topical
solution t1l1wutnn1un|WuL
uMulututunul1wutn
uMlMMMnntutltun
t:Ln 8 t 1lLnLnntWu
uLnlM uMnnntWuuLnn
uvn1u wt uuLu1un|nM
ADR t:Ln 1% W lv|nM
contact dermatitis ,rash , pruritis
un: local edema
31 Octreotide 9 Dosage/
Administration
u Octreotide WLu1
0.1 mg/ml uwun1lt 25
mcg :M1ltutLM
|l
Octreotide 0.0001 g = 1ml , uwu
n1ltu 0.000025 mg , |w:uu
:M1ltu 0.25 ml
32 Pantoprazole 11 Compatibility/
Stability
Pantoprazole (Controloc
) inj. nLnWnLnt
nn:nulMlMt1un:
nLnlvulMuu direct
iv lMvlL
Pantoprazole inj. ( 40 mg/ml )
nLnWnLlMntnn:nu NSS,
D5W, LR ( final conc 4 mg/ml)
un:nLnlvulMlMuu direct iv
vlvutt iv infusionlMuL
M|lunlvu 8 mg/hr un:
nLnlvulMuunM 72 tlL1
33 Penicillin 9 Dosage/
Administration
Wtu|Mnu 4 t uvun
1 kg uwun1uu
Penicillin V 250 mg uuM
1*4 ac untL
WL|vL:nLvlL
uuMu Penicillin W 25-50
mg/kg/day ut1lvn -8 tlL1 (
maximum dose 3 g/day) t1WtuL
uvunM 1 kg uuMulvlMW
400-800 mg/day uMuuMu
uwun1 W 1,000 mg/day t1uuM
ulMtn1|nult 1WttnM
uuMn1lv|vL:nL
34 Polyvalent
Human
mmunoglobu
lin
7 ADR/ Side
Effects
unt Polyvalent
Human mmunoglobulin
Lu1un|nM ADR
vlL
nnntWun Spontaneous
report of Adverse Drug Reaction
2004 wt Polyvalent Human
mmunoglobulin lv|nMn
coughing , dyspnoea, pruritis, rash
lMuwt|wu1 1 case |uu
35 Premarin 10 Therapeutic
use/
Efficacy/ndicati
on
w.n1unltuMlM
WLu1|luu
Premarin 0.25 mg
nLnltuulMn
ndication vlL
w.n1unlt Progynova WLu1 1
mg uu Premarin 0.25 mg
|u1n Premarin 0.25 lv
estradiol 40 pg/ml nu Progynova 1
mg lv estradiol 50 pg/ml uM
Progynova 2 mg lv estradiol 0
pg/ml t1L estradiol Ln|nult 1lt
Progynova 1 mg lnn|Wu1 Premarin
0.25 mg LnnM nvt
Premarin un: Progynova :LMu
ulLu|nlM|u |vLunu lMu
Progynova :|tu estradiol valerate
lMnwtWn|vn1 nu
premarin W conjugated equine
estrogen lMnnM t1ut1lt
|vLunulunnLnnLnnM
uvLMt:|Mu,ltnLn
uMulLu|nlM|u
3 Propylthioura
cil
4 Pregnancy/
Nursing
PTU Mulu Cat.lM
uMuvlL
Propylthiouracil (PTU) |tuult
nL Hyperthyroidism Mulu
Pregnancy category D (Lu1un
|nM teratogenic luWu)
37
Propythour
ac
4 pregnancy/nu
rsng
WtulvuLtM nLn
lvu propythourac
lMvlL
propythourac nLnutn
lM1uuL t1M1:LM:1nlt
luvu1lvuLtM u1lnMLlL
uu:ulvltuM1nn:v1lvuL
tM
38 Silver nitrate 2 Availability Silver nitrate v1u
WnM|1vut1tu1
|Mu
50%Silver nitrate cream 1uWnM
ult nnL1u|DntnL |tu
WWnMun:ut1tltDulu
l1wutnn1un
39 Spiramycin 4 Pregnancy/
Nursing
Rovamycin nLnltlM
luvu1M1WDvlL
Rovamycin v Spiramycin |tu
macrolide antibiotics Mulu
Pregnancy category C uMu1ln
MLLuLnn French
investigation in 1974 wtlLL
u1un|nM Adverse event lu
fetus un:LnMMMLnlt
Spiramycin luultLuun 15 t
lLwtn|nMuMuuu1
(harm) lu fetus
40 sulfonylurea 9 Dosage/
Administration
unnL sulfonylurea
:M1tt:unu
vnu
unnL sulfonylurea lul1wutn
n1unL 4 M W glipizide ,
glibenclamide , glimiperide ,
gliclazide t1u glipizide un:
glibenclamide |Ltt:uwL
v: delayed nMMtLu
M1uu1Wtt:uunuv
|tu|n 30 u nu glimiperide
un: gliclazide lLLWnlun delayed
nMMtLu M1uu1tt:uu
wLvlM
41 TAT 20 Others TAT Lu skin test
u1l
n TAT skin test lvlt tetanus
antitoxi |1 1:10 0M|ulM
Wvu1 0.2 ml vnlL|nMWL
WMtnMDulu 30 u unM1
WtunLnltulM
42 TAT 9 Dosage/
Administration
untuuMu TAT
ltlu|Mn
uuMu1u TAT lu|Mnun:Wlvu:
lvMLuvun W |MnLuvunM
uun 30 kg :lvuuMu 1500
unit nuWtuLuvunMLnn
30 kg :ltuuMu 3000-500 unit
43 tetanus,
luvMlvu ,
vaccine
9 Dosage/
Administration
WtuWlvu 0M Tetanus
toxiod u 28/8/50 uu
Wu 20/8/50 un
t:nLn0M
vaccine luvMlvulM
vlL
vaccine Tetanus |tu vaccine tuM
toxoid t1|tunnnM|wLu1 bac|
teria LlvwLvLMlt uMnLn
n:Mu1nulvn1 antitoxin lM
nu vaccine luvMlvu|tuWtu
tuMMMut1nnM||0w:nu
|nuu1ntnn1DLWLnuLlt
|uu 1LWnu1Wu1uu M1uu
Wtuuu1nLn0M vaccin
luvMlvuluu 30/8/50 lM
44 Triple dye 10 Therapeutic
Use/ Efficacy/
ndication
untnlt triple
dye nt 70% alcohol
|tMn:M|Mnun|nM L
t:nuDwM1nuvlL
Alcohol Lt:nuDwlun control
umbilical colonization un:nMM
|tWvu1lMMnnlt
antimicrobial u |tu triple dye
v chlorhexidine un: triple dye L
t:nuDwlunnM umbilical
colonization n|t staphylococcal
un: streptococcal organisms lu
l1wutnlMMn alchohol ,
hexachlorphene , bacitracin
ointment un: povidone iodine
45 Vancomycin 9 Dosage/
Administration
uwun1u Vancomycin
lvWtuMM|t MRSA
un: Acetinobacter uuM
u 500 mg n tlL1
untLWL
|vL:nLvlL un:n:
|tnuuu|tuutt switch
therapy :|tnuultltu
MlM1:|vL:nL
uuMu Vancomycin lunnL
WtuMM|t MRSA , MRSE ,
PRSP. uuMu|vL:nL W 1G
n 12 tlL1 lMult:u:|nlun
nL 7-14 u un:nlvu:M1M
W CrCl u1Wtu|wttuuMu
lvLWL|vL:nL lMunLW CrCl
> 50-90 ml/min uuMu|vL:nL
W 1 G n 12 tlL1 , nLW CrCl
=10 - 50 ml/min uuMu|vL:nL
W 1 G n 24-9 tlL1 un:nL
W CrCl < 10 ml/min uuMu
|vL:nL W 1 G n 4 -7 u nu
n|tnuuu switch therapy lvlt
u Sodium fusidate uuM 250-
4 Vitamin K inj. 9 Dosage/
Administration
Vitamin K inj. uuM 10
mg V OD lvuttlvu
Mn:v1 V push nt
drip un: rate |l (
l1wutn:u:LuuM 1
mg/0.5 ml M1lt 10
amp(5ml)
lv slow V infusion rate not exceed
1 mg/min dilute D5W or NSS or D5S
47 yasamin 7 ADR/ Side
Effects
Wtunuu yasmin un
LntMWL:Ln
unt:nLn
|tnuultltuMlMlMt1
Wtunuu yasmin t1|tuu
WLn|uM t:ntMu Drospirenone
3 mg + Ethinyl estradiol 30 mcg
utt 21 |LM t1ntMWL:|tu
nu1|Wu1nulLu|nlM|u
t1nu|nMnnltuL
estrogen n1 nuLn:|nMlut1 2-3
|MuununWuvult uMnlL
nLnuMnM1nnlM lv
|tnuutuMu1u|LMWLn|uM|tu
tuML|nlM|utLnMn|ML
|tu n 30 mcg |tu 20 mcg |tu
Mercilon |tuMu
48 wuu Ascaris 10 Therapeutic
use/
Efficacy/ndicati
on
wtwuu Ascaris lu
:WtulLt
lvnLMuu:l
nMM|twuu Ascaris vwuu
ln|Mu (Ascaris lumbricoides)
lMultLnu0ulMunMwt
luwuulu:|tunWu u
MutnMLt:nuDwun:uuLlt
lunnLlMun 1) Parental
Pamoate dose 10 mg/kg uMlL|nu 1
gm single dose uulLLltlu
l1wutnn1un 2)Mebendazole
dose 100 mg bid |tu|n 3 u
3)Albendazole dose 400 mg single
dose |MnuLnn 2 tun:Wlvu
ltuluuuM|Munu
11
Drug nformation
Handbook.13th
edition.200-
2007.45-47
1.Drug
nformation
Handbook.13th
edition.200-2007
.555-7 2.Drug
fact and
comparison,200.
0th
edition.714-5
3.WL
uLWL|nu1
n1.nnL1u|Dnt
nL
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
Wtuun:lWMM
|tt1nulM
MuWtu.2548.
38
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
1.uu1n
tvu0M|w
nMWL|nu1 w.
n1un
2.Drug
nformation
Handbook.13th
edition.200-
2007
3.MMs.200.85
1. Drug
nformation
Handbook.13th
edition.200-
2007. 310 2.
Drug in
pregnancy and
lactation.3rd
edition. 222-223
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
Drug nformation
Handbook
Drug nteraction
Facts
Drug nformation
Handbook
1.Drug
nformation
Handbook.11th
edition.2002-2003
.428 2. WL
Wtu.2548,31
3.Wtuun:
lWMM|t
t1nulMMu
Wtu.2548.554
Drug nformation
Handbook
1. Drug
monograph u
lvL
l1wutn
n1un 2.
|nnnntu
MM
Website : www.
1.uu1n
tvu0M|w
nMWL|nu1 w.
n1un

2.Drug
nformation
Handbook.13th
edition.200-
2007
3.Handbook on
injectable drug
.11th edition.
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
1.
Cardiovascular
Pharmacotherape
utics,2nd edition

2.http://www.rx
list.com 3.unt
lWvlun:
vnM|nM
Drug nteraction
Facts
1.WLWu
w.n1un 0tt
ttt1 1 nw. 50
Drug nformation
Handbook
Drug nformation
Handbook
Drug nformation
Handbook
Drug nformation
Handbook
1. Drug
nformation
Handbook.13th
edition.200-
2007. 2.
Drug therapy in
pregnancy.3rd
edition.40,50-52
1.Handbook on
injectable drug .
11th edition.835

2.WLnltu
nvttWnn
nunnu.2549
3.|nnnntu
1. Handbook on
injectable drug
.11th edition.919-
921
2.http://www.rx
list.com
Drug Facts and
Comparison
u
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
Drug nformation
Handbook
Spontaneous
report of adverse
drug reaction
1.Kirtly
P.jones,Estrogen
s and
Progestine:What
to use and how
to use,Clinical
obstertrics and
gynecology,1992
Dec,vol
35,No4,871-883
2.MMs,10th
edition, 2007,203-
204
1. Drug
nformation
Handbook.13th
edition.200-
2007. 1340 2.
Drug in
pregnancy and
lactation.th
edition.
2002.1180
rug
Informaton
Handbook ,
2005, p04
2HFS ,
rug
Informaton,
2004,p096
1.WLWu
w.n1un 0tt
ttt1 1 nw.
50 2.
lWw 1502
Drug in
pregnancy and
lactation.th
edition.
2002.128-9
Drug Facts and
Comparison
WLunvt
wutn 1uDS
uuLn
WnL-WMt
Muu DS
website : www.
Website : www.
Website : www.
Drug nformation
Handbook.13th
edition.200-
2007.124-125

MlWMM|t

h?
950
U1r|Dn?n?u ?n?u ?nu ?44
1 Aprsoline inj 11 Compatibility/
Stability
Aprsoline inj WnLnt
nutuMlMlMt1
un:nLn|ntllM
uu|lM
Aprsoline inj (Hydralazine inj)
nLnWnLlMnt D5W , NSS un:
|ntnvDLv1lMuu 8-12 hr
un:LuLnvndraw lnlu plastic
syringe un|ntnvDLv1luLM
:|ntllMuu 24 hr lMulLnu|nu
MunWu
Hanbook on
njectable
Drug
2 ASA 300 mg
enteric
coated
tablet,ASA
80mg
10 Therapeutic
Use/ Efficacy/
ndication
lvWtu|WuASA 300
mg enteric coated
tablet 1|LM ntASA
80mg 4 |LM |wtreat
Acute Attack L
wutntnlv
ASA 80mgMn
(uLnnnt:tL
lMuuwu|0w:1
:ttvlun:vnM
|nM )
ASA tutt enteric coated tablet |w
t1nunirritate G tract M1uMt1tn
vnMv n:|w:v lMu|tnuu
nDwPHu1|LMulLlvuMnMun:n:nu
n:|w:vuMlvn:nunln|nn
uu lMuuLnntLuw.n1unlt
uun:uW LW disintegration time 1-2hr
M1uunM1ltlu case accute attack
uwu:n1lv|Wu|wnM:u:|nn
uMnM |w:|LuMMtL|u|nu|nMun
:nnu|Ln ~5-10u un:peak
plasma concentration 15min-2hr
unnu ASALn|MuL|tu film coated
tablet |wt1nun|nMtnu
hydrolysis t1:lvMu|nLnnu L
nnu0uWnuunLnut n|Wuu|LM
|Wnt1Ln|Wuun uu1|w:nuttL
|wt1nun|Wu lLlv|nunDwML
Mnt:n1Wu1n|Wntuu uMnvt
Wtuacute attack|tuM1lvunnu
|u 1M1|Wu|wnM:u:|nn
uMnM/n:nu t1n|tuu|LMlLlM
|WntWtu|WulMMn |u1n Wtu
nulvuLnuLn t1l1wutnn1un
L ASA 2 dosage form W 300mg enteric
coated tablet,80mg chewable tablet
M1uuW|nnlv 80mg chewable tablet 4
|LM Mn
Drug
nformation
Handbook
3 AZT 05 nteraction untuMu
ln AZT nLnlt
Lntu Stavudine
lMvlL
uMulnlLnLnlvLnulM
Lu 3W W 1.AZT+d4T , 2.dd+ddC
, 3.d4T+ddC M1uu1lLnLnlv
AZT Lnt d4T lM
website :
www.
4 Bricanyl,Dilan
tin,Dormicum
11 Compatibility/
Stability
1.Bricanyl M1|ntlu
M|uuvlL vn1|tM
ltun|ntlMuu
|lv 2.Dilantin
|tMltun|ntlMuu
|lv (luM|uuun:
nvDLv1)
3.Dormicum ltlu
nlMvlL uuM
u|lv dilute nt
n:l
1.bricanyl inj (Terbutaline inj) lLM1
|ntluM|uu vn1|tMltun|ntlM
uu 48 tlL1 251W|tn|tun
2.Dilantin inj (Phenytoin inj) |tMlt
unWnLntnuunlvltu lL
W|ntlltMun:lLWutM|uu
|w::MnM:nu nvtuu1lL
WnLntnuLuLn|wu1lvltlM
Mt|u1lLuuun:lLMnM:nu
3.Dormicum inj (Midazolam inj)
nLnltlunlM uuMuM1u :
< 32 wk : initials : 0.03mg/kg/hr,
0.5mcg/kg/min (vLlv loading
doselvutt iv infusion|uu) , >
32 wk :
initials:0.06mg/kg/hr,1mcg/kg/min(
vLlv loading doselvutt iv
infusion|uu) un:nLuLnn
2|Mu-uun6|Mu:iv loading
dose 0.15 mg/kg MLMu infusion
1mcg/kg/min WnLntnu|unu
lM W NSS,D5W
Hanbook on
njectable
Drug
5 Calcium
gluconate'
10%
02 Availability uwun110%Calcium
gluconate |tuM
|MuntCalcium
gluconate 10 ml
0.45meq
l1wutnLult
vlL
Calcium gluconate l1wutn
n1unLW 10%Calcium gluconate
t1|nt 1gm u1 Calcium
gluconate un:L elemental calcium
0.45meq/1ml
u
6 Cefazolin
and
cloxacillin
10 Therapeutic
Use/ Efficacy/
ndication
cefazolinun:
cloxacillin nnu
|vLunuvlL
nLnltuunulM
vlL vLn10M
cloxacillin uM
wutn0M cefazolin
lvWtu
-Cloxacillin MulunnLpenicillin nnu
|tu bactericidal ATB WtWnL gram
positive |tu s.aureus,streptococcus
pnermoniae n|tu penicillin uvn1:
nnuWnL|tgram negative un:
anaerobe lMMu -Cefazolin Mulu
nnL Cepharosporin nnu|tu
Bactericidal antibiotic WtWnL|t gram
negative lMn1n gram positive
Cefazolin ulu 1st generation WnL|t
staph spp.,streptococcus pnermoniaelM
nu gram negative lMun enterobacter
spp., E.coli, H.influenza, Klebsiella
spp.,Pluteus spp. WtuuuMM|t
n:Mnn|nnltuunt|t|tun|vML
1 gram positive , gram negative,anerobe
vntWn antimicrobial susceptibility
n:lv|nnltulMnnnt|tLnnM
unLnlvlM nnL
Penicillin,Clindamycin,Fluoroquinolone ,
Vancomycin,Bactrim,Metronidazole
WtuuuMM|tn:MnuMlLnLn
:tMuvu1 t1nulvu|nMn S.aureus
nlv cefazolin lL|vL:nL|w:lL
WnL|tu uMn|tu gram negative lv
lM uMnulvuLnlt 3rd generation
cephalosporin u1lnML lv observe
Wulu un: MltlvltMLuwun1
Drug Facts
and
Comparison
Cefazolin,Pe
nicillin , Sulfa
10 Therapeutic
Use/ Efficacy/
ndication
Wtu:WMMLMnn
uMLt:MuwunnL
Sulfa , Penicillin,
Cefazolin lLt:
lt antibiotic MlM
prophylaxis nuWMM
nlv antibiotic prophylaxis nu
operation obstetrics and
gynecology hystectomy |tnu
lvuwtW CNAB, Bacteroidws
spp. unLnltlM lMun
1.Amoxicillin-clavulonic acid 1gm iv
, 2.Gentamicin 2mg/kg
iv+metronidazole 500mg/kg iv ,
3.Cefazolin 2 mg/kg
iv+metronidazole 500mg iv ,
4.Cefatetan 1 gm iv v
Clindamycin 600 mg iv t1Wtu L
t:MuwunnL Sulfa ,
Penicillin,Cefazolin M1uuuWlM
WGentamicin 2mg/kg
iv+metronidazole 500mg/kg iv v
Clindamycin 600 mg iv
u
8 Cefotaxime 0 ADR/ Side
Effects
untWtu
lMtu cefotaxime
Lt:Ln 1 |Mu L
nv un
tnM1nn
|tuWnLnulM
vlL
nnntWuwtCefotaxime
nLnlv|nM ADR lu:tt
Dermatologic: Rash. Pruritis.

Gastrointestinal:Diarrhea,nausea,vo
mitting,colitis un: Local pain at
injection site t:Ln 1-10% nu
ADR uwtlv|nM
headache, agitation, confusion,
fatigue un: nocturnal perspiration
uun 1%t1WtuuuWntWu
t:MnltulMtuuL
MuvlL un:nLwuuntn
|nMuuvlL un:nlt Cefotaxime
prolong lv|nM overgrowth of
nonsusceptible organism |tu
Candida un:Pseudomonas lM
AHFS: Drug
nformation
9 Ceftriaxone 09 Dosage/
Administration
untuuMu
Ceftriaxoneltlu|Mn
uuMu Ceftriaxone lu|MnW -
Mild to moderate:50-5mg/kg/day
ut1lv 1-2W1n
12-24hr(maximum:2g/day) -
Serious infection :80-100mg/kg/day
ut1lv 1-2 dose (maximum 4 g/day)
Drug
nformation
Handbook
10 Cytotec,
Magnesium
sulfate
0 ADR/ Side
Effects
Wtudrip MgSO4
un:|vut Cytotec
unLnvunu
vulntn WL
MuM lLt|nM
nu2MulMvlL
- MgSO4lv|nM hypotension
vl|MuWM1v:lM vnlv rate |
|nult lMumaximum rate infusion
2g/hr uMlv 4g/hr lMlunn
eclamsia ,tn n serum Mg >
2.5meq/l Wtu1lvuwut
unnuwt ADR nLwuunt
uuMu |tu 1|nu, nnL|uu
u1 ,nM CNS -Cytotec
suppository v misoprostal L
u1un|nMlu vunu n:vu
u tM|MuL tM|LunnL|u
tM1 tMvn1 t1luu1u
Spontaneous ADR t 2004 2006L
u1un|nM chill 1 0tt rigor 1
0tt nvtWtuuulLt
nlv rate iv MgSO4 un: base line
u1:MtMgu1Wtu t1LWnM
ADR nMgSO4lu|1WLMu
lnvMMun:vulntn nun
nuu:|nMn cytotec
AHFS: Drug
nformation
11 Desensitizati
on
20 Others vn1n antiserum
skin test lvWn
positive M1n
desensitization :L
unu1l
n desensitization luWtu
skin test antiserumWn positive
:lLLt:lutu:l|nu
|u1nnMnt1Wvu1|w
uuWtu:uw|tLvlLuu
lLLWLnLwuuntn|nMtnu
|nMuu1Duvn1lv|tL |u1n
|tutnuanaphylaxis nn
n:Mu complement lLlt|nMngE
M1uuuLWnskin test positive nW
lvM uMM1|MuLuunuw|tLun
wL1l lMult adrenaline 1:1,000
uuM 0.5mlnvtWlvu v
0.01ml/kgnvt|Mn 0MlMWvu1
v |unnL|u|L|nMtnuuw
|tL unnulv antihistamine
LMuvlv antiserum 10%
website :
www.
12 Diphenhydra
mine
10 Therapeutic
Use/ Efficacy/
ndication
untuMlM
nLnltuu
Diphenhydramine lu
nnWtuLn
Extrapyramidal
Symtom
unLnltlunnLn
Parkinsonism and drug-induced
extrapyramidal reaction lMun
Diphenhydramine HCL un:
Benztropine mestylate t1uuMu
Benztropine :lvuuM 1-4 mg
one-two times a day lMu total dose
lL|nu 6mg/day lMulvuutt ivv
im , |MnuM1uM 3t lvttuuM
uMLWL|vL:nL nuuuMu
tt:u:lvuuM 1-4 mg once
or twice a day un:vn1nlvu
dose un nWtuu1Lnu
lvuuuM 1-2 mg two or three
times a day. |MnuM1uM 3t lv
ttuuMuMLWL|vL:nL
uuLn
WnL-
WMtMu
u DS
13 Dopamine
un: Oxytocin
11 Compatibility/
Stability
unt
Dopamine un:
Oxytocin nLn drip
lvWtu1|nu
|MunulMvlL
nnntWuuLnlLwtuLnn
|unulLlMu1uDopamine un:
Oxytocin M1uulunnuLtuvlu
nv|nu|wdripulvntWtu 1
nLn drip ulMu|nu|MunulM t1
nvu|unt Dopamine lLlM
lMun Acyclovir, Amikacin,
Amphotericin B, Ampicillin,
Furosemide, Gentamycin,Heparin,
ron, Metronidazole, Nitroprusside,
PGS, Sodium bicarbonate lMu
Oxytocin L PH u 3-5
WLuu1
ntvu
0M|wnM
WL|nu1
1uDS
14 Epoetin alfa 11 Compatibility/
Stability
untepoetin
alfa vn1nWnLun
:|ntllMuunu
epoetin alfa vn1nWnLuun
nLn|ntluM|uulM 30u un:W
ltlvvLMDuluu
u
15 Esomeprazol
e
09 Dosage/
Administration
M1nlvu
Esomeprazole lMu
nlv1nuu1lv
v nLntMu
lMvlL vLun
lM|wlvnLnlv
ulMu1|vL:nL
uEsomeprazolelLnLnvnut1
tM |Wu vlv|LMuuMnuMM
uM M1uunlvuuunWtu lMu
n feed :M1utuluulvu
nLnn:uMu1nL|nL
vn1nuu1uult feed lvun
Wtu1nuu1lM
u
16 FBC and Fe
fumarate
,FeSO4
10 Therapeutic
Use/ Efficacy/
ndication
FBC and Fe fumarate
uMnM1nuu1l
MnFeSO4 vlL
FBC t:ntltMu Fe fumarate
200mg, B1 2mg ,B2 5 mcg,C20mg,
niacin 10mg, Folic acid 100 mcg ,
Calcium phosphate tribasic 100 mg
Fe fumarate uuM
200mg,FeSO4 uuM 300 mg :|vu
luFBC :L Fe fumarateuMulu
WLu1|nu |wu1uMnWulunu
FBC:lMtMLu un:uuMu1
u |nL|ultMu M1unM1u1Mu
uMMunWunWFe fumarate nu
Fe fumarateun: FeSO4 |L
tt:u|ultun:lMMu
nnu|vLunuW element iron
uMM1nututt|nnL form nt
ferrous n|vMM1formnt|nn|w
|wLWnn:nu un:n form |nn
uMnM1nuWnn:nunuMnM1
M1u ron salt % ron Fe
fumarate ~ 33 Fe gluconate ~
12 FeSO4 ~20 *|nn
fumarate Wnn:nuMnM MMtL
MnM lM elemental ron LnnM
nuADR W Wnuln |uu
Drug Facts
and
Comparison
1 Furosemide
un:
Nitroglycerine
11 Compatibility/
Stability
furosemide nLn
lvnu|Munt
Nitroglycerine lM
vlL
nnntWulLwtuLnn|unu
lLlMu1ufurosemideun:
NitroglycerineM1uu1nLnlvu
1nu|MunulM
WLuu1
ntvu
0M|wnM
WL|nu1
1uDS
18 Gentamicin,
Clocxacillin
04 Pregnancy/
Nursing
lv Gentamicin,
Clocxacillin luvu1
lvuLtM tM
nLnnuuLuLlM
vlL uMuvlL
Gentamicin, Clocxacillin nLnut
WuuuLlu:Mt|nnuu nLn
lvulunMlvuLtMlM
u
19 Glibenclamid
e,Glicazide,M
etformin,Gem
fibrozil
20 Others Glibenclamide,Glicazi
de,Metformin,
Gemfibrozil L side
effect lvv
vlL Mnn
u1u|1
spontaneous ADR
Glibenclamide Lu1uv :Mt
:ltuu 1u1u(t
2001)Gemfibrozil Lu1u hearing
loss :Mtu:ltuu 1 u1u
(t 2005) nuGlicazide,Metformin lL
Lu1u
Spontaneous
report of
adverse drug
reaction
20 Hydrocortison
e inj
11 Compatibility/
Stability
Hydrocortisone inj
WnLluNSSlMvlL
Hydrocortisone inj nLnWnLlM
ntD5/N/2, D5S ,NSS,D5W, LRS
WLuu1
ntvu
0M|wnM
WL|nu1
1uDS
21 nfluenza
vaccine
08 Toxicity/
Poisoning
WtuM1WD 2 |Mu
(1st trimester)0M
WtuluvMlvu
(nfluenza vaccine):
LuMuMnlu
WDvlL
Wtut1nulWluvMlvuL 2nnL
W Wtu|t|tu un:Wtu|tMu L
ut1tnLn0Mluvu1M1WDlu
lMLn 2-3lM uMWtuuunn1
M1WDlulMLnun t1lut:|W
lu LWtu|tMu|uu 1lLu:
|nMuMuMnluWD
WL vaccine
22 nfluenza
vaccine
10 Therapeutic
Use/ Efficacy/
ndication
|Mnu 6utnLn
0MWtut1nulW
luvMlvulMvlL
nLn0MWtut1nulWluvM
lvulM lMu0MutttuMMMu
u
23 nfluenza
vaccine
09 Dosage/
Administration
untdose u1
WtuluvMlvu
0MlvntWtu
lun0MWtuluvMlvu lu|Mn
uLnn 6|Mu-35|Mu W0M
v1nu1|Mu uu 2W1 nvt
n0MW1un lMuuuMlvW
0.25ml nvt|Mnu 3-8t lv0M
uuW1|nt|Mnu 6-35|Mu
uMltuuMu 0.5ml nuWtuL
uLnn9tuultlv0M 0.5ml
uu1W1 vn1nuuM1Ln0M
tnt tn: 1|uLlMulv0M|u1
nnL|u
WL vaccine
24 VG 11 Compatibility/
Stability
VG vn1n|tMlt
W1un :nLn
|ntllMuu|lv
VG |tMltunWltlvvLM
DuluW1|Mu
u
25 JE Vaccine 14 Contraindication
/ Precaution
JE Vaccine ltluWu
1lMlvL
JE VaccinevLltluWuM1WD u
26 ketamine 11 Compatibility/
Stability
unt
ketamine Lu
vn1n|tMltuu
|lM
nnntWulLwtuLnuu1u
ketamine vn1n|tMlt uMnn
nvuMulutulun|ntnLu
u1l1wutnn1un nvuMlvu
Lnltutt multiple dose Lu
vn1n|tMlt 14 u
u
2 ketotifen 09 Dosage/
Administration
ketotifenlv dose
|lvlu|Mnu 1t
ketotifen syr |Mnu 3 |Mu-2t
uuMu 0.5mg (0.5tab or 2.5ml)u
n:2W1
website :
www.
28 Methimazole,
PTU,Adenosi
ne,Apresoline
inj
1.Methimazole,PTU
nLnltluvu1
M1WDun:lvuLtM
lMvlL

2Adenosine,Apresolin.
M1nuun1vlL
1.Methimazole,PTU|tu antithyroid
agent Mulu pregnancy category D
unLnuwWunun:uuLlM
1vLltluvu1M1WDun:vu1lv
uLtM |u1nLu1ulv|nM
hypothyroid un:nwnlM uM
u1lnMLn|tuM1lt vu1
M1WDW|nnlt PTU |w:uw
WunlMuunMethimazole nu
vu1lvuLtMWlv Methimazole
t1LuLnnWWnMun:AAP state t1
Wunu|tnlMun:WltMu
WL:LM:1lM 2.
Adenosine,Apresolin inj |ntlu
control room temperature lMulL
M1nuun1
Drug
nformation
Handbook
29 Morphine,me
peridine
03 Pharmacokineti
cs
morphine inj. un:
meperidine inj. vn1
0Mun:|Lnnu
un::vLMnu|LlM
-PethedinevMeperidine L onset of
action: im 10-15 mins peak effect
t:Ln 1hr, duration 2-4hr -
morphine L L onset of action: iv 5-10
mins extend release epidual
injection:Lnn 48 hrs t1/2 2-4hrs
Drug
nformation
Handbook
30 Omeprazole 09 Dosage/
Administration
Omeprazole lvlu
|MnWltuuMu:
|lv
Omeprazole lL|vL:nL:ltlu|Mn
uMvn|tuM1ltuu:ulvltlu
uuM 0.6*0.mg/kg/day luMu|t
un: nLnlvtlM lMu dose 2
v1n dose un 12 hr uMlu
1uuLuuMu effective W
0.-3.5mg/kg/day
u
31 Omeprazole 14 Contraindication
/ Precaution
Omeprazole nLn
ltluvu1M1WD
un:vu1lvuLtMlM
vlL
Omeprazole nLnWu1uuLlM
1lLuu:ulvltluvu1lvuLtM
un:OmeprazolenLnuwWun
un:|WuLu1ulv|nM
teratogenicity lM |LltluuuM
therapeutic dose , OmeprazoleMu
lu category C 1Wltuu|Luul
t:lutulMWLWntWL|nu1
uMuMnluWD|uu
Drug
nformation
Handbook
32 Omeprazole
inj
09 Dosage/
Administration
omeprazole inj0Mu
n:3W1lMvlL
omeprazole inj nLn|wLuuMlM
120mg 3time/day lMlu indication
Pathological hypersecretory condition
Drug
nformation
Handbook
33 Pantoprazole
inj
11 Compatibility/
Stability
unt
Pantoprazole inj vn1
WnL:nLn|ntl
lMuu|lv
nnntWuwt |LWnLun
nLn|ntllMlL|nu 2 tlL1 un:
|L dilute|tu solution nLn|ntl
lMlL|nu 22 tlL1(vnnuWnLL
stabilizer|tu EDTA) uMn|tu
normal solution :nLn|ntllM
uu 12 tlL1
WLuu1
ntvu
0M|wnM
WL|nu1
1uDS
34 Paracetamol
inj
09 Dosage/
Administration
Paracetamol inj
nLn0M iv lMvlL
Paracetamol inj n:nuluulMuu
luMt1lt propylene
glycol,polyethylene glycol |tuM
n:nutu t1LunMlu|1WL
|uLuunvt0M iv nLn|nult
lv|nMuMuM|LM|nMuM1
vM1nulM u1lnMLlu
un:uLu Praparacetamol t1|tu
prodrug u1 Paracetamol lu
tuttn:nuulMLnuu t1
|MuLlMulLlt cosolvent vltuu
1lv0M1iv lM uMu1lnML
u1lLLuM1nnnvuu M1uu
1lLW0Mu Paracetamol 1 iv
WlvlMu0M1 im |wWL
tnMDuu1Wtu
AHFS: Drug
nformation
35 Penicillin G
sodium
09 Dosage/
Administration
:lv PGS luWtu
LuWlvu Wlvlu
uuM|lv
PGS:Adult 2-24million unit/day ut1
lvn 4 hr n severe infection |L
lvuuM 400,000unit/kg/day ut1lv
n 4 hr max dose 24million unit/day
Drug
nformation
Handbook
36 Pethidine 09 Dosage/
Administration
Wtu serum
creatinine 5mg/dl 0M
PethidinelMvlL
Pethidine injlvluWtu renal
dysfunction lvwnnM dose n1
M1u Clcr10-50 ml/min lv dose 5%
of normal dose uun 10 ml/min
lv dose 50% of normal dose Wtu
uuM1u Scr LWun CrCl=
0.85[(140-age)*Bw(kg)] / 2*Scr t1
dose tnMu1 Pethidine inj=50-5
mg im,sc
Drug
nformation
Handbook
3 Phenylephrin
e eye drop
11 Compatibility/
Stability
unt
phenylephrine eye
drop vn1nu
nL|1:
nLn|nt
nn:nu|1
unlMuu|lM
nnvuMuu1u|tu sterile
product :M1uMvnnlun|MuL
utt sterile techniqe t1nlL
nLn|MuLulunD:M1nnlM
:M1nvuMlvLWLtnMDuLn
nM lMultW:|MuLutt
freshly prepare lMultuvn1n
|MuL un:u|vnuulv1lt
Drug
nformation
Handbook
38 Pletaal 0 ADR/ Side
Effects
Pletaal ltnLlWlM
LWnlv blood
pressure MlMlvL
Pletaal tnLu1uW Cilostazol
nnuutu1n1uu1 enz.
phosphodiesterase t1lvLWn
utu1nuu1Mu1|nM|nM unt:
lv|nMvasodilation lv blood
pressure nMMn1lM
Drug
nformation
Handbook
39 Progesterone
inj
05 nteraction WtulMt
progesterone inj un:
lMtunLnlW
Mu :LWnMdrug
interaction vlL
|WuLu1unnn1Wtuuu
WLn|uM Lnt uttu: |tu
Cefadroxil, Penicillin, Macrolide uM
u1lnMLlLLvnnuuutM1
uWnMt:MtEstrogen
nMn1luWtulMtuttu: uM
lvuttu:|vnultnM
normal gut flora lv|wL
enterohepatic recirculation un:|tu
Wnlv serum level u1unMn1
u1lnMunnL anti TB |tu
Rifampicin vunnL barbiturate
:n:Mu hepatic enzyme production
lv|wL metabolism u1uWL
nuunnL anti fungal |tu
fluconazole:|wL serum level u1
uWLt1nnuWtult uWLtuM0M
1lLLWnMdrug interaction u1
u
website :
www.
40 Ranitidine 04 Pregnancy/
Nursing
Ranitidine 150 mg tab
nLnltluvu1
M1WDlMvlL
Ranitidine Mulu pregnancy cat B
lLLu1un|nM teratogenicity
nLnlvluvu1M1WDlM
Drug
nformation
Handbook
41 Sodium
bicarb inj
20 Others Sodium bicarb inj
M|tu High alert
druglul1wutn
n1unvlL
Sodium bicarb inj lLM|tu High
alert druglul1wutnn1un
u
42 Sodium
hypochlorite
11 Compatibility/
Stability
untSodium
hypochloriteLWLW1
Mvn1n|tMltuu
|lv
nnntWulLwtuLnWLW1M
uutM uMnnntnLltu11u
WnMu|MuLun:utWn|tu1
w.n1un nvuMllvLWLW1M
vn1nnn|tMlt|tu|n 3 |Mu
t1n|MuLlvnn:nu|tuutt
freshly prepare n:MnM
u
43 Sulperazone
inj
09 Dosage/
Administration
unt
Sulperazone inj
nLnWnLnt
0.9%NSSv
5%D5W lMvlL
un:nLn push u
lvntWtulMvlL
uSulperazone inj nLnWnLnt
0.9%NSSv 5%D5W lM un:
untvuuunLnlvulM
lMuu im lMun:nuu 1vial luu
nnulvLWL|uLuuu1uu
250mg/ml vlvlMuun drip
lMun:nuuMu 0.9%NSS v
5%D5W vSWF lvlMtLM
4ml (125+125mg/ml)un|1 M
lvlMtLM 20 ml(25+25mg/ml) lt
|nlunlvu 15-60 u lL
uu:ulv0MulMuu direct iv
(vLu|vM WLu1u1u11W
Sulbactam 500 mg+Cefoperazone
500 mg)
WLuu1
ntvu
0M|wnM
WL|nu1
1uDS
44 Tamiflu 09 Dosage/
Administration
M1ntuuMu
Tamiflultlu|Mn
nltulu|Mnu1lLLuLn1
Wnun|wu1w lMuLnWnL|Dnt
nuWnMu1u wt |Mnu
uu:utuun:nmetabolite
nnu:nMn1 M1uu|MnLu
Lnn 12 t :ltuluuuM
|MununtlvWlvult (uuMu
ltluWlvuW 5mg un:2W1 |tu
|n 5u)
u
45 Tienam inj 11 Compatibility/
Stability
untnLn
lv Tienam inj nu
|Munt TPN lMvlL
Tienam inj WMu mipenem 500v
mg +Cilastatin sodium 500 mg inj
lLnLnlvLnt Acyclovir,
Amphotericin B,
Metronidazole,LRS.SW, Sodium
bicarbonate,un:TPN M1uulL
nLnlv Tienam inj nu|Munt
TPN lM
WLuu1
ntvu
0M|wnM
WL|nu1
1uDS
46 Vancomycin 11 Compatibility/
Stability
uwun1ltu
Vancomycin lMuWu
heparin lock uM
wtuMnM:nu
|LWnLnu:nLn
unlulMu1l
ulv|nMincompatibility nt
VancomycinlMun
Ampicilline,Cefazolin,Cefepime,Cefot
axime,Ceftazidime,Ceftriaxone,Cefur
oxime,Chloramphenico,Co-trimoxazo
le,Dexamethazole,Heparin,Hydrocorti
zone,PGs,Phenobarbital,Phenytoin,P
iperacillin,Sodium bicarbonate un:
nguidelineu1 The American
Society of Health System:tn
lt Heparin un:saline lock lLLWL
uMnM1nulunnMn|nM
phlebitis1uu:ulvlt 0.9% sodium
chloride injection uunlt
heparin un:nlt saline flush
solution nLnnMWL|nu1lun
|nMnu1|Wu1nheparin lM |tu
n|nM induced thrombocytopenia.
Thrombosis, hemorrhage.
ncompatilbility
website :
www.
4 tL|vM|W 0 ADR/ Side
Effects
unttL|vM
|WLnu1|Wu1
:lt1 Luunlu
u1lt1
tL|vM|WLn:nWuW
anthraquinone glycosides lMun
nun:Mulvnln|nnttM 1
uLltlunnLn1Wn
uuMuu:u-tt1tL|vM|W t 3
nL/t1(t:Ln12lt) W1n:1-2
t1 t1luu 120ml/t1 uu10u
tt:uun:1W1nuuu
nu1|Wu1 -Wnuln tMLu1
LMnnttM 1|nu WnMuuMn1
vtt:uwLuutnL |tu u1
nuwn n:u |tuMu
uvLlt 1.lu|Mn
uMn 12t 2.vu1M1WD
3.WLtuv|nunt:tt1|Mu
v |tu nlnMMu
website :
www.
48 vMv1uln 10 Therapeutic
Use/ Efficacy/
ndication
vMv1ulnltuMlM
nL :u:|nuu
|lv
vMv1uln|nMn|t Human papilloma
virus(HPV) t1Lvnu type un:nlv|nM
vMu:u11nuWuuMnM1nu vM
u:|wW lMun HPV-11,HPV-16,HPV18
|tuMu un:|tu risk lv|nM cancer lu
|nML ttuu1lLLnnL
tnMDuun:Lt:nuDw LultW
nMMvMnW cryotherapy ,
electrocautery, laser therapy or surgical
removal uMn:unt:nuDwlL
uMnM1nu uMM1nu cost and side
effect un:nWuWLnnntL|tut
nvtuuLlt:|tu tropical agent
|tu n|tuuL u| :|tu topical
salicylate nu, flat warts lt topical
tretinoin or 5-fluorouracil |tuMu un:M1
ltLnt|WunnWMMu1Mu **nvt
Wtunn|tu genital warts u
Mtnu1W imiquimod 3 times/week
nuuu uu 16 wks nltLnt
interferon alfa : most effective un:
lowest recurrence rate unnuu1Lu
uML 50-80% trichloroacetic acid v
un electrosurgery, excision, laser
ablation, vLlt Podophyllin |u1nL
n|tumutagen t|tupotential
carcinogen
u
tu D
type
t:|DWnL WnL WMt 11
1 Amphotericin
B
7 ADR/ Side
Effects
unt
nLnt1nun|nM
phlebitis nnlt
u Amphotericin B
lMu1l
nLnt1nun|nM Phlebitis n
nltu Amphotericin B lMlMu 1.
ltWL|uLuuu1ulL|nu 0.1 mg /
ml 2. lt Rate lun infusion lL
Mn 2 tlL1 3. WnL heparin 1000
unit / L n1lunn:nuu 4. lv
uuttu|uu
Drug
nformation
Handbook
2 Cilostazol
,Pletaal
7 ADR/ Side
Effects
WtulMtu
Cilostazol (Pletaal )
un:M1|utn
WMM unt
M1vuMuM1nn
nunWMMvlL
Cilostazol (Pletaal ) |tuunnL
Phosphodiesterase enzyme
inhibitors LWnutu1n|n:nnLu1
|nM|nM n1Wnlv|nMlvnlL
vuMlu:v1nWMM M1uu1W
vuMuunu|utnWMM|tu|n
5 -7 u
Drug
nformation
Handbook
3 Ciprofloxacin 10 Therapeutic
Use/ Efficacy/
ndication
u Ciprofloxacin
nLnnL
Leptospirosis lM
vlL
nnWnLlMunMn1luvu
hamster wtnlt Ciprofloxacin
v Fluoroquinolone Mu |tu
levofloxacin , gatifloxacin lu form inj
lMWnlunnLu1LuunWu
1nnMlLuMnM1n doxycyclin
uMnlvuluLuLuu1lLwt
1uu1tWnnltuM1nn
u
4 Cogentin ,
Benztropine
mesylate
09 Dosage/
Administration
uuMu Cogentin lt
luuuM|l
uuMu Benztropine mesylate v
Cogentin ltMuW 1-2 mg lMu
ltlMlut1 0.5-6 mg t1M1tt
uuMMLuun:uvunu1Wtu
L1tuMu1parkinsonism u1
Wtu nvtWtu|tu
diopathic parkinsonism |Llu
uuM 0.5-1 mg lMulvun:W1nu
uu Wtut1uM1lt u
uuM 4-6 mg/day nuWtu|tu
post-encephalitic parkinsonism nu
lvu:|LlvluuuM 2 mg W1|Mu
t1luWtut1u |LluuuM
0.5 mg nuuu unWutt|wL
uuMu
website :
www.
5 contraceptive 9 Dosage/
Administration
uWLnuMLulu
l1wutnn1un n
M1nuLltutt
0n|0u:uLltlu
uuM|l
uWLn|uMLlul1wutnn1un
lMun 1. Geny FMP. :
t:ntMuMu Norgestrel 0.5 mg
+ ethinyl estradiol 0.05 mg lMuL
utt:uW tt:u|LMnu
2 |LMu un:n 2 |LMlu|n 12
tlL1ML , 2. Prevenon 28 :
t:ntMuMu Desogestrel 0.15
mg + ethinyl estradiol 0.03 mg L
utt:uWtt:u|LMnu
4 |LMu un:n 4 |LMlu|n 12
tlL1ML , 3. R - den :
t:ntMuMu Levonorogestrel
0.15 mg + ethinyl estradiol 0.03 mg
utt:uWtt:u|LMn
u 4 |LMu un:n 4 |LMlu|n
12 tlL1ML
u
6 Co-
trimoxazole
9 Dosage/
Administration
Wtu|Mnu 5 |Mu
uvunM 4 nlnnL
lMtnu0u
|tu Pneumonia un:
uwun1u
Co-trimoxazole inj.
20 mg iv q 6 hr M1
WnLnt NSS tLM
|l
Co-trimoxazole inj 1 ampule
t:ntMu Sulfamethoxazole 400
mg + Trimethoprim 80 mg ( 5 ml )
M1WnLntnn:nu 0.9% NSS
luMnu 1:25 uwun1 20 mg
u1 Trimethoprim M1uu1M1u
uL 1.25 ml un:WnLlu 0.9% NSS
= 1.25*25 = 31.25 ml
Drug
nformation
Handbook
7 Cyproheptadi
ne
10 Therapeutic
Use/ Efficacy/
ndication
u Cyproheptadine
nLnlt|tuu|u
vlMvlL
u Cyproheptadine |tuulunnL
antihistamine t1|tuuunuwuuL
nu1|Wu1nu W |wLWL
unv M1uu 1uuLuLlt
|tuu|w|wLWLunv
Lnnlt|tuuunuw lMuuuM
ultW 2 mg un: 4 W1
Drug
nformation
Handbook
8 Depakin,
Valproic acid
9 Dosage/
Administration
Depakin 400 mg M1
ltnu dilute |l
luWtulWlM
Valproic acid uuM 100 mg /ml ( 5
ml ) M1 dilute lMult NSS , D5W
v Lactated Ringer ' s solution
tLM 50 ml M1uuuuuM 400
mg 1M1ltnu 40 ml lun|
1
AHFS: Drug
nformation
9 Diazepam 7 ADR/ Side
Effects
Wtultu Diazepam
Lntu
Tranexamic acid un
Lnuwu W L
uWnnnt|ntn
uMlLLnun
untuMlM
Llnnlv|nM
nuwuttulM
Lnn
nuLn Spontaneous report drug
reaction t 2005 wtWtultu
Diazepam Lu1un|nM oral
ulceration lu:Mtu:lt uu 1
u nuWtult Tranexamic acid
uu Lu1un|nM dry mouth lu
:Mtu:lt uu 1 u unM1
tMnnuwulunnLn:M1nn
lLLWLuMnM1nu
Spontaneous
report of
adverse drug
reaction
10 Diclofenac 7 ADR/ Side
Effects
Wtuuwu
Diclofenac nLn
lvu Dynastat lM
vlL
WtuuuLt:Muwu diclofenec
LnvutL ,uuutL un:lLL
t:MltuuntMMu unn
Paracetamol 1lLnLnntlM
WtuuwuuttTrue allergy v
Pseudoallergy t1u Dynastat v
Parecoxib uu |tuulunnL cox-
inhibtor t1nMlW1n1uMnM1n
u diclofenac Ln lvnLnltu
Parecoxib lMluWtuuu
u
11 Dicloxacillin 10 Therapeutic
Use/ Efficacy/
ndication
WtulMuu1uvnL
|nut| un:nuu
unn|nt 1 |LM un
u1tMtLu
nntLwtvLnW1
lMvlL
n1nulMuu1uvnL|nut
|lv|nMn0nuMu1nnL|u
un:nnnL|un|nt|u1n
|tunMtnu1u11nulMu
tnunnlv|nMnn|ntlv
|nMWL|ttMt1M1lt:u:|n
1nu:tLutLnu0nuMuulv
|tutnMun:M1tt:uuL|t
|u1nL|tlWtu|tuLntu1L
WL lv|nMnn|nt|tuvu1un:
|ttM|wLLnuu lMuWtuM1
tt:uuL|tt:Ln 5 u -3
ntMv t1lunnuWtu
tt:uult|wu1 1 uun:lLnu
uM|u1uvLM t1vnWtunuu
Wt 5 uunntMtLu1W1
|tuunLnLwtuwulMt1
uwu:wnnnMM|t
:nLMlMuulM
u
12 Diltiazam,
Herbesser
SR
9 Dosage/
Administration
Wtultu Herbesser
SR (diltiazam 90 mg
) uuM 1x3 un
tuuMult
n1|nultvlL
nvtnnL
Hypertension un:
duration of action
u1u|tu|l
ultnL HTN lututt
capsule SR ( Cardizam SR )
nLnltlMlut1 240-360 mg /
day un:lututt Tablet ER (
Cardizem ) nLnltlMluuuM
120-540 mg/day t1Wtuuultu
Herbesser SR (diltiazam 90 mg )
uuM 1x3 1LWL|vL:nL nu
duration of action u1u Herbesser
SR uu nnntWulLwtuLn
uMwtuLnu diltiazem SR u1
tLuL duration of action |tu
|n 12 hr. t1u:|utlMnt
duration of action u1u Herbesser
SR
Drug
nformation
Handbook
13 Dopamine ,
Frozen
plasma
11 Compatibility/
Stability
Dopamine nLn
|nM drug interaction
nt Frozen plasma
lMvlL
nnntWuwt Dopamine |nM
incompatibility nt Acyclovir ,
Amikacin , Amphotericin B ,
Ampicillin , Heparin , ron,
Metronidazole , Nitropusside , PGS
un: Sodium bicarbonate ( v
nn:nuM1un ) t1lLwtuLLn
n|nM Drug nteraction nt Frozen
plasma M1uu1nLnlvuLnu
lM
u
14 Dormicum ,
Midazolam
3 Pharmacokineti
cs
M1nt 0nset of
action u1u
Dormicum
Dormicum v Midazolam tutt
oral :LnMMtLutt extremely
rapid absorption nunlvutt im
lt|nt:Ln 15 u , utt iv
lt|nt:Ln 1-5 u
Drug
nformation
Handbook
15 Enoxaparin 11 Compatibility/
Stability
Enoxaparin (clexane
prefill syring) |L
ult0MlvWtuun
:nLn|ntul
ltMlMvlL un::
|ntllMuu|l
nnntWu lLwtuLnWLW1M
u1 Enoxaparin vn1nlMuLlt
ntWtu uMnnntnLltu1
tLWWnM 1tLu1nLn
|ntullMuu 24 tlL1 lMulv|nt
ulluM|uu
u
16 Fexofenadine
, Telfast
9 Dosage/
Administration
M1ntuuMu
Fexofenadine ltlu
|Mn
uuMu Fexofenadine W 30 mg 2
W1Mu lu|MnLu 6- 11 t
nuWLuLnn 12 tuult:lt
uluuuM 60 mg un: 2 W1v
180 mg un:W1luW|tu
Seasonal Rhinitis Allergic un: ltu
luuuM 60 mg un: 2 W1 lu
Wtu|tu Chronic idiopathic
urticaria nu|Mnuuun 6 t
lLwtut1ltu1uu
Drug
nformation
Handbook
17 Floxetin ,
Levodopa,
Baclofen ,
Trihexypheni
dyl
7 ADR/ Side
Effects
uwuuMWtuWMM
M lMuWtuLu
M1tt:u W
Floxetin 20 mg ,
Levodopa 200 mg +
Benserazide 50 mg ,
Baclofen 20 mg ,
Trihexyphenidyl 2 mg
un: Clonazepam 0.5
mg WtulMvuM
tt:uult
t:Ln 7u un:uL
vvuun:tnnu
wMlL|1 un
tWtuM1
vuMuM1nnnu
WMMvlL
nnntWu wtuWtuvuM
tt:ult1vLM lL|nuu1nt
:tt|nMM1:1n bleeding
M1uu1lL|tuM1vuMu|vnu
nunWMM
Drug
nformation
Handbook
18 fluconazole 8 Toxicity/
Poisoning
Fluconazole lv|nM
hepatitis luWtu
ADs lMn %
LnWnLwtnltu
fluconazole nLwuun1uu1Mt
W |LLnltu fluconazole lu
Wtu ADs |wt1nu
Cryptococcosis uu :LWLWMtnM
u1Mtvnuutt |tu mixed cytolytic
un: Cholestatic liver tests
abnormality t1|LvuMu
fluconazole n:Muu uM|LnntL
ltlvL nuun1 M1uu1M1Wu
nWnLMltlun monitor n
1uu1Mt|vL:nLluWtu
ADs t1M1lt fluconazole |tu
:u:|nuu
u
19 Flunarizine ,
Clonazepam
8 Toxicity/
Poisoning
Wtunu Flunarizine ,
Clonazepam 0.5 mg
u1n: 30 |LM :L
unLu1l L
Antidote vlLun:
uuMun1nM|tu|l
uuMu Flunarizine LuuMun1nM
W 600 mg un:W1 t1:lvL
nu1 CNS ( ex. sedation
drawsiness, agitation) un:
cardicvascular ( ex . Tachycardia)
lMulLL Antidote ltlunnL
lMu|0w: uMnLnlv activated
charcoal |wMMttu vlv
|uu v gastric lavage t1
case uWtutt:u Flunarizine
uuM 5 mg uu 30 |LM =150
mg t1u1lLn1:Mtu overdose
nu Clonazepam uuM 0.5 mg / tab
uuMun1nM W 20 mg/ day t1:
lvLn1 CNS lM ( ex.
ntnu , tn , n|WnulvWMtnM
un: Coma ) lMulvnnLML
nwLntlv antidote W
Flumazenil V : initial dose W 0.2
mg over 30 seconds (|wL|tu
0.3 mg ) un:repeat dose W 0.5 mg
over 30 seconds nLnlvtlM
lMu|u:u:v1u1nlvu 1 u
Drug
nformation
Handbook
20 GPO-vir 20 Others untu
GPO-vir t1L
nut:ntW
D4T,3TC un:
Nevirapine :|nM
drug interaction |L
lvLntu
Fluoxetin,Haloperidol,
Chlorpromazine,Astan
e,Phenytoin un:
Ofloxacin vlL
nnntWulLwt GPO-vir
nLn|nM drug interaction |Llv
LntunnLu
Drug
nteraction
Facts
21 HBG 11 Compatibility/
Stability
unt HBG
vn1n|tMlt:
nLn|ntllMuu
|l
vn1n|tMltWltlvvLMDulu 6
tlL1 un:lMultW|ntllu
M|uunvDL 2-8 1W vL|ntlu
t1utuu1|w::lv vaccine
|nLnDwu1M| un: vaccine
:LuulMt:Ln 2 t utuM
uWnM WMMuvLMutu
nn1nultnW1
website :
www.
22 Heparin lock 9 Dosage/
Administration
unt
Heparin lock L
MnulunWnL
|tu|l Lunlv
uu1l un:LWL
W1Mu1l
n|MuL Heparin lock :lt
Heparin solution 10-100 unit/cc
vlt physiological saline solution
|wt1nunuu1Mu1|nM lMuL
unlvu W |MuL syring t
heparin 0.5 cc un: syring t
NSS 2 cc vn1nuu0MNSS |u
Medication port 1 cc MLMuMu
M1n0M|u medication port
MLMu NSS 1 cc |wlnu un:0M
heparin |u medication port ML
uMn|tunlvuutt infusion W
flush n 6 -8 hr un: heparin :L
WLW1Mvn1WnL 1 unvDLv1
website :
www.
23 HPV Vaccine 10 Therapeutic
Use/ Efficacy/
ndication
L:|1tnLMnnL
n|vMuunn
HPV vlL un:
Wtut1nuL:|1
tnLMnnnLnlv
luvu1u 45 t lM
vlL
L:|1tnLMnnunnnMM|t
HPV un u1Ltu|nu1u n |tu
nL|wWnLwuuM1uMuu1uu,
n|tnuuWuutu, nLtM
Ln un:n|tulWMMM1
|wWnLwuuv|tulWDLWLnu
tnw1 t1nltWtut1nu
L:|1tnLMnnuu u1lLLuLnlu
nltluvu1Lu 45 t uM
uu:ulvltluWvu1Luuun
26 t (0M vaccine nuL
|wWnLwuuvnuLlnnnLWn|t
ln ) |u1nWtu:t1nulM
|0w: HPV type u1lLlMLn
nLWnlW|uu M1uu1n0M
vaccinelut1u 9 - 26 t :L
t:nuDwMnM
website :
www.
24 Humulin R ,
Regular
nsulin
11 Compatibility/
Stability
Humulin R nLn
|ntlnvDLv1
lMuu|l
Humulin R utt vial 10 ml |nt
nvDLv1lMuu 1 |Mu nu
tutt Penfill syring |ntnvDL
<= 30 1W|tn|tun lMuu 1.5 |Mu
u
25 K exalate 10 Therapeutic
Use/ Efficacy/
ndication
K - exalate nLnlt
luWtu renal failure
lMvlL un:n
lvuutt Oral un:
rectal uttlvu:L
t:nuDwMn
K - exalate v Kalimate LtnLu
1uW Ca polystyrene sulfonate 5
gm powder / sac Lut1ltluWtu
LD: Hypekalemia nLn
tvulMuntt:uvlv
u1 nasogastric tube v1
enema t1nlvlMuu enema :L
t:nuDwMnM nvtnlt
Kalimake |wnM:Mt K luWtu
renal failure uu:uWlv RAAS
inhibitors ( Renin - angiotensin -
aldersteronesystem , inhibitor ) L
Mu:lLlv Serum creatinine
|nMn|tnuuutn1|wLuu
u
26 Ketalar ,
Fentanyl
4 Pregnancy/
Nursing
Ketatar un: Fentanyl
inj nLnltluvu1
lvuLtMlMvlL
Ketalar v Ketamine inj nLn
Wu1uuLlM WvuMlvuLtM
|tu|n 11 tlL1vn1lvu un:
Fentanyl nLnWu1uuLlM
|tunu WvuMlvuLtM|tu|n 10
tlL1vn1lvu
u
27 Ketoconazole 3 Pharmacokineti
cs
u Ketoconazole nu
nuvvn1v1
:MMtLlMMnM
nuLnu1Mu Ketoconazole :
MMtLlMM|Ln:|w:v|tunM
M1uu|L pH lun:|w:|wLn1uu
nMMtLun: bioavailability u1u
:nMn1 M1uu1uu:ulvnuu
Ketoconazole vn1v un:v
u1LWntunMn:Wu|W1
n:|w:vlMnMu
Drug
nformation
Handbook
28 Magnesium
sulfate
6 Formulation M1ntWL
u1u1u Magnesium
sulfate inj. Llu
l1wutnn1un
Magnesium sulfate inj. Llu
l1wutnn1un L 2 WLu1 W
10 % w/v tLM 10 ml (L Mg 8
mEq/amp v|nt 1 g/10 ml )
un:uuM 50% w/v tLM 2 ml (L
Mg 8 mEq /amp v |nt 1g/2 ml
) lMu 1 gram Magnesium sulfate =
98 mg (elemental Mg) = 4.06
mmol = 8.12 mEq elemental
Magnesium
WLuu1
ntvu
0M|wnM
WL|nu1
1uDS
29 Meropenam 11 Compatibility/
Stability
nLn drip
Meropenam inj.
wLntnlv|nM
lMvlL
nnntWuuLnlu Handbook on
njectable drug lLwtuLn
Compatibility :v1 PRC nt
Meropenam inj. uMnnntnL
ltu1tLWWnM lLuu:ulvlvu
1nu|Munu |u1nlLLuLn
WLtnMDu uMlv1 3 - way
site lM
Hanbook on
njectable
Drug
30 Metoprolol 9 Dosage/
Administration
untuuMu
Metoprolol ltlu
D: hypertension
uuMu Metoprolol ltluD:
hypertension W 100-450 mg/day
ut1lvun: 2-3 W1 lMuuuM
|LMultW 50 mg 2 W1Mu
un:tt|wLuuMuluuMn:
ntMv lMulvuuMuulut1
50-100 mg/day (JNC 7)
Drug
nformation
Handbook
31 Myiasis ,
vuu
uLn1u ,
vermectin
10 Therapeutic
Use/ Efficacy/
ndication
untult
nLvuuuLn1u
luv
nnL|wuvuuuLn1un
n Host lunnu1 Cutaneous
myiasis Lnltu|nn alcohol ,
chloroform v ether |wn1|
vuuuLn1unnuWn un:L
u1un1WLn|lunnL
Wtu myiasis Muu vermectin t1
|tu broad - spectrum antiparasitic
agent t1nnunvn1 r - amino
- butyric acid ( GABA ) tnu
t:nun:|wLntu1 GABA M
receptore tnut:n LWn
tnunuunt:nun:lv
wuuL1uLn1|tuLwMun:Mu
lunM u vermectin lMnn
uLltnL Myiasis t1Lu1u
lMWnM1lutunuun:u|0w:
lMuulututttt:u:lvlu
uuM 0.2 mg/kg /day
website :
www.
32 Nitroglycerine 11 Compatibility/
Stability
Nitroglycerine inj vn1
WnLunLWLW1M
uu|l
Nitroglycerine injection vn1WnLnt
D5W 0.9% NSS LWLW1M 48 hr.
nvDLv1 un: 7 u|L|ntlu
M|uu
Hanbook on
njectable
Drug
33 Norfloxacin 9 Dosage/
Administration
M1ntuuMu
Norfloxacin ltlu|Mn
uuMu Norfloxacin lu|Mn W 15 -
20 mg/kg/day ut1lvun: 2 W1
u
34 Norfloxacin 4 Pregnancy/
Nursing
Norfloxacin nLn
ltlu 1 st trimester
pregnancy lMvlL
Norfloxacin Mulu preqnancy
categony C nLnuwWun lu
LuLulLwtD:|nu1MWL
WMtnMlun:lv|nutM
vwn uMW:LM:1nltlu
1st trimester |u1nLu1un
|nM teratogenic lunMMn1
M1uuvnL|tuM1ltuWltlu
:u:nulL|nu 1 ntMv
Drug
nformation
Handbook
35 Penicillin 9 Dosage/
Administration
M1ntuuMu
Penicillin V lun
nL Rheumatic
Heart Disease lu
|Mnu 15 t
uuMu Penicillin V nvtnnL
Rheumatic Fever W 100,000
U/kg/day uu 10 u ( |Mn : 250 mg
v 400,000 U bid or tid , Wlvu :
500 mg bid or tid ) t1WtuuuL
u 15 t 1lvuuMultluWlvu
AHFS: Drug
nformation
36 Phenytoin 9 Dosage/
Administration
Phenyltoin uuM 50
mg prompt release
nLnlvutt 6 * 1
lMvlL
nlv Phenytoin utt prompt
release 300 mg W1|Mu :LW
pharmacokinetics uMnM1nn
lvutt extended release lMuW
Cmax un: AUC u1uutt prompt
release :n1nutt extended
release uMW Tmax :lnn|Wu1nu
t1uuMu|wLn1uulu utt prompt
release :LW bioavailability n1
n uMlLLWnMnnMuun: half
life u1u uMn1M1:1Wn
lLw1t:n1W t1:nLwuunt:Mt
ulu|nM lMu n Cp> 20 mcg/ml
lvWtu|nMn nystagmus
lM uMn Cp> 30 mcg/ml lv
|nMn ataxia, nystagmus un:
vnCp> 100 mcg/ml Wtu
|nutMlM
website :
www.
37 Plavix
,Clopidogrel ,
Contraceptive
7 ADR/ Side
Effects
un:ulMtu Plavix
lMutt:u 1 |LM
un: 1 W1 :
nLnltu
WLn|uMlMvlL
Plavix |tutnWu1u
Clopidogrel |tuunnuMun
|n:nnLu1|nM|nM Lut1ltlu
D:M1Mltu W t1nulWvnM
|nMvltuM|0utwnu , nnL|u
vlMutuM|0utwnu , vnM|nM
uM1MMu ,vnM|nMlunL1MMu ,
D:vluM|nM, D:vnM
|nMuM1nutnuMMu
nuuWLn|uMLuvLltluW|tu
lWMt |tvu,lWvl,lW|nu
|nM, |nu|nMMMMu ,lWlM,lW
DLuw ,lWnLtn ,nMuLnn 40
t ,L:|1|MuL L:|1u:ntwuu
|u1nLMnn M1uuWtuuu1
Wvnn|nu1nltuWLn|uM
Drug
nformation
Handbook
38 Salbutamol
Beradual
11 Compatibility/
Stability
Salbutamol solution
un: Beraduol solution
vn1n|tMlt|ntl
lMuu|l
Salbutamol solution vn1n|tMlt
|ntllMuu 1 |Mu nvDL <=
25 1W|tn|tun un:t1nuun1
nuBeraduol solution vn1n|tMlt
|ntllMuu 6 |Mu un:|ntlu
M|uulMulLM1t1nuun1
AHFS: Drug
nformation
39 Sandostatin ,
Pantoprazole
11 Compatibility/
Stability
unt
Sandostatin un:
Controloc (
Pantoprazole ) inj
nLnlvu1|nu
|MunulMvlL
nnntWuwt Sandostatin lL
nLnWnLlMntnn:nu|tu
Fat emulsion un:lLwtuLn
incompatibility u1 Pantoprazole
ntuMu M1uu1nLnlvu
1nu|MunulM
Hanbook on
njectable
Drug
40 Sermion ,
Nicergoline
10 Therapeutic
Use/ Efficacy/
ndication
Sermion L side effect
Mu cardiovascular
vlL
Sermion (nicergoline) L side effect
W G disturbance ( nnlLntulu
t11 ) L Hypotension
|nnuu lMulLlMnnn1 side effect
1 cardiovascular u1u
u
41 Silver
Sulfadiazine
13 Storage Silver sulfadiazine
nLn|ntluM|uu
lMvlL
silver sulfadiazine nLn|ntlM1
luM|uuun:nvDLv1 ( 25 1W )
t1:nLn|ntlMuu 3 t ML
0nn:t uMlunn|ntl
nvDLv1Lnn 25 1W :
|ntlMuun 3 t |tu nvDL 40
W nLn|ntlMuu 2 t
website :
www.
42 Sodium
valproate
6 Formulation l1wutnn1unL
Sodium valproate lu
tutt form :lt1
Sodium valproate lul1wutn
n1un L 2 dosage form W 1.
Sodium valproate 500 mg control
release tablet 2. Sodium valproate
200 mg/ml syrup
u
43 Valproic acid 11 Compatibility/
Stability
Valproic acid vn1
WnL:|ntllMuu
|l
u Valproic acid lututtu0M
lLlM|ML preservative 1nLn|nt
nvDLv1lM|wu1 24 tlL1
AHFS: Drug
nformation
44 Ventolin 11 Compatibility/
Stability
Ventolin solution un:
Beradual solution
vn1n|tMltun|nt
lMuu|l
Salbutamol solution ( Ventolin )
vn1n|tMlt|ntlMuu 1 |Mu
nvDL <= 25 1W un:M1|ntlv
wuun1 nuBeradual solution
vn1n|tMlt|ntlMuu 6 |Mu
un:uu:ulv|ntluM|uulMulL
|tuM1t1nuun1
AHFS: Drug
nformation
45 Vitamin K 3 Pharmacokineti
cs
Vitamin K 10 mg V L
duration of action
uu|l (Wtu
lMt vit K u
30/5/51 un:lMtu
warfarin utt low
dose MLluu
3/6/51 uwutt
uuMu warfarin uu
|tu high dose
|u1n NR u1Mu )
nlMt Vitamin K V :lv
prothombin time tnMlu:u:|n
12-14 hr. vn1lMtu un:L duration
lunnnut:Ln 24 tlL1 (
nn low dose vit. K 5 mg ) nunn
lt high dose wt duration of
action u1 Vit .K :uuuuu
|tuntMvlM M1uu1Wltu
warfarin luuuM|MLltnu unuM
WtuLMMML NR u1lnntM
AHFS: Drug
nformation
n
Mt
tu D
type
t:|DWnL WnL WMt
1 sosorbide
dinitrate
9 Dosage/
Administration
uwun1 sosorbide
dinitrate lv pt lu
uuM 10 mg/day (1*1
pc )lLtLWL
|vL:nLvlL
uuMu isusorbide dinitratc LuuM
ulvW Angina : 5-40 mg 4
times/day CHF : initial dose 10 mg
3 times/day target dose 40 mg 3
times/day Maximum dose 80 mg
times/day Esophageal spastic
disorders (Unlabeled use ) : oral :
5-10 mg before meals M1uulu
case uW consult uwun1ut1lt
u1lW un: confirm uuMulv
|vL:nL
2 Loxonin ,
Loxoprofen
10 Therapeutic
Use/ Efficacy/
ndication
unt Loxonin
|tuunLlW:l
Loxonin |tutnW lMuLtnLu
1u W loxoprofen M|tuunnL
Non-steroidal anti-inflammatory
drugs (NSAD) lunnL propionic lt
nLntM nMlu nMn
nnL|un|nt ntMuM1
(t1ulunnL propionic Lluw.
n1un lMun buprofen un:
Naproxen)
3 Adrenaline 9 Dosage/
Administration
untM1n
0M adrenaline utt
im luWtuuwu
lMun0M|u
nnL|uvlvnun:
nnL|uvuu L
WLuMnM1nu
vlL
Adrenaline nLntvulM1
utt iv infusion , iv direct injection
un: sc lMulLwtuLnntvu
utt im
4 Adrenaline ,
blood
11 Compatibility/
Stability
adrenaline nLnlv
Lnt|nM1nu
|MunulMvlL
nnntWu lLwtuLnn|nM
incompatibility u1u 1nLnlv
1nu|MunulM
5 Aluminium
hydroxide
7 ADR/ Side
Effects
Aluminium hydroxide
lv|nM toxicity
u1llMt1
nnntWuwtlMLnu1u
n|nM toxicity un:u1un
|nutMluWtu|tu dialysis
encephalopathy t1wtL:Mt
Aluminium hydroxide lu gray matter
lu:Mtn1 unnuwtlut
1984 LWtun 3 u lMt
aluminium hydroxide |nMD:
azotemia un:Lt1nWnLuuuu
Wtu|MnlMt aluminium n
antacid lunWtWLD:
hyperphosphatemia L:Mt serum
aluminium un: bone aluminium |wL
n1uu nnWnL|vnuunM1lv
|vunlMt oral aluminium L
WLnLwuunt plasma aluminium
lMu:Mt plasma aluminium > 100
microgram/litre :LWL|nu1Mn
|nM aluminium toxicity lMulLt
W threshold uuuu t1lLWlvL
Wn1n 100 microgram/litre
Amikacin 11 Compatibility/
Stability
Amikacin inj vn1WnL
ntnn:nu|w drip
:|ntllMuu|l
un: vial ltun:
|ntllMuu|l
Amikacin inj vn1WnL|ntllMuu 2
|Mu nvDL 2-8 1W un: 24 tL.
nvDLv1 nvt vail MMu
Lltun:u1Lu|vnu Wt|nt
vial u un:|tML|tMu 70%
Alcohol untM paralfin vial |w
t1nuntu|tu|t un:|ntlu
M|uulL|nu 24 tlL1 uMvnlL
Lul|1 sterile technique W1
u|vnlt
7 Amoxicillin +
Clavutanic
acid
4 Pregnancy/
Nursing
Augmentin nLnlt
luvu1M1WDlM
vlL
Augmentin t:ntMu Amoxicillin
+ Clavulanic acid lMu Amoxicillin
un: Clavulanic acid Mulu
Pregnancy calegory B nLnltlu
vu1M1WDlMu1tnMDuun:lL
Lu1un|nM teratogenicity
8 Amphotericin
B
,Cryptococcal
meningitis
10 Therapeutic
Use/ Efficacy/
ndication
WtuMM|t HV
uwuu0u|tu
Cryptococcal
meningitis :lvu
Amphotericin B lM
uunu
ultlunnL Cryptococcal
meningitisluWtu|tulW ADs
nvtt:|Wlulv Amphotericin
B 0.7 -1.0 mg /kg/day |tuu|Mu
u1uu 2 wk unMLMu
Fluconazole 400 mg/day |tu|n 8
wk uM|u1nwtu1unWnL
n1Wnn|w:|tn Spinal fluid
wt|tu1uuuluu 14 t1|nu1
Mnnnt|tutLnnnnL|w:
|tlLuun1 7 | M1uuWtuL
n1WnunlLMuu :wnlv
Amphotericin B MunwtlLL
|tuuMMMnu|tu|n 2-3 weeks
9 Ampicillin 7 ADR/ Side
Effects
vn10Mu Ampicillin
WtuLnuuu
vun Heart rate
un: Blood pressure
lL|tnuuutn1 |WuL
t:Muwu Capsule
M-uM1 |tuuL|t
lLttu nnu
:Llnnuwuutt
anaphylaxis lMvlL
nuwuutt anaphylaxis |nMuu
luWtu|WulMtuuwLnu
lMun:Mulvn1 gE Muuwun
gE :lt|n:tu mast cell basophill
|LlMtu|Wuuwuu cell L gE
|n:u:uMnnun:tnunn
nuwnLu1|u|uM1 lv
|nMnunM1lMvnu:tt lMu
|nMwLnuv|nM|wu1t1
:tt lMun - 1Wvu1 |tu WuWu
uM1 WunLwL un: angioedema ,
1|Muvul |tu vnMnLMt nn1
|nu1tL uuuvun , 1|Mu
v |tu Wnuln |uu tM|n1
t11 1|nu , :tt1|Mu
vulun:vnM|nM |tu
hypertension, ventricular
tachycardia, vl|Mu|vv
l|MuWM1v:, :ttt:n |tu
vLMnM , :ttutnu |tu tnn:
lLn Wtuuuvn10MLn
uuuvun un:lvt:M|n|Wu
uwuL|t 1Llnnuwuutt
anaphaxis lM 1uu:ulv consult
10 Ampicillin ,
Cefazolin
11 Compatibility/
Stability
u ampicillin un:
cefazolin nLnlv
utt direct iv lM
vlL
u Ampicillin nLnlv direct iv lM
lMun:nuulvlMWL|uLuu 125 -
500 mg/ 5 ml lt|nlunlvu
10-15 u nuu Cefazolin
nLnlv direct iv lMlMun:nuu
lvlMWL|uLuu 500 mg/ 2 ml (
dilute with 5 ml SWF ) lt|nlun
lvu 3-5 u
11 Azithromycin 7 ADR/ Side
Effects
azithromycin lv
wuMlMvlL
nnntWuuLn lLwtuLnu
azithromycin lv|nMwuM uMu
lv|nMwuM lMun tetracyclin ,
doxycyclin
12 Cefuroxime
,Glaxo
Smithkline
Formulation M1ntu
Zinnat (Cefuroxime)
tuM tablet u1 t.
Glaxo Smithkline
nLnut1vn|LMlM
vlL
u Cefuroxime (Zinnat) u1tL
Glaxo M1tt:ulMunnnu
wLuvn1Lv vLut1v
vn|LMu vn|tuM1ltu
|tnuultltuMuLut1lt
|Munu v|tnuututt
|vL:nLnvtntvulu pt.
uu
13 Chinese
restaurant
syndrome
7 ADR/ Side
Effects
Chinese restaurant
syndrome luWuw
W1tnluvuL
nunM1u1l L
un:|uM:lt1
Chinese restaurant syndrome |tu
nnLn|nMuuvn1tt:u
vuLnuWnLn
monosodium glutamate (MSG )lL
tnnlnn|nMuutM |nM
vn1ntt:uvL MSG
lutLnn1 30-0 u vDulu
2 tL. vn11:|wLtLnn
MMtL MSG WLuu1un:
:u:|n|nMnuunttLn
u1 MSG MMtLWun:un|nM
nunM1 |tu Burning sensatiion
on mouth, back of the neck , chest ,
shoulders , abdomen |tuMu nu
lvuwtnlLuu1t1:vu|1
Dulu 2-3 tL. vnwtnuu1
lvtnL|tu|MuntWtu severe
allergle reaction
14 Creatinine
clearance ,
Clcr
3 Pharmacokineti
cs
untnMWun
Creatinine clearance
(Clcr)
Clcr (ml/min) male= (140 - age )x
BW 72 x Scr Clcr (ml/min) female
= .85 x Clcr males
15 Depakin ,
Sodium
Valproate ,
Midazolam
11 Compatibility/
Stability
Depakin inj v
sodium valproate
nLnWnLnt
nn:nulM:lt1
|ntlltlMuu|l
un:lvwLnt
Dormicum 1nu
|MunulMvlL
Depakin v Sodium valproate
nLnWnL|ununtnn:nu
D5W , NSS , LRS tLM 50-100
ml vn1WnL|ntllMuu 24 tL.
nvDL 15-30 1W vL|ntluM|uu
un:lLwtuLn Compatibility
:v1 Sodium valproate nt
Midazolam (Dormicum) M1uu1
uunlvWun:nu|wWLtnMDu
u1Wtu
1 Dextromethor
phan
4 Pregnancy/
Nursing
Dextromethophan
nLnltluvu1lv
uLtMlMvlL
vn|tuM1lt Dextromethorphan
lunMlvuLtM WltMuWL
:LM:1 lMuwnltuu|0w:
|nLnl vnn|nu1n
tt:uuM|u1 lLLuLnn
utuun1uuL uMuLLn
lL|nnnM1LlnnnnutnL
1uuLlM lLwtu1un|nM
nlLw1t:n1WlunlMt
uLnLMlLLuLnunM1n1
WLtnMDu 1WltMuWL
:LM:1
17 Diclofenac 9 Dosage/
Administration
Diclofenac inj
nLnlv iv lMvlL
Diclofenac inj nLnlvlM1 im
un: iv infusion (iv drip) |uu vL
push (bolus) lMu|1 diclofenac
lunn:nu 0.9% NSSv 5%
glucose tLM 100 -500 ml lt
|nlunlvuuu 30 min- 2 hrs ,
uuMun1nMMuW 150 mg lL
WltMMMnuuun 2 u
18 Diclofenac
injection
9 Dosage/
Administration
Diclofenac injection
nLnlv V lM
vlL
Diclofenac injection nLnlvlM1
V un:M lMuLut1ltuMnM1nu
M1u ntramuscular(im) ltnLRenal
colic and biliary colic severe
migraine attack when other form of
diclofenac are considered unsultable
, ntravenous nfusion ltnLv
t1nu post-operative pain in a
hospital setting, Diclofenac injection
nLnlv ntravenous nfusion lM
uMvL0M|uvnM|nMlMuM1(V
bolus) :M1WuvuM|u|nMu1
t(ntravenous nfusion) un:M1
|1Diclofenac lunn:nulu
tLM 100ml-500ml lMu
nn:nuuuM1|tu0.9%NSSv
5%glucose buffer Mu4.2% sodium
bicarbonate 1 ml v 8.4% sodium
bicarbonate 0.5 ml Mltlun
lvuL 2 uttW 1.ltnL
Moderated to severe post-operative
pain M1lvuuuM 75 mg infuse
uu 30 min-2hrs n|tulvt
lM after 4- hrs uMuuMuLM1
19 Famotidine ,
Nimesulide ,
Orphenadrine
3 Pharmacokineti
cs
Famotidine,
Nimesulide un:
Orphenadrine LW
W1tM|tu|l
Famotidine LWW1tM 2.5-4 hr
(Chinical half life 8-12 hr ) ,
Nimesulide LWW1tM 1.8-4.7 hr
un: Orphenadrine LWW1tM 13 -
20 hr
20 Fluconazole 9 Dosage/
Administration
M1ntuuMu
Fluconazole lun
nL esophageal
candidiasis
nlt Fluconazole lunnL
esophageal candidiasis lu uun
:ltuuuM 200 mg vn1nuu
:ltluuuM 100-200 mg/day (
|wLlMn1 400mg/day ) t1lun
nLutt long term :lt|nu1
uu 3 ntMv un:vn1nvuun
:ltuMn|tu|n 2-3 week
21 gabapentin 4 Pregnancy/
Nursing
untu
Neurontin v
Gabapentin nLn
lvluvu1lvuLtM
lMvlL
Gabapentin nLnutnlM1
uuL un:lLwtuLn|nMuulu
|MnlMtuLuL M1uunlvu
WwnWn|nMuu:v1
t:lutu Wn|nuun:WL|tulu
nltu
22 Glucosamine
sulfate ,viatril-
s , Flexa
Formulation u viatril-s Lut1
ltlunnL
Osteoarthritis 0nn
:tlvtt:u
nuv 1/2 tlL1
nu Flexa t1|tu
uM|Munu
Glucosamine sulfate
:tlvtt:u
vn1v un
tvLWnM
nMMtLuvlL
u Glucosamin solfate |tuu
t:ntMu amino group Lnt
|nn anion un:WnLnt chondroitin
sulfate un:methylsulfanylmethane
t1nnntWulLwtuLnWL
uMnM1u1ntt:uunu
vvn1v
23 Griseofulvin ,
Theophylline
5 nteraction Theodur v
Theophylline nt
Griseofulvin|nM Drug
interaction nuvlL
nnntWu Theophylline un:
Griseofulvin lLLuLnn|nM Drug
nteration M1uu 1nLnlvu
LnulM
24 Haloperidol 8 Toxicity/
Poisoning
Wtunuu
Haloperidol overdose
LnWuu1 lL
tL antidote
vlL
Wtutt:uu Haloperidol
overdose unLnWuu1 |tu
nu1 extrapyramidal symptom
(EPS) t1|tunnLn:u1nL
acetylcholine |MuuuL M1uu
antidote ltM1nnu|tu
anticholinergic lMun Benztropine
mesylate inj (Cogentin) lMuuuMu
ltluWlvuW 1-4 mg/dose un:
1-2 W1 iv or im
25 Haloperidol ,
Sodium
Valproic
4 Pregnancy/
Nursing
unt Sodium
Valproic un:
haloperidol nLn
lvluvu1lvuLtM
lMvlL
u Sodium Valproic un: haloperidol
nLnutn1uuLlM 1lL
uu:ulvltluvu1M1WD
2 Leptospirosis
, sulperazone
10 Therapeutic
Use/ Efficacy/
ndication
Wtu|tu
Leptospirosis un
t:lt
Sulperazone (
Cefoperazole +
Sulbactam) lun
nLlMvlL
nnL Leptospirosis MnM W
Penicillin G uuMn1nM W ,000,000
unit/day lMuut1lv 1.5 nuuuM
n tlL1 |tu|n 7 u vlv
Ampicillin 0M|uvnM|nMM uuM
lt W 4 g/day lMuut1lv 1 G n
tlL1 MMMnu 7 u nn
Wtuuw Penicillin wn
|nnlt Doxycycline 0M|uvnM
|nMM uuMlt W 100 mg n
12 tlL1 uu 7 u , nvt
Cephalosporin un: Lincomycin L
nuL|tulMMluv1Mn1 uMu1
lLwtnWnLluWtu
27 Lincomycin 11 Compatibility/
Stability
Lincomycin vn1WnL
:|ntllMuu|l
Lincomycin vn1nWnLnLn|nt
llMuu 24 hr nvDLv1
28 Montelucust Formulation Singulair 10 mg
film-coated tablet lv
lu|Mn|nnnLn
ulttMlMvlL
lMulu|nnnnt
uuu:ulv
tt:uMu|uu
untnLn
tt:u|nulM
vlL
nuLntL MSD wt Singulair
v Montelucust 10 mg film-coated
tablet nLntMlM lMutL
uu:ulvtMWnLluv|vn
vu |tu ln ltv|vn 1
tu vwMWMu 1 dose lL
uu:ulvtMWnLntu1|vn |tu
uvu |u1nLnt:ntu
luMtlLn:nuluulvtM
|tunu t1lv|Mntt:uu
lLvLM (W1ulLLntM,lLuL)
29 Ofloxacin 4 Pregnancy/
Nursing
Ofloxacin nLnlt
luvu1M1WDlM
vlL ( uWD 31
week )
Ofloxacin Mulu Pregnancy
Categories C lMuLu1un|nM
teratogenicity lunMMn1un:wt
lunWnLuttWtWLlunML
WD M1uu:ltuulMnM|Luul
t:lutulMWLntWL|nu1
uMuMnluWD|uu
u1lnMLLuLnnWnLutt
retrospective uu 25 nWnL
u1un|nM anomalies lu infants
uLlMtu Ofloxacin n1uL:
lLLu1u|nM major congenital
malfesmation nML M1uu1lLWlt
ofloxacin luvu1M1WD
30 Phenobarbital 9 Dosage/
Administration
Phenobarbital lv iv
WnLntnu:l
lMt1 un:lv rate
|llu|Mn
Phenobarbital nLn|unulMnt
nn:nu NSS , D5W , RS , LS
lMu dilute uMu sterile water 10
ml un:0Mutlu rate 25-50
mg/min ( maximum rate 100 mg/
u ) luWlvu un: 1 mg/kg/u lu
|Mn
31 Phenobarbital 7 ADR/ Side
Effects
Phenobarbital
nLn|nM cross
reactivity nt
carbamazepine vlL
unutnL Aromatic ring ulu
lW1n1 t1lMun Phenytoin,
Phenobarbital ,carbamazepine
wtLnuwuLnu ( Cross
reactivity ) lMn1 75% t1unutn
u:ltlMu1tnMDu lMun
Valproic acid, Gabapentin ,
Topiramate un: Benzodiazepine
32 Phenobarbital 11 Compatibility/
Stability
Phenobarbital inj
vn1n|1un
|ntlltlMnvlL
un:|ntllMuu|l
nnntnLtLWu|uu
Gardinal inj (Phenobarbital ) :t
vn1n|1unnLn|ntul
ltlMuu 15 tlL1nvDLv1 (
25 1W)
33 Phenytoin 3 Pharmacokineti
cs
Phenytoin LWW1
tM|tu|l
Phenytoin L elimination half-life = 22
hr ( range : 7 - 42 hrs ) oral
34 Phenytoin
Clonazepam
5 nteraction Phenytoin nt
Clonazepam nLn
|nM drug interaction
nuvlL
Phenytoin |nM Drug nteraction nt
clonazepam lMuL Significance
:Mt 4 (onset = delayed,day to
week, severity = modurates ,
documentation = Possible) t1
t:nuDwu1u phenytion v
clonazepam :nMn1v|nMwLn
Phenytoin lMunnlnn|nM W
n phenytoin ltn:Munnu
u clonazepam nuWnu1
clonazepam M phenytoin u1lL
tnnlnuutM nMn drugs
interaction Wlv observe
t:nuDwu1u1 2 M L1
n|nMwLnu Phenytoin uM
u1lnMLu1LulMuu1|1n
|nMwLn phenytoin un:nlL
nLnWtWLntnlM lMuL
clinical trial 2 u1u:t n
nlvu1 2 MWnulLLWnM:Mt
u phenytoin lu|nM
35 Piperacillin +
Tazobaetam
,Tazocin
11 Compatibility/
Stability
Tazocin vn1 dilute
|ntllMuu|l
Tazocin (Piperacillin + Tazobaetam)
inj vn1WnL|ntllMuu 48 tlL1
nvDL 2-8 1W un: 24 tL.
nvDLv1
3 Roxithromyci
n , Sypjilis
10 Therapeutic
Use/ Efficacy/
ndication
Wtu|tu Sypjilis
un:Lt:Muw
Penicillin :nLMu
Roxithromycin lM
vlL u1l
nLnlt Roxithomycin lun
nL syphilis lM lMultuluuuM
150 mg bid uu 14 u
37 Silver nitrate 10 Therapeutic
Use/ Efficacy/
ndication
50% Silver nitrate
solution nLnlt
u:|wWlM
vlL
nnntnL|DntnuWunWnMu
wt 50% Silver nitrate solution
nLnuLltt|nu:|wWlM
uMt|n:|tuuM un:lL
nnuntnlLLuWnt|nuu
38 streptokinase 9 Dosage/
Administration
unt
streptokinase L
unWnLuun:n
tvuu1l
unWnLuun:ntvuu1
streptokinase LWLuMnM1nuML
ut1lt M1u 1. acute myocardial
infarction : V 1.5 million units over
0 minutes. lMu dilute 2 X 750,000
unit vials lMult 5% dextrose 5 ml
un:|1lvlMnn:nu 1.5 million
units to 150 ml D5W lt|nlvu
uu 0 u 2. acute pulmonary
embolism ( APE) : V 3 million units
over 24 hrs. lMu dilute 4 X 750,000
unit vials lMult 5% dextrose 5 ml
un:|1lvlMnn:nu 3 million
units to 250 ml D5W lMulvu
250,000 unit ( 23 ml) lt|nuu 30
u MLMu 100,000 units/hour (
9 ml/ hours) for 24 hrs
39 Syphilis ,
Guildline
10 Therapeutic
Use/ Efficacy/
ndication
Syphilis ltu:l
nLlMnunn
Benzathine Penicillin
G
u|tu 1st choice lun Tx
Syphilis W parenteral penicillin G
vnWtuLt:MuwunnL
Penicillin uultlM lMun oral
tetracyclin 500 mg x 4 pc (14 day)
v doxycycline 100 mg x 2 pc ( 14
day)
40 Tetanus
toxiod
11 Compatibility/
Stability
Tetanus toxiod tuM
Multiple dose vn1|tM
ltunnLn|ntl
ltMlMuu|l
tetanvs toxiod tuM muitiple dose
vn1|tMltunnLn|ntlltlM
uu 24 tL. ( nvDL 2-4 1W)
41 Tetralogy of
Fallot
9 Dosage/
Administration
Wtu new born u
t:Ln 1 |Mu
uwuu0u|tu
TOF n1Mltw.L
uwulvuASA 15
mg OD unt
maximum dose |tu
|l
TOF uLn Tetralogy of Fallot
|tu congenital heart defect lMuL
WLWMtnMlu 4 Muvu1 lMun
ventricular septal defect (VSD) ,
pulmonic stenosis, overriding aorta
and right venticular hypertrophy
WtuLnLD: cyanosis nn
uMoxygen nLnnLMuu
WMMun:nltu nvtWtuu
uuwun1ltu ASA 15 mg OD
(uuMu ASA MuW 2-5 mg/kg)
WtuuuLuvun 2.915 kg M1uu
uuMu 15 mg WtulMt|tu
uuMun1nMlLLntt|wLlMn
42 Veraapmil 4 Pregnancy/
Nursing
Verapamil tuM
tt:unLnlt
luvu1M1WDlM
vlL
Verapamil Mulu Pregnancy
category C W wt teratogenicity lu
nMMn1uMlLwtvu1lLLuLn
nWnLuttWtWLlunMLWD
un:nMMn1 u1lnML
verapamil nLnWunlM t1n
nWnLutt Retrospective lu
nMMn1 (vu ,n:Mu) lLwtn
|nM teratoginicity uMt1nWnL
wt|nM teratogenicity un:|nMn
MuluvuMn1 lMu|tuWnL
nwLnu |u1nlvuuuMn1
nltluLuLun1 | unnu
LnWnLlunMLWDlut1 1 st
trimester wt|nM cardivascular
defict 1.3% uMuLnulLwt
WLnLwuu:v1untn|nM
cardiovascular defect M1uuWWnM
u1unLnltlunMLWDt1
1 st trimester lMlMutWn fetal
problem
43 Vitamin B 12 3 Pharmacokineti
cs
Vitamin B12 inj ut
Wu1lM M1tt
uuMuluWtu
dialysis vlL
Vitamin B12 inj v|unnt
Mecobalamin v Cyanocobalamin
nnutn1uMun:nn Convert
|tuactive enzyme lu|u|u Wu
:ttlvn|uu|nMMt (extemsive
enterohepatic recycling) Lt1nu
nnutn1lM 1lLLuLnn
ttuuMuluWtulWlM
qs
Drug
nformation
Handbook
MM
Hanbook on
njectable
Drug
website :
www.google.c
om
website :
www.pharmac
y.psu.ac.th
WLuu1
ntvu
0M|wnM
WL|nu1
1uDS
Drug
nformation
Handbook
MlWMM
|t
u
WLuu1
ntvu
0M|wnM
WL|nu1
1uDS
website :
www.google.c
om
website :
www.google.c
om
website :
www.wikipedi
a.org
Drug
nformation
Handbook
website :
www.globalph
.org
WLnltu
nvt
tWnn
nunnu
Martindale 33
th edition
u
website :
www.wikipedi
a.org
Drug
nformation
Handbook
Up to Date
database
website :
www.wikipedi
a.org
Drug
nteraction
Facts
Drug
nformation
Handbook
Drug
nformation
Handbook
www.google.c
om
WLuu1
ntvu
0M|wnM
WL|nu1
1uDS
Wuuu
Singulair
tL MSD
Drug in
Pregnancy
and Lactation
, th edition
www.
vhpharmsci.c
om
WLn
t:|Luun:
MMML ADR
uLnn
tLu
Drug
nformation
Handbook
Drug
nformation
Handbook
tLWWnM
website :
www.thailabo
nline.com
1uWnMu
w.n1un
Up to Date :
database
website :
www.wikipedi
a.org
|nnnnt
u
website :
www.wikipedi
a.org
Drugs in
Pregnancy
and Lactation
, th edition
Drug
nformation
Handbook
nM
t
tu ID
type
t:|D
WnL
WnL WMt
1 Amitriptylin
e
04 Pregnancy/
Nursing
untL
u1un|nM
teratogenicity u1
nuLlMt
u'Amitriptyline
un:M1WDvlL
nnntWuwt L
nWnLLnMMMLn
uu 522,630 u LM
lMtu 'Amitriptyline un:
M1WD 1uL 86 ulMtu
lut1 1 st trimester wt 1 uL
D:nt (uMu1lLlM
uuuuu1tM|u|nMn
Amitriptyline ) wt 4 uL
WLWMtnM L un:|tL
lvuntnM nunnWnL
|tunWnLlun 229,1010
u wtnLWLWMtnM
25 u (5.4) nLM
lMtu Amitriptyline lut1 1
st trimester M1uunltu
'Amitriptyline luvu1M1WD
Wwnt:lutun:WL
|nu1:lMt
2 Fluorouracil
,
Methotrexat
e
08 Toxicity/
Poisoning
unt antidote
u1u
methotrexate un:
Iluorouracil
lLL antidote nvtu
methotrexate un: Iluorouracil
1uvnWtulMtu|nuuuM
lvttMM1u 1.methotrexate:
nwL lMun Wnuln |uu
WL1 :|tunMun:lM
u unLnwL W n
hydration un: alkalization :
tut1nunMnM:nuu1
MTX un: metabolite u1LulM
v hemodialysis 2.
Iluorouracil nwL lMun
Wnuln |uu 1|nu WL1
lvnnLutt:Wtt:W1
MLn un:WMMML CBC
u1lnntM
3 Augmentin
Prednisolone

Pseudoephed
rine
04 Pregnancy/
Nursing
u augmentin
prednisolone un:
pseudoephedrine
nLnltluvu1
M1WD 2 |Mu
lMvlL
u augmantin t:ntMu
amoxycillin un: cavulanic acid
Mulu preg cat B nLn
ltlMluvu1M1WDnuu
prednisolone Mulu preg cat D
lut1 1 st trimester Lu1u
n|nMntlM 1W
vnn|nu1 nltu un:
pseudoephedrine Mulu preg
cat C Lu1un|nMn
tlM WwnWL|nu1
ntt:lutu|nMuu nnlMu
nt Wvnn|nu1nltu
prednisolone un:
pseudoephedrine nu augmantin
nLnlvlM
4 CeItriaxone
, Gentamicin
09 Dosage/
Administration
unt
uuMu ceItriaxone
un: gentamicin
ltlunnt1nu
n|nM severe
inIection luWtu
|Mn
uuMu ceItriaxone ltlu
nnt1nun|nM severe
inIection luWtu|Mn W 80-100
mg/kg/day ut1lv 1-2 W1
(maximum dose 4 g/day) nu
uuMu gentamicin ltW 2.5-5
mg/kg/dose ut1lvn 8 tlL1
5 Cerebrolysin 09 Pregnancy/
Nursing
cerebrolysin
nLnltluvu1
M1WDlMvlL
lLwtu1un|nMwLMM
ulunMlMt cerebrolysin
un:u1lLwtuLnnWnLlu
LuLuluvu1M1WD
lMu|0w:t1 1 st trimester
L1luvu1lvuLtM M1uu
1Wlt|L|tu1 lMulv
Wu1n1WL|nu1ntt:lutu
:lMt
6 Chikugunya,
tWunuu
20 u ('
pathology)
WtuLWuuw1M
uLun:|tL
uwuu0u
|tulWtWunuu
unulW
ulv|nMn
M1nnlMvlL
lWtWunuu |tunMM|t
ln Lu1nu|tuwv: lMu
Wtu:Lnlun1u1
|0utwnu LWuuM1ML1nu
MuM1 n|Mu W tMML
u wtun|nt|0utwnu
lMuLnuuu|tu
ntMvv|tu|Mu u1lLL
nnL|w:nvtlWu
uM:lvnnLutt
t:Wtt:W1
Chloral
hydrate
06 Formulation Chloral hydrate ML
|DntMt:L
nut:ntu1
paraben concentrate
vlL M1|ntl
luM|uuvlL
un:|ntlMuu
|lv
Chloral hydrate syrup u1 w
n1un WnMMLMt|Dnt
l1wutn0tttt 2006 t1L
paraben concentrate |tu
nut:ntluMt t1
l1wutnn1unnvuMlvu
Luvn1WnM|tu|n 6 |Mu
lMu|ntlluM|uu|wnL
WLW1Mu1u
8 Chloroquine 0 ADR/ Side
EIIects
Chloroquine lt
:u:|nlun
|nM
photosensitivity
uu|lv
nnntWulLwt:u:|n
lun|nM photosensitivity n
u Chloroquine uMLu1u
nLnlv|nM
photosensitivity nu
Chloroquine lM wtuMD:
Pruritus |nMlMvn1nltu
lt 6-48 tlL1 D:nWL|tnuu
Ln|nMvn1lMtu 2-5 |Mu
9 Cloxacillin ,
Clindamycin
03 Pharmacokinet
ics
untu
Cloxacillin un:
Clindamycin M1
ttuuMulu
WtulWlMvlL
u Cloxacillin un: Clindamycin
lL|tuM1ttuuMulu
WtulWlM uM clindamycin
:M1ttuuMu|0w:lu
WtulWMt|tu severe hepatic
disease |uu
10 Cloxacillin 03 Pharmacokinet
ics
u 'Cloxacillin L
halI-liIe |lv
u 'Cloxacillin L elimination
halI-liIe |nt 0.5-1.5 tlL1
luWtuD:lMtnM
11 DeIeroxamin
e
methanesulI
onate
(DesIeral)
09 Dosage/
Administration
unt
DeIeroxamine
methanesulIonate
(DesIeral) WnLnt
nn:nulMlM
t1 un:Lun
lvuu1l
DesIeral |unulMntnn:nu
NSS , D5W uuMulvlu
WlvuW 1.acute : ltuuMu
1000 mg lt|nlvu 15
mg/kg/hr ( v 40-50 mg/kg/hr)
uMlL|nu 125 mg/hr MLMu
500 mg q 4 hr (maximum dose : 6
g/day) 2. Chronic: utt im lt
uuMu 500-1000 mg/day (|
1u 500 mg : SWFI 2 ml) 2. iv
(patient with severe toxicity) : lt
uuMu 2 g (max rate 15
mg/kg/hr) Note: n:nuu 500
mg Mu SWFI 5 ml unWnLnt
NSS v D5W 150 ml
12 Domperidon
e
,Metoclopra
mide
1 Pharmacology/
Mechanism
oI action
nnlnu1
domperidone un:
metoclopramide
uMnM1nu
u1lW
uLltLnu
vlL
metoclopramide nnuutu1
nWnuln|uulMuutu1
dopamine (D2) receptor 1
peripheral un: central nervous
system uMvnlvuluuuMn1
:LWnutu1 serotonin receptor
Mu nu domperidone n
nuutu1 dopamine (D2)
peceptor |0w:nuperipheral
lvlL|nMn
extrapyramidal symtom |vLuu
metoclopramide un:lLLnu
utu1 serotonin receptor un:
nnntWuuLnwtlLL
guideline vuLnlMuu:u
lvltu metoclopramide un:
domperidone Lnu |u1nL
nnlnnnnulnn|Wu1nu
lMun|nnltuLn|nnlt
metoclopramide luWlMtu
vn|WLun:|nMnWnuln
13 Flunarizine 0 ADR/ Side
EIIects
Ilunarizine L
unn
u1|Wu1
nLnlvvu
tLlMvlL
nu1u spontaneous ADR
2005 wtLu1un|nM
D: Iace edema 3 u , oedema
1 u un: mouth oedema 2 u
14 Flunarizine
Pregnancy
04 Pregnancy/
Nursing
WtulvuLtM
nLnltu
Ilunarizine lMvlL
nnntWuuLn lLwt
uLnnutun1uuL
u1u Ilunarizine uMu1ln
MLlLwtuLnuuuun1
WLtnMDuMnluuL
lMtu M1uu1Wltulu
nnLWL|tu1|uu
15 Fluoxetine,
Clonazepam,

Phenobarbit
al
04 Pregnancy/
Nursing
nLnlvu
Fluoxetine,
Clonazepam,
Phenobarbital lu
vu1M1WD 2
|MulMvlL
clonazepam Mulu Pregnancy
category D lMuwtu1un
|nM oroIacial cleIts , cardiac
malIormations luWtulMt
uu uMlunWnLMLnnt
lLwtu|wLWL|nu1lun
|nMWLWMtnMM1nn t1
vn|tuM1ltu
wnltluWtu|tu severe
anxiety disorder nu Fluoxetine
Mulu Pregnancy category C
|tuunLn|nnltlMnn
LWL|tuM1ltulMu
Wu1n1WnMun:Wn|nu:
lMt nu phenobarbital Mu
lu Pregnancy category D 1W
vnn|nu1nltuuluvu1
M1WD
16 Folic acid 0 ADR/ Side
EIIects
Folic acid lv
|nML |tLlM
vlL
nnntWuwt Folic acid
lv|nMnu1|Wu1lMuu
nwtlM lMun Wu
uM1vnMnLvMM Wnuln
|uu ntnu Mu|Mu uMlLwt
u1un|nML|tL
1 Erythropoiet
in , Epoetin
, 'Hemax,
Recommon
10 Therapeutic
Use/ EIIicacy/
Indication
unt
Hemax un:
Recommon L
eIIicacy uMnM1
nuvlL W
|nnltMlM1:
WLW
nnWnLwtHemax un:
Recommon L eIIicacy lL
uMnM1nu uMuMnM1lu
|1u1Wun:nuu1Wtu
lunnL 1u Hemax LW
62 t/ 4000 iu nu
Recommon Wt:Ln
1430/500 iu t1lMuWMWM
ntMvwt Hemax L
Wltuuunun:nLnlt
luWtutM1lM luun:
Recommon lLnLnlt
nutM1lM
18 BacloIen ,
Carbidopa ,
Comtan ,
Entacapone
,
Haloperidol
, Levodopa'
,Levomed
0 ADR/ Side
EIIects
WtulMtu
levomed , bacloIen
un: haloperidol
lMuWtu
tt:uu
u1M|u1
Duvn1lMtu
comtan |wLLn 1
M un:|nMD:
hypotension un
tn
M1nnu:|nM
nuMlM
u levomed (t:ntMuu
levodapa 250 mg un: carbidopa
25 mg) , bacloIen L1
haloperidol nLnlv|nM
nu1|Wu1|nunt:tt
cardiovascular lM lMulv
|nM orthostatatic hypotension,
arrhymia, chest pain, hypotension,
syncope, palpitation, phlebitis t1
|LWtulMtu comtan
(entacapone) |wLL 1lv
|wLWL|nu1u1n|nMD:
hypotension |wLuu ( comtan
nLnlv|nMn
orthostatatic hypotension lM
4.3) t1nvtWtuuu
M1wnttuuMulvL
WL|vL:nLMlt
19 MetIormin 09 Dosage/
Administration
lt metIormin 850
mg 2x2 lMvlL
uuMu metIormin n1nM|nt
2.55 G Mu nltuuMu
850 mg 2x2 :lMuuMu 3,400
mg v 3.4 G Mu t1|nu
uuMun1nMMuu1
metIormin uMu1lnML
nLnltlMluuuM 850 mg
utt 1x3 Mu
20 Metoclopra
mide
01 Pregnancy/
Nursing
u metoclopramide
nLnltluvu1
M1WDlMvlL
u metoclopramide Mulu
Pregnancy category B t1u
nLnWu1nltnnlM
uMu1lnMLnLnltuu
lMWuu1tnMDuMnM
:u:|nM1DD
21 NiIedipine 09 Dosage/
Administration
untuuM
u niIedipine lu
Wlvu
uuMu niIedipine luWlvu W
initial dose : sustained release 30
mg un:W1 v 10 mg 3
time/day , usaul dose : 10-30 mg 3
time/day v 30-60 mg un:
W1 (maximum dose): 120-180
mg Mu (nLn|wLuuMu
lMlut1 -14 u) 1ulL
|tuM1ttuuMulu
Wtu hemodialysis un:
peritoneal dialysis nvtWtu
Ln1uu1Mtwnw1
WnMuuMun1 50-60
22 OIloxacin 4 Pregnancy/
Nursing
vu1lvuLtM
nLnlv
OIloxacin lMvlL
OIloxacin nLnutWuuuL
lMuMlutLnuu (Relative
inIantdose 3.2) American
academy oI Pediatrics (AAP) :t
nLnltuulMlunMlv
uLtM uMu1lnMLL
u1un|nM arthropathy lu
Muu1nMlMtuu
M1uu1WltMuWL
:LM:1lunMlvuLtM
23 Omeprazole
(Ocid)
11 Compatibility/
Stability
Omeprazole (Ocid)
vn1WnLun|nt
luu|l
nnntnLtLWuu
vuu 0cid (Omeprazole ini )
u1|Ln:nuulu SWFI 10
ml nLn|ntllMuu 4 hr
nvDLv1 un:vn1|1
Mu D5W v NSS 100 ml :
|ntllMuu 6 hr ,12 hr
MLnMtnvDLv1
24 Omeprazole 0 ADR/ Side
EIIects
omeprazole
nLnlv|nM
nu1|Wu1
uuuvunlM
vlL (u1vLM
Wtult W
omeprazole
domperidone air-x)
omeprazole lv|nMn
uuuvunlMuun 1
lMunu1|Wu1wtlMtu
:LntMWL: (3-) Lu
11 (3-4) 1|nu (3-4) tM
1 Wnuln (2-5) nuu
domperidone un: air-x lLwt
nLnlv|nMnuuu
vunlM
25 Penicillin ,
PGS
11 Compatibility/
Stability
PGS nLn|ntl
luM|uuvn1|tMlt
W1unuu|l
PGS vn1n|tMltW1un
nLn|ntlluM|uulMuu
u un:|ntnvDLv1lMuu
24 hr
26 Phenytoin 3 Pharmacokinet
ics
WtuL liver
enzyme n1nLn
ltu phenytoin lM
vlL un:ltu
:llMt1
unutnWvnn|nu1lu
Wtun1uu1Mt
tnw1 W Phenobarbital ,
phenytoin ,carbamazepine,valproic
acid |u1nwtu|vnu
lv|nM hepatotoxic lMLnn
antiepileptic agent tuMu
nuWtuLn1uu1Mt
tnw1nLnltunutn
gabapentin , topiramate, un:
levetiracetam lM|u1nlLnn
metabolize WuMt 1|nM
hepatotoxic lMuu un:unutn
luw.nLn|nnltlM W
gabapentin un: topiramate nu
u clonazepam un:
oxcarbazepine lvltlM|L
|tu|u1nLn metabalize
WuMt|tunulvu
2 Phytonadion
e , 'Vitamin
K
9 Dosage/
Administration
Vitamin K 0M iv
push lMvlL
WnLntnu:l
lMt1
Vitamin K v Phytonadione
nLntvulM1utt im,
sc, iv push un: iv inIusion lMu
lvuutt iv push :lt rate lL
|nu 1 mg/ min nunu
nLnWnL|unulM W D5W ,
D5S , NSS , un: RLS
28 Potassium
chloride
11 Compatibility/
Stability
Potassium chloride
ini un: Sodium
chloride ini
nLnlv1nu
|MunulMvlL
Potassium chloride ini un:
Sodium chloride ini nLnlv
1nu|MunulM
29 Rabies
vaccine
20 Others untM1
nlv rabies
vaccine
nlv PCEC 1 IM 1,2,3,4
1.Post-exposure,not previously
vaccinated lv 0.5 ml IM u 0 3
14 28 un:lv human rabies
immune globulin 20 International
Units/kg IM 2. Post-exposure,
previously vaccinated lv 0.5 ml
IM u 0,3 3. Pre- exposure,
primary immunization lv 0.5 ml
IM u 0 ,,21v 28 4.
Pre-exposure,booster
immunization 1 ml IM lvML
WL|tu|w maintain serum
titer lvLn 1:5 (WtuL
WL|nu1 test n 6 |Mu lLL
WL|nu1 test n 2 t )

un:nlv PCEC 1 ID 1,2
1. Post- exposure, not previously
vaccinated L 2 regimens W
8-Site Regimen uun : 0.1 ml
30 Roxithromyc
in
04 Pregnancy/
Nursing
u roxithromycin
nLnlvluvu1
M1WDun:lvuL
tMlMvlL
nnntWulLwtuLnWL
tnMDuu1nltu
roxithromycin luvu1M1WD
un:lvuLtM M1uuW
vnn|nu1nltuuvnLWL
|tuM1ltuM1nn W|W
:1u1lnntM
31 Tatenus
toxoid
09 Dosage/
Administration
WtulMttatenus
toxoid lMulMt
dose unluu 31
L W 52 un: dose
2 u 2 nw 52
unt:L
uunluu1l
u tatenus toxoid Lun
tvutt im lMulvuuuM
0.5 ml lu dose un un:lv dose
2 tluntMv 4-8 vn1n
0Mu dose un un:lv dose 3
lu|Mu 6-12 vn1n dose
2 M1uuluWtuuu
wnlv0Mu dose 2 lvL
luntMv 4-8 utnu 2
nw 52 un:uM0M dose 3
MLlu|Mu 6-12 vn1nuu
1ul1wutnn1un
nvuMlv0Mulu|Mu 0, 1,
M1uuuuWtuuW0Mu
W1Mltluu 2 LW 52 un: 2
nu 52 MLnMt
32 Tolterodine 0 ADR/ Side
EIIects
u tolterodine
nLnlv|nM
nu1|Wu1 v
l|MuWM1v:
utt Iibrillation
lMvlL
u tolterodine luuuMn1
nLnlv|nMnu1|Wu1
lMunLnlv|nMD:v
l|MuWM1v:LnnLn: QT
prolong v tachycardia lM (
1) uu:ulv:1nltu
tolterodine luWtuLD:
congenital prolong QT v
WtulMtQT prolonging drug
(class Ia v III antiarrhythmics
drugs) 1uWtu|nMn
u1|Wu1M1nnuu:ulv
|tnuultltuMuuu
33 Hepatitis
Vaccine ,
nnln
09 Dosage/
Administration
nLnlt vaccine
nnln un:
vaccine hepatitis
wLnulMvlL
nlt Vaccine nnln lu|Mn ~
12 t lv0M 2 |uL v1nu 4-8
ntMv nu vaccine hepatitis A
lu|Mn ~ 12 t lv0M 2 |uL v1
nu 6-12 |Mu nuLnwt
nLntv vaccine 2 tuM
u1MuwLnulM lMutv
uuuWun:u1 un:WMMML
nlu |u1nvaccine 1
n1lv|nMnlulM
34 Vitamin B1 9 Dosage/
Administration
VitaminB1 v
Thiamine nLn
tvuutt iv
push v iv drip
lMvlL vn drip
Wlt|nuu
|lv un:
nLnWnLlu
nulM
VitaminB1 v Thiamine
nLntvuutt im v
slow iv uut:Ln 30 min
lMunultlMun D5W v
0.9 NSS
35 Vitamin C 09 Dosage/
Administration
uuMu1 Vitamin
C ltnvt
t1nuvM |nt
|lv
uuMu1 Vitamin C ltn|w
vtt1nuvM |nt 1-3 g
Mu uM|LMuLn1|Dnt
nuWnMu1u wt n
MMtLu1u:|nMuuu1
nMvn1lvluuuMn1 (|nu 1 g
/u) t1uuM 1.5 g /u wt
nMMtLu1MLut :nMn1
|vn 50 M1uuvnltn|w
vtt1nuvM uu:ulv
tt:uuuM 1g Mu t1
wtlvWnlunnMWL
uu1un::u:|n|tuvM
uMlLlMtunMtMnnlun
|nMvM
36 AlIusozin ,
Xatral XL
09 Dosage/
Administration
Xatral XLL max
dose |lv
uwun1 1x2 |Wu
LnWnLn1n
ltuuuMuL
nuvlL
Xatral XL L max dose |nt 10
mg Mu nnntWu
uuLn pubmed wtlL|Wu
LnWnLnlv AlIuzosin
utt extended release uuM 20
mg MuLnu uuMtnMlt
W AlIuzosin utt extended
release 10 mg Mu
3 Sermion ,
Nicergoline
10 Therapeutic
Use/ EIIicacy/
Indication
Sermion L side
eIIect Mu
cardiovascular
vlL
Sermion (nicergoline) L side
eIIect W GI disturbance ( nnlL
ntulut11 ) L
Hypotension |nnuu lMu
lLlMnnn1 side eIIect 1
cardiovascular u1u
38 Silver
SulIadiazine
13 Storage Silver sulIadiazine
nLn|ntlu
M|uulMvlL
silver sulIadiazine nLn|nt
lM1luM|uuun:nvDLv1
( 25 1W ) t1:nLn|ntlM
uu 3 t ML0nn:t uMlu
nn|ntlnvDLv1
Lnn 25 1W :|ntlMuu
n 3 t |tu nvDL 40 W
nLn|ntlMuu 2 t
39 Sodium
valproate
6 Formulation l1wutn
n1unL Sodium
valproate lu
tutt Iorm
:lt1
Sodium valproate lul1wutn
n1un L 2 dosage Iorm W 1.
Sodium valproate 500 mg control
release tablet 2. Sodium
valproate 200 mg/ml syrup
40 Valproic
acid
11 Compatibility/
Stability
Valproic acid vn1
WnL:|ntllM
uu|l
u Valproic acid lututtu
0MlLlM|ML preservative 1
nLn|ntnvDLv1lM
|wu1 24 tlL1
41 Ventolin 11 Compatibility/
Stability
Ventolin solution
un: Beradual
solution vn1n
|tMltun|ntlM
uu|l
Salbutamol solution ( Ventolin )
vn1n|tMlt|ntlMuu 1
|Mu nvDL 25 1W
un:M1|ntlvwuun1 nu
Beradual solution vn1n|tMlt
|ntlMuu 6 |Mu un:uu:u
lv|ntluM|uulMulL
|tuM1t1nuun1
42 Vitamin K 3 Pharmacokinet
ics
Vitamin K 10 mg IV
L duration oI
action uu|l
(WtulMt vit K
u 30/5/51 un:
lMtu warIarin
utt low dose
MLluu
3/6/51 uwutt
uuMu warIarin
uu|tu high dose
|u1n INR u1
Mu )
nlMt Vitamin K IV :
lv prothombin time tnMlu
:u:|n 12-14 hr. vn1lMtu
un:L duration lunnnu
t:Ln 24 tlL1 ( nn low
dose vit. K 5 mg ) nunnlt
high dose wt duration oI
action u1 Vit .K :uuuuu
|tuntMvlM M1uu1W
ltu warIarin luuuM|MLlt
nu unuMWtuLMMML
INR u1lnntM
qs
website :
www.
Drug
InIormation
Handbook
u
uuLn
up to date
website :
www.
website :
www.
|DntMt
l1wutn
t 2006 ,
1u|Dnt
nLn
WnM
AHFS: Drug
InIormation
Drug
InIormation
Handbook
Drug
InIormation
Handbook
WLu0M
w n1un
u
spontaneous
ADR 2005
uuLn
Up to date
WLnlt
unvt
tWnn
nunnu
AHFS: Drug
InIormation
website :
www.
Drug
InIormation
Handbook
AHFS: Drug
InIormation
uuLn
up to date
Drug
InIormation
Handbook
WLnlt
unvt
tWnn
1
nuwu
u (
tLu)
Drug
InIormation
Handbook
WL
uu
1n
tvu
0M|wnM
WL|nu1
1uDIS
u
Hanbook on
Iniectable
Drug
uuLn
up to date
v}{
MIM
website :
www.
uuLn
up to date
WLWtu
Hanbook on
Iniectable
Drug
website :
www.
AHFS: Drug
InIormation
v}{
website :
www.
v}{
AHFS: Drug
InIormation
AHFS: Drug
InIormation
AHFS: Drug
InIormation
nM
t tu IDtype t:|DWnL WnL WMt
1 Albendazole 10
Therapeutic Use/
EIIicacy/
Indication
Albendazole 400*2 # 30 tab lt
nLlW:l
Albendazole : oral : - neurocysticercosis
( M1uunL1) : 60 kg : 15
mg/kg/day unlvun: 2 W1 uu
8-30 u ~60 kg : 400*2
-
2 ceIazolin 7 ADR/ Side EIIects
WtuLt:MuwunnL sulIa
nLnltu ceIazolin lM
vlL
ceIazolin lM|u1n|tuu
Antibiotics Wun:nnLnulW1n1u
uMnM1nu lLLn cross reactivity
3 ceIazolin 11
Compatibility/
Stability
CeIazolin |1luuun1
lMutt periternal dislysis lM
vlL vn1|1|ntllM
uu|l
nnntnLuLnuun1lM
t:ntMunvnutuMuMn
nntWulu Handbook on iniectable
wtLuLn|0w:|LWnLnt D5W
un: 0.5 NSS t1nLnWnL|u
nulM
4
ceIoperazone
sulbactam
9
Dosage/
Administration
untuuMuu1
sulperazone un:nlv
sulperazone 2 g v q 12 h |tu
uuM|vL:nLvlL
tuttu1u sulperazone W
sulperazone 2 g :L ceIoperazone 1 g
un: sulbactan 1 g nvtuuMuu1
sulperazone :uuuntut1ltM1u
- InIectious
disease oI Abdomen : ceIoperazone 2 g
q 12 h - UTI : ceIop
5 ceIotaxime 10
Therapeutic Use/
EIIicacy/
Indication
normal dose u1 claIoran lu
WutnM
uuMutnMltu1nlt
ceIotaxime luWlvuun:|MnLu
Lnn 12 t uult:ltluuuM 1-2
g IV Q 12 hr lMunLuuun 12
t :ltluuuM 50-100 mg/kg nu
t1uuMuulvuuMulL
|nuluuMn:lWlM |tu n|tu
septicemia 2g iv q6-8hr, skin inIectn 1g
iv q12hr, abdominal inIectn no
complicat 1g iv q12hr,c complicate 1-
2g iv q8hr, bacterial meningitis 8-12g iv
q4-6hr
6 CeItriaxone 7 ADR/ Side EIIects
u ceItriaxone L ADR lv
|nM pancytopenia lMvlL
u Antibiotics Lnu1|Wu11
hematology lv norrow damage
lMun chloramphenical , penicillin ,
cephaIosporins , sulIonamides ,
amphotericin B , dapsone, sterptonycin
t1tulunnL cephalosporins
lv|nM pancytopenis lM lMu
ceItriaxone wtn|nM eosinophilia
(6), leukopenia(2.1),
thrombocytopenia(1), neutropenia
(1) t1nu1|Wu1u:Muu
vnvuMuu1M| lunlvu
1WMMMLM CBC Wtu
|nu1Mn|nMD:pancytopeniaMu
7
Cloxacillin ,
ceItriaxone
7 ADR/ Side EIIects
u cloxacillin un: ceItriaxone
vnlvwLnu:lv|nM
nuwuttvuuM1 MuM1
n0M cloxacillin lLlMLu1u
lv|nMvuuM1 (Ilushing) uMn
0MceItriaxone wtu1un|nM
Ilushing 1 nunlvu1 2 M
LnunlLlMlv|nMnvu
uM1|wLLnuu uMuuunt rate lu
ntvu1n1M lMu
CeItriaxone lvutt iv bolus 0M|u
1vnM|nMMlu|nlLuun
2-4 u |wt1nuD:vnM
|nMMn|nt lvutt iv inIusion
|tu|nlLuun 30 u nvt
u cloxacillin lvutt direct iv t
uu 2-4 u lvutt iv inIusion
uu 30-40 u vn0Mu1 2 M
lvWtuunWtuLnvuuM1n
lvttntvulMu|wL|nlu
n inIusion lvuuuu
8 Dicloxacillin 4
Pregnancy/
Nursing
DicloxacillinltluWtuM1WD
6 |Mu lMvlL
Dicloxacillin Mulu Pregnancy
categom B nLnltlMu1
tnMDuluvu1M1WDn trimaster
9 Doxazosin 11
Compatibility/
Stability
Cadura XL nLnvnut1W1
lMvlL
Cadura XL v u Doxazosin
mesylate controlled - release 4 mg tab
t1uulututttnMtnuMu
nLt nunnLuuuu
lLM1tt:uutu vnut1
W1|LMu:lv|nunDwn|tu
centrolled release un: u:
tnMtnunLluulvWtu
lMtuluuuM|nunuwu
M1n uu:ulvltuuM 2 mg M
|LM
10 epoetin 9
Dosage/
Administration
Wtuuu Hemax 4000 iu L
nw.n1un wLL NSS 2
ml lLtlt:l
uuMuLn|nuvlL
Hemax L generic name W epoetin
uuMu|LMu 25-50 iu/kg iv v sc
ntMvn: 3 W1 uuMun1nM W
200 iu/kg ntMvn: 3 W1
l1wutnn1unn1tuntL
Bio sidus t1u 1 nn1:
t:ntMu Mu epoetin uttW1
11 epoetin 9
Dosage/
Administration
Wtuuu Hemax 4000 iu L
nw.n1un wLL NSS 2
ml lLLtlt:l uuM
uLn|nultvlL
Hemax L generic name W epoetin
uuMu|LM 25-50 /| v sc
ntMvn: 3 W1 uuMun1nM W
200 iu/kg ntMvn: 3 W1 M1
wutnn1unn1tutL bio
sidus t1u 1 nn1 :t:ntMu
12 ERIG 9
Dosage/
Administration
ERIG LnnvuMuuMu
n1nMlvlM (Maxinum dose )
vlL |u1nuuMulv
:uuntuvunMWtuvn
WtuLuvunMLn:unlu
lMu1l
nnntnLtLu ERIG v
Equine rabies immunoglobulin uuM
tnMltW 40 IU/kg lMuu1lLL
reIerence nvuM maximum dose
u1 ERIG M1uu1tL1uu:u
lv0MuuuMMLuvunMu1
Wtu uLWtu:LuvunMLn
13 Iamciclovir 9
Dosage/
Administration
Iamvir ltnL recurrent herpes
simplex utt long term lt dose
|lnuuu|lM1
moniter :l un:L1uu
1tLt:nuDwvlL
Iamvir v Iamciclovir nLnlt
nL Recurrent herpes simplex un:
nLnltt1nu nnnt|tutu1
herper simplex lM t1nt1nuuu
WltluWtuLWLuu1lun
nnt|tut
14 Iusidic acid 7 ADR/ Side EIIects
Iusidic acid L SIG lv
1|nulMvlL
Iusidic acid : ADR signiIicant : GI :
anorexia , dyspepsia , diarrhea ,
epigastric , distress , n/v
15 Glycerin 11
Compatibility/
Stability
Wtu|tu Peptic ulcer lv
glycerin WnLluunLunL
ntMunt1WlvWnL
lunn:nulM
Glycerin nLnuu:ulvWnLlu
u|tnlM vnWtutt:unt
unLuntM11uu:ulv
|tnuu|tuWnLluu|tnuu (n
uu:ulvWnLluunL|u1n
nntntMlLuu1u) M1uu
|wWLtnMDuun:t1nun
u1|Wu1luWtuuu1lLWlt
unLt1L pH 3.5
16 heparin lock 9
Dosage/
Administration
pt. on heparin lock Ln|MuL
WnLuu1l
uuMWL|uLuulvt:nuDw
lLlM:tltM|uluuuLntn
WL|uLuu 100 units/ml nMD:
pheblitis lM w.|nnWnMDnv
WL|uLuu 50 units/ml |un
heparin 1:100 Ior Ilushing (heparin
conc. 5000 units per ml diluted in 0.9
NSS qs
17
HPV ,
Cervirix
2 Availability
l1wutnn1unLWtu
t1nuL:|1tnLMnnvlL
u0Mu1l t1nulMnt
Wtut1nuL:|1tnLMnnL
n|vMn|t Human papillomavirus
(HPV) type 16,18 Lut1lt nLn
t1nulMu1Lt:nuDwlu
Wvu1u 15-25 t lMu0M 3 dose W
|Mu 0,1 ,6 LuLn1Wnun
un:unnLnt1nulMuuu1
uu 5 t n0MluWlvuu 26-56
t lLLuuu:ulv0M|u1nn
0MLt:lutunu1lL|WuL
|wWnLwuuLnu
18 Kaletra
7,10
,11
ADR/ Side EIIects
1.nuu kaletra unLn
tM1Ln 1|nu :vuM
nuuMvlL 2. nuu kaletra
|wt1nunMM|t HIV
M1nuuu|l 3.kaletra L
WnMMtvlL 4. kaletra |nM
DI nt Omeprazole vlL
1.Kaletra t:ntMuu lopinavir
ritonavir :Lnu1|Wu1wttu
W 1|nu (5-27) Wnuln (5-16)
,tM1 (2-10) , |uu (2-14)
lLWvuMnuulvnuM|u1un:
nuut1nu/nL 2. u kaletra
|wt1nunMM|t HIV uu 28 u
19
KCL,Ca
gluconate
11
Compatibility/
Stability
nLnWnL KCL nt Ca
gluconate lMvlL
nLnWnL KCL nt Ca gluconate lM
20
medroxy
progesterone
14
Compatibility/
Stability
Wtuvu1 LlWt:M W
lWvl nLnuu|nu
t:|MulMvlL
nLntt:ulM uMlLWu
|nu 10 u un:lLWuMMMnu
vnuW1
21 Methotrexate 9
Dosage/
Administration
WtuWDlutnn L:Mt
Beta-HCG n1 uwuM1nn1
lt0Mu Methoterxate Wlv
luuuM|l
nlvnLnlvlM 2 tutt W
1 . single dose
lv IM uuM 50 mg/m2 luuun
u1nnLun:uu:ulvMM
:Mt HCG W1 2 luu 7 vn1lv
u - nnM:Mt HCG luu 7
un:lLlMnMn1 25 nuun -
nnM:Mt serum HCG lu
:v1u 4 un: 7 nMn1uun
15 WlvWtulMt MTX 50
mg/m2 W1 2 vn1nuunMM
:Mt serum HCG vn1nulvu
M|u1uu 4 u nuuMMML
serum HCG nntMvun:1
MlL| uuMun1nMlL|nu 3
dose 2. Multiple
dose lv MTX 1 mg/kg/day lu
tutt im v iv luu 1,3,5 un:
7 Lnt oral leucovorin 0.1 mg/kg
luu 2,4,6 un: 8 MMMLM:Mt
serum HCG luu 1,3,5 un: 7 -
vnwt serum HCG nMn1 ~15
n|MLnnLnvuMlvulM -
vnwt serum HCG nMn1 15
22 Misoprostol 9
Dosage/
Administration
uuMu Maximum dose u1
cytotec lututtu|vutt1
WnM |tu|lluWlvu
uuMultluWlvuuuntnD:
u1WtuW 1.
Abortion 800 mcg vaginally time one
dose 2. Cervical
ripening procedure (induction oI labor)
23 Nicardipine 11
Compatibility/
Stability
Nicardipine WnLntnu:l
lMt1un:l1wutnL
WLu1|l
Nicardipine nLnWnL|unulMnt
D5S ,D5S/2 , D5W , 1/2NSS ,NSS lL
WWnLnt Ringen solution , lactated
w. LWLu1 2 mg/ml uuMt
24 Octreotide 11
Compatibility/
Stability
Octreotide nLnlvWu1
cut down tube Lnt kcl lM
vlL
nnntWu MIMS 2006 ,
Micromedex , Drug InIormation
Handbook wtlLnLnlvLnu
lM ( incompatibilily) uMnuLn
paranteral drug therpy mancal in
vancouver general hospital 2002
nLnlvLnulM M1uu lLW
lvu octerotide un: kcl Wu1nu
iv |Munu
25
Omeprazole,
Lansoprazole
7 ADR/ Side EIIects
Omeprazole un: Lansoprazole
LlW1n1WnunuvlL
lLuw Omeprazole uMnu
lansoprazole lM
omeprazole un: pantoprazole LvL
methoxy un: diIluoromethoxy chain
utu benzimidazole rings nu
lansoprazole un: rabeprazole lLLvL
uutu benzimidazole rings uML
triIluoroethoxy un: methoxypropoxy
tu pyridine rings M1uuvnuwu
lansoprazole :nLnuwu
rabeprazole uMlL|nMnuwu
omeprazole un: pantoprazole
26 paraquat 8
Toxicity/
Poisoning
pt. nu paraquat L antidote
nLvlLu1l
lLL antidote ltnLnwLn
Paraquat uMLnnL|t1MuW
|uu|wWnLLn
nM|tun1W lvnuluu vlv
MLu|nn|uL|uLu |tuMuun
tun1l1wutnt1nttMlu
l1wutnut1|tu 3 uuMuW 1.
t1nunMMtL1nlnlMulv
Fuller's earth 150gu1nMnuLnt
MOM 30ml q6hr uWtunu 2.|1
nutnunn|nMlMulv
u|nn1 iv rate 250ml/hr Lnt
Iurosemide 3.t1nunnu
|u|uu11nu 1Mlvnt|ulv
dexa 5mg iv q6hr un: cyclophosphate
5mg/kg/day iv ut1lvn 8 hr
27 Primaquine 9
Dosage/
Administration
M1ntuuMu1u
Primaquine lunnL Malaria
( P.Virax)
uuMu Primaquine ltlunnL
Malaria W 15 mg/day (base) once
daily Ior 14 days or 45 mg base once
weekly Ior 8 weeks
28 Ritonavir 11
Compatibility/
Stability
Wtu:ltu: 1 u uMM1
tt:uu Ritonavir |n
19.00 u. 1unntnL
|tu:M1uulnlun
u:MMuuu1vlL
u Ritonavir luuttuWttn tnM
unW|ntluM|uunvDL 2-8
1W vnunLnvDL (uu
n 25 1W ) WltuDulu 30
u un:lLlvulMuun1vulu
LWLun1 Wtu:uult
29 smecta 7 ADR/ Side EIIects
smecta Lu1ulv|nM
nuwuvlL
smecta (Dioctahedral smectiee) lt
nL acute& chronic diarrhoea Mu
lunnLu non-systemic
antidiarrhealagent nnu|tu
mucoprotective un: absorbs
enterotoxins , rotavirus ltlM1lu|Mn
un:Wlvu nnWnLu1DWt
30
Sodium
citrate
11
Compatibility/
Stability
Sodium citrate M1|ntluM|uu
vlL un:nvuMlvLu
vn1WnMuu|lM un:vn1
|tMltW1unnLn|ntl
lMuu|l
Sodium citrate nLn|ntllM
nvDLv1lMulLM1ut|uu lMu
nvuMlvLuvn1nuWnM|tu
:u:|n 6 |Mu uMlLLuLnlu
|1u1:u:|nu1uuvn1n
|tMltW1un1uuuunt
LMuunvuMu1uMn:
l1wutnMLWL|vL:nL
31
SulIamethoxa
zole
3 Pharmacokinetics
SulIamethoxazole L halI-liIe
|l
SulIamethoxazole L elimination
halI-liIe 9 hrs
32 Tamsulosin 10
Therapeutic Use/
EIIicacy/
Indication
untLu Harnal lu
tutunuu1
l1wutnn1unvlL un:
nlLLnLnltuMlM
MuulMt1
u Harnal vLtnLu1u
Tamsulosin Lut1ltlunnL
Bladder outlet disturbance oI lower
Urinary tract symptoms (LUTS)
associated w/benigy prostatic
hyperplasia t1|WuLuuulutut
unuu1M1wutnn1un M
33 tetanus toxoid 9
Dosage/
Administration
Wtu0M tetanus toxoid |uLun
|Lu 6 n.w. 52 :nLn
0M|uL 2 v1n|uLunlM
uu|l
Tetanus toxoid 0M|unnL|u
tLn 0.5 ml uu1vLM 3 |uL
lMu0M|uL 2 v1n|uLun 4-8
ntMv un:|uL 3 v1n|uL 2
6-12 |Mu Wtu0M|uLun|L|Mu
nLDwuu M1uuW0M|LMu|uL
1 lvL
34 thophylline 3 Pharmacokinetics halI - liIe , thophylline |tu|l
halI - liIe u1u theophylline LWL
vnuvnn MLt1u lW|tu
un:t:Mnnttv |tu
- lu|Mnu 1-4 t :L
W t1/2 |0nuu 3.4 hr (1.2 -26.5 hr)
35 ticlopidine 7 ADR/ Side EIIects
nuwuWvuM
tt:uu Ticlid nu
WvuMtt:uu Ticlopidine
nultnuwu 7 u
36 TriIlusal 10
Therapeutic Use/
EIIicacy/
Indication
Grendis Wu:l
Grendis LtnLu1u TriIlusal
MulunnL Antipletelet aggregation
nnuutu1n1uu1|ultL
(do-oxygenase (COX) |tnn|nM
|nMLnn vascular endolhellal all
(1nM cerebral henaorrhagie) Lut1
ltluWtuLWL|nu1Mn|nM
recurrent myocardial inIarction v
stable or unstable angina v stroke
uuMtt:u 1x2 v 2x1 vn1
vu eIIicacy lLuMnM1
37 Uralyte-U 2 Availability
lututuw.Lu Uralyte-U
vlL nlLLltMlM|tuu
nnuu
u Uralyte-U lMMMnntutu
w.n1un lLLMu|uLuu
Uralyte-U t:ntMu K Na
hydrogen Citrate ltnLu|nMn
uric acid , cystine stone , Ca Oxalate,
wnlvuMuLlutt.w.
uu |tu ultnLu|nMn
|nnuWn|tuL |tu diuretic ,ult
nLu|nMn oxalate |tu B6,
cholestyramine, ultnLu|nM
n|nn uric acid |tu allopurinol,
sodium bicarbonate,ultnLu
|nMn cystine stone |tu sodium
bicarbonate
38 Vitamin E 20 Others Vitamin E 1 mg LnuuM
Vitamin E 1 mg |nt 1.5 IU
(international unit)
39 warIarin 9
Dosage/
Administration
untuuMu warIarin
un:utt:uu
uuMu|LMu W 5 mg/day |tu|n
2-5 u vn1nuuttuuMuML
Prothrombin time maintainance dose
W 2-10 mg /day utt:uu :
lLWtt:uuwLv
un:Wtt:uun:W1|n
|Munuu1nu
40
WtulW
luvMlvu
4
Pregnancy/
Nursing
WtulWluvMlvunLn
ltntvu1lvuLtMlMvlL
nlLlMM1nlvuLtMnu
uvLnvtnltWulWluvM
lvu W - WL
t:Mnuwlulnwn
- Wunn1Llun1

|u1nWvu1lvuLtWlLlMulu
uvLlt1nLnlvlMlMulLM1
vuMlvuLtM
|nn11
Drug
InIormation
Handbook
website :
www.
website :
www.
website :
www.
MIM
Drug
InIormation
Handbook
Hanbook on
Iniectable Drug
Drug
InIormation
Handbook
MIM
MIM
MIM
fvvaccine
uLnn
vuuWnMu
|MuLun:
utW
|t w.n1un
up to date
Wikipedia ,
Micromedex
Drug
InIormation
Handbook
MIM
Hanbook on
Iniectable Drug
Hanbook on
Iniectable Drug
Drug
InIormation
Handbook
Drug
InIormation
Handbook
Drug
InIormation
Handbook
Hanbook on
Iniectable Drug
website :
www.
poison 2000
up to date
Drug
InIormation
Handbook
MIM
Drug
InIormation
Handbook
Drug
InIormation
Handbook
MIM
Drug
InIormation
Handbook
u
MIM
MIM
website :
www.
Drug
InIormation
Handbook
WL vaccine
n h?

U1r|Dn?n?u ?n?u ?nu

1
9,
7
Dosage/
Administration, ADR
WtuuMu1uL
lvM |wut
uLnuMlM
uMu WnMWn|nu
u1u|wWL
ML|nnuutu
2 Acyclovir tablet 4 Pregnancy/ Nursing
Acyclovir tab nLn
lvluvu1lvuLtM
lMvlL
Acyclovir nLnlvluvu1lvuLtM
lMtnMDuuWunuuLuu
3
Antivenin
malayan pit viper
7 ADR/ Side EIIects
Wtu skin test
wtuw Antivenin
malayan pit viper (|tL
1n:t:) vnuL|
1lu D5W 100 v
200 ml :LWnM
nuw|tLvlL
tLnnult|1lLLWnM
tnuDLl|nu nlv|tL1vnM
|nMMt :tunMtnunuwlM
lMutnM:lvuu 30 un1 1 tlL1
4 Aspro 1 IdentiIication Aspro Wu:l
Aspro W Aspirin Ltutt tablet 320 mg
,500 mg un: eIIervescent tab 500 mg
tL Bayer Schering Pharma
5 BCG vaccine 9
Dosage/
Administration
Wtu0MWtu BCG
vn10MlLLMLuu
|nMuu:0MtnM1
v1n|uLunuu
|l
|L0MWtu BCG 1nu:tnu
|0w:|tu vn10M:|nMMLvu1ML
nnu|tuvu1t1LnuMnnun:uv1lM
|1t1W1:nnu|tuvu1un:
uMntlMvnuW1nu:nnu|tu
uWnlunM t1tnu|0w::|nM
vn1n0M 2-3 ntMv Wtuuu0M
|L 27 MnWL 52 0MLt:Ln 16 u
t1nn1ulut1|nMtnu|0w:
un:n0MWtunn|nult lvlL
tnDuuWn|tulM uM1nu
nLnn1DLWLnulM 1WnuLu
6
Benzathine
benzyl penicillin
11
Compatibility/
Stability
Benzathine benzyl
penicillin 1.2 mu ini L
uWnLu1l
Benzathine benzyl penicillin : im : 600,000
unit WnLnt SWFI 1.5 ml M1uu uuMu
Benz. pen G 1.2 mu WnLnt SWFI 3 ml
un:W0MDulu 24 tlL1
7
Bromhexine,
Theodur ,
Roxithromycin
7 ADR/ Side EIIects
WtulMt
Bromhexine, Theodur ,
Roxithromycin vn1n
tt:uuWtuL
ntnun1uuu
vunlLt|nM
nuMlM
nnntWulu Textbook oI ADR
(Davies DM.) unLn|nMn
tn seizures lM Wu Theophylline un:
uLnn Handbook oI Drug InIormation
wt Theophylline :Mtulu|nM~35
mcg/ml :lv|nMnlnu
(ventricular tachycardia) , tn
(Seizure),Irequent PVC nlvu
Theophylline LntunnL macrolide
(roxithromycin) :|nM Drug interaction
Mnu:Mt 2, onset:delayed (uu|tuu
vntMv ) WLuu1:Mttunn1
|nn11|tnW unnL
macrolide :ltutu1nuttu1u
theophylline lvLu theophylline lu
n:un|nM|wLuuu|nMwLnulM
8
Budesonide
Inhaler
9
Dosage/
Administration
Budesonide Inhaler lv
uuM 1600 mcg/day
lMvlL
nnntWuwt Budesonide nasal
Inhalation : 200-400 mcg twice initially
which may be increase up to 800 mcg twice
daily M1uu budesonide nLn|wL
uuMlMun1 800 mcg un: 2 W1
9
Calcium
carbonate tablet
3 Pharmacokinetics
calcium carbonate
WLu1 350 mg , 100
mg L equivalene to
calcium |l n
calcium carbonate 350 mg equivalent to
calcium 140 mg calcium carbonate
1000 mg equivalent to calcium 400 mg
calcium carbonate :L elemental calcuim

CeIoperazone
ini.
7 ADR/ Side EIIects
lW1n1nulvuu1
ceIoperazone lv
M1lv Vitamin K
Muu nnln:l
Wtunun
|tuM1lMt
vitamin k vlL
ceIoperazone L N- methyl - thio - retrazole
(NMTT) side chain t1:uMu1n
n1|W:v vitamin k - dependent clotting
Iactors lMuutu1 vitamin k epoxide
reductase 1t1nun activation u1
prothrombin n1Wnlv|nM
hypoprothrombinemia nMnn1 vitamin
K lv|nM|nMnlM nlv vitamin
MuuluWtulMt ceIoperazone lL
|tuM1lvluWtunu uMW
t:|LunnLn:Wtu WLtu|nu1W
poor nutritional status, malabsorption,

CeItrixone,
CeIepime
7 ADR/ Side EIIects
ceItrixone un:
ceIepime |nM cross
reactivity vlL
ceItriaxone un: ceIepime LlW1n1 R1-
side chain |vLunuM1uu1|nM cross
sensitivity lMvnWtuLt:MuwMlM
Mvu1nlLWn1ltunM

CeIuroxime
suspension
9
Dosage/
Administration
ceIuroxime susp L
uuMu|llun
nL pharygistis lu|Mn
uuMu ceIuroxime susp lu|Mn W 20
mg / kg /day ut1lvun: 2 W1 |tu
|nuu 10 u
Chikungunya 10
Therapeutic Use/
EIIicacy/ Indication
Chikungunya lv|nM
exIoliative lMvlL
unnL
chikungunya u1l
nunM11Wvu1u1lW
chikungunya W LWuuM1uuML1nu
(nM uuuu)Wuutt MP rash Wu
vlLWuwtWun:w1unL |wMutn
MLWu:nn|tuuu un:vulM|1
Dulu 7-10 u nnLlW
chikungunya : lLLnnL|w:
|:1nnL|tuuttt:Wtt:W1
|tu tMu lvuw|tLn vLlv
unlwu|w::lv|nMnlM1u
Clindamycin 9
Dosage/
Administration
Clindamycin Lu
tt:uu1llt
nu:l|1
Clindamycin 600 mg/4ml nLn|1
Mu 0.9 NSS v D5WtLn 50 ml
tvuutt iv inIusion uu 10-60 mins
M|lL|nu 30 mg/min (lL|nu 1,200
mg/hr) WL|uLuuvn1|1ulLW
|nu 18 mg/ml vLtvuutt IV
bolus unnunLntvutt im
lM lMuuuMulL|nu 600 mg Mn
u1|uL 1 W1 nn:nuun:M|
0MW uuMu 300 mg nn:nu 50 ml
|n0M 10 mins,uuMu 600 mg
nn:nu 50 ml |n0M 20 mins,
uuMu 900 mg nn:nu 50-100 ml

Cloxacilline,CeIt
riaxone
11
Compatibility/
Stability
cloxacilline lv IV line
|Munu ceItriaxone
lMvlL
nnntWulLwtuLn compatibility
:v1 cloxacillin un: ceItriaxone 1lL
Wlv1nu|Munu
Dexamethasone 7 ADR/ Side EIIects
Wtu0M
dexamethasone un
|nMWuuM1uuvn1n
0MultlLuuW1
untnLn
|tnuu|tu0M
hydrocortisone lM
vlL
nlW1n11|WLu1 dexamethasone
wtLWLuMnM1n hydrocortisone
un: prednisolone W dexamethasone L
CH3 LMuvu1 16 |wLuuL t1lLLlu
hydrocortisone un: prednisolone ML
lW1n1u1 dexamethasone Mulu
nnLwutnunuw1Wvu1uu
un:LnuwuLnnLuun
hydrocortisone un: prednisolone t1u1
n1LlW1n1ulunnL|Munu un:
LnwttnunuwlMtu un:wt
nuwuLltu1
hydrocortisone-17-butyrate Wtuuu
nLntt:u prednisolone lMlMu

Diazepam
iniection
9
Dosage/
Administration
Diazepam ini ltlun
nL alcohol
withdrawal symptom L
uuMn1nMnLn
ltlM|tu|l
uuMu|LMult W Diazepam 5-10 mg
iv q 5 mis un:1WtunntuMlLMuL
uuMulvn:nLLnnM (massive
cumulative dose)~500 mg lu|nLnn
60-90 mins t1:lv|nu1MnnMn

Diazepam
iniection
9
Dosage/
Administration
Diazepam 10 mg drip
lvntnWnL|l
rate |lv
nlv diazepam drip W|1luM
~ 1:40 v/v v 5 mg/50ml - 5 mg/100 ml
lu 0.9NaCl, 5 dextose in Ringer's v
Lactated Ringer's iniection M|lu
nlvulLW|nu 5 mg/min
Digoxin 9
Dosage/
Administration
M1nlv digoxin 0.25
mg MWtulMuuM
utt IV direct M1
|MuLuu1l
digoxin LluWL|uLuu 250 mcg/ml vn
lv1 IV nLnlv direct IV lMulv
|tu|nu1uu 5 uuultlMu:
diluted v undiluted nlM lunn diluted
lv dilute lMult SWFI v dextrose 5
v NaCl0.9 lMulvWL|uLuu
nMuu1uuM1|nt 4 |u1
uuMultt1luWtuuult 0.25 mg
M1uuW:ltulutLn 1 ml ult
dilute lMuMn:nuu1MuulM
tLM|nt un:lv

Dobutamine,
Dopamine
11
Compatibility/
Stability
dobutamine nt
dopamine nLnlv
IV line |MunulMu
Wu1 Y-site lM
nnntWuuLnD:WL|unulM
u1u1 2 Mwt dobutamine un:
dopamine nLnlv IV line |MunulMu
Wu1 Y-site lM

Dobutamine,
Dopamine
11
Compatibility/
Stability
dobutamine nt
dopamine nLnlv
IV line |MunulMu
Wu1 Y-site lM
nnntWuuLnD:WL|unulM
u1u1 2 Mwt dobutamine un:
dopamine nLnlv IV line |MunulMu
Wu1 Y-site lM

Dobutamine,
Dopamine,
Sodium
bicarbonate
11
Compatibility/
Stability
dobutamine v
dopamine nLn drip
Wnt sodium
bicarbonate lMvlL
dobutamine incompat nt sodium
bicarbonate nu dopamine incompat nt
nn:nuM1 M1uu1 2 M 1lL
nLn drip Wnt sodium bicarbonate lM
Dopamine 11
Compatibility/
Stability
Dopamine nLnlv
IV line |Munt Mg
Su4 lMvlL
nnntWulLwtuLnWL|unulM
vlL:v1 dopamine un: MgSo4
M1uu |wWLtnMDuu1Wtu1lL
Wlvu 2 tuM IV line |Munu

Dopamine ,
Acetar
11
Compatibility/
Stability
WtulMt Dopimine
1vnM|nMM
un:uwulMn1nu
W Acetar lvWtu
1unt Acetar
nLnlv Ilush nu
lvu Dopamine un:
nLnlv Acetar M
Acetar solution t:ntMu Na 130 mEq ,
K 4 mEq , Ca 2.7 mEq , Cl 108.7 mEq
un: acetate 28 mEq nnntWu wt
u Dopimine nLn|unulMnnt
electrolyte nMlu Acetar solution M1uu
Acetar solution 1nLnlt Ilush nu
lvu Dopamine un:nLnlv Acetar
solution MltlM

Dopamine,
Clindamycin
11
Compatibility/
Stability
Dopamine nLnlv
Lnu clindamycin
iniection lMvlL
nnntWuuLnlLwtuLnn
Mnt compatibility :v1 dopamine
un: clindamycin iniection M1uu1uu:u
lvuuunnu

Dopamine,
Dobutamine
11
Compatibility/
Stability
Dopamine WnL|unu
lMnt Dobutamine
vlL
Dopamine nLnWnL|unulMnt
Dobutamine L1lvWu Y-site lMuM
lLLuLnnWnLlu syringe |Munu

Doxazosin,
AlIuzosin
7 ADR/ Side EIIects
Wtuuw doxazosin
utt hypersensitivity
M1nt
Doxazosin un:
alIuzosin LlW1n1
WnuWn1nuvlL
un:WltuMlMuu
Doxazosin un: alIuzosin (Xatral) L
lW1n11|WLWnuWn1nu lMu|tu
quinazoline-derivative Wtuuu|nM
hypersensitivity M Doxazosin M1uu1
Wvnn|nu1u AlIuzosin Mu lMult
Tamsulosin t1|tu -1 - adrenergic
blocking agent |tu|MunuuMLlW1n1
M1n doxazosin un: AlIuzosin lMu
Tamsulosin |tu
sulIamoylphenthylamine-derivative uMM1
dT vaccine 10
Therapeutic Use/
EIIicacy/ Indication
vu1M1WDWlMt
Wtu dt dose 2 v1
n dose unlMuu
|l un:uuuWlvu
1M10MlvL
vu1M1WDlMtWtu TT/dT 2 W1
:u:v1:v1W1lLuun 4
ntMv:u:v1:v1W1 2 n1 u
WnMlLuun 4 week un:lL|nu 3 t

endotracheal
drug
administration
9
Dosage/
Administration
untLuM
lMt1nLntv
1 endotracheal lM
unLntv1 endothacheal lM
lMun adrenaline , atropine , nalexone ,
lidocaine, vasopressin |tuMu
Flunarizine 7 ADR/ Side EIIects
Flunarizine nLn
lv|nMWnu1|Wu1M
:ttvlvnM|nM
lMvlL
Flunarizine |tuulunnL selective
calcium channel blocker LlW1n11
|WLun:nu1|DntuWnunt
cinnarizine nu1|Wu1wttu W
11 tL uvun|wL nnWuuLnlL
wt Ilunarizine nlv|nMn
u1|Wu11:ttvlun:vnM|nM
Flunarizine 7 ADR/ Side EIIects
Flunarizine nLn
lv|nMWnu1|Wu1M
:ttvlvnM|nM
lMvlL
Ilunarizine |tuulunnL selective calcium
channel blocker LlW1n11|WL
un:nu1|DntuWnunt
cinarizine nu1|Wu1wttu W
11tL uvun|wLnnWuuLn lM
wt Ilunarizine nlv|nMn
u1|Wu11:ttvlun:vnM|nM
uMLnWnL1 Pharmacodynamic
:t Ilunarizine LWnM negative
FosIomicin 9
Dosage/
Administration
FosIomicin nLnlv
luuuM 4 g q 8 hr lM
vlL
uuMu IosIomycin t1|tuu1utu1
lLLuLnu0Mlu|LnuuMu Adult
dose W 2 g iv q 12 hr un|u menigitis 2 g
iv q 6-8 hr , Osteomyelitis 4 g iv q 12 hr ,
Maximun dose 16 g/day nWnLWtu
lMtu 12g/day t1u1lL|nu maximum
dose M1uunLnlvuluuuM 4 gm iv
GeloIusine 9
Dosage/
Administration
GeloIusine nLn
load lMvlL
geloIusine 500 ml uMn: 1 ml t:ntMu
succineylsted gelatin 40 g , Na 154 mmol ,
Cl 120 mmol Lut1lt|w|wLtLM
luWtunu|nu|nMvulu1nu
nnu|nu|nMlutLn|ut| 1
oI body weight nLnlv IV load lu
5-10 ulM un:1L sign u1
hypovolaemia Muuun:nMM:Mt
Hct lMuM1lLMn 25 uuMu
Gentamicin 4 Pregnancy/ Nursing
u Gentamicin nLn
ltluvu1lvuLtM
lMvlL
u Gentamicin nLnWunuuLlM
uu un:MMtLn1|Muvuu
1nLnltluvu1nn1lvuLtMlM
uMWltu1:LM:1 |u1n
|nMWnu1|Wu1M1|Muvu1
nlM lMu|WuL case report wt
LMlMtu Gentamicin Lnt
Clindamycin nLnnu:|tu
Ln|nMuMn1|nuu1n
GriseoIulvin 4 Pregnancy/ Nursing
Wtuvu1lvuLtM
tt:uu
GriseoIulvin 500 mg 1*2
nLnlvuLtMlM
vlL
lLLuLnnutu GriseoIulvin n1
uuL uMLu1uuunLn
nlv|nML:|1lMlunMMn1 M1uu
Wvnn|nu1nltuulunMlvuLtM
Wwn|nnltuu |tu
Ketoconazole v Iluconazole uu
Hemax 9
Dosage/
Administration
uwun1lt Hemax
4000 units sc t1M1
|1W1unt SWFI 2
ml nLnut10MlM
nLn|1u Hemax 4000 units nt
SWFI 2 ml vn1ut10M SC uuuu1n: 1
ml lMvnuvu1 W |1 Hemax
4000 units nt SWFI 1 ml un0M SC
Levophed 2 Availability
l1wutnn1unL
u levophed vlL
WLu1|l
Levophed (LtnLu1u W
Novepinephrine ini) tLWWnM W
hospin IPL asia paciIic t1lLwn|u
lututu w. uM|nn Norpin
tLWWnM W Dalim biothech uu
Measles vaccine 11
Compatibility/
Stability
Measles vaccine
unnlt diluent
ntLulvL
nLn reconstitute
Munn:nuulM
Measles vaccine W reconstitute Mu
diluent tLuWnMLlv|uu

Meropenem,
cloxacillin , TPN
11
Compatibility/
Stability
unt
Meropenem , cloxacillin
, TPN nLnlv1
nu|MunulMvlL
nnntWuuLnlu Handbook on
Iniectable drug lLLuLn compatibility
:v1 Meropenem , cloxacillin ,TPN 1
uu:uWlvuunnunu|wWL
Methimazole 9
Dosage/
Administration
uwuM1nu
Methimazole uu PTU
1*1luWtuM1WD
untnLn
lvlMvlL
PTU un: Methimazole Mulu pregnancy
category D 1W nlvuluvu1LWD
:lvn|nu1Mn|nM
hypothyrodism , goiter lMun:|nu1M
aplasia cutis , anal atresia , esophageal
atresia , development delay lMvnn
expose M Methimazole 1uu:uu PTU
|tuuMun|nnltluvu1LWD
un::lt Methimazole lunnuw PTU
vlLMtnu1vMtnu1M PTU
uu lMuuuMultWltluuuM
MnMLt:nuDwlunnL PTU

Methylergonovin
e ,
methylergometrin
9
Dosage/
Administration
Methergin n10M im q 6
hr x 2 dose lMvlL
methylergometrine 0.2 mg iv or im
nLn0MtlMlMuv1n dose un
2-4 hrs M1uuuwun10M im Q 6 hr

Methylprednisolo
ne
9
Dosage/
Administration
uwun1
Methylprednisolone 440
mg/h in 24 hr |Dntn
uuL 24 vials uM
wutnWunlM 22
vials wutnnLn
WnLulvvLMM
|MulMvlL
vn1nWnLun|nt
Methylprednisone 440 mg/hr in 24 hr W
M1lM 10,560 mg in 24 h u 500 mg/bot
M1ltu 22 bot lMunlvulvWnLnt
SWFI nLnWnLwLnulMnlvu
Wlv bolus 36-42 ml Dulu 15 u
un: maintain IV Mu NSS lu 45 u
vn1nuulv maintemance dose
6.48-7.56 ml/hr |tu|n 23 hr uvn1
WnLnt SWFI lv|ntnvDL 20-25 HC

Metronidazole
ini
11
Compatibility/
Stability
Metronidazole ini
vn1n|tMlt|ntl
ltMlMuu|l
LuLnvn1nWnLlt W Metronidazole
ini vn1nWnLMununvt iv drip
nLn|ntlltlMuu 24 tlL1 uM
lLLuLnvn1n|tMuMlt

N-acetylcysteine
(NAC)
nLnlv NAC luW
lMtwLnu
paracetamal Luu|nu
48 tL. lMvlLun:
M1lvltuu|l
NAC :lvt:lutun1nMluWtu
lMtu|nuuuMLunlL|nu 8-10
tlL1uMuL:lv NAC unWtu
lMtu|nuuuMLun 36 tlL1 nu1
Lt:lutulunnMWLuu1u1n
nuMtn1lM lMuuuMulv W
NAC 150 mg/kg imIuse lu|n 60 u
nuuMLMu 50 mg/kg inIuse lu|n
Lnn 4 tlL1MLMu 6.25 mg/kg/hr
un:lvuun:1|ultLMtun: INR
NorIloxacin 9
Dosage/
Administration
NorIloxacin lvlu|Mn
u 9 |Mu uu~9 kg
M1lvtt:u
u1l
norIloxacin uuMu 15-20 mg/kg/day ut1
lvun: 2 W1 |Mnuvun 9 kg M1lM
tt:uuMu 15*9 135 mg/day
uuMuML 67.5 mg noIloxacin 5 ml
LMu 100 mg M1uuWtuuu
tt:uuW1n: 3/4 tut un: 2

Omeprazole,met
hylcobalt,
Sermian
7 ADR/ Side EIIects
unt 1.
Omeprazole Ln
u1|Wu11lMvlL
2.methylcobalt :n:nL
lu1nulv|nM
uMulMvlL
3.Sermian Ln
u1|Wu1u1lt1
4.un:uLn
Wnuln|uu WL
MuMnvMMLu11 |tu
nu1|Wu1nu
vlL
1.Omeprazole Lnu1|Wu1M1u tM
WL: (3-7) , Lu11(2),1|nu (3-4),
tM1 (2-5), Wnuln (2-4) , |uu
(2-3) , 1Wn (1-2) |tuMu uut
tMtutnL1tnn:un:lL
uu:ulvltluWtulWMtuMlLlM
nnn1WtulWlM1lLu:LWnMlM
2.methylcobalt v mecobalamin v
vitamin b12 M|tuMLun:nuluu
nMn1tnn:lMlLn:nLlu
1nu 3. sermian v niceergoline L
nu1|Wu1wtlMun WLMulnvM
M Lu11 WLWMtnM1|Muv
(Wnuln 1|nu) nuuM1Wvu1
11uu un:uulLvnt 4.nunM1
WtutnW Wnuln|uu |nM
nlW GERD Wtu|tuuvlL
|nMnnu1|Wu1nun1nuLn
nM W sermion 1n1LW omeprazole
nunLu11 WLMulnvMM
|nMnlWt:nv|nLvlWu
utuW1uv|tunu1|Wu1
nun1nuLnnMW sermion
Oseltamivir 9
Dosage/
Administration
Wtu|Mnuvun 8
nlnnL u 8 |Mu
:lvu oseltamivir
uuM|l
uuMu oseltamivir u1|Mnuuun
1 t lLuuntuvunM t1LuuMuM1u
6-11 |Mu uuMtt:u 25 mg bid
MMMnuuu 5 u

Oseltamivir
(TamiIlu)
9
Dosage/
Administration
TamiIlu uuMltnL
un:t1nuluWlvu
lvtt:uu1l
TamiIlu v u Oseltamivir WLu1 75
mg/cap uuMltlunLnMM|t
lnluvMlvu|Mn 10 t Wlvuun:|Mn
u ~ 13 t W 75 mg un: 2 W1|tu
|nuu 5 u nuuuMt1nunMM
|tlnluvMlvutuM|un:t W 75

Pethidine,
Meperidine
9
Dosage/
Administration
u pethidine lv1 IV
push nLnlt SWFI
lMvlLun:WL
|uLuultu 1:10
nnM1vlL
meperidine nLnWnL (compatibility)
lM1lu 0.9NSS , SWFI un: D5W
nvtnlvu IV push uuuu:ulv
uu1t lMuWL|uLuuuu:uW
10 mg/ml t1vn|MuL 1:10 (u|uLuu 50
mg/ml) :lMWL|uLuunMu|wu1 2.5
mg/ml M1uuW: dilute u 50 mg/ml
Phenobarbital ini 11
Compatibility/
Stability
Phenobarbital ini vn1
|1u|ntlltlM
uu|l
Phenobarbital ini vn1|1u|ntllt
uu 15 tlL1 nvDLv1 lLLuLn
|L|ntluM|uu
Pseudoephedrine 4 Pregnancy/ Nursing
u pseudoephedrine
nLnutWuuuL
lMvlL
pseudoephedrine utWuuuLlMt:Ln
0.5 u1uuMutt:u|ult
un:ulMuu 24 tL. The American
Academy oI Pediatrics (AAP) :tn
nn1|nM uLtt:uu
pseudoephedrine lLwtWLWMtnMlM
lu|Mnnn1MunLn

Ranitidine,
Hyoscine ini.
11
Compatibility/
Stability
Ranitidine un:
Hyoscine iniection |nM
incompatibility nu
vlL
Ranitidine un: Hyoscine iniection lL|nM
incompatibility lu syringe nn
Mntwtu1n1L physical
compatibility 1 macroscopically un:
microscopically |tu|n 1 tlL1
nvDL 25 HC un:L physical
Rubella vaccine 10
Therapeutic Use/
EIIicacy/ Indication
Rubella vaccine vn1lM
tWtu nLnL
DLWLnuulMnt
vn1lMtWtut1nulWvM|uLu
:MtDLMuuuuun1 16 t
unnu nnntWuluuuLn
Drug Dex wt Rubella vaccine (0M SC )
nLnn:MuDLWLnulMLnn 10 t
uMnlvWtu MMR vn1nLWnlWvM
|uLu lLnLnt1nun|nMlW
vnMWLuu1u1lWlM

Sandostatin,
Omeprazole
11
Compatibility/
Stability
Sandostatin nt
Omeprazole lvnu
|MunulMvlL
nnntWulLwtuLnnMnt|u
nu:v1 Sandostatin un: Omeprazole
1lLtu1n1M:WnL|unu
lMvlL M1uu1uu:ulLW
tvu1n1MWu IV line |Munu
Sertaline (zoloIt) 5 Interaction
untn
tt:ulnL nL
un:uWnLLWnM
u zoloIt vlL
nnntWuwtu1unut1
MwLwlu Journal oI Psychopharmacology ,
Feb 12, 2009 |1 recurrent relapses oI
depression in a patrent established on
sertaline aIter taking herbal medicinal
mirtures a herb - drug interaction t1
Dtun1WtunLnWLn
tL|WMuu sertaline lMunvn1
tt:u ayurvedic herbal mixture nnt
Lnnnt|tutnt1|nuu1nt
pharmacokinetic herb-drug interaction W
nLulwltnMt:nuDwu sertaline
t1nLulwnnn1|tu nL
(terminalia chebula v commiphora
Snake bite 10
Therapeutic Use/
EIIicacy/ Indication
WtulMu1nM uMuw
u panicillin utt
anaphylaxis :wn
lvu Antibiotic M
lvulMuu
1nM :wtLn:L commonly isolated
pathogens W P.areuginosa , Proteus spp.,
Bacteroides Iragilis , clostridium spp. u
antibiotic uu:ulvltW ceItriaxone 1-2
g IV q 12-24 h v ampicillin/sulbactam
1.5-3.0 g IV q 6 h uMluWtu
uuuwu penicillin unLn
|nnltlMW clindamycin 150-300 mg po
qidTMP/SMZ 1 double strength tab bid
v clindamycin 150-300 mg po
streptokinase 9
Dosage/
Administration
n skin test u1u
streptokinase 1 ID L
n|MuLuu1l
unMnt|wuu allergic response
nuu1lLLuu|tnuuuulu
nnM1nMntWtu W|tutu
t1uuu:ulvltu skin test lMult
streptokinase lv1 ID unuWnlu
15-20 u lunuun|MuL|wlv
1 ID uunnWuuLnlLLu
uu:ulMult 1M1ltvnnn|
1ulMuuuunlv|1ulMult
0.9NSS un: D5W 5 ml (u
streptokinase 1.5x10
6
units) lMuWu u
Wuu1uMlLW|uu|w:lv|nM
w1 nuu|1MlMult 0.9NSS
v D5W uLtLMWt 10 ml un
1unn:nulMuL 0.1 ml t1:LM
uu 15,000 units uL|1nW1u
TPN 11
Compatibility/
Stability
untu
MltunLnWnL
|unulMnt TPN
vlL lMun amikacin
, Gentamicin
,Iurosemide , Ientanyl ,
midazolam,
dexamethasone ,
aminophylline
nnntWulu Handbook on Iniectable
drug un:lM|utnM TPN lnn|Wu1
LnnMlu handbook lLL Zn nMuL
|vLununMu1w. wt Mntlu
Y-site wtD:|unulMnvtu
Iurosemide , amikacin , Ientanyl ,
dexamethasone un: aminophyline (uMn
t:ntMu Ca 600 mEq |nMn
MnM:nuu1M|) MntluvnM
Mn1|MunuwtD:|unulMnvt
u gentamicin t1nM TPN L Ca 10 mEq
un: K 20 mEq :WnL|unulM uM|nM
nMnM:nulu TPN nML Ca 20
mEq,K 25 mEq nvt Midazolam lL
nLnWnL|unt TPN nMlt
|ut|Wu11lu Y-site un: vnMMn1
Tropper V 1 IdentiIication Tropper V Wu:l nnntWulLwtLtu Tropper V

Vancomycin ,
ceIrom
9,
10
Dosage/
Administration
WtuWMMvn1lMt
u vancomycin , ceIrom
|tu|n 11 u
Lunn:
|tnuu|tuunultM
lMlM
|u1nlLlMLnn1MWLlM
|tuwun1ltuutt empirical
therapy vnwnnu0M|nnlt
vancomycin |wWtWnL|tMu
MRSA utuMtt:u|nnltlM W
sodium Iucidate (250) 2x3 pc nvt
CeIpirome (ceIrom) WtWnL|t
Pseudomonas aeuginosa,MSSA utuM
tt:u|nnltW CiproIloxacin
(500) 1x2 pc
VenoIer 11
Compatibility/
Stability
VenoIer vn1n|tMlt
|ntluu|l
VenoIer v Iron sucrose vn1n|tMlt
vvn1n|1lu 0.9NSS nLn
|ntlltlMDulu 48 tlL1 nvDLlL
|nu 25 HC (uLnntL l|w )
qs
ML
|nnuutu
Advances in
Pharmacotherapenti
cs and pharmacy
WuuwLu w.
LutMl .
1347
website :
www.google.com
Wtuun:lWMM
|tt1nulM
MuWtu
WLu0M
Drug Interaction
Facts
Drug InIormation
Handbook
WLtutuw.
n1un
WLnM
lW1n1unt
nuwuuLnnL
Drug InIormation
Handbook,15th ed.
website :
www.moph.go.th
Drug InIormation
Handbook
Hanbook on
Iniectable Drug
uptodate 2007
uptodate 2007
AHFS: Drug
InIormation
Drug InIormation
Handbook
Hanbook on
Iniectable
Drug,11th ed.
Hanbook on
Iniectable
Drug,11th ed.
Drug InIormation
Handbook
Hanbook on
Iniectable Drug
Hanbook on
Iniectable Drug
Hanbook on
Iniectable Drug
uptodate
AHFS: Drug
InIormation
|nn
t:ntn
t:tL |1n
tvWtu.
nLn
Drug InIormation
Handbook
Drug InIormation
Handbook
Drug InIormation
Handbook
micromedex
MIM,112th ed.2008
u
WLnltu
tWnn
nunnu ,2549
u
AHFS: Drug
InIormation
Drug InIormation
Handbook
Drug Interaction
Facts
Hanbook on
Iniectable Drug
WLu0M
WLnltu
nvttWnn
nunnu
u
Drug InIormation
Handbook
uu1
ttMnMun
WtuMM|t
vMM|t
luvMlvunu
wuulvLtuM|
(H1N1)
pack insert
Drug InIormation
Handbook
tLu gardinal
AHFS , Drug in
Pregnancy and
lactation
Hanbook on
Iniectable Drug
WL vaccine
Hanbook on
Iniectable Drug
website :
www.medworm.co
m
Harrison volume 1
Drug InIormation
Handbook
Hanbook on
Iniectable Drug
website : www.
uLnntL
l|w
B?
Gu
h?

950
U1r|Dn
?n?u
?n?u ?nu
1 Acetylcystein
e
9 p' dynamics /
efficacy
untuuMu
acetylcyteine tutt
tt:ulunlt|tu
antidote u1
paracetamol overdose
uuMu acetylcysteine lt W
140 mg/kg un:MLMuuuM 70
mg/kg n 4 tlL1 uu 17
dose
2 Acetylcystein
e
4 pregnancy/nursi
ng
nLnltu
acetylcysteine un:
Benadryl luvu1
M1WD 4 |Mu lMvlL
u acetylcysteine un: benadryl
Mulu pregnancy category B
t1uLnnWnLlunMMn1
wtlLnlv|nMWLtnMMM
u un:u1lLLu1uWL
WMtnMlMluLuLu 1u:ltu
12 tuMlMu1tnMDu
3 Acetylcystein
e
9 p' dynamics /
efficacy
uwun1 acetylcysteine
tuttu0M |wunwL
nu Paracetamol lMu
lv Acetylcysteine uu
3 dose uM function Mt
lLMuu untn
n1ltu dose 4 :LWn
u1l
u Paracetamol uuM 10 G :
lvMtnnnuDulu 12
tlL1 t1nlt Acetylcysteine
|tu Antidote u1 Paracetamol
uu :lvu 3 dose uMnnu
WtulMt Paracetamol |tu
:u:|nuu|nultnu:
lMtnnL M1uuW consult
uwunW1|wM|uunnL
Mlt
4 Acetylcystein
e
7 ADR/side
effects
tu|nLlv|nM
anaphylactoid reaction
n Fluimucil inj lun
nLWtu Paracetamol
overdose L:lt1
Anaphylactoid reaction |tu
rash,flushing,chest
pain,tachycardia,fever,hypotensio
n,angioedema,broncospasm |tu
nlLw1t:n1Wu1vu1u1
ndripuut1|nMnn0Mu
|uvnM|nMMMuM|
|nultun:tnun|nMu1
uuntuuMu M1uu1wt
vn1nlv loading dose
unnunnWnLwt
WtuLt:MDLuwlMun
asthma,atopic dermatitis,allergic
rhinitis un: allergic conjunctivitis
|tu rish factor vu1lv
|nMtnu anaphylactoid
reaction n V lM|wLuu
5 Actrapid 6 Formulation Wtu|WulMtu
Actrapid Lnw.L.
lMLwtuwuw.
n1unuMuM1nnlLL
luw.lLtnLn
lt Humulin-R uulM
vlL
Actrapid un:Humulin-R ulu
nnL Regular nsulin uMLWL
uMnM1nulunuu1
Pharmakinetic M1u Actrapid HM
L onset 0-5 hr,Peak 1-3 hrun:
Duration 8 hr nu Humulin-R
onset 0-5 hr,Peak 2-4 hr un:
Duration 6 hr t1:|vuLW1
6 Acyclovir 7 ADR/side effect WtulMtn0M
acyclovir Lun 10 u
:LWnMMtvlL
WtulMtu acyclovir Lun 10
u t1uuLn metabolism
WuMt|wu1|nnuu ( small
amount ) un:utn1tnn:
1lLLWnMn1uu1Mt uM
nWtuLt:M|tulWMtL
nu M1LnMMMLW
enzyme u1Mtu1M|u1
7 Acyclovir 11 compatibility/St
ability
untWLW1Mu1
u Acyclovir injection 1
tuttnn:nuun:W1
uv1
lututtW1uv1vn1nWnLnt
sterile water for injection un u
:LWLW1M 12 tlL1
nvDLv1 vnn|nu1n|ntu
luM|uu|u1nlvu
MnM:nu un:1tuMnn:nu
un:W1uv1|L|1Mu NSS
v D5W un :LWLW1M 24
tlL1nvDLv1 lLW|nt
uluM|uu
8 Acyclovir 9 P'dynamics/effic
acy
untWtulW
Bell's pulsy lMtu
acyclovir uu 4 |LM
un: 5 W1 |tu|n 7
u LWL|vL:nLvlL
9 Acyclovir 10 Therapeutic
use/
Efficacy/ndicati
on
untu Acyclovir
Lut1lt:l un:M1
ttuuMuluWtulW
lMvlL (uwun1lt
utt oral)
Acyclovir Lut1ltlunnL
genital herpes simplex
virus,herpes labialis(Cold
score),herpes zoster (Shigles),
HSV encephalitis,
Varicella-Zoster (chicken pox)
lMunlvuutt oral :tt
uuMuluWtulWlM M1u
ClCr 10-25 ml/min:800 mg q 4 hr
n1 800 mg q 8 hr, ClCr <10
ml/min:200 mg q 4 hr v 200
mg q 8 hr v 400 mg q 12 hr n1
200 mg q 12 hr vlvlu
uuM 800 mg q 4 hr n1 800 mg q
12 hr
10 Acyclovir ,
Cloxacillin ,
Dexamethaso
ne ,
Ranitidine
11 Compatibility/St
ability
u Acyclovir , Cloxacillin
, Dexamethasone ,
Ranitidine nLn drip
lu|nu|MunulMvlL
u Acyclovir , Ranitidine un:
Dexamethasone nLn drip
wLnulM lMulvuWu1 Y-
site nu Cloxacillin lLLuLn
11n1 |u1nlLLtuttuu
luM1t:|W u1lnML
Cloxacillin lv|nMn irritate
lM1u1uu:ulvuunlvLnt
uMu
11 Adrenaline 11 compatibility/St
ability
nLnWnL adrenaline
ntnn:nu 0.9 %
NSS un: 5% D/W lM
vlL
nLnWnLlM1ntnn:nu
0.9 % NSS un: 5% D/W
12 Adrenaline 8 Toxicity/Poisoni
ng
WtulMt Adrenaline
inj. luuuM 1: 10 un:
WtuLuuM pupil lvu
uu unt|tuWn
n Adrenaline vlL
nlMt Adrenaline |nuuuM
lv pupil LuuMlvu
WMtnMlM t1Wtuuu|tu
WnnnlMtu|nuuuM
13 Adrenaline 7 ADR/ Side
effects
WtuLn
anaphylaxis uwun1
Adrenaline (1:1000) 0.5
ml M uMwutnlv
direct V unt:
|nMuMuntWtu
vlL un:vn10Mu
Wtutuuuuvun
Lnuu:|nuu1nt
0MuWM1vlL un:
Adrenaline Lnuuuu
vnMnLvlL
Adrenaline inj. (1:1000) ltlu
case anaphylaxis uuMultW
0.3-0.5 mg M tlMn 15-20
u nunlv direct V uuM
ultW 0.1-0.25 mg nvt
case ultuuMu M L0M V
lvuuMun1ltnuu:u
un:n0Mutt direct V u:
nnu|n M vn10Mu
Wtu1tuu1uuuvunu
nlv V u:ltvl|uu 1
Ln:lvuuluWtu cardiac
arrest M1uu case uW mornitor
HR,BP Mu n HR > 100 W1/
u M1u1uwutMu
un: adrenaline Lnulun
uuuvnMnLnMu
14 Adrenaline 9 Dosage/
Administration
unt Adrenaline
L maximum dose |tu
|l |Llvutt V
infusion
nlv Adrenaline utt iv
infusion :M1|MuL adrenaline
1:1000 lvlMWL|uLuu 8 v 4
mcg/ml ( dosage range 1-4
mcg/ml ) lMuMnlvu
|LMuW 0.1 mcg/kg /min
u1lnMLlLWlvu|nu 5
mg/u
15 Adrenaline 9 Dosage/
Administration
untM1n0M
adrenaline utt im lu
Wtuuwu lMun0M
|unnL|uvlvnun:
nnL|uvuu LWL
uMnM1nuvlL
Adrenaline nLntvulM
1utt iv infusion , iv direct
injection un: sc lMulLwtuLn
ntvuutt im
16 Adrenaline ,
blood
11 Compatibility/
Stability
adrenaline nLnlv
Lnt|nM1nu
|MunulMvlL
nnntWu lLwtuLnn|nM
incompatibility u1u 1nLn
lv1nu|MunulM
17 Adrenaline
inJ
11 Compatibility/
Stability
Adrenaline inj un
nM|uuLuvLMu
u1l
u adrenaline unnM|uu
:nvuMuvLMu|vn 1 t
utnuunnM|uuun:
M1lL|nuuvLMunvuM
tuvnMu
18
Albendazole 10
Therapeutic
Use/ Efficacy/
ndication
Albendazole 400*2 # 30
tab ltnLlW:l
Albendazole : oral : -
neurocysticercosis ( M1uunL1)
: <60 kg : 15 mg/kg/day unlv
un: 2 W1 uu 8-30 u >
60 kg : 400*2
-
cysticercus cellulosac : 400*2
uu 8-30
19 Alcohol 4 pregnancy/nursi
ng
tLnunnunn
LnnnL1:LWnM
nluvu1M1WD
unnunMulu Pregnancy
Category D t1unnun:LWn
lv|nMWLWMtnM|un "
Fetal Alcohol Syndrome" W
lvnL1WMtnM wMuntn1
n|u|MtlMWMtnM M1uu
vu1LWDlLWtt:u
unnun t1MLunvuMu1
American council on science and
health vu1LWDlLWlMt
unnun|nu 30 ml Mu
20
Alfusozin ,
Xatral XL
09 Dosage/
Administratio
n
Xatral XLL max dose
|lv uwun1 1x2
|WuLnWnLn1
nltuuuMuL
nuvlL
Xatral XL L max dose
|nt 10 mg Mu n
nntWuuuLn pubmed
wtlL|WuLnWnLn
lv Alfuzosin utt extended
release uuM 20 mg Mu
Lnu uuMtnMlt W
Alfuzosin utt extended
release 10 mg Mu
21 Alkaline
phosphatase
20 Others WtuLW alkaline
phosphatase nMn1
nLnutnWn1Wnun
lMu1lt1
Alkaline phosphatase |tu
|ultLwtlMlun:Mn Mt n
un:wtlMlutLnn1lulMun:
nln luWtu|tu biliary
canaliculi n|ultLu
WMtnM:|tuMtutnD:lW
|nuntn:MnvD:Ln
nnuuWn|tuLnn:Mn lu
WtulWMt:Mt|ultLulu
|nM:n1uu |u1n1|Mu
uMMMu nvtnutnWn
1WnunuunvtWnMn1wt
lMluWLD:
hypophosphatemia,hypothyroidis
m un: D:wlDtun
22 Aluminium
hydroxide
7 ADR/ Side
Effects
Aluminium hydroxide
lv|nM toxicity u1llM
t1
nnntWuwtlMLn
u1un|nM toxicity un:
u1un|nutMluWtu|tu
dialysis encephalopathy t1wt
L:Mt Aluminium hydroxide lu
gray matter lu:Mtn1
unnuwtlut 1984 L
Wtun 3 u lMt
aluminium hydroxide |nMD:
23 Amikacin 11 compatibility/St
ability
Amikacin |L|MuL|tu
uvuMM:LWLW1
Mu1l
|L|ntluM|uu:LWLW1M 7
u uMn|ntunM|uu:LWL
W1M 24 tlL1
24 Amikacin 11 Compatibility/
Stability
Amikacin inj vn1WnLnt
nn:nu|w drip :|nt
llMuu|l un: vial
ltun:|ntllMuu
|l
Amikacin inj vn1WnL|ntllM
uu 2 |Mu nvDL 2-8 1W
un: 24 tL. nvDLv1
nvt vail MMuLltun:u1L
u|vnu Wt|nt vial u un:
|tML|tMu 70% Alcohol un
tM paralfin vial |wt1nu
ntu|tu|t un:|ntluM|uu
lL|nu 24 tlL1 uMvnlLLul
|1 sterile technique W1u
|vnlt
25
Amitriptylin
e
04 Pregnancy/
Nursing
untL
u1un|nM
teratogenicity u1
nuLlMtu'
Amitriptyline un:
M1WDvlL
nnntWuwt L
nWnLLnMMML
nuu 522,630 u
LMlMtu 'Amitriptyline
un:M1WD 1uL 86 u
lMtulut1 1 st
trimester wt 1 uLD:
nt (uMu1lLlM
uuuuu1tM|u|nMn
Amitriptyline ) wt 4 uL
WLWMtnM L un:|
tLlvuntnM nun
nWnL|tunWnLlu
n 229,1010 u wt
nLWLWMtnM 25 u
(5.4%) nLMlMtu
Amitriptyline lut1 1 st
trimester M1uunltu
'Amitriptyline luvu1
M1WDWwnt:lut
un:WL|nu1:lMt
26 Amlodipine 7 ADR/side effect WtulMtu amlodipine
unLntntL
vutL MtL un
tnltuM1nn
lv|nMWn|vnulM
vlL
nnntWuuLn wtu1u
n|nM face edema n
amlodipine t1lut 2000-2003
wtWtuuu 3 u ulu
:Mtu:lt 2 u un::lt
1 u un:wtu1un|nM
edema periorbital ( MtL )
uu 2 u lMu:MtWL
u:|tuuu:ltun::lt
27 Amoxicillin 9 p' dynamics /
efficacy
uwun1ltu Amoxicilliin
( 250 ) 1* 3 pc ,
Augmentin ( 375 ) 1*3 pc
, Roxithromycin (150 )
1*2 pc lLtltu
M1nnLnulMvlL
Augmentin |tuuWtWnL|t
gram - positive , gram - negative
uMlLWtWnL atypical
pathogen |tu Mycoplasma ,
Chlamydia spp. t1
Roxithromycin LWnM|tM1nn
M1uu1nLnlvlM|w
nLnMM|t1|Muvul
28 Amoxicillin +
Clavutanic
acid
4 Pregnancy/
Nursing
Augmentin nLnltlu
vu1M1WDlMvlL
Augmentin t:ntMu
Amoxicillin + Clavulanic acid lMu
Amoxicillin un: Clavulanic acid
Mulu Pregnancy calegory B
nLnltluvu1M1WDlMu1
tnMDuun:lLLu1un|nM
teratogenicity
29 Amphetamin
e
13 other unt Antidote u1
u Amphetamine
Antidote u1 Amphetamine W
Propanolol inj. lMuwLu1
Amphetamine :lv|nMn
Sinus tachycardia v
Ventricular arrythymia nvt
WtuLn stable un
wnlv Propanolol tuM
tt:u ( w. n1unlLL
tuttu0M )
30 Amphotericin
B
7 ADR/side effect nLnuntuv
Thrombophlebitis n
nltu Amphotericin B
lMu1lt1
nLnuntuv Throbophlebitis
n AmphotericinB lMlMuu
slow infusion , infuse uWu1
central line , lt small bone
needle , rotate side of infusion ,
use of dilute solution ( < 0.1 mg/
ml ) , addition of 500 - 1000 U of
heparin / liter of solution
31 Amphotericin
B
11 compatibility/St
ability
Amphotericin B nLn
WnLnt NSS lMvlL
lLnLnWnL Amphotericin B
nt NSS lM |u1n:lvu
MnM:nu
32 Amphotericin
B
11 compatibility/St
ability
Amphotericin B vn1n
WnLun nLn|ntl
lMuu|l
nLn|ntnvDLv1lMuu
24 tlL1 un:nLn|ntluM|uu
lMuu 1 ntMv
33 Amphotericin
B
7 ADR/ Side
Effects
untnLn
t1nun|nM phlebitis
nnltu
Amphotericin B lMu1l
nLnt1nun|nM Phlebitis
nnltu Amphotericin B lM
lMu 1.ltWL|uLuuu1ulL|nu
0.1 mg / ml 2. lt Rate lun
infusion lLMn 2 tlL1 3. WnL
heparin 1000 unit / L n1lu
nn:nuu 4. lvuuttu
|uu
34 Amphotericin
B
,Cryptococcal
meningitis
10 Therapeutic
Use/ Efficacy/
ndication
WtuMM|t HV uwu
u0u|tu
Cryptococcal meningitis
:lvu Amphotericin B
lMuunu
ultlunnL Cryptococcal
meningitisluWtu|tulW ADs
nvtt:|Wlulv
Amphotericin B 0.7 -1.0 mg /
kg/day |tuu|Muu1uu 2 wk
unMLMu Fluconazole 400
mg/day |tu|n 8 wk uM
|u1nwtu1unWnLn1
Wnn|w:|tn Spinal fluid
wt|tu1uuuluu 14 t1
|nu1Mnnnt|tutLnn
nnL|w:|tlLuun1 7 |
M1uuWtuLn1WnunlL
Muu :wnlv Amphotericin
B MunwtlLL|tuu
MMMnu|tu|n 2-3 weeks
35 Ampicillin 11 compatibility/St
ability
Ampicillin vn1nWnL
unnLn|ntllMuu
|l
Ampicillin vn1nWnLunWlt
Dulu 1 tlL1
36 Ampicillin 7 ADR/ Side
Effects
vn10Mu Ampicillin
WtuLnuuuvun
Heart rate un: Blood
pressure lL|tnuuutn1
|WuLt:Muwu
Capsule M-uM1 |tuu
L|tlLttu
nnu:Llnnuwu
utt anaphylaxis lM
vlL
nuwuutt anaphylaxis
|nMuuluWtu|WulMtuuw
Lnu lMun:Mulvn1 gE
Muuwun gE :lt|n:tu
mast cell basophill |LlMtu
|Wuuwuu cell L gE |n:u:
uMnnun:tnunnnuw
nLu1|u|uM1 lv|nM
nunM1lMvnu:tt lMu
|nMwLnuv|nM|wu1t1
:tt lMun - 1Wvu1 |tu Wu
WuuM1 WunLwL un:
angioedema ,1|Muvul |tu
vnMnLMt nn1|nu1tL uuu
vun , 1|Muv |tu
Wnuln |uu tM|n1t11
1|nu , :tt1|Muvulun:
vnM|nM |tu hypertension,
ventricular tachycardia, vl|Mu
|vvl|MuWM1v:, :tt
t:n |tu vLMnM , :tt
utnu |tu tnn:lLn Wtu
uuvn10MLnuuuvun
un:lvt:M|n|WuuwuL
37 Ampicillin ,
Cefazolin
11 Compatibility/
Stability
u ampicillin un:
cefazolin nLnlvutt
direct iv lMvlL
u Ampicillin nLnlv direct iv
lMlMun:nuulvlMWL|uLuu
125 - 500 mg/ 5 ml lt|nlun
lvu 10-15 u nuu
Cefazolin nLnlv direct iv lM
lMun:nuulvlMWL|uLuu
500 mg/ 2 ml ( dilute with 5 ml
SWF ) lt|nlunlvu 3-5
u
38 Antihypertens
ive agent
10 Therapeutic
use/Efficacy/ndi
cation
untultlu
nnLWLMulnvM
n1luWtuL Scr=2
nLnltuMlM|w
WLtnMDunLnlt
HCTZ lMvlL
nWunW CrCl luWtu
uu |nt 34 ml/min t1unM
WLMunnL Diuretic |tu HCTZ
lLM1ttuuMu vnWtuL
Mnn1 10-50 ml/min u
nnnLvu1lLM1ttuuMu
W Calcium channel blocker
|u1nutn1lMuu
Mu1unnLuluw.W
Amlodipine 5,10 mg ,Felodipine
5,10 mg nuu|tvuWtu
tt:uuun:uW Metformin
uuwtWtuLW Scr 1.5
mg/dl lu|wWtu|tuuvLlt
u1u|u1nlv|nMD:
lactic acidosis un:luWtuuu
Scr =2 mg/dl 1uu:ulv
|tnuultltuMu |tu Glipizide
lMuWtuLW CrCl 10-50
ml/min lvnMuuMun1 50%
39 Aprsoline inj 11 Compatibility/
Stability
Aprsoline inj WnLntn
utuMlMlMt1 un:
nLn|ntllMuu
|lM
Aprsoline inj (Hydralazine inj)
nLnWnLlMnt D5W , NSS
un:|ntnvDLv1lMuu 8-12
hr un:LuLnvndraw lnlu
plastic syringe un|nt
nvDLv1luLM :|ntllM
uu 24 hr lMulLnu|nuMu
nWu
40 Arthalgia 20 others Arthalgia LWLvLu
u1l
Arthalgia utn tMuM
ntMu
41 ASA 300 mg
enteric
coated
tablet,ASA
80mg
10 Therapeutic
Use/ Efficacy/
ndication
lvWtu|WuASA 300
mg enteric coated tablet
1|LM ntASA 80mg 4
|LM |wtreat Acute
Attack Lwutntn
lv ASA 80mgMn
(uLnnnt:tLlMu
uwu|0w:1:tt
vlun:vnM|nM )
ASA tutt enteric coated tablet |w
t1nunirritate G tract M1uMt1tn
vnMv n:|w:v lMu
|tnuunDwPHu1|LMulLlvuMnM
un:n:nun:|w:vuMlv
n:nunln|nnuu lMuuLnn
tLuw.n1unltuun:uW LW
disintegration time 1-2hr M1uunM1
ltlu case accute attack uwu:n1lv
|Wu|wnM:u:|nnuMnM |w:
|LuMMtL|u|nu|nMun:nnu
|Ln ~5-10u un:peak plasma
concentration 15min-2hr unnu
ASALn|MuL|tu film coated tablet
|wt1nun|nMtnu hydrolysis
t1:lvMu|nLnnu Lnnu0u
WnuunLnut n|Wuu|LM|Wnt
1Ln|Wuun uu1|w:nuttL
|wt1nun|Wu lLlv|nunDw
MLMnt:n1Wu1n|Wntuu uM
nvtWtuacute attack|tuM1lv
unnu|u 1M1|Wu|wnM
:u:|nnuMnM/n:nu t1n|tu
u|LMlLlM|WntWtu|WulMMn
|u1n WtunulvuLnuLn t1
l1wutnn1un L ASA 2 dosage
form W 300mg enteric coated
M1uuW
42 Atropine 9 p' dynamics /
efficacy
untuuMu1u
Atrpine un: 2-PAM lu
n|tu Antidote u1u
LuLn1
uuMu1u Atrpine lun|tu
Antidote u1uLuLn1W 1-2 mg
iv v im lMulvtlMlu|n
20-30 u un:1lLwtn
1 muscarinic nu 2-PAM :
ltuuM 1-2 g lMuWnLnt
0.9%NSS 100 ml t1:lvulMu
u infusion un:lt|nlunlv
u 15-30 u nu dose nMlt
lvvn1n dose un 1 tlL1
nn muscle weakness lLM
uu
43
Augmentin
Prednisolo
ne
Pseudoeph
edrine
04 Pregnancy/
Nursing
u augmentin
prednisolone un:
pseudoephedrine
nLnltluvu1
M1WD 2 |MulM
vlL
u augmantin t:ntMu
amoxycillin un: cavulanic
acid Mulu preg cat B
nLnltlMluvu1M1WD
nuu prednisolone Mu
lu preg cat D lut1 1 st
trimester Lu1un|nM
ntlM 1W
vnn|nu1 nltu un:
pseudoephedrine Mulu
preg cat C Lu1un|nM
ntlM Wwn
WL|nu1ntt:lutu
|nMuu nnlMunt W
vnn|nu1nltu
prednisolone un:
pseudoephedrine nu
augmantin nLnlvlM
44 Augmentin
syrup
9 Dosage/Admini
stration
unt|Mnu 4
ut uvun 20 kg
uwun1lt Augmentin
syrup 1.5 tut un: 4
W1 untuuM
un1ltM1nnLWL
|vL:nLvlL
lL|vL:nL|u1n uuMu
Augmentin syrup uu:ulvltlu
|Mnu 2-6 t (13-21 kg)W
25/3.6 MKD (mild to moderate
infection) un: 45/6.4 MKD
(serious nfection)t1Wun
uuMun1nMMLuvunu1
WtuuuW 1,028 mg/day uM
uuMuuwun1|tu 1,368
mg/day t1|tuuuMun1n
uuMuuu:ulvltMu
45 Azithromycin 7 ADR/ Side
Effects
azithromycin lvwuM
lMvlL
nnntWuuLn lLwtuLn
u azithromycin lv|nMwu
M uMulv|nMwuM lMun
tetracyclin , doxycyclin
46 Azithromycin,
Cefuroxime
tablet
10 Therapeutic
use/
Efficacy/ndicati
on
Wtu|tuvn|ntlMtu
Cefuroxime tablet un:
Azithromycin LnulL
t|vL:nLvlL
|tnlWwtluWtuvn|nt
|0utwnu vn|tu|tutW|u
lMun S.pneumoniae un:
25-50 ,H.nfluenzae un: 15-30
, M.catarrhalis un: 8-20 |t
u wtlM|tu S.pyogenes,
Enteric bagteria, S.aureus,
P.aenginasea t1u Azithromicin
nWtWnL|tnlWnWu
un: Cefuroxime nWtWnL|t
nlWnWu|tunu M1uuW
|nnlt|wu1M|Mu nvt
uu1n|nnuMuntwlu
nnLD:vtunn1n|nt
|0utwnulut:|WluW Day
0:Amoxycillin, Amoxycillin(High
dose 80-90 MKD), Azithromycin,
Clarithromycin Fail day3:Co-
amoxiclav(high-dose),
Cefuroxime, Cefdinir
47 AZT 05 nteraction untuMuln
AZT nLnltLntu
Stavudine lMvlL
uMulnlLnLnlvLnu
lMLu 3W W 1.AZT+d4T ,
2.dd+ddC , 3.d4T+ddC M1uu1
lLnLnlv AZT Lnt d4T lM
48
Baclofen ,
Carbidopa
, Comtan ,
Entacapon
e ,
Haloperidol
,
Levodopa'
,Levomed
07 ADR/ Side
Effects
WtulMtu
levomed , baclofen
un: haloperidol lMu
Wtutt:uu
u1M|u1
Duvn1lMtu
comtan |wLLn 1
M un:|nMD:
hypotension un
tnM1nn
u:|nMnuMlM
u levomed (t:ntMuu
levodapa 250 mg un:
carbidopa 25 mg) , baclofen
L1 haloperidol nLn
lv|nMnu1|Wu1
|nunt:tt cardiovascular
lM lMulv|nM
orthostatatic hypotension,
arrhymia, chest pain,
hypotension, syncope,
palpitation, phlebitis t1|L
WtulMtu comtan
(entacapone) |wLL 1
lv|wLWL|nu1u1n
|nMD: hypotension
|wLuu ( comtan nLn
lv|nMn orthostatatic
hypotension lM 4.3%) t1
nvtWtuuuM1
wnttuuMulvL
WL|vL:nLMlt
49 Baclofen,
Tolperisone
7 ADR/Side effect unttt:u
u Baclofen un:
Tolperisone |tu
:u:|nvnu|Mu:
|nMnu1|Wu1:l
lMt1
Tolperison ltt|n
|nuntn|n1Mu1nnL|u
un:tuWnunnL|u vnlt
|tu|nuunu1|Wu1
wtlMW nnL|uuu1
Wnuln|uu tnuv1 Wuv1
lLntu1 tMWL: WLMu
lnvMM lM nu Baclofen
nu1|Wu1wtlMW 11
uu WLMulnvMM u|wnu
Mw Wnuln|uu tMWL:
un:uulLvnt unnu
nlLw1t:n1WwtlMuu
W nutnn:tu |t1tL
ntnu Mu|Mu tL|W t:n
vnu |tuMu
50 Bactrim 10 Therapeutic use untuuMu1u
Bactrim ltlunnL
PCP luWlvu
uuMu1u Bactrim ltlun
nL Pneumocystic W 15-20 mg
u1 Trimethoprim /day lMuut1
lvn 6 - 8 tlL1
51 Band,PMNs 20 others untWLvLu
u1W band un:
PMNs wtnnM
u11v1ttMn
Band vLun1 Muu1|LM
|nMunntnMtnunLlu
n:un|nM|nMuu|u1n
nMM|t L:|1|LM|nMuv
nnu|nu|nM nu PMNs
vLun1 |LM|nMutuMvu1W
neutrophil
52 BCG vaccine 11 Compatibility/
Stability
BCG vaccine vn1WnL
nLn|ntlMuu|l
BCG vaccine WnLunlvlt
vLMDulu 8 tlL1 :v1n
ltlv|ntlunvDL 2-8 1W
|tn|tun luM|uuvn:Mn
uuu1MnM|nun:t1nulLlv
nnun1 vL1llunvDLv1
53 Benzathine
benzylpenicilli
n
9 Dosage/
Administration
untuuMu
Benzathine
benzylpenicillin lun
nLWtu|tu Syphilis
WtuWlvu|tu Syphilis utt
|0utwnu:lt Benzathine
benzylpenicillin utt single dose
2,400,000 unit nulunn
Wtu|tuLuun 1 t uuM
ult W 2,400,000 unit
ntMvn:W1|tu|n 3 ntMv
54 Benzathine
Penicillin G
11 compatibility/St
ability
uwun10M Benzathine
Penicillin G 1.2 MU utt
M lLtLu|MuL
u1l
|MuLlMun:nuu 1.2 MU lu
unnu 3.6 ml
55 Bricanyl,Dilan
tin,Dormicum
11 Compatibility/
Stability
1.Bricanyl M1|ntlu
M|uuvlL vn1|tMlt
un|ntlMuu|lv
2.Dilantin |tMltun|nt
lMuu|lv (luM|uu
un:nvDLv1)
3.Dormicum ltlun
lMvlL uuMu|lv
dilute ntn:l
1.bricanyl inj (Terbutaline inj) lL
M1|ntluM|uu vn1|tMltun
|ntlMuu 48 tlL1 251W
|tn|tun 2.Dilantin inj
(Phenytoin inj) |tMltunWnL
ntnuunlvltu lLW
|ntlltMun:lLWutM|uu
|w::MnM:nu nvtuu1
lLWnLntnuLuLn|wu1lv
ltlMMt|u1lLuuun:lL
MnM:nu 3.Dormicum inj
(Midazolam inj) nLnltlu
nlM uuMuM1u : < 32 wk :
initials : 0.03mg/kg/hr,
0.5mcg/kg/min (vLlv loading
doselvutt iv infusion|uu) ,
> 32 wk :
initials:0.06mg/kg/hr,1mcg/kg/min
(vLlv loading doselvutt iv
infusion|uu) un:nLu
Lnn2|Mu-uun6|Mu:iv
loading dose 0.15 mg/kg MLMu
infusion 1mcg/kg/min WnLnt
nu|unulM W NSS,D5W
56 Calcitonin 7 ADR/Side effect unt Calcitonin
(Calco) Lnu1|Wu1
nuun:uW:1
:lt1
Calco v salmon calcitonin inj
nu1|Wu1wtlM > 10%
W Facial flushing , Wnuln ,
1|nu, |tv un:tL
t|n0M 1-10% :
57 Calcium
gluconate
6 formulation 10% Calciun gluconate
L elemental calcium n
mg
10% Calcium gluconate lu
l1wutnn1un LuuM 10 ml
t1t:ntMu calcium gluconate
1 g un:L elemental calcium 90
mg
58 Calcium
gluconate'
10%
02 Availability uwun110%Calcium
gluconate |tuM
|MuntCalcium
gluconate 10 ml 0.45meq
l1wutnLult
vlL
Calcium gluconate l1wutn
n1unLW 10%Calcium
gluconate t1|nt 1gm u1
Calcium gluconate un:L
elemental calcium 0.45meq/1ml
59 Calcium
gluconate inj
9 P'dynamics/effic
acy
Ca gluconate inj nLn
0M V push lMvlL
Ca gluconate inj nLn0Mutt
direct V lM lMulLM1|1
lMulvluM| 0.5-2 ml/min
nlvu||nult:lv|nM
hypotension , arrhythmia
60 Cal-D-Vita 4 pregnancy/nursi
ng
unt CDV
nLnlvlMluvu1lv
uLtMvlL
CDV v Cal-D-Vita t:ntMu
Ca 600mg,vitamin D3 400 units
M 1 |LM nnWnLnlt
vitamin D luvu1lvuLtM
wtvitamin D nnutn1
uuLluuuuuun: The
Nation Academy of Sciencer
uu:ulvltluvu1lvuLtMlu
uuM 400units un:nLnlvlu
uuM low dose lMuMlLuu:ulv
luuuMn1 t1lunnuWtu
lMtun: 1|LM(Vitamin D 400
units) M1MLuu:u
61
cefazolin 7
ADR/ Side
Effects
WtuLt:MuwunnL
sulfa nLnltu
cefazolin lMvlL
cefazolin lM|u1n|tuu
Antibiotics Wun:nnLnu
lW1n1uuMnM1nu lLLn
cross reactivity
62
cefazolin 11
Compatibility/
Stability
Cefazolin |1luuu
n1lMutt periternal
dislysis lMvlL vn1|
1|ntllMuu|l
nnntnLuLnuun1lM
t:ntMunvnutuMuMn
nntWulu Handbook on
injectable wtLuLn|0w:|L
WnLnt D5W un: 0.5% NSS t1
nLnWnL|unulM
63 Cefazolin 3 Pharmacokineti
cs
luWtulMtu
Cefazolin :v1n
haemodialysis lLt
u:nnnMnlM
vlL
Cefazolin nLnnn dialyze lM
t:Ln 20 - 50 % M1uu1W
lvuvn1n hemodialysis
vlv supplement dose 0.5 - 1
nL vn1n dialysis
64 Cefazolin 7 ADR/Side
effects
Wtuuwu cefazolin
lLtLlnn:
uwunnL Penicillin lM
vlL u1l
n|nMnuwulunnL
Cephalosporin ut1lM|tu 3
nn W
1. nn antigenic determinant W
Beta-lactam ring Wtuuw
Cephalosporin MlMMvu1 nL
lnnn1:uw Cephalosporin M
u MunM unnuuu1L
lnnn1:uwunnL Beta-lactam
|tu Penicillin lM|tunu
2. nn antigenic determinant W
side chain u1 Cephalosporin
Wtuuw Cephalosporin MlMM
vu1Llnn:uwu Cephalosporin
MuvunnL Penicillin |0w:M
L side chain |vLunu|uu
3. nn antigenic determinant W
lW1n1u1u1lL|nnnWtu:uw
Cephalosporin |wu1M|Mu|uu
u1lnM uLn|Lluttu
wtnu|tu side chain u1
Cephalosporin |tu antigenic
determinant lMtuLnnnuu1
Beta-lactam ring
65 Cefazolin
and
cloxacillin
10 Therapeutic
Use/ Efficacy/
ndication
cefazolinun: cloxacillin
nnu|vLunuvlL
nLnltuunulM
vlL vLn10M
cloxacillin uMwutn0M
cefazolinlvWtu
-Cloxacillin MulunnLpenicillin
nnu|tu bactericidal ATB
WtWnL gram positive |tu
s.aureus,streptococcus pnermoniae
n|tu penicillin uvn1:nnu
WnL|tgram negative un: anaerobe
lMMu -Cefazolin MulunnL
Cepharosporin nnu|tu
Bactericidal antibiotic WtWnL|t
gram negative lMn1n gram
positive Cefazolin ulu 1st
generation WnL|t staph
spp.,streptococcus pnermoniaelM nu
gram negative lMun enterobacter
spp., E.coli, H.influenza, Klebsiella
spp.,Pluteus spp. WtuuuMM|t
n:Mnn|nnltuunt|t|tu
n|vML1 gram positive , gram
negative,anerobe vntWn
antimicrobial susceptibility n:lv
|nnltulMnnnt|tLnnM u
nLnlvlM nnL
Penicillin,Clindamycin,Fluoroquinolone
,Vancomycin,Bactrim,Metronidazole
WtuuuMM|tn:MnuMlL
nLn:tMuvu1 t1nulvu|nM
n S.aureusnlv cefazolin lL
|vL:nL|w:lLWnL|tu uMn|tu 66 Cefazolin,Pe
nicillin , Sulfa
10 Therapeutic
Use/ Efficacy/
ndication
Wtu:WMMLMnn uML
t:MuwunnL Sulfa ,
Penicillin, Cefazolin
lLt:lt antibiotic
MlM prophylaxis nu
WMM
nlv antibiotic prophylaxis nu
operation obstetrics and
gynecology hystectomy |tnu
lvuwtW CNAB, Bacteroidws
spp. unLnltlM lMun
1.Amoxicillin-clavulonic acid 1gm
iv , 2.Gentamicin 2mg/kg
iv+metronidazole 500mg/kg iv ,
3.Cefazolin 2 mg/kg
iv+metronidazole 500mg iv ,
4.Cefatetan 1 gm iv v
Clindamycin 600 mg iv t1Wtu
Lt:MuwunnL Sulfa ,
Penicillin,Cefazolin M1uuuW
lM WGentamicin 2mg/kg
iv+metronidazole 500mg/kg iv
v Clindamycin 600 mg iv
67 Cefdinir 11 other WtulMt hepatitis B
vaccine Lun 2 |uL uM
WtuM1tt:uu
Cefdinir lvM1|nu
n0M vaccine lu|uL 3
nlt unt:
0M vaccine lu dose 3
lM|Ll
hepatitis B vaccine |tu vaccine
tuMMMu t1nLn0MlMlu
:v1lMtu cefdinir lMulL
M1|nun0Mnlt
68
cefoperazone
+sulbactam
9
Dosage/
Administration
untuuMuu1
sulperazone un:nlv
sulperazone 2 g v q 12 h
|tuuuM|vL:nL
vlL
tuttu1u sulperazone W
sulperazone 2 g :L
cefoperazone 1 g un: sulbactan
1 g nvtuuMuu1
sulperazone :uuuntut1lt
M1u -
nfectious disease of Abdomen :
cefoperazone 2 g q 12 h - UT
: cefop
69 Cefotaxime 07 ADR/ Side
Effects
untWtulMt
u cefotaxime L
t:Ln 1 |Mu Ln
v untn
M1nn|tuWnLnu
lMvlL
nnntWuwtCefotaxime
nLnlv|nM ADR lu:tt
Dermatologic: Rash. Pruritis.

Gastrointestinal:Diarrhea,nausea,
vomitting,colitis un: Local pain at
injection site t:Ln 1-10%
nu ADR uwtlv|nM
headache, agitation, confusion,
fatigue un: nocturnal
perspirationuun 1%t1Wtu
uuWntWut:Mnltu
lMtuuLMuvlL un:
nLwuuntn|nMuuvlL
un:nlt Cefotaxime prolong
lv|nM overgrowth of
nonsusceptible organism |tu
Candida un:Pseudomonas lM
70
cefotaxime 10
Therapeutic
Use/ Efficacy/
ndication
normal dose u1 claforan
luWutnM
uuMutnMltu1nlt
cefotaxime luWlvuun:|MnL
uLnn 12 t uult:ltlu
uuM 1-2 g V Q 12 hr lMunL
uuun 12 t :ltluuuM
50-100 mg/kg nu t1uuMuu
lvuuMulL|nuluuMn:
lWlM |tu n|tu septicemia 2g
iv q6-8hr, skin infectn 1g iv
q12hr, abdominal infectn no
complicat 1g iv q12hr,c
complicate 1-2g iv q8hr, bacterial
meningitis 8-12g iv q4-6hr
71 Cefpirome 9 p' dynamics /
efficacy
M1ntuuMu
Cefpirom ltlun
nLWtu Pneumonia
uuMu1u Cefpirome ltnL
lWMM|t1|Muvulnun1
|tu D:tMn|nt W 1 - 2 g
V n 12 tlL1 t1M1Ln
ttuuMuluWtuLn
1uu1lMtnw1 |u1nu
Lnutn1lM|tuvnn
72 Ceftriaxone 11 Compatibility/
Stability
uwun10Mu
ceftriaxone 100 mg utt
M lvWtu|Mn un
tM1WnLntM
n:nulMlutLn|l
1:LWL|vL:nL
u ceftriaxone utt M lv
|nMnn|nt tMt|n0MlM
M1uu1uu:ulvWnLuuuM
250 mg M 1% lidocaine 2 cc
uwun1 100 mg M1uuM1lt
nn:nu 1% lidocaine 0.5 cc
73 Ceftriaxone 11 compatibility/St
ability
Ceftriaxone vn1nWnL
unnLn|ntllMuu
|l
nLn|ntnvDLv1lMuu
24 tlL1 un:nLn|ntluM|uu
lMuu 3 u
74 Ceftriaxone 11 compatibility/St
ability
Ceftriaxone vn1n
reconstituted Mu SWF
nLn|ntllMuunu
vn1n reconstituted uLWL
W1M 3 unvDLv1 un: 10
u|L|ntluM|uu
75 Ceftriaxone 7 ADR/Side effect untWtuL
t:Muwu Penicillin
WtuLt:Muwu Penicillin L
lnn:uwunnL
76 Ceftriaxone 09 Dosage/
Administration
untuuMu
Ceftriaxoneltlu|Mn
uuMu Ceftriaxone lu|MnW
-Mild to
moderate:50-75mg/kg/day ut1
lv 1-2W1n
12-24hr(maximum:2g/day) -
Serious infection :
80-100mg/kg/day ut1lv 1-2
dose (maximum 4 g/day)
77
Ceftriaxone 7
ADR/ Side
Effects
u ceftriaxone L ADR
lv|nM pancytopenia
lMvlL
u Antibiotics Lnu1|Wu1
1 hematology lv norrow
damage lMun chloramphenical ,
78
Ceftriaxone
,
Gentamicin
09 Dosage/
Administratio
n
untuuMu
ceftriaxone un:
gentamicin ltlu
nnt1nun|nM
severe infection lu
Wtu|Mn
uuMu ceftriaxone ltlu
nnt1nun|nM severe
infection luWtu|Mn W
80-100 mg/kg/day ut1lv
1-2 W1 (maximum dose 4
g/day) nuuuMu
gentamicin ltW 2.5-5
mg/kg/dose ut1lvn 8
tlL1
79 Ceftriaxone,
lidocain,
Theophylline
4 Pregnancy/
Nursing
WtuM1WD 5 |Mu
lMtu Theophylline
un:uwuM1n0M
Ceftriaxone+lidocain lv
WtulLtnLn
lvuM1nnlMvlL
Theophylline Mulu Pregnacy
category C t1nltluWtu
M1WD:M1wnn1Wn
lMtMuMu:|nMuu t1
WtulMt Calcium,Vitamin B
complex un: Obimin AF LMu
lMulL|nM Drug nteraction nu
Ceftriaxone+Lidocain Mulu
Pregnancy category B nLnlt
luWtuM1WDlMu1tnMDu
80 Ceftriaxone,
Penicillin G
Sodium,
18 Alternative
medicine
WtulMtu PGS 2 mu
q6hr un: Ceftriaxone 2
gm OD vn1nuuLWu
uuuwu off Ceftriaxone
u1|MulLt
nLnltuMlMuu
un:vnuwu off PGS
Mu:ltMlMuulM
nLn|tnuunnLultltunnL
u |tu lt Ciprofloxacin inj.
uu Ceftriaxone |u1nLnu
WtWnL|tutW|unLntlM
nuvnuwuM1n off PGS
lt clindamycin inj. uulMlu
nWtWnL|tutW|unL
tnun: anaerobe uMvn
M1n|nn Cephalosporin lv
|nnltMlLL Side chain
|vLuntMLt:Muw
81 Cefuroxime
,Glaxo
Smithkline
6 Formulation M1ntu Zinnat
(Cefuroxime) tuM tablet
u1 t. Glaxo Smithkline
nLnut1vn|LMlM
vlL
u Cefuroxime (Zinnat) u1tL
Glaxo M1tt:ulMun
nnuwLuvn1Lv vL
ut1vvn|LMu vn|tuM1
ltu |tnuultltuMuL
ut1lt|Munu v|tnuu
tutt|vL:nLnvtn
tvulu pt. uu
82 Celebrex ,
Norflex ,
darac
7 ADR/Side effect WtulMtu Celebrex
un: Norflex Lnvu
nn|tuuu lLWu |ttn
MLuwun1 darac
un: Mydocalm uMWtu
lt darac un: Norflex L
nvunn uMlLLWu
untWtuuw
uvlL
nnntWu celecoxib lv|nM
ADR 1 Dermatologic utt
skin rash lM 2.2% nuu Norflex
lv|nMtnuv1 1 u ,mouth
irritation 1 u un:wtu1u
nuwuttWu nu darac lLwt
u1uuutMlv|nMn
M1nn uMwtu1u|nM
nuwuttWu|tunu u1ln
MLWtnt:Mun:MMMLn
ltuu1Wtuun:t:|Lun|nM
ADR nW1
83 Celecoxib,
darac
10 Therapeutic use untLnWnL
nlt celecoxib Lnt
darac |wlv
WnnnLluMulMt1
nnntWuuLnwtlLL
1uuun:u1unltu
combine :v1 darac un:
NSAD Mu |u1n|wLWL
|nu1lun|nM gastrointestinal
damage
84 Cephalexin 4 Pregnancy/
Nursing
Cephalexin v Keflex
nLnltlMluvu1
M1WD 7 |MuvlL
Cephalexin v Keflex Mulu
Pregnancy category B lLwt
teratogenic luvu un:luWu L
nWnLltu Cephalexin
:v1M1WDuu 46 Wu lL
wtWnu1ulu fetus un:lM
MMMLnunWnMuu 2
|Mu uu 2 uwttnM
85 Cephalospori
n
2 Availability unt third
generation cephalosporin
tuMtt:ulu
l1wutnL:lt1
lul1wutnn1un third
generation cephalosporin LM
|Mu W cefdinir vtnW
omnicef
86
Cerebrolysi
n
09 Pregnancy/
Nursing
cerebrolysin nLn
ltluvu1M1WDlM
vlL
lLwtu1un|nMwLM
MulunMlMt
cerebrolysin un:u1lLwt
uLnnWnLluLuLulu
vu1M1WDlMu|0w:t1 1
st trimester L1luvu1
lvuLtM M1uu1Wlt
|L|tu1 lMulv
Wu1n1WL|nu1nt
t:lutu:lMt
87
Chikugunya
, tWunuu
20 u ('
pathology)
WtuLWuuw1M
uLun:|tL
uwuu0u|tu
lWtWunuu un
ulWulv
|nMnM1nnlM
vlL
lWtWunuu |tunMM
|tln Lu1nu|tuwv:
lMuWtu:Lnlun1
u1|0utwnu LWuuM1ML
1nu MuM1 n|Mu
W tMMLu wtu
n|nt|0utwnu lMuL
nuuu|tuntMvv
|tu|Mu u1lLLnnL
|w:nvtlWu uM:lv
nnLuttt:Wtt:W1
88 Chinese
restaurant
syndrome
7 ADR/ Side
Effects
Chinese restaurant
syndrome luWuwW1t
nluvuLn
unM1u1l L
un:|uM:lt1
Chinese restaurant syndrome
|tunnLn|nMuuvn1
tt:uvuLnuWnL
n monosodium glutamate
(MSG )lLtnnlnn|nMuu
tM |nMvn1ntt:uv
L MSG lutLnn1 30-60 u
vDulu 2 tL. vn11:
|wLtLnnMMtL MSG WL
uu1un::u:|n|nMn
uunttLnu1 MSG MMtL
Wun:un|nM nunM1 |tu
Burning sensatiion on mouth,
back of the neck , chest ,
shoulders , abdomen |tuMu
nulvuwtnlLuu1t1:
vu|1Dulu 2-3 tL. vnwt
nuu1 lvtnL
|tu|MuntWtu severe allergle
reaction
89 Chlopromazin
e
10 Therapeutic use nLltu
Chlopromazine tutt
tt:u lunnL
nn:nlMvlL
nLnlt Chlopromazine
tutttt:ulunnL
nn:nlM lMultuuuM
25-50 mg un: 3 - 4 W1
90
Chloral
hydrate
06 Formulation Chloral hydrate ML
|DntMt:L
nut:ntu1
paraben concentrate
vlL M1|ntllu
M|uuvlL un:|nt
lMuu|lv
Chloral hydrate syrup u1
w n1un WnMMLMt
|Dntl1wutn0tttt
2006 t1L paraben
concentrate |tu
nut:ntluMt t1
l1wutnn1unnvuMlv
uLuvn1WnM|tu|n 6
|Mu lMu|ntlluM|uu|w
nLWLW1Mu1u
91
Chloroquin
e
07 ADR/ Side
Effects
Chloroquine lt
:u:|nlun|nM
photosensitivity uu
|lv
nnntWulLwt
:u:|nlun|nM
photosensitivity nu
Chloroquine uMLu1u
nLnlv|nM
photosensitivity nu
Chloroquine lM wtuM
D: Pruritus |nMlM
vn1nltult 6-48 tlL1
D:nWL|tnuu Ln|nMvn1
lMtu 2-5 |Mu
92 Cilastazol ,
Pentoxifylline
10 Therapeutic use Wtu|tu intermittent
claudication ulLt
LuunLnltlu
nnLnM1nn
lMvlLun|vun
Cilastazol un:
Pentoxifylline
D:ntMu|tuW1W
|n|MunvnM|nMuM1MMu
(intermittant claudication) n
nntWuuLnwtultlu
nnLD:M1nnultlu
nnLD:M1nn W
cilostazol un: pentoxifylline un:
lLuu:uuu (Ln1
vasodilators) lunnLD:
M1nn nn|tut|utnlt
cilastazol un: pentoxifylline lu
nnL intermittant claudication
wt cilostazol Mn
pentoxifylline u1LuunWu
93 Cilostazol
,Pletaal
7 ADR/ Side
Effects
WtulMtu Cilostazol
(Pletaal ) un:M1|ut
nWMM unt
M1vuMuM1nnnu
nWMMvlL
Cilostazol (Pletaal ) |tuunnL
Phosphodiesterase enzyme
inhibitors LWnutu1n|n:nnL
u1|nM|nM n1Wnlv|nM
lvnlLvuMlu:v1nWMM
M1uu1WvuMuunu|ut
nWMM|tu|n 5 -7 u
94 Cimetidine inj 7 ADR/Side effect uwun10Mu cimetidine
V push wutn0Mu
lvntWtuvn10Muwt
LuuM1ML|nu|nM
0MlLt|nMn:l
ntvu cimetidine injection
lunnlv M nLnlvlMlMu
lLM1|1uMlunnlv direct
V uu:ulv0Mt >5 u lMu
dilute lvlMWL|uLuuL 20 ml
lMu|1nt 0.9%Nacl lu
nnWtuuuuuM1MLuu
t|n|nu|nM|nMn 0Mu
||nult v |1uuult
lv:Wu|W1|nu|nM
95 Ciprofloxacin 10 Therapeutic
Use/ Efficacy/
ndication
u Ciprofloxacin
nLnnL
Leptospirosis lMvlL
nnWnLlMunMn1luvu
hamster wtnlt
Ciprofloxacin v
Fluoroquinolone Mu |tu
levofloxacin , gatifloxacin lu form
inj lMWnlunnLu1L
uunWu1nnMlLuMnM1n
doxycyclin uMnlvuluLuLu
u1lLwt1uu1tWnnlt
uM1nn
96 Ciprofloxacin,

Metronidazol
e,
Doxycycline
5 nteraction unt
Ciprofloxacin ,
Metronidazole un:
Doxycycline nLn|nM
D nulMvlL
nnntWuuLnlLwtu1
3 tuM |nM drug interaction nu
97 Clarinase 7 ADR/Side
effects
WtuLt:Muwu sulfa
nLnltu clarinase
lMvlL
Clarinase t:ntMuu
Loratadine un: Pseudoephedrine
t1|tuulLL Sulfonamide |tu
nut:nt 1nLnltlu
Wtuuwu sulfa lM
98 Clindamicin 4 pregnancy/nursi
ng
Clindamicin inj . nLn
lvluWtulvuLtMlM
vlL
Clindamicin nLnutn1
uuLlM|nnuuun:|Wuwt
u1u:u1n|tu|nM
nLMlMtu Clindamicin
Lnt Gentamicin M1uu1W
ltuu1:LM:1un:MMML
nu1nu1lnntM
99 Clindamycin 11 compatibility/St
ability
untntvu
un:WLW1Mu1u
clindamycin
u Clindamycin LWLu1 150
mg/ml tLMt 4 ml tv
ulMu|1ulvlMWL|uLuu
600 mg/50 ml Mu D5W v
NSS lt|nlunlvu 30 u
un:n:nuLWLW1M 24 tlL1
nvDLv1
100 Clindamycin 9 Dosage/
Administration
Clindamycin inj. WL
|uLuu 600 mg/4 ml
nLnlvuutt direct
iv lMvlL
u Clindamycin lLnLnlv1
direct iv lM uMnLnlvlMlMu
u0M deep im un: infusion
|uu |u1nulv|nM
phebitis lM lMu|LlvulMuu
deep im uuMuM1lL|nu 600
mg nunlvlMuu iv infusion
:M1 dilute Mu NSS, D5W
un:WL|uLuuu1ulL|nu 18
mg/ml lt:u:|nlunlvu
10 - 60u un:M|lun
lvulL|nu 30 mg/min
101
Cloxacillin 03 Pharmacokin
etics
u 'Cloxacillin L
half-life |lv
u 'Cloxacillin L elimination
half-life |nt 0.5-1.5
tlL1 luWtuD:lMtnM
102 Cloxacillin 7 ADR/side effect Wtultu Cloxacillin inj.
unLnuuuvun
vullLn |tun|vM
nnuwulMvlL
nuwulMuLn uuuvun
vtun:vullLn |tu
nuwuutt Anaphylatic shock
uMu1lnMLWLnt:|Lu
n|nMuu|tun|vMn
nuwu Cloxacillin ltu1
vlL
103
Cloxacillin ,
ceftriaxone
7
ADR/ Side
Effects
u cloxacillin un:
ceftriaxone vnlvwL
nu:lv|nMnuw
uttvuuM1 MuM1
n0M cloxacillin lLlMLu1u
lv|nMvuuM1 (flushing)
uMn0Mceftriaxone wtu1u
n|nM flushing < 1% nunlv
u1 2 MLnunlLlMlv|nM
nvuuM1|wLLnuu uM
uuunt rate luntvu1
n1M lMu Ceftriaxone lvutt
iv bolus 0M|u1vnM|nMM
lu|nlLuun 2-4 u |w
t1nuD:vnM|nMMn|nt
lvutt iv infusion |tu|nlL
uun 30 u nvtu
cloxacillin lvutt direct iv t
uu 2-4 u lvutt iv infusion
uu 30-40 u vn0Mu1 2
MlvWtuunWtuLnvu
uM1nlvttntvulMu|wL
|nlun infusion lvuuuu
104
Cloxacillin
,
Clindamyci
n
03 Pharmacokin
etics
untu
Cloxacillin un:
Clindamycin M1
ttuuMuluWtu
lWlMvlL
u Cloxacillin un:
Clindamycin lL|tuM1
ttuuMuluWtulWlM
uM clindamycin :M1tt
uuMu|0w:luWtulW
Mt|tu severe hepatic
disease |uu
105 Cloxacillin inj. 11 Compatibility/
Stability
Cloxacillin inj. vn1WnL
nLn|ntllMuu|l
Cloxacillin WnLnt NSS v
D5W LWLW1M 2 tlL1
nvDLv1 un: 24 tlL1|L
|ntluM|uu
106 Cloxacillin,Di
cloxacillin
9 Dosage/Admini
stration
untu
Cloxacillin un:
Dicloxacillin LuuMu
ltuMnM1nuu1l
uuMltu1u Dicloxacillin W
|MnLuvunM < 40 kg ltuuM
12.5 - 25 LnnnLMnlnnLM
u ut1lvn 6 tlL1 , |Mnun:
WlvuLuvun > 40 kg ltuuM
125 - 250 LnnnL n 6 tlL1
lMuu1 2 tuMLnu1|Dnt
u|vLunuun:nLnlt
uunulM |wu1uMuuMnltu
u1 dicloxacillin :Mn
cloxacillin t:LnW1vu1|uu
( ltun: 4 W1n 6 tlL1
|vLunu) |u1nn
tt:uuluuuM|nu
:Mtulu|nMu1 dicloxacillin
:Lnn cloxacillin t:Ln 2
|
107 Cogentin ,
Benztropine
mesylate
09 Dosage/
Administration
uuMu Cogentin ltlu
uuM|l
uuMu Benztropine mesylate
v Cogentin ltMuW 1-2
mg lMultlMlut1 0.5-6 mg t1
M1ttuuMMLuun:uvun
u1WtuL1tuMu1
parkinsonism u1Wtu
nvtWtu|tu diopathic
parkinsonism |LluuuM
0.5-1 mg lMulvun:W1nu
uu Wtut1uM1lt u
uuM 4-6 mg/day nuWtu
|tu post-encephalitic
parkinsonism nulvu:|Llv
luuuM 2 mg W1|Mu t1lu
Wtut1u |LluuuM 0.5
mg nuuu unWutt|wL
uuMu
108 contraceptive 9 Dosage/
Administration
uWLnuMLulu
l1wutnn1un n
M1nuLltutt
0n|0u:uLltluuuM
|l
uWLn|uMLlul1wutn
n1un lMun 1. Geny FMP. :
t:ntMuMu Norgestrel 0.5
mg + ethinyl estradiol 0.05 mg
lMuLutt:uW tt:u
|LMnu 2 |LMu un:n 2
|LMlu|n 12 tlL1ML , 2.
Prevenon 28 : t:ntMu
Mu Desogestrel 0.15 mg +
ethinyl estradiol 0.03 mg Lu
tt:uWtt:u|LMnu
4 |LMu un:n 4 |LMlu|n
12 tlL1ML , 3. R - den :
t:ntMuMu
Levonorogestrel 0.15 mg +
ethinyl estradiol 0.03 mg u
tt:uWtt:u|LMnu
4 |LMu un:n 4 |LMlu|n
12 tlL1ML
109 Co-
trimoxazole
9 Dosage/
Administration
Wtu|Mnu 5 |Mu
uvunM 4 nlnnL
lMtnu0u|tu
Pneumonia un:uwu
n1u Co-trimoxazole inj.
20 mg iv q 6 hr M1
WnLnt NSS tLM
|l
Co-trimoxazole inj 1 ampule
t:ntMu Sulfamethoxazole
400 mg + Trimethoprim 80 mg (
5 ml ) M1WnLntnn:nu
0.9% NSS luMnu 1:25
uwun1 20 mg u1
Trimethoprim M1uu1M1uu
L 1.25 ml un:WnLlu 0.9%
NSS = 1.25*25 = 31.25 ml
110 Creatinine
clearance ,
Clcr
3 Pharmacokineti
cs
untnMWun
Creatinine clearance
(Clcr)
Clcr (ml/min) male= (140 - age )x
BW 72 x Scr Clcr (ml/min)
female = 6.85 x Clcr males
111 Cyproheptadi
ne
10 Therapeutic
Use/ Efficacy/
ndication
u Cyproheptadine
nLnlt|tuu|u
vlMvlL
u Cyproheptadine |tuulunnL
antihistamine t1|tuuunuwuu
Lnu1|Wu1nu W |wL
WLunv M1uu 1uuL
uLlt|tuu|w|wLWLun
vLnnlt|tuuunuw
lMuuuMultW 2 mg un: 4
W1
112 Cytarabine 9 Dosage/
Administration
u Cytarabine nLn
0MlMuu sc lMulLM1
dilute lMvlL (uuM
ult 30 mg)
Cytarabine |tuulunnL
antimetabolite WL|uLuu low
dose (100-200 mg/m2 ) nLn
lv1 im, sc, iv lMlMulLM1
dilute uMnltuWL|uLuun1
( 1-3 g/m2) M1lvlMuu infusion
lMu dilute Mu D5W v NSS
tLM 250 -1,000 ml un:lt
|nlunlvu 1-3 tlL1
113 Cytotec,
Magnesium
sulfate
07 ADR/ Side
Effects
Wtudrip MgSO4 un:
|vut Cytotec unL
nvunu vul
ntn WLMuM lL
t|nMnu2Mu
lMvlL
- MgSO4lv|nM
hypotension vl|MuWM1v:lM
vnlv rate ||nult lMu
maximum rate infusion 2g/hr uM
lv 4g/hr lMlunn eclamsia ,
tn n serum Mg > 2.5meq/l
Wtu1lvuwut
unnuwt ADR nLwuu
ntuuMu |tu 1|nu,
nnL|uuu1 ,nM CNS
-Cytotec suppository v
misoprostal Lu1un|nMlu
vunu n:vuu tM|MuL
tM|LunnL|u tM1 tM
vn1 t1luu1uSpontaneous
ADR t 2004 2006Lu1un
|nM chill 1 0tt rigor 10tt
nvtWtuuulLtnlv
rate iv MgSO4 un: base line u1
:MtMgu1Wtu t1LWnM ADR
nMgSO4lu|1WLMulnvM
Mun:vulntn nunnu
u:|nMn cytotec
114
Deferoxami
ne
methanesul
fonate
(Desferal)
09 Dosage/
Administratio
n
unt
Deferoxamine
methanesulfonate
(Desferal) WnLnt
nn:nulMlMt1
un:Lunlvu
u1l
Desferal |unulMnt
nn:nu NSS , D5W
uuMulvluWlvuW
1.acute : ltuuMu 1000
mg lt|nlvu 15 mg/kg/hr
( v 40-50 mg/kg/hr) uM
lL|nu 125 mg/hr MLMu
500 mg q 4 hr (maximum
dose : 6 g/day) 2. Chronic:
utt im ltuuMu
500-1000 mg/day (|1u
500 mg : SWF 2 ml) 2. iv
(patient with severe toxicity)
: ltuuMu 2 g (max rate
15 mg/kg/hr) Note: n:nu
u 500 mg Mu SWF 5 ml
unWnLnt NSS v D5W
150 ml
115 Depakin ,
Sodium
Valproate ,
Midazolam
11 Compatibility/
Stability
Depakin inj v sodium
valproate nLnWnL
ntnn:nulM:lt1
|ntlltlMuu|l
un:lvwLnt
Dormicum 1nu
|MunulMvlL
Depakin v Sodium valproate
nLnWnL|ununtnn:nu
D5W , NSS , LRS tLM
50-100 ml vn1WnL|ntllMuu
24 tL. nvDL 15-30 1W vL
|ntluM|uu un:lLwtuLn
Compatibility :v1 Sodium
valproate nt Midazolam
(Dormicum) M1uu1uunlv
Wun:nu|wWLtnMDuu1
Wtu
116 Depakin,
Valproic acid
9 Dosage/
Administration
Depakin 400 mg M1lt
nu dilute |llu
WtulWlM
Valproic acid uuM 100 mg /ml (
5 ml ) M1 dilute lMult NSS ,
D5W v Lactated Ringer ' s
solution tLM 50 ml M1uu
uuuM 400 mg 1M1ltnu
40 ml lun|1
117 Deparon 10 Therapeutic use u Deparon Wu:l L
ut1ltu1l
Deparon LtnLu1uW
Analgin nnulMunMn
tM n arthritis untMv
118 Desensitizati
on
20 Others vn1n antiserum
skin test lvWn positive
M1n
desensitization :L
unu1l
n desensitization luWtu
skin test antiserumWn positive
:lLLt:lutu:l|nu
|u1nnMnt1Wvu1
|wuuWtu:uw|tL
vlLuu lLLWLnLwuunt
n|nMtnu |nMuu1
Duvn1lv|tL |u1n|tu
tnuanaphylaxis nn
n:Mu complement lLlt|nMn
gEM1uuuLWnskin test positive
nWlvM uMM1|MuLuunuw
|tLunwL1l lMult adrenaline
1:1,000uuM 0.5mlnvtWlvu
v 0.01ml/kgnvt|Mn 0MlM
Wvu1v |unnL|u|L
|nMtnuuw|tL unnu
lv antihistamine LMuv
lv antiserum 10%
119 Dextromethor
phan
4 Pregnancy/
Nursing
Dextromethophan
nLnltluvu1lvuL
tMlMvlL
vn|tuM1lt
Dextromethorphan lunMlvuL
tM WltMuWL:LM:1
lMuwnltuu|0w:|nL
nl vnn|nu1ntt:u
uM|u1 lLLuLnnutuu
n1uuL uMuLLnlL|nnn
M1LlnnnnutnL1
uuLlM lLwtu1un|nM
nlLw1t:n1Wlun
lMtuLnLMlLLuLn
unM1n1WLtnMDu 1Wlt
MuWL:LM:1
120 Diamicron
MR
6 formulation u Diamicron MR
nLnut1W1lMvlL
u Diamicron MR lLuu:ulv
ut1W1 |u1nu|tututt
Modified release tablet
121 Diazepam 4 pregnancy/nursi
ng
uwun1 Diazepam lv
WtuM1WD uMu
M1nnMulu Category
D unt:L
transquilizer MlMt1
unnL Minor transquilizer lMun
alprazolam , Chlodiazepoxide ,
Clonazepam , Diazepam ,
Lorazepam |Wuwtu1ulu
lMLn 1 lv|nM
122 Diazepam 9 p' dynamics /
efficacy
Antidote u1 Diazepam
W:l un:Lun
tvuu1l
Antidote u1 Diazepam W
Flumazenil LtnW Anexate
Lutvu W uuM|LMu 0.2
mg iv bolus vnWtulL
Mtnu1Mu|LlvW1un
nLnlvtlMluuuM 0.3 mg iv
bolus Dulu 1 u lMu total
dose lL|nu 3 mg
123 Diazepam 7 ADR/ Side
Effects
Wtultu Diazepam
Lntu Tranexamic
acid unLnuwu
W LuWnnnt|ntn
uMlLLnun
nuLn Spontaneous report
drug reaction t 2005 wt
Wtultu Diazepam Lu1u
n|nM oral ulceration lu:Mt
u:lt uu 1 u nu
124 Diazepam inj. 9,10 Dosage/Admini
stration,Therap
eutic use/
Efficacy/ndicati
on
untuu1lu
nnLntnM|u1
(stetus epilepticus) un:
nWnLu Diazepam
inj. |wvuMlvWtu|w
t1nunMnM:nu
nnL SE |LMunlv
Diazepam V 10 mg lL|nu 2
mg/min vnu1lLvuMtnWu load
Phenytoin 20 mg/kg rate lL|nu
50 mg/min vnu1lLvuMtn
lv V Diazepam t v V
Phenytoin |wL|MLluuuM 5
mg/kg nvtnlv Diazepam
lMult:uu:ulvutt V
direct uMvn|tuM1lvutt
infusion M1:1|1MnM:nu
|u1nun:nuulMuu
nn:nuuu:ulvltW D5W,
NSS 0.9% |1luMnu >
1:40 v/v nuunu:MnM:nu
t1n|1WL|uLuuu:L
WLW1M 6 tlL1 un:WL
|uLuu >1:50 v/v :LWLW1M
24 tlL1
125 Diclofenac 7 ADR/ Side
Effects
Wtuuwu Diclofenac
nLnlvu Dynastat
lMvlL
WtuuuLt:Muwu
diclofenec LnvutL ,uuu
tL un:lLLt:MltuuntM
Mu unn Paracetamol 1
lLnLnntlMWtuuwu
uttTrue allergy v
Pseudoallergy t1u Dynastat
v Parecoxib uu |tuulunnL
cox- inhibtor t1nMlW1n1
uMnM1nu diclofenac Ln
lvnLnltu Parecoxib lMlu
Wtuuu
126 Diclofenac 9 Dosage/
Administration
Diclofenac inj nLnlv
iv lMvlL
Diclofenac inj nLnlvlM1 im
un: iv infusion (iv drip) |uu
vL push (bolus) lMu|1
diclofenac lunn:nu 0.9%
NSSv 5% glucose tLM
100 -500 ml lt|nlunlvu
uu 30 min- 2 hrs , uuMu
n1nMMuW 150 mg lLWlt
MMMnuuun 2 u
127 Diclofenac
injection
9 Dosage/
Administration
Diclofenac injection
nLnlv V lMvlL
Diclofenac injection nLnlv
lM1 V un:M lMuLut1lt
uMnM1nuM1u ntramuscular(im)
ltnLRenal colic and biliary
colic severe migraine attack
when other form of diclofenac are
considered unsultable ,
ntravenous nfusion ltnLv
t1nu post-operative pain in a
hospital setting, Diclofenac
injectionnLnlv ntravenous
nfusion lMuMvL0M|uvnM
|nMlMuM1(V bolus) :M1
WuvuM|u|nMu1t
(ntravenous nfusion) un:M1
|1Diclofenac lunn:nu
lutLM 100ml-500ml lMu
nn:nuuuM1|tu0.9%NSS
v 5%glucose buffer Mu4.2%
sodium bicarbonate 1 ml v
8.4% sodium bicarbonate 0.5 ml
MltlunlvuL 2 uttW
1.ltnLModerated to severe
post-operative pain M1lvu
128 Diclofenac
sodium inj.
9 Dosage/Admini
stration
Diclofenac sodium inj.
nLn0M V lMvlL
Diclofenac sodium inj. nLn0M
V lMlMuuuMuWlvW
1mg/kg V push v slow V
infuion nlt Diclofenac
sod.25mg/ml M nvtlv V W
|1lv|tu 5 mg/ml Mu NSS
nuun1lv V infusion t
|tu|nuun 10 u lMu
Loading dose 75 mg Mnuu1
lv 5 mg/hr
129 Dicloxacillin 9 p' dynamics /
efficacy
Dicloxaciliin ltluuuM
|l un:uMnM1nu
Cloxacillin u1l
uuMltu1u Dicloxacillin W
|MnLuvunM < 40 kg ltuuM
12.5 - 25 LnnnLMnlnnLM
u ut1lvn 6 tlL1 , |Mnun:
WlvuLuvun > 40 kg ltuuM
125 - 250 LnnnL n 6 tlL1
lMuu1 2 tuMLnu1|Dnt
u|vLunuun:nLnlt
uunulM |wu1uMuuMnltu
u1 dicloxacillin :Mn
cloxacillin t:LnW1vu1|uu
( ltun: 4 W1n 6 tlL1
|vLunu) |u1nn
tt:uuluuuM|nu
:Mtulu|nMu1 dicloxacillin
:Lnn cloxacillin t:Ln 2
|
130 Dicloxacillin 9 p' dynamics /
efficacy
uwun1u Dicloxacillin
uuM 500 mg tt:u
2 * 4 ac unt
uuMulvn1|nult
vlL
uuMu dicloxacillin luWtuL
uvunMLnn 40 kg W 250
- 500 mg bid - qid M1uuuuM
un11n1|nult W consult
uwunW1
131 Dicloxacillin 10 Therapeutic
Use/ Efficacy/
ndication
WtulMuu1uvnL|nut
| un:nuuunn|nt
1 |LM unu1tMtLu
nntLwtvLnW1lM
vlL
n1nulMuu1uvnL|nut
|lv|nMn0nuMu1
nnL|u un:nnnL|u
n|nt|u1n|tunMtnu1
u11nulMutnun
nlv|nMnn|ntlv|nMWL
|ttMt1M1lt:u:|n
1nu:tLutLnu0nuM
uulv|tutnMun:M1tt:u
uL|t|u1nL|tlW
tu|tuLntu1LWL lv|nM
nn|nt|tuvu1un:|ttM
|wLLnuu lMuWtuM1
tt:uuL|tt:Ln 5 u
-3 ntMv t1lunnuWtu
tt:uult|wu1 1 uun:lL
nuuM|u1uvLM t1vn
WtunuuWt 5 uunn
tMtLu1W1|tuunLnL
wtuwulMt1uwu:wn
nnMM|t:nLM
lMuulM
132
Dicloxacillin 4
Pregnancy/
Nursing
DicloxacillinltluWtu
M1WD 6 |Mu lMvlL
Dicloxacillin Mulu Pregnancy
categom B nLnltlMu1
tnMDuluvu1M1WDn
trimaster
133 Digoxin,Grise
ofulvin
5 nteraction untu Digoxin
un: Griseofuvin |nM
drug interaction nulM
vlL
nnntWulLwtu Digoxin
un: Griseofuvin |nM drug
interaction nu
134 Dilantin inj. 11 compatibility/St
ability
Dilantin inj. nLnWnL
ntnn:nulMlMt1
nLnWnLnt 0.9 % NSS un:
Ringer lM uMlLnLnWnLnt
5% un: 10 % Dextrose water
lM |u1n:lvMnM:nu
un:|LWnLunWltu lL
WutM|uu|w:lvu
MnM:nulM
135 Diltiazam,
Herbesser
SR
9 Dosage/
Administration
Wtultu Herbesser SR
(diltiazam 90 mg ) uuM
1x3 untuuM
ultn1|nultvlL
nvtnnL
Hypertension un:
duration of action u1u
|tu|l
ultnL HTN lututt
capsule SR ( Cardizam SR )
nLnltlMlut1 240-360 mg /
day un:lututt Tablet ER (
Cardizem ) nLnltlMluuuM
120-540 mg/day t1Wtuuu
ltu Herbesser SR (diltiazam
90 mg ) uuM 1x3 1LWL
|vL:nL nu duration of action
u1u Herbesser SR uu n
nntWulLwtuLn uMwt
uLnu diltiazem SR u1tL
uL duration of action |tu|n
12 hr. t1u:|utlMnt
duration of action u1u
Herbesser SR
136 Diltiazem 4 p' dynamics /
efficacy
untuuM|LMu
u1u Diltiazem
Angina Pectoris : uuMu|LMu
W 120-180 mg once daily (
maximum dose : 480 mg/ day )
Hypertension : uuMu|LMu W
180-240 mg/day
137 Dimenhydrina
te
7 ADR/side effect untu
Dimenhydrinate nLn
lv|nMnuwuutt
fixed drug eruption lM
vlL un:nnLn:u1
nuwu|tuu1l
nnLn:u1 fixed drug eruption
:Lt1nnL uttM|u :u:
un|L:LnuM1M MLM1
nn1u1Wu|tunuM1Wnv
nL1 nWtuLnuwLn
M1nn1u1Wu|tuMLunlM
lMuwtu1unuwuuttu
luWtultu Dimenhydrinate
:MtWLu:|tuutt certain
6 ikp , probable 29 u ,
Possible 3 u un: unlikely 1
u ( u1u spontaneous report
of adverse drug reaction 2003 )
138 Dimenhydrina
te inj
7 ADR/Side effect uwun10Mu
dimenhyrinate V tn
Wtu|nMntL
uM1t|n0M lLt
|nMn:l
Dimenhydrinate tutt0M
nLnlvlMutt M v V lMu
nlvutt V uuMu 50 mg u1
Dimenhydrinate :M1|1nt
0.9%NSS 10 ml un:M1tv
utu1uu 2 u
139 Dimenhydrina
te inj.
9 Dosage/Admini
stration
Dimenhydrinate inj.
nLnWnLnt
nn:nu:lun:L
untvu1l
|u1nWtuuu|Wu
0Munnnunt
Dimenhydrinate inj. nLnlv
lM1 M un: V un:vnlvutt
V nLnWnLnt 0.9%NSS
uu 10 ml 0Muu 2 u
140 Dimenhydrina
te,
Loperamide
10 Therapeutic use untun
tt:uu uuMu
uW:1un:uuu:u
luntt:uu
Dimenhydrinate un:
Loperamide luWn1u
Dimenhydrinate uuMultW
50-100 mg v 1-2 |LMn 6 hr
LuW:1un:Wuu:ulun
tt:uuW ulv11
uu tnLnun:Wuv1 Wn1u
lMMuLnntnM1W
ltuluuuMMnMlvWnn1nM
Loperamide uuMu
uu:unn1|Muuttwnu
|LMuuuMu 4 mg MLMu 2
mg vn1nnu uuMulL|nu
un: 16 mg uW:1un:
uuu:uW unM:tt
t:nnunn11lv11
uuun:tnuv1lMuu:ulvML
u lunnWn1u:lMnu
lv|nMn1WnlMLnn
tnM
141 Diphenhydra
mine
10 Therapeutic
Use/ Efficacy/
ndication
untuMlM
nLnltuu
Diphenhydramine lu
nnWtuLn
Extrapyramidal Symtom
unLnltlunnLn
Parkinsonism and drug-induced
extrapyramidal reaction lMun
Diphenhydramine HCL un:
Benztropine mestylate t1uuMu
Benztropine :lvuuM 1-4 mg
one-two times a day lMu total
dose lL|nu 6mg/day lMulvu
utt ivv im , |MnuM1uM 3t
lvttuuMuMLWL|vL:nL
nuuuMutt:u:lv
uuM 1-4 mg once or twice a day
un:vn1nlvu dose un n
Wtuu1LnulvuuuM
1-2 mg two or three times a day.
|MnuM1uM 3t lvttuuMu
MLWL|vL:nL
142
Domperido
ne
,Metoclopra
mide
17 Pharmacolog
y/
Mechanism
of action
nnlnu1
domperidone un:
metoclopramide
uMnM1nuu1l
WuLltLnu
vlL
metoclopramide nnu
utu1nWnuln|uu
lMuutu1 dopamine (D2)
receptor 1 peripheral un:
central nervous system uM
vnlvuluuuMn1:LWn
utu1 serotonin receptor
Mu nu domperidone n
nuutu1 dopamine (D2)
peceptor |0w:nu
peripheral lvlL|nM
n extrapyramidal
symtom |vLuu
metoclopramide un:lLL
nuutu1 serotonin receptor
un:nnntWuuLn
wtlLL guideline v
uLnlMuu:ulvltu
metoclopramide un:
domperidone Lnu
|u1nLnnlnnnnu
143 Dopamine 11 compatibility/St
ability
M1nWnL Dopamine
nt Dextrose solution
LWL|uLuu 12 % lM
vlL
lMutnM Dopamine uuM
200-400 mg :WnLnt D5W
vnu|unulMlutLM
200-500 ml unM1 Dopamine
nLnWnL|unulMnt
nn:nu Dextrose M1uu1
u:WnLntnn:nu dextrose
LWL|uLuun1uulM
144 Dopamine ,
Frozen
plasma
11 Compatibility/
Stability
Dopamine nLn|nM
drug interaction nt
Frozen plasma lMvlL
nnntWuwt Dopamine
|nM incompatibility nt Acyclovir ,
Amikacin , Amphotericin B ,
Ampicillin , Heparin , ron,
Metronidazole , Nitropusside ,
PGS un: Sodium bicarbonate (
vnn:nuM1un ) t1lLwt
uLLnn|nM Drug nteraction
nt Frozen plasma M1uu1
nLnlvuLnulM
145 Dopamine inj. 11 Compatibility/St
ability
unt Dopamine
nLnlv1|nu
|Munt 50% Glucose
lMvlL
Dopamine lLLu1u|unu
lLlMnt 50 % Glucose M1uu1
nLnlv1|nu|MunulM
146 Dopamine
inj.,
Protamine inj.
11 Compatability,S
tability
untnLnlv
DoPAmine inj.nt
Protamine inj. unWtu
1nu|MunulM
vlL

DoPAmine lLnLnWnLnt
Acyclovir Amikacin,
Amphotericin B, Ampicillin,
Furosemide, Gentamicin,
Heparin, ron, Metronidazole,
Nitropusside, PGS, Sodium
bicarbonate (vnn:nuM1
un ) M1uu DoPAmine nLn
lv1nu|Mununt Protamine
lM un: Protamine LW pH 6-7
t1Lnu|tunn11nLnlv
LnulM
147 Dopamine
un: Oxytocin
11 Compatibility/
Stability
untDopamine
un: Oxytocin nLn
drip lvWtu1|nu
|MunulMvlL
nnntWuuLnlLwtuLn
n|unulLlMu1uDopamine
un: Oxytocin M1uulunnuL
tuvlunv|nu|wdripu
lvntWtu 1nLn drip ulMu
|nu|MunulM t1nvu|u
nt Dopamine lLlM lMun
Acyclovir, Amikacin,
Amphotericin B, Ampicillin,
Furosemide,
Gentamycin,Heparin, ron,
Metronidazole, Nitroprusside,
PGS, Sodium bicarbonate lMu
Oxytocin L PH u 3-5
148 Dopamine,
Amiodarone
11 Compatibility/
Stability
unt Dopamine
un: Amiodarone
nLnlvWtu1|nu
|MunulMvlL
nnntWuuLnwtnLn
lvu Dopamine un:
Amiodarone 1|nu|MunulM
|u1nlLwtuLnWLlL|u
nuu1u
149 Dormicum ,
Midazolam
3 Pharmacokineti
cs
M1nt 0nset of
action u1u Dormicum
Dormicum v Midazolam
tutt oral :LnMMtLutt
extremely rapid absorption nu
nlvutt im lt|nt:Ln 15
u , utt iv lt|nt:Ln
1-5 u
150 Doxazosin 7 ADR/ Side
Effects
Doxazosin nLnlv
|nMnuwuuttWulMn
|t|tuM
nnntWu wt'u
Doxazosin Llnnlv|nMn
uwuuttWulM 1% un:|nM
pruritis lM 1 %
151
Doxazosin 11
Compatibility/
Stability
Cadura XL nLnvn
ut1W1lMvlL
Cadura XL v u Doxazosin
mesylate controlled - release 4
mg tab t1uulututt
tnMtnuMunLt nu
nnLuuuu lLM1
tt:uutu vnut1W1
|LMu:lv|nunDwn|tu
centrolled release un: u:
tnMtnunLluulv
WtulMtuluuuM|nun
uwuM1n uu:ulvltuuM
2 mg M|LM
152 Doxycycline 9 uwun1uu
Doxycycline (100) 1x2 pc
lvWtu|Mn u 1 t
lMu|MuL|tuuu
nvt|Mn unt
uuMuM1nnLWL
|vL:nLvlL
nnntWuu1lLwtuLnWL
tnMDuu1nltu Doxycycline
luWtuLu < 18 t t1nlt
uuluWtuLnwMun
n1n:Mnun:wu Wlut1W1
vn1u1nM1WD t1un|nM
un:|MnLu < 8 t W
vnn|nu1nltuu |u1nLWn
lvnu1wuWMtnMun:u1wt
u1un|nM enemel
hypoplasia nMu
153 Doxycycline 10 Therapeutic use untWtu|MnL
D:|nu1Mn|tu
malaria :nLnltu
doxycycline lunnL
lMvlLun:LuMlM
nt1nLnltlMlu
Wtuuu
unLnltlunnL
Ln|u lMun chloroquine,
quinidine, primaquine,
doxycycline tetracycline un:
clindamycin uMu doxycycline L
unMu1nltlu|MnuM
n 8 t 1|tnuuLlt
clindamycin lMultuluuuM
8-25 mg/kg/day ut1lv 3-4 W1/
u
154 Drug use in
Mycoplasma
pneumonia
infection
10 Therapeutic
use/
Efficacy/ndicati
on
Wtu|Mnu 4 |MuL
t:Muwu Penicillin
un: admit Mu|1
Pneumonia uwu
M1nltunLn
WtWnL|t
Mycoplasma pneumonia
lutu0MlLt:
ltuMlM
nnLunLnWtWnL|t
Mycoplasma pneumonia lMW
unnL Fluoroquinolones lMun
Ciprofloxacin,Levofloxacin,Moxiflo
xacin |tuMu unnuu1nnL
Macrolides lMun
Erithromycin,Azithromycin,Clarithr
omycin uMuLlututt0Mlu
w.:|tuulunnL
Fluoroquinolones t1lMun
Ciprofloxacin,Levofloxacin t1
uLnnltlu|M:Luu1
nMun:M1:1 ADR lu:tt
neuromuscular&skeletal lMun
arthralgia, arthritis, tendonitis
uuMuuu:uM1u u
Ciprofloxacinlu neonate :7-40
MKD ut1lvn12hr,lu children:
20-30 MKD ut1lvn12hr nu
uLevofloxacinchildren: 5-10
MKDoselvn24hr uuMun1nM
W 500 mg
155 dT vaccine 10 Therapeutic
use/Efficacy/ndi
cation
untnLnlt
dT v DT vaccine uu
Tetanus toxoid lMvlL
nLnlt dT uu Tetanus
toxoid lM |w: Tetanus toxoid
t:ntMu purified tetanus
toxoid lutLn 5-10 Lf/0.5 ml
nu dT t:ntMu purified
tetanus toxoid lutLn 5-10
Lf/0.5 mlun: purified diphtheria
toxoid 1-2 Lf/0.5 ml t1:|vu
dT un: TT LtLnpurified
tetanus toxoid M dose |nu
156 dT vaccine 4 Pregnancy/
Nursing
uwun10M dT vaccine
0.5 ml M luvu1M1WD
6,8 |Mu lLt
nLn0MlMvlL
dT vaccine t:ntMu purified
tetanus toxiod 5-10 Lf un:
purified diphtheria toxoid 1-2
Lf/0.5 ml Mulu Pregnancy
category C uMnLn0Mluvu1
M1WDlM t1:tut1nulW
tM:unlunun|nMlMM
ttuWtulWtM:unwt
Ln|tu|MnlMvWtulL|Wu
lMtWtuLnuvlMtlL
Wt |tDLWLnunn0M
Wtulv|MnlMvWlvuM
n:Mtt1nulWlM 1L
uuWM:u dT Lltuu TT
lunt1nulWtM:unlu|Mn
lM t:tn1lt un:vu1
M1WD
157 DTP vaccine 2 Availability unttnWu1
DTP vaccine lut:|W
lu un: DTP vaccine
ut1n|tunt:|D
un:t:|DlMlv|nM
nlulMuunM
vaccine DTP L 2 tuM W tuM
|ML|tnnun:tuMlLL|tnn lMu
vaccine tuMlLL|tnn:lv|nM
nlulMuun un:tnW
u1 vaccine DTP tuMlLL|tnn
W Acelluvax
TM
, Acelluvax (
DTPa ) , TripAcel (DTPa) ,
nfanrix ( DTPa) , Boostrix ( dTpa
)
158
Duphalac

9 Dosage/Admini
stration
unt Duphalac

|LltluWlvu:M1lt
uuMu|lM un:L
onset u1u|tuu1l
Duphalac

v Lactulose L
uuMultnvtn
constipation luWlvu W 15-30
ml/day nLn|wLuuMulMn1
60 ml/day lMuut1lv 1-2 W1
(WL|uLuuu1u 10 g/15ml)
:u:|nlunnnuu1uW
24-48 tlL1nnu colon
lMun|wLu1 osmotic colon
159 Duxaril 7 ADR/Side effect untDuxaril L
Wnu1|Wu1lvWtu
|nMnuulLvntlM
vlL
u Duxaril t:ntMuMu
nWu Almimitrine 30 mg un:
Ranbasine 10 mg nnntWu
uLn wt Duxaril nLnlv
|nMnlLw1t:n1WlMu
tnunuuvntlM
160 Dynastat 11 Compatibility/
Stability
nnlLLMn:nu
ntLu Dynastat
nLnn:nuntM
n:nu:llMt1
Mn:nunLnltn:nuW1
u dynastat nu0MlvWtulMW
0.9%NSS, D5W , 0.45%NSS
LRS lMu|LWnLuunWltlv
vLMDuluW1|Mu
161 Dynastat 7 ADR/Side effect WtuLt:Muwu sulfa
lMtu Dynastat wt
Wtu|nMWu lLt
WtuLt:Muw sulfa
:uw Dynastat vlL
Dynastat v Parecoxib :LnM
lW1n1|tu Sulfonamide derivative
t1lu|nnnntuLW|MuvLlt
luWtuLt:MuwulunnL
sulfonamide |w::LWL|nu1M
n|nMnlLw1t:n1W1Wvu1
uu1 u1lnMLnWnLutt
retrospective cohort |w|W:vW
Lt:MnuwuMuntwnnL
sulfonamide LWL|nu1:uwuL
sulfonamide |tunut:ntlLlt
uMuntwLnuu|wu1lM |L
|utntWlLLt:MuwuMuntw
nnL sulfonamide Lnu lMu
nWnLlunnLWLt:Muw
uMuntwnnLsulfonamide uu
969 Wu |tut|utntnnLW
uu 19,257 Wu lLLt:Muwu
MuntwnnLsulfonamide Wn
nWnLwt Wtu 9.9% lunnLL
t:MuwuMuntwnnLsulfonamide
|nMnuwuu|LlMtulunnL
sulfonamide lLltuMuntw
|utntWtulLLt:Mnuwu
MuntwnnLsulfonamide |nMn
uwuu 1.6% |LlMtunnL
sulfonamide lLltuMuntw
162 Elthroxine 9 p' dynamics /
efficacy
Wtu|Mnu 15 u
nLnltu Elthroxine
uuM 1*1 OD lMvlL
uuMu Elthroxin Lut1ltlu
nnLlW Hypothyroidism
(Cretinism ) t1nltulu|Mnuu
uuMult:uuntuvunun:
u u1|Mn lMu|Mnu 15 u
WltuuuM 10 -15 mcg /kg/u
(u Eltroxin 1 tab Lu
Levothyroxine 0.1 mg v 100
mcg ) M1uu1Wtuvun
Mu1|MnnuWunvuuMu
|vL:nL
163 Enoxaparin 13 other untutvu
Clexane nnM1
ntvu Clexane
(Enoxaparin) 1.
Wlvu clexane 1lMWvu1
lMu0Mu|ulMWvu1t|nWu1
vu1Muu1u1nMWult
1u1vuvvn1nlMlMun
0Mnntnu:v1Mutuun:u
2.
W0MlMuu1|uLluuuM10n
ntWvu1t1nntM1uuMu
uvuLLun:utlMuWvu1:
nnunuuLMnM|nn0M
u 3. nu0Mu
lLM1lnw1nW
164 Enoxaparin 3 Pharmacokineti
cs
unt Enoxaparin
Luuulu1nu
uu|l
Elimination half life u1u
Enoxaparin |Llvutt single
dose :u 4.5 tlL1 uMnlv
utt repeated dose :u
t:Ln 7 tlL1
165 Enoxaparin 11 Compatibility/
Stability
Enoxaparin (clexane
prefill syring) |Lult
0MlvWtuun :nL
n|ntulltMlMvlL
un::|ntllMuu|l
nnntWu lLwtuLnWL
W1Mu1 Enoxaparin vn1nlM
uLltntWtu uMnn
ntnLltu1tLWWnM 1
tLu1nLn|ntullM
uu 24 tlL1 lMulv|ntullu
M|uu
166 Ephredine 6 formulation nLnlt 3 % ephredine
nasal spray vuMW
WtulMvlL
Ephredine nasal spray 3 % |tu
|DntMtu1l1wutn t1L
nuWnLu1 Ephredine un:
Sterile water un:lLLWn|nuutt
systemic lu1nu un:|tun
lt|wv1Wnnnnu|0w:
M1uu1nLnltvuMWWtu
lM
167
epoetin 9
Dosage/
Administration
Wtuuu Hemax 4000
iu Lnw.n1un
wLL NSS 2 ml lL
tlt:l uuM
uLn|nuvlL
Hemax L generic name W
epoetin uuMu|LMu 25-50
iu/kg iv v sc ntMvn: 3 W1
uuMun1nM W 200 iu/kg
ntMvn: 3 W1 l1wutn
n1unn1tuntL Bio sidus
t1u 1 nn1:t:ntMu M
u epoetin uttW1tlu vial
wLMu SWF
168
epoetin 9
Dosage/
Administration
Wtuuu Hemax 4000
iu Lnw.n1un
wLL NSS 2 ml lLL
tlt:l uuM
uLn|nultvlL
Hemax L generic name W
epoetin uuMu|LM 25-50 /|
v sc ntMvn: 3 W1 uuM
un1nM W 200 iu/kg ntMvn:
3 W1 M1wutnn1unn1t
utL bio sidus t1u 1 nn1
:t:ntMu Mu epoetin
uttW1tlu vial wLMu SW
169 Epoetin alfa 11 Compatibility/
Stability
untepoetin alfa
vn1nWnLun:|ntl
lMuunu
epoetin alfa vn1nWnLuun
nLn|ntluM|uulM 30u un:
WltlvvLMDulu7u
170
ERG 9
Dosage/
Administration
ERG LnnvuMuuM
un1nMlvlM (Maxinum
dose ) vlL |u1n
uuMulv:uunt
uvunMWtuvn
WtuLuvunMLn:
unlulMu1l
nnntnLtLu ERG
v Equine rabies
immunoglobulin uuMtnMltW
40 U/kg lMuu1lLL reference
nvuM maximum dose u1
ERG M1uu1tL1uu:u
lv0MuuuMMLuvunMu1
Wtu uLWtu:LuvunMLn
171 Erythopoietin 11 Compatibility/
Stability
unt
Erythopoietin nlLlM
|ntluM|uu:|ntlMuu
nu
nnntWuuLnwt
Recormon nLn|ntlun
M|uulMuu 3 u nu Hemax
un: Eprex lLwtuLnWLW1M
u1u|LlLlM|ntluM|uu t1
nD:tnM|ntluM|uu
Recormon :|ntlMuu 24 |Mu
nu Hemax un: Eprex :|nt
lMuu18 |Mu
172 Erythromycin 9 p' dynamics /
efficacy
M1n|tnuuuu1
Wtun Erythromycin
lt|tu Roxithromycin
:M1lt dose |l
un:uMnM1nuu1llu
uMn:t1u
uuMu Erythromycin lu|Mn W
30 - 50 mg/kg/day ut1lvn 6 -
8 tlL1 un:uuMuluWlvuW
250-500 mg n 6 - 12 tlL1
nuuuMu Roxithromycin lu
nun|nMun:lu|Mn ltuuM
2.5 - 5 mg/kg un: 2 W1 un:
uuMultluWlvu W 150 mg
un: 2 W1
173 Erythromycin 9 p' dynamics /
efficacy
WtuLt:M|tulW
heart un:uwu Penicillin
:lt erythromycin |w
t1nunuwu M1lt
uuMu|l
nlt erythromycin |tu dental
premed surgery n erythromycin
|tut|nn ethylsuccinate :lt
uuM 800 mg uMn|tut|nn
stearate :lt 1 gm lMu
tt:unuvMnn 2
tlL1 un:vn1nuun 6 tlL1
lvtt:unW1lMunMuuM
un1W1vu1u1 dose un
174 Erythromycin 10 Therapeutic use untnLnlt
uMlMuu
Erythromycin 1 G
tt:utlL1 19 ,
18 , 9 nunWMM
colorectal Lnt
Neomycin sulfate 1 G
lMt1
nntWuuLnlLwtLn
uu:ulvltutt:uMu
uM:uu:u second line lun
nL W Cefoxitin 2 G iv |L|L
MLu v Cefazolin 1-2 G iv
Lnt metronidazole 0.5 G iv
lunt1nunMM|tnun
WMM Colorectal
175
Erythropoie
tin ,
Epoetin ,
'Hemax,
Recommon
10 Therapeutic
Use/
Efficacy/
ndication
unt Hemax
un: Recommon L
efficacy uMnM1nu
vlL W|nnltM
lM1:WLW
nnWnLwtHemax
un: Recommon L efficacy
lLuMnM1nu uM
uMnM1lu|1u1Wun:
nuu1WtulunnL
1u Hemax LW 762
t/ 4000 iu nu
Recommon Wt:Ln
1430/500 iu t1lMuWMWM
ntMvwt Hemax L
Wltuuunun:
nLnltluWtutM1
lM luun: Recommon lL
nLnltnutM1lM
176 Esomeprazol
e
13 other WtulMtu1nuu1
lvv (NG tube) lL
tM1tvu
Nexium u1l
Nexium v Esomeprazole |tu
unnu|uunLnut1W1
lMuMvLtM|LMuvn|tuM1
lvututtu1nuvlvu
|LMultutunnW:LnuMn
Mu1|LMuwt pellets n:u
luuun1lv1nuvlM
177 Esomeprazol
e
7 ADR/Side effect unt
Esomeprazole tab lv
|nMnWnuln tM
1lMvlLun:|nMuu
n %
Nexium v Esomeprazole L
u1un|nM nausea un:
abdominal pain lM 4%
178 Esomeprazol
e
4 pregnancy /
nurse
Nexium tablet nLn
ltluvu1lvuLtMlM
vlL
u1lLwtnWnLluWu
esoimeprazole nnutn1
uuLvlL u1lnML wt
u1u omeprazole t1|tu
unnL|MununLnutn
1uuLlM 1lLuu:ulvltlu
vu1lvuLtM
179 Esomeprazol
e
09 Dosage/
Administration
M1nlvu
Esomeprazole lMun
lv1nuu1lvv
nLntMulMvlL
vLunlM|wlv
nLnlvulMu1
|vL:nL
uEsomeprazolelLnLnvn
ut1 tM |Wu vlv|LMu
uMnuMMuM M1uunlvuuun
Wtu lMun feed :M1utu
luulvunLnn:u
Mu1nL|nL vn1nuu1u
ult feed lvunWtu1nuu1
lM
180 Esomeprazol
e inj.
11 Compatability,S
tability
untuNexium
inj. nLnWnLnt
nn:nulMlMt1un:L
unWnLuu1lun:
M1lvulMult|n
|lMun::M1lvutt
V direct v drip
Nexium inj. v Esomeprazole
inj. nLnltlM1utt V direct
un: drip (nfusion) lMunlvutt
V direct lvWnLuuuM 40 mg
nt 0.9% NSS 5 ml lt|nu1
uu 3 u nuutt V infusion
lvWnLnt 0.9% NSS 100 ml lt
|nuuu1uu 10-30 u
un:lLuu:ulvWnLnt
nn:nuMu|u1nLuLnlL
|wu1wlu|1u1 stabiity un:
compatibility u1u
181 Ethambutol 3 P'Kinetic uwun1 Ethabutol lu
uuM 7.5/kg/day lu
WtulMu ( CrCl = 43.7
) untM1tt
nMuuMuvlL
lMultuuMu1u Ethambutol
W 15-25 mg/kg/day nun
ttuuMuluWtuLW GFR =
10-50 ml/min ttlMulvu
n 24 - 36 tlL1 uMt1MlL
uu:ulvttuuMuluWtu
LW GFR 10 - 50 ml / min unM1
WtuuulL|tuM1
lMtnttuuMu uMu1l
nMLuuMuWtulMtM
|nult
182
famciclovir 9
Dosage/
Administration
famvir ltnL recurrent
herpes simplex utt long
term lt dose |lnu
uu|lM1 moniter
:l un:L1uu1t
Lt:nuDwvlL
famvir v famciclovir nLnlt
nL Recurrent herpes simplex
un:nLnltt1nu nnnt
|tutu1 herper simplex lM t1
nt1nuuuWltluWtuL
WLuu1lunnnt|tut
183 Famotidine ,
Nimesulide ,
Orphenadrine
3 Pharmacokineti
cs
Famotidine, Nimesulide
un:Orphenadrine LW
W1tM|tu|l
Famotidine LWW1tM 2.5-4 hr
(Chinical half life 8-12 hr ) ,
Nimesulide LWW1tM 1.8-4.7
hr un: Orphenadrine LWW1
tM 13 - 20 hr
184 FBC 8 Toxicity/Poisoni
ng
WtuM1WDtt:u
u FBC 34 |LM un
t:LuMu
vlL u1l ( Wtu
uvun 60 kg )
FBC t:ntMu Fe fumarate
200 mg , Vitamin B1 2 mg ,
Vitamin B2 2 mg , Vitamin B 12
5 mg , VitaminC 20 mg , Niacin
10 mg , Folic acid 100 mcg , Ca
phosphate tribasic 100 mg t1
WtulMtwLuu1lMvn
lMt elemental iron |nun 60
mg/kg t1LnunM1W shock ,
coma , seizure , G bleeding,
v metabolic acidosis (Fe
fumarate 200 mg L elemental
iron = 66 mg ) WtuuulMtu
FBC 34 tab t1|nt 37.4
mg/kg t1u1lLn1nD:|tu
wLn|vnn u1lnMLM1
observe n|tuwLn|vnn
M1nnu1Mu
185 FBC and Fe
fumarate
,FeSO4
10 Therapeutic
Use/ Efficacy/
ndication
FBC and Fe fumarate
uMnM1nuu1l Mn
FeSO4 vlL
FBC t:ntltMu Fe fumarate
200mg, B1 2mg ,B2 5
mcg,C20mg, niacin 10mg, Folic
acid 100 mcg ,Calcium
phosphate tribasic 100 mg
Fe fumarate uuM 200mg,FeSO4
uuM 300 mg :|vuluFBC
:L Fe fumarateuMuluWL
u1|nu |wu1uMnWulunu
FBC:lMtMLu un:uuM
u1u |nL|ultMu M1unM1
u1Mu uMMunWunWFe
fumarate nuFe fumarateun:
FeSO4 |Ltt:u|ultun
:lMMunnu|vLunuW
element iron uMM1nututt
|nnL form nt ferrous n|vM
M1formnt|nn|w|wLWn
n:nu un:n form |nn
uMnM1nuWnn:nun
uMnM1M1u ron salt % ron
Fe fumarate ~ 33 Fe
gluconate ~12 FeSO4 ~20
*|nn fumarate Wn
186 Fentanyl 10 Therapeutic use untnLnlv
fentanyl luWtu|MnlM
u1lt1
luut1lt sedative/analgesia
nLnlvutt slow V push lu
uuM 1-4 mcg/kg/dose nLn
tlMn 2-4 tlL1 nM1n
utt Continuous nLnlvlM
lMulvuutt V bolus luuuM
|LMu 1-2 mcg/kg un:MLMu
0.5-1 mcg/kg/hr un:nLnWnL
lMntnn:nu D5W v NSS
187 Ferrous
sulfate
9 p' dynamics /
efficacy
untuuMu
ferrous sulfate lu|Mn
u 5 ut uvun 18 kg
lunnLD:uMuM
|vnn
lu|MnLD:uMuM|vnn :lv
elemental ion luuuM 3 - 6
mg/kg/day lMuut1lvun: 2 - 3
W1 ( Fer-in-sol 0.6 ml
t:ntMu ferrous sulfate 75
mg t1:lvuM|vnn 15 mg)
188 Fexofenadine
, Telfast
9 Dosage/
Administration
M1ntuuMu
Fexofenadine ltlu|Mn
uuMu Fexofenadine W 30 mg
2 W1Mu lu|MnLu 6- 11
t nuWLuLnn 12 tuu
lt:ltuluuuM 60 mg un:
2 W1v 180 mg un:W1luW
|tu Seasonal Rhinitis Allergic
un: ltuluuuM 60 mg un: 2
W1 luWtu|tu Chronic
idiopathic urticaria nu|Mnu
uun 6 t lLwtut1ltu1uu
189 Floctafenine 7 ADR/side effect untu
Floctafenine ,
Orphenadrine un:
Etoricoxib MlMlv|nM
nlLw1t:n1WlMu
lv|nMnMtLlM
LnnM
nntWuuLnnWuuMMML
nulLw1t:n1Wnnlt
WnMDnvnuDwu1n:1
nunnu wt Floctafenine
nLnlv|nMnlLw1
t:n1WlM W eye abnormality ,
eye irritation , eye pain , eyelid
oedema un: oedema periorbital
nu Orphenadrine un:
Etoricoxib lLwtu1un|nM
nulLw1t:n1WMM
190 Floctafenine 7 ADR/side effect Floctafenine nLn
lv|nMnWnuln
|uulMvlL
nWL Spontaneous report of
adverse drug reaction t 2003
u1WuuMMMLnulLw1
t:n1WnnltWnMDnv
nuDw nun1uWn:nLn
vun:u n:1
nunnuwt Floctafenine
nLnlv|nMn|uu
:MtWLu:|tuuttu:lt 3
u un::Mt:lt 1 u
191 Floxetin ,
Levodopa,
Baclofen ,
Trihexypheni
dyl
7 ADR/ Side
Effects
uwuuMWtuWMMM
lMuWtuLuM1
tt:u W Floxetin
20 mg , Levodopa 200
mg + Benserazide 50
mg , Baclofen 20 mg ,
Trihexyphenidyl 2 mg
un: Clonazepam 0.5 mg
WtulMvuM
tt:uultt:Ln
7u un:uLvvu
un:tnnu wMlL|1
untWtuM1
vuMuM1nnnu
WMMvlL
nnntWu wtuWtu
vuMtt:ult1vLM lL
|nuu1nt:tt|nMM1:1
n bleeding M1uu1lL
|tuM1vuMu|vnunun
WMM
192 Fluconazole 10 Therapeutic
use/
Efficacy/ndicati
on
uwun1lt Fluconazole
luuuM 600 mg/day
luWtu HV |tu
cryptococcal meningitis
lMtu Amphotericin
B Wt 14 u un:lL
tuuMuM1nn
ltlMvlL
uuMulMultu1
Fluconazole ltluWtu
cryptococcal meningitis W 400
mg/day |tu|n 8 ntMv
vn1nlMt Amphotericin B
0.7-1.0 mg/kg/day |tu:u:|n
u1uu 2 ntMv nvt
nlv Fluconazole luuuM
600 mg/day lvMn
nM|tnulunuvn1Mn
uuMu 400 mg/day un:L
nWnL|tut|ut efficacy
:v1 Fluconazole luuuM
600 mg/day nt traconazole
600 mg/day |tu:u:|n 10
ntMv luWtulMt
Amphotericin B |tu|n 2
ntMvLun wt CSF
sterilization rate u1
Fluconazole group un:
traconazole group |nt 100
un: 94% MLnMt (P= 0.26)
M1uunnWnLuuMu
M1nn1nLnltlM
193 fluconazole 8 Toxicity/
Poisoning
Fluconazole lv|nM
hepatitis luWtu ADs
lMn %
LnWnLwtnltu
fluconazole nLwuun1u
u1Mt W |LLnltu
fluconazole luWtu ADs |w
t1nu Cryptococcosis uu :L
WLWMtnMu1Mtvnuutt
|tu mixed cytolytic un:
Cholestatic liver tests abnormality
t1|LvuMu fluconazole n:M
uu uM|LnntLltlvL nuun1
M1uu1M1WunWnLMlt
lun monitor n1uu1Mt
|vL:nLluWtu ADs t1M1lt
fluconazole |tu:u:|nuu
194 Fluconazole 9 Dosage/
Administration
M1ntuuMu
Fluconazole lunnL
esophageal candidiasis
nlt Fluconazole lunnL
esophageal candidiasis lu u
un:ltuuuM 200 mg
vn1nuu:ltluuuM 100-200
mg/day (|wLlMn1
400mg/day ) t1lunnLutt
long term :lt|nu1uu 3
ntMv un:vn1nvuun:lt
uMn|tu|n 2-3 week
195
Flunarizine 07 ADR/ Side
Effects
flunarizine Lun
nu1|Wu1
nLnlvvu
tLlMvlL
nu1u spontaneous
ADR 2005 wtLu1u
n|nM D: face edema 3
u , oedema 1 u un:
mouth oedema 2 u
196 Flunarizine ,
Clonazepam
8 Toxicity/
Poisoning
Wtunu Flunarizine ,
Clonazepam 0.5 mg
u1n: 30 |LM :Lu
nLu1l L Antidote
vlLun:uuMun1nM
|tu|l
uuMu Flunarizine LuuMu
n1nMW 600 mg un:W1 t1:
lvLnu1 CNS ( ex.
sedation drawsiness, agitation)
un: cardicvascular ( ex .
Tachycardia) lMulLL Antidote
ltlunnLlMu|0w: uM
nLnlv activated charcoal
|wMMttu vlv|uu
v gastric lavage t1 case
uWtutt:u Flunarizine
uuM 5 mg uu 30 |LM =150
mg t1u1lLn1:Mtu overdose
nu Clonazepam uuM 0.5
mg / tab uuMun1nM W 20
mg/ day t1:lvLn1
CNS lM ( ex. ntnu , tn , n
|WnulvWMtnM un: Coma )
lMulvnnLMLnwL
ntlv antidote W Flumazenil V :
initial dose W 0.2 mg over 30
seconds (|wL|tu 0.3 mg )
un:repeat dose W 0.5 mg over
30 seconds nLnlvtlMlMu
197
Flunarizine
Pregnancy
04 Pregnancy/
Nursing
WtulvuLtM
nLnltu
flunarizine lMvlL
nnntWuuLn lLwt
uLnnutun1
uuLu1u flunarizine uM
u1lnMLlLwtuLn
uuuun1WLtnMDuM
nluuLlMtu M1uu
1WltulunnLWL
|tu1|uu
198
Fluorouracil
,
Methotrexat
e
08 Toxicity/
Poisoning
unt antidote
u1u methotrexate
un:fluorouracil
lLL antidote nvtu
methotrexate un:
fluorouracil 1uvnWtu
lMtu|nuuuMlvttM
M1u 1.methotrexate: n
wL lMun Wnuln |uu
WL1 :|tunMun:
lMu unLnwL W
n hydration un:
alkalization :tut1nu
nMnM:nuu1 MTX un:
metabolite u1LulM v
hemodialysis 2. fluorouracil
nwL lMun Wnuln
|uu 1|nu WL1 lv
nnLutt:Wtt:W1
MLn un:WMMML
CBC u1lnntM
199
Fluoxetine,
Clonazepa
m,
Phenobarbi
tal
04 Pregnancy/
Nursing
nLnlvu
Fluoxetine,
Clonazepam,
Phenobarbital lu
vu1M1WD 2 |Mu
lMvlL
clonazepam Mulu
Pregnancy category D lMu
wtu1un|nM
orofacial clefts , cardiac
malformations luWtu
lMtuu uMlunWnL
MLnntlLwtu|wL
WL|nu1lun|nMWL
WMtnMM1nn t1vn
|tuM1ltuwn
ltluWtu|tu severe
anxiety disorder nu
Fluoxetine Mulu
Pregnancy category C
|tuunLn|nnltlM
nnLWL|tuM1ltu
lMuWu1n1WnMun:Wn|nu
:lMt nu phenobarbital
Mulu Pregnancy category
D 1Wvnn|nu1nltuu
luvu1M1WD
200 Fluticasone
propionate
2 Availability u Fluticasone
propionate lu
l1wutnn1un Lt
nWu1l
u Fluticasone propionate lu
l1wutnn1un |tuuWnL
:v1 Fluticasone propionate
un: Salmeterol LtnW W
Seretide
201
Folic acid 07 ADR/ Side
Effects
Folic acid lv|nM
L |tLlMvlL
nnntWuwt Folic
acid lv|nMn
u1|Wu1lMuu n
wtlM lMun Wu uM1
vnMnLvMM Wnuln
|uu ntnu Mu|Mu uM
lLwtu1un|nML|
tL
202 Folinic acid 9 p' dynamics /
efficacy
untuuMu folinic
acid ltt1nunnM
lun:Mnnu
Pyrimethamine un:
Sulfadiazine
u Pyrimethamine un:
Sulfadiazine |tuultnL
D:nL1n|ntn|t
Toxoplasma ondii t1Wnu1|Wu1
u1u1 2 tuMuW nMlun:Mn
nvtnltnLluD:MM|t
:u:|0utwnu :lt folinic acid
uuM 10 mg/u Lnt
sulfadiazine 1- 2 g n 6 tlL1
Lnt Pyrimethamine uuM 100
-200 mg lMutt:uu1uu
6 ntMv nunlt|wt1nu
nnnt|tut :lt folinic acid
uuM 10 mg / u tt:u
Lnt sulfadiazine 0.5 - 1 g u
n: 4 W1 Lnt pyrimethamine
25 - 75 mg/u
203 Folodipine 4 Pregnancy/nursi
ng
unt felodipine
nLnltluvu1M1WD
lMvlL
u felodipine |tuuMulu
Pregnancy cat.C 1WWu1WnM
un:Wn|nu:lMnnltu
204 Fuller's earth 9 p' dynamics /
efficacy
untuuMu1u
Fuller's earth lunlt
|tu Antidote
uuMu1u Fuller's earth W lv
uuuM 30 % w/v suspension
tLn 200-500 ml n 2 tlL1
|tuuu 3 dose lMulvLnt
5% W/V magnesium sulfate v
manitol
205 Furosemide 11 compatibility/St
ability
Furosemide inj. nLn
WnLntnn:nulMlM
t1
nLnWnL furosemide inj. nt
0.9 % NSS, nn:nu Dextrose
water un: Ringer lactate
solution lM
206 Furosemide,
Torsemide
10 Therapeutic
Use/ Efficacy/
ndication
unt furosemide
nt Torsemide LWL
uMnM1nuu1l
Furosemide un: Torsemide M
ulunnLu Loop Diuretics t1L
uuMnM1nu W Torsemide L
duration unun:LWLu1
n1n un:lv|nM hypokalemia
uun Furosemide
207 Furosemide
un:
Nitroglycerine
11 Compatibility/
Stability
furosemide nLnlv
nu|Munt
Nitroglycerine lMvlL
nnntWulLwtuLnn|u
nulLlMu1ufurosemideun:
NitroglycerineM1uu1nLnlv
u1nu|MunulM
208
fusidic acid 7
ADR/ Side
Effects
fusidic acid L SG lv
1|nulMvlL
fusidic acid : ADR significant : G
: anorexia , dyspepsia , diarrhea ,
epigastric , distress , n/v
209 G-6-PD 8 Toxicity/
Poisoning
ulMt1lLWltlu
Wtu|tu G-6-PD
G-6-PD |tu|ultLulu
1nuun:lu|tn|LM|nMuM1
lMuLvut1nulLlvltMu
u1|tn|LM|nMuM1nnnu t1
vnuM|ultLM1nn:lv
|LM|nMuM1uMnlM1u t1u
Wvnn|nu1luWtu|tulWu
W unnL sulfa (Bactrim),
Primaquin ,Phenazopyridine ,
Vitamin C ( high dose ) , Aspirin
|tuMu
210 Gabapentin 7 ADR/side effect Wtutt:uu
Gabapentin unLn
uuu1Ln un
t|nMnu
M1nnvlL
nnntWuuLn wt
Gabapentin nLnlv|nM
nulLw1t:n1WM:tt
neuromuscular un: skeletal lM
t1W wtn myalgia lM
t:Ln 2% u1lnMLuu:u
lvWtuwtuwu|wvn|vM
nW1vu1nM1nn|nM
nn|vMulMnvlL
211 gabapentin 4 Pregnancy/
Nursing
untu
Neurontin v
Gabapentin nLnlv
luvu1lvuLtMlM
vlL
Gabapentin nLnutnlM
1uuL un:lLwtuLn
|nMuulu|MnlMtuLuL
M1uunlvuWwnWn
|nMuu:v1t:lutu
Wn|nuun:WL|tulunltu
212 Gentamicin 4 pregnancy/nursi
ng
WtulvuLtM nLn
lv gentamicin inj. lM
vlL
Gentamicin |tuuMuntwlu
nnL aminoglycoside nLnut
n1uuLlM|nnuu ( small
amount ) u1lnML|Wuwt
u1u:u1n|tu
|nMluLMlMtu
gentamicin Lnt Clindamycin
un:nM1nnlMvult|L
vuMu M1uu1Wltu1
:LM:1un:MMMLnu1
nu1lnntM
213 Gentamicin 7 ADR/side effect gentamicin inj. nLn
lv|nMwLMlMlM
t:Lnnuvn1n
lMtu ( WtulMtu
uuM 240 mg iv OD )
unnL aminoglycoside nLn
lv|nM acute renal failure lM
un: 10 - 30 u1Wtultu
lMuwtnnMn1u1Mn
n1u1|vn glomerulus
un::Mt Scr :Wu|wLuu
vn1ltut:Ln 3 - 5 u un:W
CrCl nMn1Dulu 6 - 10 uu1
n|LnLMuu un:D:lM
u|0utwnun|nMuuvn1
vuMulM 1u|w:unnn:nL
ulu|u|uu1lMlM|tu|nuu
214 Gentamicin
nj.
7 ADR/side
effects
untu
Gentamicin inj.lv|nM
WulMn|t|tuM
n Spontaneous Report of
Averse Drug Raction 2003 wt
nLnlv|nM rash lu:Mt
u:lt 19 u,:lt 19 u
un:lLu:lt 2 u un:n
Druginformation Handbook
2003-2004 wtnLnlv
|nM skin itching,reddening of
skin,rash lMt:Ln 1-10%
215 Gentamicin
nj.
7 ADR/Side
effects
unt Gentamicin
nLnlv|nM rash
lMvlL un:L
|t|tuMn|nM|tu
u1l
Gentamicin nLnlv|nM
nlLw1t:n1Wlu:tt
Wvu1 lM1utt Skin
itching,reddening of skin un:
rash lMuwtMn|nMt:Ln
1-10% u1WlMtuu
216 Gentamicin
nj.
11 compatibility/St
ability
unt Gentamicin
inj. |tMltun|vnlu
vial |ntlMnu
nnntWuuLnLWuu:un1
WLW1Mu1u Gentamicin inj.
lunn multiple dose vial lv
|ntuwuun1un:vn1nltun
u|vnlv|ntluM|uuun:uL
u 24 tlL1
217 Gentamicin,
Clocxacillin
04 Pregnancy/
Nursing
lv Gentamicin,
Clocxacillin luvu1lv
uLtM tMnLnnu
uLuLlMvlL uMu
vlL
Gentamicin, Clocxacillin nLn
utWuuuLlu:Mt|nnuu
nLnlvulunMlvuLtMlM
218 Glibenclamid
e,Glicazide,M
etformin,Gem
fibrozil
20 Others Glibenclamide,Glicazide,
Metformin, Gemfibrozil L
side effect lvv
vlL Mnnu1u
|1 spontaneous ADR
Glibenclamide Lu1uv
:Mt:ltuu 1u1u(t
2001)Gemfibrozil Lu1u
hearing loss :Mtu:ltuu
1 u1u(t 2005) nu
Glicazide,Metformin lLLu1u
219 Glipizide 3 P'kinetics unt glipizide
utn1lMun:Ln
ttuuMuu1l
Glipizide utn1 urine
60-80% lMu 91-97% ulut
metabolites nun 11% utn
1 feces nttuuMuu1
glipizide luWtuLD:lM
tnw1 W
Dose for normal renal
function: 2.5-15 mg q 24h
Adjustment for renal function
(GFR,ml/min) >50
10-50 <10
100% 50%
50%
220 Glucosamine
sulfate ,viatril-
s , Flexa
6 Formulation u viatril-s Lut1ltlu
nnL Osteoarthritis
0nn:tlv
tt:unuv 1/2
tlL1nu Flexa t1
|tuuM|Munu
Glucosamine sulfate :t
lvtt:uvn1v
untvLWn
MnMMtLuvlL
u Glucosamin solfate |tuu
t:ntMu amino group Lnt
|nn anion un:WnLnt
chondroitin sulfate un:
methylsulfanylmethane t1n
nntWulLwtuLnWL
uMnM1u1ntt:uu
nuvvn1v
221
Glycerin 11
Compatibility/
Stability
Wtu|tu Peptic ulcer lv
glycerin WnLluunL
unLntMunt1
WlvWnLlunn:nulM
Glycerin nLnuu:ulvWnL
luu|tnlM vnWtu
tt:untunLuntM1
1uu:ulv|tnuu|tuWnLlu
u|tnuu (nuu:ulvWnL
luunL|u1nnntntMlL
uu1u) M1uu|wWL
tnMDuun:t1nun
u1|Wu1luWtuuu1lLWlt
unLt1L pH 3.5
222 Glyceryl
Trinitrate
4 pregnancy/nursi
ng
WtulMtu
Nitroglycerine inj. |L
uu uunLnlvuL
tMlMvlL
lLwtuLn Nitroglycerine L
nutn1uuLvlL
u1lnMLuLWW1tM
t:Ln 1-4 u un:Wtu
lMtuM1uM|Lu M1uu1
nLnlvuLtMlM
223 GPO-vir 20 Others untu GPO-vir
t1Lnut:ntW
D4T,3TC un: Nevirapine
:|nM drug interaction
|LlvLntu
Fluoxetin,Haloperidol,Chl
orpromazine,Astane,Phen
ytoin un: Ofloxacin
vlL
nnntWulLwt GPO-vir
nLn|nM drug interaction |L
lvLntunnLu
224 Griseofulvin ,
Theophylline
5 nteraction Theodur v
Theophylline nt
Griseofulvin|nM Drug
interaction nuvlL
nnntWu Theophylline un:
Griseofulvin lLLuLnn|nM
Drug nteration M1uu 1nLn
lvuLnulM
225 H.pylori 10 Therapeutic use unt:ltulM
nL H.pylori lMt1
lLltu Clarithromycin
nMnL H.pylori nLWLuwu
:tt1|Muvuv1t:|W
luuu:u un:|tunMulLlt
Clarithromycin WnMM1u
Lansoprazole v Omeprazole
v Ranitidine + Amoxicillin +
Metronidazole Wtuuw
Penicillin lvlt Tetracycline uu
lMuuuMuuu:u W
Lansoprazole 30 mg bid v
Omeprazole 20 mg bid v
Ranitidine 400 mg bid ,
Amoxicillin 1,000 mg bid v
Tetracyclin 500 mg qid ,
Metronidazole 400 mg bid
226 Haemophlus
nfluenzae
type B
vaccine
10 Therapeutic
use
/Efficacy/ndicati
on
untun:|uM
u1uLnWtuutlu|1
u1uWlMtWtu
un:t1|n0M
Wtut1nulWMM|t|uvL
nL1n|ntn|t HB uu:u
lv0Mlu|Mnu 2 |Mu lMu
uu|uLun:t1|n0Muuu
ntu|L0Mun:tuMu1Wtu
lt (Mun:|uMML
|nn11)unnulL
|tuM10Mn:Mulu|MntnM
uMuu:ulv0Mn:MulunnL|nu
1nW1|Lu 18 |MulMuM1
v1n|uLnMuu1uu 2
|Mu
227 Haloperidol 7 ADR/side effect WtuLn
extrapyramidal symptom
nnltu Haloperidol
nLnunlulMu1l
nunluD: Extrapiyramidal
symptoms nLnlMlMultu
Anticholinergic tuM
antiparkinson lMultu
Diphenhydramine inj. 50 mg ( 2
mg/kg to a maximum of 50 mg
for children ) vlt Benztropine
2 mg V. For adult
228 Haloperidol 8 Toxicity/
Poisoning
Wtunuu Haloperidol
overdose LnWuu1
lLtL antidote
vlL
Wtutt:uu Haloperidol
overdose unLnWuu1 |tu
nu1 extrapyramidal
symptom (EPS) t1|tunnLn:
u1nL acetylcholine |Mu
uuL M1uu antidote ltM1
nnu|tu anticholinergic lMun
Benztropine mesylate inj
(Cogentin) lMuuuMultlu
WlvuW 1-4 mg/dose un: 1-2
W1 iv or im
229 Haloperidol ,
Sodium
Valproic
4 Pregnancy/
Nursing
unt Sodium
Valproic un: haloperidol
nLnlvluvu1lvuL
tMlMvlL
u Sodium Valproic un:
haloperidol nLnutn1
uuLlM 1lLuu:ulvltluvu1
M1WD
230 HBG 11 Compatibility/
Stability
unt HBG
vn1n|tMlt:nLn
|ntllMuu|l
vn1n|tMltWltlvvLM
Dulu 6 tlL1 un:lMultW
|ntlluM|uunvDL 2-8 1W
vL|ntlut1utuu1|w::
lv vaccine |nLnDwu1
M| un: vaccine :Luu
lMt:Ln 2 t utuMuWnM
WMMuvLMutunn1
nultnW1
231 Heparin 11 Compatibility/
Stability
unt Heparin L
uvn1WnLnu
Heparin nLnWnLlMnt D5W
un: NSS lMuvn1WnL:LWL
W1M 1 unvDLv1 un:w.
n1unnvuMlvLuvn1n|tM
lt 14 u (muitiple dose)
232 Heparin 9 Dosage/
Administration
uwun1 Heparin drip
900 unit /hr M1nt
u|MuLunvtWtu
uu
u Heparin lul1wutnn1un
LuuM 5,000 unit/ml uwun1
900 unit/hr |w:0:uu:M1lt
Heparin (900/5,000)= 0.18 ml /hr
, ratelunlvu Heparin uuM
900 unit W 18 ml/hr |w:0:uu
lu 18 ml :L Hepain u 0.18 ml
un:L NSS v D5W u 17.82
ml t1nltnn:nu NSS v
D5W tLM 100 ml n:M1lt
Heparin ( 0.18*100)/17.82 = 1 ml
233 Heparin lock 9 Dosage/
Administration
unt Heparin
lock LMnulun
WnL|tu|l Lunlv
uu1l un:LWLW1
Mu1l
n|MuL Heparin lock :lt
Heparin solution 10-100 unit/cc
vlt physiological saline
solution |wt1nunuu1Mu1
|nM lMuLunlvu W |MuL
syring t heparin 0.5 cc un:
syring t NSS 2 cc vn1n
uu0MNSS |u Medication port 1
cc MLMuMuM1n0M|u
medication port MLMu NSS 1
cc |wlnu un:0M heparin |u
medication port ML uMn|tu
nlvuutt infusion W flush
n 6 -8 hr un: heparin :L
WLW1Mvn1WnL 1 u
nvDLv1
234
heparin lock 9
Dosage/
Administration
pt. on heparin lock Ln
|MuLWnLuu1l
uuMWL|uLuulv
t:nuDwlLlM:tltM|ulu
uuLntnWL|uLuu
100 units/ml nMD: pheblitis lM
w.|nnWnMDnvWL|uLuu
50 units/ml |un heparin 1:100
for flushing (heparin conc. 5000
units per ml diluted in 0.9% NSS
qs
235 Hepatitis 8 Toxicity/Poisoni
ng
Wtu TB LD:|nu1
Mn|nMMtn|nt
nM1nn|nMnu
MlMlMt1 un:Lun
unluu1l
pt. |nMD:Mtn|ntuttlL
uu1lvvuMunuuu u
WnnMvuu1MttnMv
WnlL|nu 3 |u1WtnM un:
lvMn1ltun:uuu uM:lL
lt RMP Lnt PZE n n
WtuLD:Mtn|ntuu1lv
vuMunuuu uMnM1nlt
unLnlWM lvlt
Streptomycin , Ethambutol un:
Ofloxacin nWtuLW liver
function test WMtnMlL|nu 3 |
lvltnM 2HRE/7HR uMn
WtuLW liver function test
WMtnM|nu 3 | lvltnM
2HES/16HE un::M1MW
SGOT un: SGPT n 2 ntMv
236
Hepatitis
Vaccine ,
nnln
09 Dosage/
Administratio
n
nLnlt vaccine
nnln un: vaccine
hepatitis wLnu
lMvlL
nlt Vaccine nnln lu
|Mn > 12 t lv0M 2 |uL v1
nu 4-8 ntMv nu vaccine
hepatitis A lu|Mn > 12 t
lv0M 2 |uL v1nu 6-12
|Mu nuLnwt
nLntv vaccine 2
tuMu1MuwLnulM lMu
tvuuuWun:u1 un:
WMMMLnlu
|u1nvaccine 1n1lv
|nMnlulM
237 Hepatitis B
vaccine
13 other Wtu0M hepatitis B
vaccine Lun 7 u
un:M1n0M vaccine
luvMlvu :M1|u
t1nu
nLn0M vaccine luvMlvulM
|nu lMulLM1|u:u:|nlu
n0M
238 Hepatitis B
vaccine
7 ADR/side effect nlv Hepatitis B
vaccine lutWWnlL
tMu|1LDL
MuuvlL :|nM
uMuvlL u1l
nlv vaccine HBV v HBG
lunnLDLMuuuun lL
lv|nMuMuuM:lv
nu|tn1|nuWL|tu
239
HPV ,
Cervirix
2 Availability
l1wutnn1unL
Wtut1nuL:|1tn
LMnnvlL u0M
u1l t1nulMnt
Wtut1nuL:|1tnLMnnL
n|vMn|t Human
papillomavirus (HPV) type 16,18
Lut1lt nLnt1nulMu1
Lt:nuDwluWvu1u 15-25
t lMu0M 3 dose W |Mu 0,1
,6 LuLn1Wnunun:un
nLnt1nulMuuu1uu 5
t n0MluWlvuu 26-56 t
lLLuuu:ulv0M|u1nn
0MLt:lutunu1lL|WuL
|wWnLwuuLnu
240 HPV Vaccine 10 Therapeutic
Use/ Efficacy/
ndication
L:|1tnLMnnLn|vM
uunn HPV vlL
un:Wtut1nuL:|1
tnLMnnnLnlvlu
vu1u 45 t lMvlL
L:|1tnLMnnunnnMM|t
HPV un u1Ltu|nu1u n
|tu nL|wWnLwuuM1uMuu1
uu, n|tnuuWuutu,
nLtMLn un:n|tu
lWMMM1|wWnLwuuv|tu
lWDLWLnutnw1 t1nlt
Wtut1nuL:|1tnLMnnuu
u1lLLuLnlunltluvu1L
u 45 t uMuu:ulvltlu
Wvu1Luuun 26 t (0M
vaccine nuL|wWnLwuuv
nuLlnnnLWn|tln )
|u1nWtu:t1nulM|0w:
HPV type u1lLlMLnnLWnlW
|uu M1uu1n0M vaccine
lut1u 9 - 26 t :L
t:nuDwMnM
241 Humulin - N 11 compatibility/St
ability
Humulin - N vn1n|tM
lt nLn|ntlMuu
|l
u insulin nLn|ntluM|uulM
uu 1 |Mu
242 Humulin R ,
Regular
nsulin
11 Compatibility/
Stability
Humulin R nLn|nt
lnvDLv1lMuu
|l
Humulin R utt vial 10 ml |nt
nvDLv1lMuu 1 |Mu
nututt Penfill syring |nt
nvDL <= 30 1W|tn|tun lM
uu 1.5 |Mu
243 Hydergine
FAS
10 Therapeutic use Hydergine FAS
nLnlt|wLWLlu
|MnlMvlL
nnntWuuLnu1lLwtnu
Hydergine FAS Llt|w|wL
WLlu|Mn
244 Hydralazine 8 Toxicity/Poisoni
ng
Wtu|Mn|tu SLE
nLnlMtu
Hydralazine lMvlL
nltu Hydralazine
|vuuulv|nM SLE luWtulM
uu:ulvvuMulunnlvWn +
ANA ( Antinuclear antibody )
vWtunMunt v
ranal function nMn1 un:lMuuM
uLnn 200 mg/day nvt
Wtuuu|tu SLE uunuML
admit Munu un:WnM
ANA |tu negative un:Wtu
lMtu Hydralazine Luuun
M1uu1lLlM|tuuvLltu1
Wtuuu un:nltunMWL
Mu hydralazine n|tuM|nnlu
WtulMu
245 Hydralazine
inj.
11 compatibility/St
ability
Hydralazine inj.Lun
lvu1lun:WnLnt
nn:nu:l
Hydralazine inj.uu:ulvutt M
v V push t (uun 1
u ) lMulLM1|1(nnu
|tunn:nu) un: monitor BP
n 5 u nvtnlvuutt
nfusion L standard dilution W
WL|uLuu 0-20 mg/50ml rate 30
u ,WL|uLuu 21-40 mg/100
ml rate 30 u , WL|uLuu
Lnn 40 mg/250 ml rate 1
tlL1 lMunn:nu|nnltW
NSS lunn|tuuttW1uv1
un:M1nlvutt V push 1
M1|1uMu NSS v SW
nuunWulvWtu
246 Hydralazine
inj.,
Dihydralazine
inj.
9 Dosage/Admini
stration
unt
Hydralazine inj uMnM1
n Dihydralazine inj.
u1l lunltnM
WLMuunWtuun:
Hydralazine inj
nLnWnLntnn:nu
(solvent) tuMlMlMt1
Hydralazine un: Dihydralazine
Lut1ltlunnMWLMulnvM
|vLunu lMu Hydralazine L
uuMultW 10-40 mg lMu
|LluuuMM nu nuulv
tlMn 3-6 tlL1ML|tu
lMuuuMun1nMlL|nu 400
mg/day nu Dihydralazine L
uuMultW 6.25 mg lMu0M
t t:Ln 2 u un:
lvtlM lMuv1nut:Ln
20-30 u nut:nuDw
un:nu1|Wu1 wtlL
uMnM1nununn:nu
nLnWnLnulMnt Hydralazine
W dextrose solution, Ringer's
lactate solution un: sodium
chloride solution
247 Hydrocortison
e ,
Prednisolone,

Dexamethaso
ne
3 P'kinetics unt equivalent
dose :v1
Hydrocortisone ,
Prednisolone un:
Dexamethasone
:.4.47ti.4id App74imate
eq:ivaent d48e Hydrocortisone
20 mg
Prednisolone
5 mg
Dexamethasone
0.75 mg
248 Hydrocortison
e inj
11 Compatibility/
Stability
Hydrocortisone inj WnL
luNSSlMvlL
Hydrocortisone inj nLnWnL
lMntD5/N/2, D5S ,NSS,D5W,
LRS
249 Hyoscine 4 pregnancy/nursi
ng
u Hyoscine nLnlt
luvu1M1WD 7 |Mu
lMvlL
Hyoscine M|tuulunnL
Pregnancy category C t1u1lL
wtuLnnltuluvu1LWD
M1uuWltuu|LLWL|tu
|uu
250 buprofen 4 pregnancy /
nurse
buprofen nLnltlu
vu1lvuLtMlMvlL
buprofen nLnWu1uuL
lMuMwtlutLnuu 1Wlt
MuWL:LM:1
251 mipramine 4 pregnancy/nursi
ng
untnLnlv
mipramine luvu1lv
uLtMlMvlL
|u1nunLnlM1uuLlL
uu:ulvlt AAP(The American
Academy of Pediatrics) lvulu
:Mt concern
252 ndapamide 8 formulation ndapamide vLt
nW Natrilix
nLnut1W1|LMulM
vlL
ndapamide v Natrilix |tuu
vLut1 tM |Wu vlv|LM
uuMnlMu|MMuM
253 ndinavir /
Ritonavir
4 pregnancy/nursi
ng
Wtu HV M1WDun:
uwu Nevirapine un:
Efaverenze nLnltu
ndinavir un: Ritonavir
lMvlL
u Saquinavir - soft gelatin
capsule ( Fostaras )/ Ritonavir
t1|tuunnL protease inhibitor
nltluuuM 800/100 mg bid
luWtuM1WD :Mtulu
n:un|nM:|wu1wMnn
nu vltluuuM 1000/100
nlM nu ndinavir lLuu:ulv
ltluWtuM1WD |u1nlv
:Mt billirubin n1uu t1lt
n:Mulv|nMD: physiologic
hyperbilirubin |wLuulM
unnuuuMu1 booster
indinavir |vL:nLluWtu
M1WDu1LuLnnMun:u1lL
tuuMult
254 nfluenza
vaccine
9 Dosage/Admini
stration
unt|Mnu 2 t
nLnlMtWtu
luvMlvulMvlLun:
Lunlvu1l
WtuluvMlvunLnlvlu
|MnuLnn 6 |Muuult
M1uu|Mnu 2 t1nLnlvlM
lMulvluuuM 0.5 ml uu 1-2
W1 |Mnuuun 9 t W0M
n1|uLv1nu 1 |Mu nvtn
0MW1un
255 nfluenza
vaccine
08 Toxicity/
Poisoning
WtuM1WD 2 |Mu(1st
trimester)0MWtuluvM
lvu (nfluenza vaccine)
:LuMuMnlu
WDvlL
Wtut1nulWluvMlvuL 2
nnLW Wtu|t|tu un:Wtu
|tMu Lut1tnLn0Mlu
vu1M1WDlulMLn 2-3lM
uMWtuuunn1M1WDlulM
Lnun t1lut:|Wlu LWtu
|tMu|uu 1lLu:|nM
uMuMnluWD
256 nfluenza
vaccine
10 Therapeutic
Use/ Efficacy/
ndication
|Mnu 6utnLn0M
Wtut1nulWluvM
lvulMvlL
nLn0MWtut1nulW
luvMlvulM lMu0MutttuM
MMu
257 nfluenza
vaccine
09 Dosage/
Administration
untdose u1
WtuluvMlvu 0M
lvntWtu
lun0MWtuluvMlvu lu|Mn
uLnn 6|Mu-35|Mu W
0Mv1nu1|Mu uu 2W1
nvtn0MW1un lMuuuM
lvW 0.25ml nvt|Mnu 3-8t
lv0MuuW1|nt|Mnu
6-35|Mu uMltuuMu 0.5ml
nuWtuLuLnn9tuult
lv0M 0.5ml uu1W1 vn1n
uuM1Ln0Mtnt tn: 1|uL
lMulv0M|u1nnL|u
258 nsulatard
HM penfill
3,6 Pharmacokineti
cs/Formulation
unt nsulatard
HM Penfill nLnlt
Humulin N uulMvlL
nsulatard HM Penfill t:ntMu
Neutral sophan (NPH) nsulin
(Human monocomponent
recombinant DNA origin) Mu
lunnL ntermediate acting
nsulin |tu|Munt Humulin N
lMuLW Pharmacokinetic M1u
Humulin N L onset 1-2 hr,peak
6-12 hr un: duration 18-24 hr
nu nsulatard HM onset 1.5
hr,Peak 4-12 hr un:duration 24
hr :|vuuLW|Dnt
nuWnMlnn|Wu1nu1lt
uunulM
259 nsulin 6 formulation untnLnlt
nsulin Muuu nsulin
Lispro lMvlL
nsulin lispro |tututt nsulin
nnu| t1nLnlt
Regular nsulin uulM|u1n
|tu nsulin tuMnnu|
|tunuuM:LWLuMnM1nulu
u1u1 onset un: Duration W
Lispro insulin :L onset 0.5 - 1
tlL1 un:L Duration u 8 - 12
tlL1 nu Regular insulin :L
onset 0.25 tlL1 un:L
Duration u 6 - 8 tlL1
260 nsulin,Hepari
n,ventolin,Ber
aduol solution
11 compatibility/St
ability
unt:u:|n
vLMuu1u multiple
dose u1 nsulin,
Heparin,
ventolin,Beraduol solution
u|tu multiple dose u1w.
n1unnvuMuvLMuvn1n
|tMlt M1u nsulin 1 |Mu,
Heparin 14 u, ventolin un:
Beraduol solution 1 |Mu
261 rbesartan 7 ADR/side effect uwun1ltu rbesartan
uuM 600 mg lvnt
Wtu unt:L
WnMWtuu1lt1
uuM|LMuu1u rbesartan W
150 mg un:W1 un:nLn
|wLuuMulMn1 300 mg un:
W1 lMun|wLuuMuLnn
300 mg vut1 dose u
n|tuun: 2 W1 nlLLWn
lvWnnnL|tnuuutn1ltn
|ML
262 soniazid 6 formulation uwun1 soniazid lu
Wtu|Mn 30 mg /u :
nLn|MuL|tuuu
lMvlL un:|ntllM
uunu
lul1wutnn1unL soniazid
uuM 100 mg tablet uu:ulv
tMun:WnLntu 60 ml Mu 1
|LM lMutt:uun:W1 W1
n: 20 ml t1ntMWnL 1 W1:
LtLnnlt 3u lLuu:ulv
tMWnLutLnLn |u1n
ulMun1un:WLu 1W
|ntulluM|uu un:lLWWnL
nt suspending |u1n
lvuMnM:nu
263 soniazid ,
Rifampicin ,
Pyrazinamide
, Ethambutol
4 pregnancy/nursi
ng
WtuM1WD 4 |Mu
nLntu TB nM
HRZE lMvlL
u soniazid , Rifampicin ,
Pyrazinamide Mulu category
C nu Ethambutol Mulu
Category B t1nltunLn
lWluvu1M1WD L 2 nM W 1.
2 HRE/7 HR + Vitamin B 6 25
mg/day ( ATS ) 2. 2HRZE/4HR
+ Vitamin B 6 25 mg/day ( WHO
) M1uunltnMu1 WHO n
nLnltulM
264 sosorbide
dinitrate
9 Dosage/
Administration
uwun1 sosorbide
dinitrate lv pt luuuM
10 mg/day (1*1 pc )lL
tLWL|vL:nL
vlL
uuMu isusorbide dinitratc L
uuMulvW Angina : 5-40
mg 4 times/day CHF : initial
dose 10 mg 3 times/day target
dose 40 mg 3 times/day
Maximum dose 80 mg times/day
Esophageal spastic disorders
(Unlabeled use ) : oral : 5-10 mg
before meals M1uulu case u
W consult uwun1ut1ltu1
lW un: confirm uuMulv
|vL:nL
265 sosorbide
mononitrate
9 Dosage/
Administration
unt Monolin
lLM1lvnu |n
09.00un: 15.00 u.
Monolin v sosorbide
mononitrate MulunnL Nitrate
LnuuuuvnM|nMvl un
nLuLtuvlu|1 tolerance
(uMu) Luuu:ulun
t1nun|nM tolerance lMun
lvuluuuMM, nMWLnlu
ntvu, |nnlt
short-acting nitrate, lvLt1vuM
ltu (Nitrate free-interval) ,
WnLuntvu|vL:nL
luuMn: dosage form nvtu
Monolin 20 mg Luuu:uW
lvun: 2 W1 v1nu 7 tlL1
lMuuL 2 v1nLunlu
unMltlLMn 17 tlL1 |tu
08.00,14.00 u. v 09.00,15.00
u. nLnt1nu tolerance un:
L efficacy M
266 traconazole 10 Therapeutic use u traconazole |tu first
line drug lunnL
Oropharyngeal
candidiasis vlL
traconazole |tu Second line
drug lunnL Oropharyngeal
candidiasis lMultuluuuM
200 mg/day tt:uu
MMMnu 10-14 u nuult
|tu first line drug W
Clotrimazole L ( 10 mg ) un:
5 W1 v Ketoconazole (200 mg
) un: 2 W1
267 traconazole,
Omeprazole
5 nteraction untu
traconazole un:
Omeprazole |nM Drug
interaction nuvlL
un:Lununluu1l
u traconazole un:Omeprazole
|nM interaction nulMuL onset
utt rapid; severity utt
modurate ; documentation utt
suspected lMu Omeprazole LWn
nMnvn1nMlun:|w:v
1LWnnMnuMnMu1
traconazole lvnMnMMtL
un:nMnuu1 traconazole 1
uu:ulvtt:uuv1nu
u1uu 2 tlL1
268 VG 11 Compatibility/
Stability
VG vn1n|tMltW1
un :nLn|ntllM
uu|lv
VG |tMltunWltlvvLM
DuluW1|Mu
269 JE Vaccine 14 Contraindication
/ Precaution
JE Vaccine ltluWu1
lMlvL
JE VaccinevLltluWuM1WD
270 K exalate 10 Therapeutic
Use/ Efficacy/
ndication
K - exalate nLnltlu
Wtu renal failure lM
vlL un:nlvu
utt Oral un: rectal
uttlvu:L
t:nuDwMn
K - exalate v Kalimate Lt
nLu1uW Ca polystyrene
sulfonate 5 gm powder / sac L
ut1ltluWtuLD:
Hypekalemia nLntvu
lMuntt:uvlvu1
nasogastric tube v1 enema
t1nlvlMuu enema :L
t:nuDwMnM nvtn
lt Kalimake |wnM:Mt K lu
Wtu renal failure uu:u
Wlv RAAS inhibitors ( Renin -
angiotensin -
aldersteronesystem , inhibitor )
LMu:lLlv Serum
creatinine |nMn|tnuuutn1
|wLuu
271
Kaletra
7,10,
11
ADR/ Side
Effects
1.nuu kaletra unL
ntM1Ln
1|nu :vuMnuuM
vlL 2. nuu kaletra
|wt1nunMM|t HV
M1nuuu|l
3.kaletra LWnMMt
vlL 4. kaletra |nM D
nt Omeprazole vlL
1.Kaletra t:ntMuu lopinavir
+ ritonavir :Lnu1|Wu1
wttu W 1|nu (5-27%)
Wnuln (5-16%) ,tM1 (2-10%)
, |uu (2-14%) lLWvuMnu
ulvnuM|u1un:nuut1nu/
nL 2. u kaletra |wt1nu
nMM|t HV uu 28 u
272 Kamilosan 2 Availability w.n1unL Kamilosan
wuWvlL |tuu ED
v NED
v1uLu Kamilosan M spray
ltwulut1tn |tuu NED
273 Kayexalate 10 Therapeutic use nlt Kayexalate nu
tt:uM1WnLnt
:l u1lun:Lut1
ltlunnLD::l
Kayexalate v Sodium
polystyrene sulfonate ltlun
nLD:ltuMn|tuLlu|nMn1
t1:wttuluWtulWlM|1
uuLu|nuW lvWtu1Wn
un:ntMlLM nutt:u1
uu:ulvWnLnt sorbitol t1
lMult:WnLnt sorbitol
WL|uLuu 20%
274 KCL,Ca
gluconate
11
Compatibility/
Stability
nLnWnL KCL nt Ca
gluconate lMvlL
nLnWnL KCL nt Ca
gluconate lM
275 Ketalar ,
Fentanyl
4 Pregnancy/
Nursing
Ketatar un: Fentanyl inj
nLnltluvu1lvuL
tMlMvlL
Ketalar v Ketamine inj
nLnWu1uuLlM WvuM
lvuLtM|tu|n 11 tlL1vn1
lvu un: Fentanyl nLn
Wu1uuLlM|tunu WvuM
lvuLtM|tu|n 10 tlL1vn1
lvu
276 ketamine 11 Compatibility/
Stability
untketamine L
uvn1n|tMltuu
|lM
nnntWulLwtuLnuu1
uketamine vn1n|tMlt uM
nnnvuMulutulun|nt
nLuu1l1wutnn1un
nvuMlvuLnltutt
multiple dose Luvn1n|tMlt
14 u
277 Ketoconazole 4 pregnancy /
nurse
nLnltu
Ketoconazole |wnL
Vaginal candidiasis lu
WtuM1WD 6 |Mu lM
vlL
u Ketoconazole Mulu
pregnancy category C uMu1l
nML nltuuluWtuLu
WD 6 |Mu lLlMlv|nM
WLWMtnMMnluWD
278 Ketoconazole 3 Pharmacokineti
cs
u Ketoconazole nu
nuvvn1v1:
MMtLlMMnM
nuLnu1Mu Ketoconazole
:MMtLlMM|Ln:|w:v
|tunM M1uu|L pH lun:|w:
|wLn1uu nMMtLun:
bioavailability u1u:nMn1
M1uu1uu:ulvnuu
Ketoconazole vn1v un:
vu1LWntunMn:Wu
|W1n:|w:vlMnMu
279 Ketoconazole
/ Nevirapine
5 nteraction uwun1ltu Nevirapine
Lntu Ketoconazole
untLWL
|vL:nLvlL un:vn
|tnuuu|tu
Fluconazole :
|nMtnu:v1u
vlLu1l
Ketoconazole |LlvLnt
Nevirapine wt Ketoconazole
:LW AUC nMn1 63 % un:
lv:Mtu Nevirapine n1uu
15-30 % 1lLuu:ulvltLnu
nu Fluconazole |LlvLnt
Nevirapine wt:LWn|wL
Cmax , Cmin un: AUC u1
Nevirapine t:Ln 50 % M1uu
1M1:LM:1lunltLnu
nvtWtuuuuu:ulv
|tnuu|tuutuMunnu
|0w: |tu Clotrimazole tuM
Luu
280 Ketoconazole
, buprofen ,
Roxithromyci
n, Norgesic
7 ADR/Side effect WtulMtu
Ketoconazole ,
buprofen, Roxithromycin
un: Norgesic un
tuMlMLu1u
lv|nMnuwutt
MtLun:WMLnlMt1
nnntWuuLn wt
buprofen Lu1un|nMn
WMLn:Mt certain 1 u un:
|nMnMtL:Mt certain
10 u ,probable 107 u ,
possible 53 u nu
ketoconazole wtnMtL
:Mt certain 1 u , probable 2
u ,possible 1 u u
Roxithromycin wtnMtL
:Mt probable 4 u un:
possible 1 u nuu norgesic
lLwtu1u|nMnM1nn
281 Ketoconazole
, Norfloxacin
4 Pregnancy/
Nursing
u Ketoconazole un:
Norfloxacin nLnut
n1uuLlMvlL
u Ketoconazole nLnutn
1uuLlM 1lLuu:ulvltlu
vu1lvuLtM nu Norfloxacin
lLLuLnunnutn1
uuLvlL 1lv:1nltu
luvu1lvuLtM
282 ketotifen 09 Dosage/
Administration
ketotifenlv dose |lv
lu|Mnu 1t
ketotifen syr |Mnu 3 |Mu-2t
uuMu 0.5mg (0.5tab or 2.5ml)
un:2W1
283 Lactulose 10 Therapeutic use untuuMuu1
lactulose ltluWtu
cirrhosis Ln
hepatic encephalopathy
uuMuu1 lactulose tutt
tt:uW lactulose 20-30 g
(30-45 ml) n 1-2 hr nuu
nttuuMuluuMn:ulMu
lvLnnuun: 2-3 W1 u
MLWunMuuMun1|tu
60-100 g (90-150 ml) Mu

Rectal administration: 200 g (300
ml) |1Mu 700 ml (uv
NSS) lvu1vunlMuWu
rectal balloon catheter un: retain
30-60 u n 4-6 hr
284 Leptospirosis
, sulperazone
10 Therapeutic
Use/ Efficacy/
ndication
Wtu|tu Leptospirosis
unt:lt
Sulperazone (
Cefoperazole +
Sulbactam) lunnL
lMvlL
nnL Leptospirosis MnM
W Penicillin G uuMn1nM W
6,000,000 unit/day lMuut1lv
1.5 nuuuM n 6 tlL1 |tu|n
7 u vlv Ampicillin 0M|u
vnM|nMM uuMlt W 4
g/day lMuut1lv 1 G n 6
tlL1 MMMnu 7 u nn
Wtuuw Penicillin wn
|nnlt Doxycycline 0M|uvnM
|nMM uuMlt W 100 mg
n 12 tlL1 uu 7 u , nvt
Cephalosporin un: Lincomycin
LnuL|tulMMluv1Mn1
uMu1lLwtnWnLluWtu
285 Leuprorelin
acetate
10 Therapeutic
use/
Efficacy/ndicati
on
untut1ltu1
u Leuprorelin acetate
3.75 mg injection |nu
|ulul1wutn
Leuprorelin acetate v
Enantrone Lut1ltM1u nL
lW Endometriosisn stage - V
ltnLn|u1nnnL|u
LMnn(uterine fibroid) |wnM
uuMu1|u1nnunWMM
un:ltnLlWL:|1ML
nnvLn:u:nnnL
286 Levofloxacin 7 ADR/ Side
Effects
WtulMtu
Levofloxacin (500) un:
Lnvt|vuu L
||uu uuuvun
untn
M1nn|tunuwu
vlL
Levofloxacin |tuunnL
Fluoroquinolone t1wt ADR
uuLnW < 1% lMun
anaphylactoid reaction , acute
renal failure,
arthalgia,bradycardia |tuMu t1
nWtu|tuuuM1t:|Lu
nLwuuntnWtulMtu
vlL un:vnWtulLnLn
uMnM1nnlM uu:ulv
WtutnLuwu|w
tt|tnuunltuun:|W:1
nltuMlt
287 Levofloxacin 11 Compatibility/
Stability
unt
Levofloxacin vn1n|tM
lt nLn|ntlltlM
uu|l
Levofloxacin lututtu0M
vn1nWnLWL|uLuu 5
mg/ml nLn|ntllMuu 72
tlL1nvDLv1 un:n|nt
luM|uu :nLn|ntllMuu
14 u un:n|ntlut1utuu1:
nLn|ntllMuu 6 |Mu uM
|LuLltunvLunntltut
uu1n un:vLuulMutnn
lvu |w:lvu
|nLnDwlM
288 Levothyroxine 3 Pharmacokineti
cs
u Levothyroxine
nLnWu1uuLlM
vlL
u Levothyroxine nLnut
n1uuLlM M1uu1Wlt
MuWL:LM:1luvu1lvuL
tM
289 Lidocaine inj 11 Compatibility/
Stability
wutnuu lidocaine
inj lt|ntluM|uut:Ln
3 tlL1lLt:
lvLtuvMWLW1M
u1uvlL
Lidocaine inj tnM:LWLW1M
MnvDLv1lL|tuM1|nt
luM|uu nnntWuuLnn1
WLW1Mu1 lidocaine inj L
nWnLn1WLW1Mu1
lidocaine |LWnLlu 5%DW |nt
luM|uu (4 C) un:nvDLv1
(30 C) uu 30, 60 un: 120u
wtlLLnnu|nuu|nMuu
un:uLWLW1MMun1 120
unWnL1nvDL 30
un: 4 C u1lnML Xylocaine
Topical lututt spray, viscous
liquid, jelly |tututtlLuu:u
lv|ntluM|uu|u1n|nM
nMnM:nuuMnntL
n:nulvLlMnuLM11l
nvDLv1 M1uulunnulLu
lvuLtuv|1WLW1M
|tnuult nLnuLltlMn
290 Lincomycin 9 p' dynamics /
efficacy
WtunLnlMtu
Lincomycin utt M
uuM 600 mg un: 2
W1lMvlL ( tnM0M
un:W1 )
nLn0MlMlu more severe
infection
291 Lincomycin 11 Compatibility/
Stability
Lincomycin vn1WnL:
|ntllMuu|l
Lincomycin vn1nWnLnLn
|ntllMuu 24 hr nvDLv1
292 Loratadine,
salbutamol
4 Pregnancy/
Nursing
WtuM1WD 2 |Mu
tt:uu
Clarityne,Ventolin lu1st
trimeter :|nMuMu
ntnluWDlMvlL
Loratadine Mulu Pregnancy
category B lLwt teratogenic lu
nMuMu1lLLuLnluWu n
cohort study lLwtnWnLlu
Wuu1lnMLnuLntL
uWWnMu1ulLwt
teratogenic lunM nu
salbutamol Mulu Precnancy
categry C Lu1un|nM
Adverse event lu maternal &
fetal t1uLlt systemic salbutamol
wt|nM tachycardia,
pulmonary edema un: death u1
lLLuLnuu:ulvlt systemic
beta-agonist Mu uMLuLnn
lt nhaled-salbutamol lu
maternal & fetal lLLn
|tnuuutn1u1:ttlvn|uu
|nMu1LuunWuuMLuuluL
n|nM Hyperglycemia luuL
w nt|nMHypoglycemia lu
nluWDnvtuL|tu
|tvuun:lt salbutamol lun
dosage form unnuwtn
293 Loxonin ,
Loxoprofen
10 Therapeutic
Use/ Efficacy/
ndication
unt Loxonin
|tuunLlW:l
Loxonin |tutnW lMuLt
nLu1u W loxoprofen
M|tuunnL Non-steroidal
anti-inflammatory drugs (NSAD)
lunnL propionic ltnLn
tM nMlu nMnnnL|u
n|nt ntMuM1 (t1
ulunnL propionic Lluw.
n1un lMun buprofen un:
Naproxen)
294 M.tussis 7 ADR/side
effects
untLu1u
n|nMnlLw1
t:n1Wnu M.tussis
t1vlL
nu1u Spontaneous report
of ADR 2003 wtu1un|nM
anaphylactic shock lu:Mtu:
lt 1 u,|nM angioedima lu
:Mtu:lt 2 u un: |nM
Face oedema lu:Mt:lt 1
u t1:wt M.tussis uL|tu
unLut:tuuMnLu1u
n|nMnlLw1t:n1W
uu1lM
295 MAC 10 Therapeutic use untuu1n
nLlWMM|t0u
lnn Mycobacterium
Avium Complex (MAC)
luWtu|MnWlvu
nMultlunnL
disseminated MAC un:t1nu
nnnt|tutlMu maintenance
therapy ltMnMtM (un|ulu
nnWtulMtuMulnutt
HAART uDLWLnu|wLuu >100
cells/mm3 |tu|nuu (M1uM 6
|Mu) un:lMtnnL MAC >
1 t uultlLLnt1n1nMM
|tnLn:vuMnnL
MAC lM ) W Clarithromycin 500
mg un: 2 W1 v azithromycin
500 mg un: 1 W1 Lnt
ethambutol 15-25 mg/kg/day
296 Magnesium
inj
11 compatibility/St
ability
untnLnWnL
Magnesium inj. nt
Aminoparen lMvlL
Magnesium sulfate |unulLlM
nt Sodium bicarbonate un:
phosphate t1 Aminoparen |tu
nn:nuu1 amino acid L
nuWnLu1|nn Sodium M1uu
1lLuu:ulvWnLLnuv
|tnuultltnn:nu amino acid
lLLnuWnLu1 Sodium uu
297 Magnesium
sulfate
8 Toxicity/Poisoni
ng
WtulMt magnesium
sulfate V drip unL
ntM un
t|tuWnnn
lMt magnesium vlL
|u1n Magnesium sulfate LWn
nMn1uu1 neuromuscular
transmission 1LWnM:tt
nnL|ulv|nMntv
paralysis lM lMu|0w:WtuL
lW neuromuscular disease (|tu
myasthenia gravis) vnuuu
nLnutu1 neuromuscular
LntnlMtu magnesium
sulfate n:u1lv|nMn
M1nnlM1uuu 1unLwuu
nt:Mt Mg lu|nMMu1W
MMML:Mt Mg lu|nMLMu
298 Magnesium
sulfate
6 Formulation M1ntWLu1
u1u Magnesium
sulfate inj. Llu
l1wutnn1un
Magnesium sulfate inj. Llu
l1wutnn1un L 2 WLu1
W 10 % w/v tLM 10 ml (L
Mg 8 mEq/amp v|nt 1 g/10
ml ) un:uuM 50% w/v tLM
2 ml (L Mg 8 mEq /amp v
|nt 1g/2 ml ) lMu 1 gram
Magnesium sulfate = 98 mg
(elemental Mg) = 4.06 mmol =
8.12 mEq elemental Magnesium
299 Manitol 11 Compatibility/
Stability
uwun1 drip manitol 8
cc uu 30-60 u lL
tnLn dilute u
lMvlLun:ltnu
:l
Manitol nLn|1lMnt D5W
lMuWL|uLuunMulLW|nu
15% |u1nwtWL
|uLuuLnn 15% manitol
MnM:nulMnvDLM
300 Maxifed 10 Therapeutic use Maxifed t:ntMu
Mu:lt1
Maxifed t:ntMu
Pseudoephedrine 80 mg un:
Guaifenesin 780 mg
301
medroxy
progesterone
14
Compatibility/
Stability
Wtuvu1 LlWt:M
WlWvl nLn
uu|nut:|Mu
lMvlL
nLntt:ulM uMlLW
u|nu 10 u un:lLWu
MMMnuvnuW1
302 Mefenamic
acid
4 pregnancy /
nurse
Mefenamic acid nLn
ltluvu1lvuLtMlM
vlL
Mefenamic acid lv|nM
toxicity of mefenamic acid 1W
vnn|nu1ltlt Nsaid uuu
|tu buprofen , Diclofenac
303 Meropenam 9 p' dynamics /
efficacy
Meropenam un: Tienam
LWnnLtMuMnM1nu
u1lluu1u1uuM
ltun:WnnLtMu1u
|LltluWtu|MnLu
7 |Mu
meropenem ltlul1wutnL
uuM 1 g nu Tienem |tuu
WnL:v1 mipenem un:
Cilastatin t1uuMu Meropenem
ltlu|Mnu 7 |Mu W 20 - 40
mg/kg n 8 tlL1 ( maximum
dose W 2 g n 8 tlL1 ) nu
Tienem uuMultW 15 - 25
mg / kg / dose n 6 tlL1 (
non-CNS infection )
304 Meropenam 9 p' dynamics /
efficacy
uwun1u Meropenem
lMulL:t|nltlun
drip t1tnMuwu:n1
drip lMult|n 3 tlL1
unt:lt|n
drip |tuu1ulMvlL
lMutnM Meropenem nLnlv
lMlMuu infuse V t1lt|nlu
nlvuLnn 15 - 30 u
305 Meropenam 11 Compatibility/
Stability
nLn drip Meropenam
inj. wLntnlv|nM
lMvlL
nnntWuuLnlu Handbook
on njectable drug lLwtuLn
Compatibility :v1 PRC nt
Meropenam inj. uMnn
ntnLltu1tLWWnM lL
uu:ulvlvu1nu|Munu
|u1nlLLuLnWLtnMDu
uMlv1 3 - way site lM
306 Meropenam,
Tienam
11 Compatibility/
Stability
u Meropenam un:
Tienam LWLW1M
vn1WnLu1l
u Meropenam LWLW1Mvn1
reconstitute (500mg/10ml) Mu
0.9% NSS 24 tlL1 un:|L
Dilute lvnn:nuLWL|uLuu
1-20 mg/ml :LWLW1M 48
tlL1 |L|ntluM|uuun:W1M 8
tlL1|L|ntnvDLv1 uM
nltnn:nuu|tuM
n:nu W 5%Glucose v D5S
u:LWLW1M 14 tlL1 |L
|ntluM|uu un: 2 tlL1
nvDLv1 nu Tienam
nLnWnLlM1nt NSS un:
Dextrose lMuu:LWLW1M 24
tlL1 |L|ntluM|uu un: 4
tlL1nvDLv1
307 Meropenem 11 compatibility/St
ability
Meropenem nLnWnL
ntnn:nulMlMt1
|LM1n drip ulvun
Wtu
Meropenem nLnWnLlMnt
5%dextrose un: 0.9% NSS uM
WLW1Mvn1WnL:uMnM1nu
W |LWnLnt 5%dextrose :L
WLW1M 3 tlL1 un:|LWnL
nt 0.9% NSS :LWLW1M 8
tlL1 15-25 1W|tn|tun
308 Meropenem 11 compatibility/St
ability
u0M meropenem
vn1n|tMlt :nLn
|ntullMuu|l
|LWnLnt D5W :LWLW1M 1
tlL1nvDLv1un: 6 tlL1
|L|ntluM|uu nWnLnt NSS
:LWLW1M 4 tlL1
nvDLv1un: 24 tlL1|L
|ntluM|uu
309
Metformin 09 Dosage/
Administratio
n
lt metformin 850 mg
2x2 lMvlL
uuMu metformin n1nM
|nt 2.55 G Mu nlt
uuMu 850 mg 2x2 :lM
uuMu 3,400 mg v 3.4
G Mu t1|nuuuMu
n1nMMuu1 metformin
uMu1lnMLnLnltlM
luuuM 850 mg utt 1x3
Mu
310 Methimazole,
PTU,Adenosi
ne,Apresoline
inj
1.Methimazole,PTU
nLnltluvu1
M1WDun:lvuLtMlM
vlL
2Adenosine,Apresolin.
M1nuun1vlL
1.Methimazole,PTU|tu
antithyroid agent Mulu
pregnancy category D unLn
uwWunun:uuLlM 1vLlt
luvu1M1WDun:vu1lvuLtM
|u1nLu1ulv|nM
hypothyroid un:nwnlM uM
u1lnMLn|tuM1lt
vu1M1WDW|nnlt PTU
|w:uwWunlMuun
Methimazole nuvu1lvuLtM
Wlv Methimazole t1LuLn
nWWnMun:AAP state t1Wu
nu|tnlMun:WltMu
WL:LM:1lM 2.
Adenosine,Apresolin inj |ntlu
control room temperature lMulL
M1nuun1
311
Methotrexate 9
Dosage/
Administration
WtuWDlutnn L
:Mt Beta-HCG n1
uwuM1nn1lt0Mu
Methoterxate Wlvlu
uuM|l
nlvnLnlvlM 2 tutt W
1.
single dose lv M uuM 50
mg/m2 luuunu1nnL
un:uu:ulvMM:Mt HCG
W1 2 luu 7 vn1lvu -
nnM:Mt HCG luu 7
un:lLlMnMn1 25% nuun -
nnM:Mt serum HCG lu
:v1u 4 un: 7 nMn1uu
n 15% WlvWtulMt MTX
50 mg/m2 W1 2 vn1nuun
MM:Mt serum HCG
vn1nulvuM|u1uu 4
u nuuMMML serum HCG
nntMvun:1MlL|
uuMun1nMlL|nu 3 dose
2. Multiple dose
lv MTX 1 mg/kg/day lututt
im v iv luu 1,3,5 un: 7
Lnt oral leucovorin 0.1 mg/kg
luu 2,4,6 un: 8 MMMLM
:Mt serum HCG luu 1,3,5
un: 7 -vnwt serum HCG
312 Methyldopa,L
evodopa,rbe
sartan
5 nteraction WtuLt:Mltu
sinemet |wnLn
Parkinson MLWtu
lMtu rbesartan un:
Methyldopa |wL|MLun:
vn1nltuWtuL
n|uuWL: Lnu
unt|tuWnn
nltuLnuvlL
nltu Levodopa Lnt
Methyldopa lv|nM
nteraction lu:Mt significance
5 lMuL onset utt rapid ,
documentation utt possible ,
un: severity utt minor nuu
rbesartan |tuunnL
Angiotensin - receptor blocker
(ARB) t1Wnu1|Wu1u1unnLu
lv|nMnu1|Wu1 W |uu
WL:un: hyperkalemia 1
|tultlMn|uuWL:
|nMnulunnL ARB
313 Methylprednis
olone
9 p' dynamics /
efficacy
untuntv
u Methylprednisolone (
uwun10Mulv|Mnlu
uuM 500 mg )
nLnlvuutt iv infusion
lMunn:nultlMW D5W
vnlvuluuuM|nt 15
mg/kg v > 1 g Wlt|nlv
uuun 1 tlL1
314
Metoclopra
mide
01 Pregnancy/
Nursing
u metoclopramide
nLnltluvu1
M1WDlMvlL
u metoclopramide Mulu
Pregnancy category B t1
unLnWu1nltn
nlM uMu1lnML
nLnltuulMWuu1
tnMDuMnM:u:|n
M1DD
315 Metoprolol 9 Dosage/
Administration
untuuMu
Metoprolol ltluD:
hypertension
uuMu Metoprolol ltluD:
hypertension W 100-450
mg/day ut1lvun: 2-3 W1
lMuuuM|LMultW 50 mg 2
W1Mu un:tt|wLuuM
uluuMn:ntMv lMulvuuM
uulut1 50-100 mg/day
(JNC 7)
316 Metronidazol
e
4 pregnancy /
nurse
Metronidazole tablet
nLnltluvu1lvuL
tMlMvlL
Metronidazole nLnWulM
1uuL 1lLuu:ulvlt
:v1lvuLtM
317 Metronidazol
e
10 Therapeutic use untnLnlt
Metronidazole 400 mg 4
tab utt single dose lu
nnL T. vaginalis lM
vlL
uu:ulvlt metronidazole 2 g
single dose v 500 mg un: 2
W1 MMMnu 7 u ( nvtn
ltuluvu1M1WD uu:ulvlt
Clotrimazole vaginal tablet uu
lut1lMLnun )
318 Metronidazol
e
4 pregnancy/nursi
ng
u Metronidazole
nLnltluvu1M1WD
4 |MulMvlL
Metronidazole Mulu
Pregnancy category B t1L
unvuMlv|tu contraindication
lut1lMLnunu1nM1WD
uMnLnltlMlut1lMLn 2
un: 3 M1uuWtuM1WD 4
|Mu MululMLn 2 1
nLnltuulM
319 Milk of
Magnesia (
MOM)
3 P'kinetics Wtu|tulWlM LW
creatinine clearance 10
ml/ min unt:
ltu:tu M.O.M lM
vlLun::ttnlt
ulMu1l
WtulWlM LW clearatinine
clearance 10 ml/min lMuulu
D:nMuu1lWlM ( end
stage renal disease ; ESRD) n
lt M.O.M. 1|nu1Mntnw1
u1nutnu1 magnesium
1lM |u1nlMLn1u
nMn1 1Wvnn|nu1nltu
:tuL magnesium |tu
nut:nt lMu|tnuultlt
u:tu Senokot v Bisacodyl
uu
320
Misoprostol 9
Dosage/
Administration
uuMu Maximum dose
u1 cytotec lututtu
|vutt1WnM |tu|l
luWlvu
uuMultluWlvuuuntnD:
u1WtuW 1.
Abortion 800 mcg vaginally time
one dose 2.
Cervical ripening procedure
(induction of labor) 25 mcg
vaginally n 3-4 tL. ( maximum
dose 400 mcg)
321
Mobic

,Colch
icine
9 Dosage/Admini
stration
WtulMtu Mobic

un: Colchicine un
tuMlM
nLnvuMtt:u
lMvtt:u|0w:
|nLn|uu
u Mobic

v Meloxicam |tu
ut|ntM t1M1
tt:uvn1vu lMu
tt:u|LLntM nu
Colchicine :nMnn1nM
lv|nMntMtLun:n|nt
1Wtt:uuMLuwun1
un:1n1uuwuuMwt|w
MMMLMnluW1Mlt
322 Montelucust 6 Formulation Singulair 10 mg
film-coated tablet lvlu
|Mn|nnnLnulttM
lMvlL lMulu|nn
nntuuu:ulv
tt:uMu|uu
untnLn
tt:u|nulM
vlL
nuLntL MSD wt
Singulair v Montelucust 10 mg
film-coated tablet nLntMlM
lMutLuu:ulvtMWnLlu
v|vn vu |tu ln
ltv|vn 1 tu vwMW
Mu 1 dose lLuu:ulvtMWnL
ntu1|vn |tu uvu
|u1nLnt:ntuluMt
lLn:nuluulvtM|tu
nu t1lv|Mntt:uu
lLvLM (W1ulLLntM,lLuL)
323 Montelukast 6 Formulation unt
montelukast uuM 10 mg
nLnWnLnt
suspending agent lvnt
WtulMvlL un:u:
LWLW1MvlL
u1l
Montelukast v Singulair L
nut:ntluMt|tu
hydroxypropyl cellulose lactulose
monohydrate, Magnesium
stearate un: microcystalline
cellulose t1nut:ntM1nn
lvu|nMWLtulM1u M1uu
nWnL|tututtuu1lL
|vL:nLun:uM1nnM1|nt
lvwuun1un:WLtu 1lL
uu:ulvWnLlvntWtu uMnL
WL|tu1 lvWnL|1
luMnu|vL:nLun:
tt:uu
324 Morphine 9 p' dynamics /
efficacy
nunWnMuvun 3
kg vnM1nltu
t|ntMvn1
nWMM :ltu
morphine v fentanyl
inj. lMvlL
nt|ntMvn1n
WMMlMult morphine M1lt
WL:LM:1n1|u1nu|un
nL1lvnMnvullM
lMu|0w:lu|Mnun|nMn
nMu:t u1lnMuu:u
uuM V infusion ltlLW|nu
0.015 - 0.02 mg/kg/hr un:|W
:1nvulu1lnntM nu
fentanyl injection u1lLtn1
WLtnMDuun:t:nuDw
lunnLlu|Mnuuun 2 t
325 Morphine 7 ADR/side effect Morphine lv|nMWu
uwuttlMlMt1 LM
n|nM|tu|l un:L
WnM:tt1|Mu
vulvlL
Morhine lv|nMWuuwutt rash
LnnM lMuwtu1un|nM
rash 19 u 1n1LWWuuw
uttWu ( Pruritis ) 14 u
unnuwtLn|nM
respiratory depression 2 u
326 Morphine 9 p' dynamics /
efficacy
Antidote u1 morphine
W:l M1ltuuM
|l un:Lnnlnn
nnuu1l
Antidote u1 morphine W
naloxone nnu|tu pure
opioid antagonist lMu|ultuu1
tun:uu morphine receptor
lMuuuMu1 naloxone ltnL
D:lMt opioid |nuuuM W
0.4 - 2 mg V un:nLnlvt
lMn 2-3 u nunlt|wnM
nnMt:nnunn1n
unnL opioid ltuuM 100 mcg -
200 mcg ( 1.5 - 3 mcg/kg ) t1
uuMu naloxone Lltlu
l1wutnn1un W 400
mcg/ml , 1 ml
327 Morphine nj. 9 Dosage/Admini
stration
untLn chest
pain uwun1 morphine
sulfate uuM 3 mg V
unt:lvut
lM|Ll
uuMu morphine |Llvutt V
nLlvulMluuuM 2.5-5 mg
n 3-4 tlL1 un:nLnlvu
tlMn 5 u vn|tu uM
u1lnMLWLn monitor
respiratory and mental status un:
bood pressure lMunlvu
:M1 dilute Mu SWF v NSS
4-5 ml un:lt|nlunlvu
3-5 u
328 Morphine
inj.,
Pethidine inj.
11 Compatibility/
Stability
Morphine inj., Pethidine
inj. |vnn|tMltL
uu1nM|uun
u1l lvnLn
ultltMlMun:uM|n
nvLMuu1u
nnntWuwtLnWnL
stability u1 morphine inj. wt
LMut|nuu1lMun tuMu1
syringelt|ntu,WL|uLuu
u1u,nn:nult|1,
nvDL|ntnLu un:un1
wt|ntlMuu 14 u,30 u
v 6 ntMvt1t1nuuMwMn1
lu|1tLnMu|Lult:
u1lvnulunnLuMLlMwMn1
|1 Sterility t1LWLnWuLn
luu0M t1u0MlMult
vn1nWnLnLn|ntllMuu
24 tlL1 uL|1nt
SW,D5W v NSS lM
nn:nulnlLLnvn|vn1u
|ntluM|uuv 22 1W
|tn|tun un:|ntluLM vn
nn:nu|tnuu|tun|vn1|uL
n1uMnunM1u|nLnDw
unlLWltM uMnn
ntnLltu1tLWWnMlL
uu:ulvuu morphine un:
pethidine inj. |tMltunLltM
329 Morphine,me
peridine
03 Pharmacokineti
cs
morphine inj. un:
meperidine inj. vn10M
un:|Lnnuun::
vLMnu|LlM
-PethedinevMeperidine L onset
of action: im 10-15 mins peak
effect t:Ln 1hr, duration
2-4hr -morphine L L onset of
action: iv 5-10 mins extend
release epidual injection:Lnn
48 hrs t1/2 2-4hrs
330 Multivitamin
syr.
9 Dosage/Admini
stration
untuuMuu1
MTV syr. ltlu|Mnu
uun 1 t
Multivitamin syrup v Complevit
syrup Llul1wutnn1un
uMn: 5 ml t:ntMu vitamin
A 1990 U , vitamin D 150 u, B1
1 mg, B2 1 mg, B6 1 mg, B12 2.5
mcg, Vitan E 7.5 mg, Vitamin C
35 mg, Nicotinamide 10 mg ,
Calcium pantothenate 5 mg un:
folic acid 0.1 mg t1uuMu
uu:ulu|Mnu 1-6 t W 5 ml
OD uMnLnn 6 t W 5-10
ml OD nvtuuMuuu:ulu
|Mnu uun 1 t :|tuutt
MTV drop lMuuMnM1nu
|nnuuW |Mnuuun 1 t
W 0.5 ml uMnLnn 1 t W 1
ml OD
331 Mybacin 7 ADR/Side effect WtuLt:Muwu
Roxithromycin unL
W1un1nuuwu Mybacin
lLtMu
Neomycin Llu Mybacin
:LlnnuwuLnnL
lMvlL
Mybacin t:ntMu Neomycin
sulfate (equivalence to neomycin
base 2.5 mg),Bacitracin 100 unit,
Amylocain HCl 0.5 mg Mu
Neomycin Lluu Mybacin uu
|tuulunnL Aminoglycoside L
nulunL|tutW|u
Neomycin LlnnuwuLnnLlM
nt Framycetin, Gentamycin,
Kanamycin, Paromonycin,
Spectinomycin, Streptomycin,
Tobramycin nvtnuwuL
nnLnt Roxithromycin u1lLwt
uLn nnntWuuLn
|wL|MLwt Ln1unuw
Mybacin wtW pruritus,
maculo-papular rash, urticaria lM
332 Myiasis ,
vuu
uLn1u ,
vermectin
10 Therapeutic
Use/ Efficacy/
ndication
untultnL
vuuuLn1uluv
nnL|wuvuuuLn1u
nn Host lunnu1
Cutaneous myiasis Lnlt
u|nn alcohol , chloroform v
ether |wn1|vuuuLn1u
nnuWn un:Lu1un1
WLn|lunnLWtu
myiasis Muu vermectin t1|tu
broad - spectrum antiparasitic
agent t1nnunvn1 r -
amino - butyric acid ( GABA )
tnut:nun:|wLntu1
GABA M receptore tnu
t:n LWntnunuun
t:nun:lvwuuL1
uLn1|tuLwMun:MulunM
u vermectin lMnnuLltnL
Myiasis t1Lu1ulMWnM1
lutunuun:u|0w: lMuu
lututttt:u:lvlu
uuM 0.2 mg/kg /day
333 Nevirapine,
Phenytoin
5 nteraction WtulMtuMuln
nM 1 t1Lnut:nt
u1 Nevirapine un:
lMtu Phenytoin L
Mu untu|nM
D MnuvlL un:
vnL D M1unluu1l
Nevirapine |LltLnt
Phenytoin u Phenytoin ltL
Wnlv:Mtu Nevirapine nMn1
lMuu1n1M: metabolite
Wu cytochrome P450 unlu
lMunttuuMu Nevirapine
vltuMutnlLWunnlnu
334
Nicardipine 11
Compatibility/
Stability
Nicardipine WnLntn
u:llMt1un:
l1wutnLWLu1
|l
Nicardipine nLnWnL|unulM
nt D5S ,D5S/2 , D5W , 1/2NSS
,NSS lLWWnLnt Ringen
solution , lactated w. LWL
u1 2 mg/ml uuMt 2 ml (4
mg / amp)
335
Nifedipine 09 Dosage/
Administratio
n
untuuMu
nifedipine luWlvu
uuMu nifedipine luWlvu
W initial dose : sustained
release 30 mg un:W1
v 10 mg 3 time/day ,
usaul dose : 10-30 mg 3
time/day v 30-60 mg u
n:W1 (maximum dose):
120-180 mg Mu (nLn
|wLuuMulMlut1 7-14
u) 1ulL|tuM1tt
uuMuluWtu
hemodialysis un: peritoneal
dialysis nvtWtuL
n1uu1Mtwnw1
WnMuuMun1 50-60%
336 Nifedipine SR 9 p' dynamics /
efficacy
Wtultu Nifedipine SR
uwuM1n|tnuuu
lvWtu|tu Amlodipine
:M1ltuuMu|l
uuMu Nifedipine SR W 20-40
mg bid nuuuMu Amlodipine
W 5 - 10 mg /day t1n
tt:uu Nifedipine SR u
n: 2 W1 lvWtunL
tt:uulM un:lv
WnnnLlLM|W nu
Amlodipine tt:u|wu1un:
W1 LWnlvnLnWtWL
WLMulnvMlMu1nL|nL
MnMu un:lLlv|nM reflex
tachycardia
337 Nifuroxazide 10 Therapeutic
use/
Efficacy/ndicati
on
Nifuroxazide |tu
antibiotic nnLlM
Nifuroxazide |tuunvtnL
n1|nu nnuutt broad
spectrum lLLn:tulu
nnLlM |tuultlunnLt:|W
ultun:lLWuwtuLnnlt
uuLnun
338 Nitrofuradone 7 ADR/ Side
Effects
lul1wutnn1un|Wu
wt case uwu
nitrofuradone vlL
u Nitrofuradone v
Nitrofurazone v Furacin |tu
anti- infective ltnLuWn burn
skin grafting Lulututt
cream , ointment, topical solution
t1l1wutnn1un|WuLuMu
lututunul1wutn uM
lMMMnntutltunt:Ln
8 t 1lLnLnntWuuLnlM
uMnnntWuuLnnuvn1
u wt uuLu1un|nM
ADR t:Ln 1% W lv|nM
contact dermatitis ,rash , pruritis
un: local edema
339 Nitroglycerin
inj
13 other untuWnLu NTG
1:10 WnLu1l
NTG 1:10 vLuWLWnLu 1
mg Mnu 10 ml lMunu
nLnltWnLlMW NSS v
D5W lMulvlMWL|uLuulL|nu
400 mcg/ml lMultuMun v
hard solid plastic |tu
polyethylene , polyolefin vnn|nu1
PVC |u1nLWnMMttu
340 Nitroglycerine 11 Compatibility/
Stability
Nitroglycerine inj vn1
WnLunLWLW1Muu
|l
Nitroglycerine injection vn1WnL
nt D5W 0.9% NSS LWLW1M
48 hr. nvDLv1 un: 7 u
|L|ntluM|uu
341 Norfloxacin 4 pregnancy/nursi
ng
Norfloxacin nLnlv
luvu1lvuLtMlM
vlL
lLt norfloxacin utn
1uuLvlL uM|Llvu
uuM 200 mg 1tn|wu1W1
|MulLwtLunnutn1
uuL uMnlvuluuuMn1uu
vlvuvnu dose |tultlM
u:nnutn1uuL un:
|nMWnulLw1t:n1WM
nlM |tu arthropathy ,
phototoxicity 1lLuu:ulvltlu
vu1lvuLtM
342 Norfloxacin 4 pregnancy /
nurse
untu
Norfloxacin nLnlt
luvu1M1WD 7 |Mu
lMvlL
nlt Norfloxacin lu:v1
M1WDlLwtLWL|nu1M
nluWD uL:LuLn
u1ulv|nMWLWMtnM
u1MulunMMn1|Lltlu
uuMn1 1M1:LM:1nlt
lut1 first trimester
343 Norfloxacin 9 Dosage/
Administration
M1ntuuMu
Norfloxacin ltlu|Mn
uuMu Norfloxacin lu|Mn W 15
- 20 mg/kg/day ut1lvun: 2 W1
344 Norfloxacin 4 Pregnancy/
Nursing
Norfloxacin nLnltlu
1 st trimester pregnancy
lMvlL
Norfloxacin Mulu preqnancy
categony C nLnuwWun
luLuLulLwtD:|nu1MWL
WMtnMlun:lv|nutM
vwn uMW:LM:1n
ltlu 1st trimester |u1nL
u1un|nM teratogenic lu
nMMn1 M1uuvnL
|tuM1ltuWltlu:u:nu
lL|nu 1 ntMv
345 Norfloxacin,
Metronidazol
e
7 ADR/Side effect |Mnu 6 |Mu vun 6.5
kg ltwtuwuWnun
uwutn|tutMLM
un:tMlLLMlMu
Norfloxacin (100) 3/4x3
pc un: Metronidazole
(200) 1x2 pc uLt
Duvn1|MnlMuuMu
nntnu1unt:
|tuuMuvlL
uuMu Norfloxacin uu:ulu
|Mn:1nnMM|t
shigella (tMlLLM) W 15-20
mg/kg/day uu 3-5 u nuuuM
u metronidazole ltlun
nLtMLM (amebiasis) W
35-50 mg/kg/day uu 10 u uM
Norfloxacin LuW:1nltlu
|Mn|u1nwtu1un|nMu
n|nt (arthropathy) lu
nMMn1un:LtuvM
nwMun:Mnu1|Mn 1W
ltu|L|tuun:lt|tu
:u:|nnu |LwnuuM
u Norfloxacinu1WtulMt
:LnnuuMuu:u 1
W|W:1nun|nt tL
MLu
346 Octreotide 9 Dosage/
Administration
u Octreotide WLu1
0.1 mg/ml uwun1lt 25
mcg :M1ltutLM
|l
Octreotide 0.0001 g = 1ml ,
uwun1ltu 0.000025 mg ,
|w:uu:M1ltu 0.25 ml
347
Octreotide 11
Compatibility/
Stability
Octreotide nLnlv
Wu1 cut down tube
Lnt kcl lMvlL
nnntWu MMS 2006 ,
Micromedex , Drug nformation
Handbook wtlLnLnlv
LnulM ( incompatibilily) uM
nuLn paranteral drug therpy
mancal in vancouver general
hospital 2002 nLnlvLnu
lM M1uu lLWlvu octerotide
un: kcl Wu1nu iv |Munu
348
Ofloxacin 4 Pregnancy/
Nursing
vu1lvuLtM
nLnlv Ofloxacin
lMvlL
Ofloxacin nLnutWu
uuLlMuMlutLnuu
(Relative infantdose = 3.2%)
American academy of
Pediatrics (AAP) :t
nLnltuulMlunMlv
uLtM uMu1lnMLL
u1un|nM arthropathy
luMuu1nMlMtuu
M1uu1WltMuWL
:LM:1lunMlvuLtM
349 Ofloxacin 4 Pregnancy/
Nursing
Ofloxacin nLnltlu
vu1M1WDlMvlL (
uWD 31 week )
Ofloxacin Mulu Pregnancy
Categories C lMuLu1un
|nM teratogenicity lunMMn1
un:wtlunWnLuttWtWL
lunMLWD M1uu:ltuulMn
M|Luult:lutulMWL
ntWL|nu1uMuMnlu
WD|uu u1lnMLLuLn
nWnLutt retrospective
uu 25 nWnLu1un
|nM anomalies lu infants uL
lMtu Ofloxacin n1uL:lLL
u1u|nM major congenital
malfesmation nML M1uu1lL
Wlt ofloxacin luvu1M1WD
350 Omeprazole 6 formulation Omeprazole nLn
feed lMvlL
Omeprazole uuM 20 mg
capsule |tuuulututt
nnu|uu t1|tututtlL
WtM uMn|tuM1lvu
tuttu1 NG tube nLnlv
lM lMu|tM capsule nunWnL
ntu
351 Omeprazole 4 pregnancy/nursi
ng
WtuM1WD 2 |Mu
un:lMtu omeprazole
unt:LWnM
nM1WDvlL
Omeprazole Mulu Pregnancy
Category C vLun1 LnWnL
nltulunMMn1un:wtWn
ulLw1t:n1WMMu uMu1
lLLnWnLtM|uluLuLu
M1uunltu omeprazolelu
vu1M1WDW|tut|ut
t:lutu:lMtLnnWn|nu
:|nMuuvlL u1lnML
Wvnn|nu1nlt omprazole
lut1 3 |Muunu1n
M1WDv|tnuultltuMu
tnMDuLnn |tu Ranitidine
( Mulu pregnancy category B )
352 Omeprazole 11 compatibility/St
ability
Omeprazole inj.
nLnWnLntnn:nu
lMlMt1
Omeprazole inj. nLnWnLnt
nn:nu NaCl 0.9 % , 5%
Dextrose water 5 ml lun
reconstitute t1u reconstitute
un nLn Dilute |tunn:nu
100 ml lMultnn:nu|Munu
353 Omeprazole 09 Dosage/
Administration
Omeprazole lvlu|Mn
WltuuMu:|lv
Omeprazole lL|vL:nL:ltlu
|Mn uMvn|tuM1ltuu:u
lvltluuuM 0.6*0.7mg/kg/day
luMu|tun: nLnlvtlM
lMu dose 2 v1n dose un
12 hr uMlu1uuLuuMu
effective W 0.7-3.5mg/kg/day
354 Omeprazole 14 Contraindication
/ Precaution
Omeprazole nLnlt
luvu1M1WD un:vu1
lvuLtMlMvlL
Omeprazole nLnWu1
uuLlM 1lLuu:ulvltluvu1
lvuLtM un:Omeprazole
nLnuwWun un:|WuL
u1ulv|nM teratogenicity
lM |LltluuuM therapeutic
dose , OmeprazoleMulu
category C 1Wltuu|Luul
t:lutulMWLWntWL
|nu1uMuMnluWD
|uu
355
Omeprazol
e
07 ADR/ Side
Effects
omeprazole nLn
lv|nMn
u1|Wu1uuuvun
lMvlL (u1vLM
Wtult W
omeprazole
domperidone air-x)
omeprazole lv|nMn
uuuvunlMuun 1 %
lMunu1|Wu1wtlM
tu:LntMWL:
(3-7%) Lu11 (3-4%) 1|nu
(3-4%) tM1 Wnuln
(2-5%) nuudomperidone
un: air-x lLwtnLn
lv|nMnuuuvunlM
356
Omeprazol
e (Ocid)
11 Compatibility/
Stability
Omeprazole (Ocid)
vn1WnLun|ntl
uu|l
nnntnLtLWuu
vuu 0cid (Omeprazole
inj ) u1|Ln:nuulu
SWF 10 ml nLn|ntl
lMuu 4 hr nvDLv1
un:vn1|1Mu D5W
v NSS 100 ml :|ntl
lMuu 6 hr ,12 hr
MLnMtnvDLv1
357 Omeprazole
inj
09 Dosage/
Administration
omeprazole inj0Mun:3
W1lMvlL
omeprazole inj nLn|wLuuM
lM 120mg 3time/day lMlu
indication Pathological
hypersecretory condition
358 Omeprazole
injection
11 Compatibility/
Stability
Losec injection nLn
n:nuW1untnn:nu
lMlMt1|u1n solvent
uuM 10 ml tLlv
LlLlM:t|tuM
n:nutuMlM
nLnn:nuW1u Losec lMnt
Sodium chloride 0.9% v
Dextrose 5% in water lM uM1
tL:uu:ulvltMn:nu
u1tLlvL|uu
359
Omeprazole,
Lansoprazole
7
ADR/ Side
Effects
Omeprazole un:
Lansoprazole L
lW1n1WnunuvlL
lLuw Omeprazole
uMnu lansoprazole lM
omeprazole un: pantoprazole L
vL methoxy un: difluoromethoxy
chain utu benzimidazole rings
nulansoprazole un:
rabeprazole lLLvLuutu
benzimidazole rings uML
trifluoroethoxy un:
methoxypropoxy tu pyridine
rings M1uuvnuwu
lansoprazole :nLnuwu
rabeprazole uMlL|nMnuwu
omeprazole un: pantoprazole
360 OMV 11 compatibility/St
ability
OMV LunWnLu1l OMV WnLlMu unn:nunM
2 WnLn1lunM 1 ( W1uv1)
nn:nuWnLun:ultWnL
ntnn:nulv1vnM|nM
361 Ondansetron 10 Therapeutic use uwun1ltu
Ondansetron 1 amp iv
prn luWtu severe
emesis untL
WL|vL:nLvlL
u1l ( WtulMtu
|WLttMLt:Ln 1
Mu )
Ondansetron Lut1ltlun
nLvt1nun|uu
|nuu1ntnnt:n
Serotonin ( 5-HT) t1Ltt
nWulv|nMnWnuln
|uulMu|0w:luWtulMt
u|WLttM , 1nttMv
vn1nnWMM t1nlvu
Ondansetron :uu:ulv|tu
uttM1|nun:un:uu1lLL
uLnnutnuun1nlMt:lutu
u1u:uluWtuLn
Wnuln|uulM|nMuuun
362 Ondansetron 11 compatibility/St
ability
Ondansetron nLn
WnLntnn:nulMlM
t1
Ondansetron nLnlvlMuu iv
lMlMulLM1 dilute lt|nlvu
2-5 u uMnM1n dilute
nLn|1lMnt D5W v
NSS 50-100 ml un:lt|nlu
nlvuuu 15-30 u
363 Pantoprazole 11 Compatibility/
Stability
Pantoprazole (Controloc
) inj. nLnWnLnt
nn:nulMlMt1un:
nLnlvulMuu direct
iv lMvlL
Pantoprazole inj. ( 40 mg/ml )
nLnWnLlMntnn:nu NSS,
D5W, LR ( final conc 4 mg/ml)
un:nLnlvulMlMuu direct
iv vlvutt iv infusionlMu
LM|lunlvu 8 mg/hr
un:nLnlvulMuunM 72
tlL1
364 Pantoprazole
inj
11 Compatibility/
Stability
unt
Pantoprazole inj vn1
WnL:nLn|ntllM
uu|lv
nnntWuwt |LWnLun
nLn|ntllMlL|nu 2 tlL1
un:|L dilute|tu solution
nLn|ntllMlL|nu 22 tlL1
(vnnuWnLL stabilizer|tu
EDTA) uMn|tu normal solution
:nLn|ntllMuu 12 tlL1
365 Paracetamol
inj
09 Dosage/
Administration
Paracetamol inj nLn
0M iv lMvlL
Paracetamol inj n:nuluulM
uu luMt1lt propylene
glycol,polyethylene glycol |tuM
n:nutu t1LunMlu|1
WL|uLuunvt0M iv nLn
|nultlv|nMuMuM|LM
|nMuM1vM1nulM
u1lnMLluun:uLu
Praparacetamol t1|tu prodrug
u1 Paracetamol lututt
n:nuulMLnuu t1|MuLlMu
lLlt cosolvent vltuu 1
lv0M1iv lM uMu1lnMLu1
lLLuM1nnnvuu M1uu
1lLW0Mu Paracetamol 1
iv WlvlMu0M1 im |wWL
tnMDuu1Wtu
366
paraquat 8
Toxicity/
Poisoning
pt. nu paraquat L
antidote nLvlL
u1l
lLL antidote ltnLnwL
n Paraquat uMLnnL
|t1MuW|uu|wW
nLLnnM|tun1W lvnu
luu vlvMLu|nn|uL|uL
u |tuMuuntun1
l1wutnt1nttMlu
l1wutnut1|tu 3 uuMuW
1.t1nunMMtL1nlnlMulv
Fuller's earth 150gu1nMnu
LntMOM 30ml q6hr uWtu
nu 2.|1nutnunn|nM
lMulvu|nn1 iv rate
250ml/hr Lntfurosemide 3.
t1nunnu|u|uu1
1nu 1Mlvnt|ulv dexa
5mg iv q6hr un: cyclophosphate
5mg/kg/day iv ut1lvn 8 hr
367 PCEC 10 Therapeutic use untunlvWtu
PCEC t1nulWwL
nuututtnunLWnlW
n0MWtut1nuMWwLnuu
tuttnunLWnlW (PCEC) lv
0MWtu 1 dose |unnL|u v
0.1 ml 0M|uluWvu1t|n
vlvnluu 0 , 7 un: 21 v
28 (n0MlLM1u|nnuun
uLtlM ) |MnWltuuMu1
Wtu|ntWlvu
368 PCEC 10 Therapeutic use untnM10M
PCEC lututt M M1
ltun ml
lunn0M PCEC utt M M1
lt vaccine 1 ml
369 PCEC, ERG 10 Therapeutic use Wtu|WulMtn0M
vaccine PCEC un: ERG
t1nuwLnuutWt
WnLun|Lt 47 L
W1ulMuuLnMLlL
tM1|L0MlvL
vlLun:vnM1n0M
ERG MuM1|LlvL
vlL
Wtu|WulMtWtulWwLnuu
ttuM|tnn|w:|nu1vlu|tM
wntnu (PCEC) Wt W
nLnu |LnLWnlWnW1un:
|tuM1lMtnnL nLn
lvnnLlMun0M|uLn:Mu
un:lL|tuM1lv RG lMun
0M|unnL|u 1 dose v0M
|uluWvu1 1 M (tLnWtu
0.1 v 0.2 ml) t|nvlvn
lMu0M 1 W1 (u 0) lunn
WtulMtWtu|uLnMu < 6
|Mu un:0M 2 W1 (u 0 un:
3) lunnWtulMtWtu|uL
nMu > 6 |Mu
370 Penicillin 9 p' dynamics /
efficacy
uwun10M Benzathine
Penicillin G 1.2 MU utt
M |tuM1Ln test
nuvlL un:Lun
tvuu1l
lunnu Wtu|Wutt:uu
Penicillin V un:lL|WuLt:M
uwu lL|tuM1 test
nvtutvuutt M lv
n:nuu 1.2 MU ntunnu 3.6
ml
371 Penicillin 9 Dosage/
Administration
Wtu|Mnu 4 t uvun
16 kg uwun1uu
Penicillin V 250 mg uuM
1*4 ac untL
WL|vL:nLvlL
uuMu Penicillin W 25-50
mg/kg/day ut1lvn 6-8 tlL1 (
maximum dose 3 g/day) t1
WtuLuvunM 16 kg uuMu
lvlMW 400-800 mg/day uM
uuMuuwun1 W 1,000
mg/day t1uuMulMtn1
|nult 1WttnMuuMn1lv
|vL:nL
372 Penicillin 9 Dosage/
Administration
M1ntuuMu
Penicillin V lunnL
Rheumatic Heart
Disease lu|Mnu 15 t
uuMu Penicillin V nvtn
nL Rheumatic Fever W
100,000 U/kg/day uu 10 u (
|Mn : 250 mg v 400,000 U
bid or tid , Wlvu : 500 mg bid or
tid ) t1WtuuuLu 15 t 1
lvuuMultluWlvu
373
Penicillin ,
PGS
11 Compatibility/
Stability
PGS nLn|ntl
luM|uuvn1|tMlt
W1unuu|l
PGS vn1n|tMltW1un
nLn|ntlluM|uulMuu
7 u un:|ntnvDLv1
lMuu 24 hr
374 Penicillin ,
skin test
13 other Wtuuwu Penicillin
uwun1ltu
Cephalosporin inj.
untLun
skin test u1lun:
|tuM1vlL
uLn|1n skin test u1
unnL cephalosporin u1L
Wuu1nM lMuwtn|nn
WL|uLuu|vL:nL lL:Wu
|W1Wvu1un:nMnt|tu
tnnWuu1u|tnWtu
:uwu1 u1lnML
tuvunutnWn nnWn
nMnt|tunt |u1nlu
ttuu1lLLlW1n1lMv
metabolite lMu1unnLu|tu
detergenic determinant t1
nLnn:Munn1 gE
antibody 1lv|nMWnnt
n1lM un:u1lLLuLnuuuu
Wnntn1M1nn|nMuut:Ln
un:|l nvtn|MuL
nn:nu Cefazolin |w skin
test WL|uLuu|LMuu1u
330 mg/ml :M1|1nWL
|uLuu|LMu 10 | |wlvlM
WL|uLuulL:Wu|W1Wvu1
375 Penicillin G
sodium
09 Dosage/
Administration
:lv PGS luWtu
LuWlvu Wlvlu
uuM|lv
PGS:Adult 2-24million unit/day
ut1lvn 4 hr n severe
infection |LlvuuM
400,000unit/kg/day ut1lvn 4
hr max dose 24million unit/day
376 Pethidine 09 Dosage/
Administration
Wtu serum creatinine
5mg/dl 0MPethidinelM
vlL
Pethidine injlvluWtu renal
dysfunction lvwnnM dose
n1M1u Clcr10-50 ml/min lv dose
75% of normal dose uun 10
ml/min lv dose 50% of normal
dose WtuuuM1u Scr L
Wun CrCl=0.85[(140-age)*
Bw(kg)] / 72*Scr t1 dose tnM
u1 Pethidine inj=50-75 mg im,sc
377 Pethidine 7 ADR/side effect M1n|tut|utWn
MunlLw1t:n1W
u1 Pethidine un: tramol
Mn|nMnWnuln
|uulu|Mn|ut
nWMMML tonsil un:
nnMnvulluWlvu
lu|Mnu 4 - 7 t |utn
WMMML tonsil wt pethidine
nLn:1tntMlMMn
tramol nunu1|Wu1 W
Wnuln |uu wtlLuMnM1
nu nunnMnvul wt
tramol nMnvuluun
pethidine un: morphine
378 Phenobarbital 4 pregnancy/nursi
ng
Phenobarbital nLnlt
luvu1M1WDlMvlL
nlLlMnLnltuM
lMuulMt1
nltuMuntnlu:v1
M1WD lv|nMWL
WMtnMMnluWD uM
u1lnMLnltu:v1
M1WD:|nMWn|nuuun:
tnulv|nMntn:v1M1WD
M1uulunnWtunLn
WtWLntnlMMuunutn
tt:uuunun:wtLn
M1WDluDuvn1 nlL|tuM1
|tnuutuMvuuMu1u
tt:uu uMlvtt
:u:|nlunlvu lMu
|tnuu|tutt:uuun: 2 -
4 W1 |wnM:Mtu1u
lv|nMwL uMlunnWtuu1
WLntnlLlMlvltuuMu
uunMnLnWtWLn
tnlM un:Wlv folic acid L
MuMnMnM1WD
379 Phenobarbital 9 p' dynamics /
efficacy
untnLnlt
uMlMuu
Phenobarbital inj. lu
Wtu|MnlMt1 un:M1
ltluuuM|l
nLnlt Phenyltoin inj. uulM
lMuuuMult W Loading dose
ltuuM 15 - 20 mg/kg , nitial
dose ltuuM 5 mg/kg/day in 2
divided dose , 6 mo. - 3 yr lt
uuM 8 - 10 mg/kg/day , 4 - 6 yr
ltuuM 7.5 - 9 mg/kg/day , 7 - 9
yr ltuuM 7 - 8 mg/kg/day , 10 -
16 yr ltuuM 6 - 7 mg/kg/day
380 Phenobarbital 9 Dosage/
Administration
Phenobarbital lv iv
WnLntnu:llMt1
un:lv rate |llu|Mn
Phenobarbital nLn|unulM
ntnn:nu NSS , D5W , RS ,
LS lMu dilute uMu sterile
water 10 ml un:0Mutlu
rate 25-50 mg/min ( maximum
rate 100 mg/ u ) luWlvu un:
1 mg/kg/u lu|Mn
381 Phenobarbital 7 ADR/ Side
Effects
Phenobarbital nLn
|nM cross reactivity nt
carbamazepine vlL
unutnL Aromatic ring ulu
lW1n1 t1lMun Phenytoin,
Phenobarbital ,carbamazepine
wtLnuwuLnu ( Cross
reactivity ) lMn1 75% t1unu
tnu:ltlMu1tnMDu
lMun Valproic acid, Gabapentin
,Topiramate un: Benzodiazepine
382 Phenobarbital 11 Compatibility/
Stability
Phenobarbital inj vn1n
|1un|ntlltlMn
vlL un:|ntllMuu
|l
nnntnLtLWu|uu
Gardinal inj (Phenobarbital )
:tvn1n|1unnLn
|ntulltlMuu 15 tlL1
nvDLv1 ( 25 1W)
383 Phenylephrin
e eye drop
11 Compatibility/
Stability
unt
phenylephrine eye drop
vn1nunL|1
:nLn|ntnn:nu
|1unlMuu|lM
nnvuMuu1u|tu sterile
product :M1uMvnnlun
|MuLutt sterile techniqe t1n
lLnLn|MuLulunD:
M1nnlM :M1nvuMlvL
WLtnMDuLnnM lMult
W:|MuLutt freshly prepare
lMultuvn1n|MuL un:u
|vnuulv1lt
384 Phenyltoin 9 p' dynamics /
efficacy
uwun1 phenyltoin 8
cap stat MLMu 300
mg hs wutnlvWtu
tt:uu stat dose
Mu 15.00 u. lLt
M1nuunW1|Ll
uuMu maintainence dose :
lvnW1lLW|n 12 tlL1
vn1n|Lu dose un ( loading
dose )
385 Phenyltoin 11 compatibility/St
ability
Phenyltoin inj. vn1n
WnLun nLn|ntu
llMuu|l
|L|1unWltu lLW
utM|uu |w::lvu
MnM:nu
386 Phenytoin 9 P'dynamics/effic
acy
unt phenytoin
utt prompt un:
extended capsule
nLnlvutt|Munu
W 3*1 hs lMvlL n
lLlMuntL
WLuMnM1nuu1l
nlvu phenytoin ( extened )
utt 3*1 :LWnM1u1 C max
nt C min Lnnnlvuutt
1*3 (prompt) un:nlvuutt
1*3 v 3*1 M1Wu1n1 side
effect un: compliance u1Wtu
nuWnnnL:lLM1nuLn
uMt1nWnLwtnlv
prompt phenytoin :lvW
Cmax u1un1nnlvulu
tuttu t1nlvututt
prompt ( lLlt extended ) lL
nLnlv|wu1 dose |Mulu 1
ulM 1:M1lvuutt 1*3
(un: 3 W1)
387 Phenytoin 9 Dosage/
Administration
Phenyltoin uuM 50 mg
prompt release nLn
lvutt 6 * 1 lMvlL
nlv Phenytoin utt prompt
release 300 mg W1|Mu :LW
pharmacokinetics uMnM1n
nlvutt extended release
lMuW Cmax un: AUC u1u
utt prompt release :n1n
utt extended release uMW
Tmax :lnn|Wu1nu t1uuMu
|wLn1uulu utt prompt release
:LW bioavailability n1n uM
lLLWnMnnMuun: half life
u1u uMn1M1:1Wn
lLw1t:n1W t1:nLwuunt
:Mtulu|nM lMu n Cp> 20
mcg/ml lvWtu|nMn
nystagmus lM uMn Cp> 30
mcg/ml lv|nMn
ataxia, nystagmus un:vnCp>
100 mcg/ml Wtu|nutMlM
388
Phenytoin 3 Pharmacokin
etics
WtuL liver
enzyme n1nLn
ltu phenytoin lM
vlL un:ltu:l
lMt1
unutnWvnn|nu1lu
Wtun1uu1Mt
tnw1 W Phenobarbital ,
phenytoin ,
carbamazepine,valproic acid
|u1nwtu|vnu
lv|nM hepatotoxic lM
Lnn antiepileptic agent
tuMu nuWtuLn
1uu1Mttnw1
nLnltunutn
gabapentin , topiramate,
un: levetiracetam lM
|u1nlLnn metabolize
WuMt 1|nM hepatotoxic
lMuu un:unutnluw.
nLn|nnltlM W
gabapentin un: topiramate
nuu clonazepam un:
oxcarbazepine lvltlM
|L|tu|u1nLn
389 Phenytoin 3 Pharmacokineti
cs
Phenytoin LWW1tM
|tu|l
Phenytoin L elimination half-life =
22 hr ( range : 7 - 42 hrs ) oral
390 Phenytoin
Clonazepam
5 nteraction Phenytoin nt
Clonazepam nLn|nM
drug interaction nu
vlL
Phenytoin |nM Drug nteraction
nt clonazepam lMuL
Significance :Mt 4 (onset =
delayed,day to week, severity =
modurates , documentation =
Possible) t1t:nuDwu1u
phenytion v clonazepam :
nMn1v|nMwLn Phenytoin
lMunnlnn|nM W n
phenytoin ltn:Munnuu
clonazepam nuWnu1
clonazepam M phenytoin u1lL
tnnlnuutM nMn
drugs interaction Wlv observe
t:nuDwu1u1 2 M
L1n|nMwLnu
Phenytoin uMu1lnMLu1L
ulMuu1|1n|nMwLn
phenytoin un:nlLnLn
WtWLntnlM lMuL clinical
trial 2 u1u:t nnlv
u1 2 MWnulLLWnM:Mtu
phenytoin lu|nM
391
Phytonadio
ne ,
'Vitamin K
9 Dosage/
Administratio
n
Vitamin K 0M iv push
lMvlLWnLnt
nu:llMt1
Vitamin K v
Phytonadione nLn
tvulM1utt im, sc, iv
push un: iv infusion lMu
lvuutt iv push :lt rate
lL|nu 1 mg/ min nun
unLnWnL|unulM W
D5W , D5S , NSS , un:
RLS
392 Piperacillin +
Tazobaetam
,Tazocin
11 Compatibility/
Stability
Tazocin vn1 dilute |nt
llMuu|l
Tazocin (Piperacillin +
Tazobaetam) inj vn1WnL|ntl
lMuu 48 tlL1nvDL 2-8
1W un: 24 tL. nvDLv1
393 Plavix
,Clopidogrel ,
Contraceptive
7 ADR/ Side
Effects
un:ulMtu Plavix
lMutt:u 1 |LM u
n: 1 W1 :nLnlt
uWLn|uMlMvlL
Plavix |tutnWu1u
Clopidogrel |tuunnuMu
n|n:nnLu1|nM|nM Lut1
ltluD:M1Mltu W t1nu
lWvnM|nMvltuM|0utwnu
, nnL|uvlMutuM
|0utwnu , vnM|nMuM1MMu
,vnM|nMlunL1MMu , D:
vluM|nM, D:vnM|nM
uM1nutnuMMu
nuuWLn|uMLuvLltluW
|tulWMt |tvu,lWvl,
lW|nu|nM, |nu|nMMMMu ,
lWlM,lWDLuw ,lWnLtn ,nM
uLnn 40 t ,L:|1|MuL
L:|1u:ntwuu |u1nLMnn
M1uuWtuuu1Wvnn|nu1
nltuWLn|uM
394 Pletaal 07 ADR/ Side
Effects
Pletaal ltnLlWlM L
Wnlv blood pressure
MlMlvL
Pletaal tnLu1uW
Cilostazol nnuutu1n
1uu1 enz.
phosphodiesterase t1lvL
Wnutu1nuu1Mu1|nM|nM
unt:lv|nMvasodilation lv
blood pressure nMMn1lM
395 Polyvalent
Human
mmunoglobu
lin
7 ADR/ Side
Effects
unt Polyvalent
Human mmunoglobulin
Lu1un|nM ADR
vlL
nnntWun Spontaneous
report of Adverse Drug Reaction
2004 wt Polyvalent Human
mmunoglobulin lv|nMn
coughing , dyspnoea, pruritis,
rash lMuwt|wu1 1 case |uu
396 Potassium
chloride
11 Compatibility/
Stability
WtulMt 5% D/N/2
500 cc luM| 80
cc/hr tnWtuLW
K+ |nt 2.8 t1Mn
WtnM uwu1n1lvWnL
Potassium chloride 40
mEq luuMu|nn
M1nn unt
nLnWnLlMvlL
ntvu potassium chloride
|Llv1 peripheral line WL
WL|uLuulL|nu 40 mEq/L un:
M|lunlvulLW|n
10 mEq/hr nvtWtuuu
nnlv Potassium chloride 40
mEqluu|nn 500 cc WL
|uLuu:|nt 80 mEq/L t1
WL|uLuu:|nunuu:ul
un:lvWtu|nu1Mn
|nMvnM|nMMn|ntlM
397
Potassium
chloride
11 Compatibility/
Stability
Potassium chloride
inj un: Sodium
chloride inj nLn
lv1nu|MunulM
vlL
Potassium chloride inj un:
Sodium chloride inj nLn
lv1nu|MunulM
398 Potassium
chloride,Sodi
um
bicarbonate
11 Compatibility/St
ability
untu0M
Potassium chloride un:
Sodium bicarbonate WnL
|unulMvlL
u 2 MunLnlvLnulMlMu
|tunWnL WL|uLuu
Potassium chloride 2.4 mEq/L
lMultnn:nu D5W wtuL
physical compatible 24 hr
399 Potassium,
Sodium,Phos
phate
13 other unt daily
requirements u1
Potassium, Sodium, un:
Phosphate lu|Mnu 1
t
Daily elelectrolyte requirements
lu infants/children W

Sodium 2-6 mEq/kg
Potassium 2-4
mEq/kg
Phosphate 0.5-1 mmol/kg
400 Prednisolone 4 pregnancy/nursi
ng
WtulvuLtM nLn
ltu Prednisolone lM
vlL
nnWnLvu1lvuLtM 6
u wt|Ltt:u
Prednisolone 10 - 80 mg/day
wt:Mtu prednisolone lu|nM
u1LMLWL|uLuut:Ln 5
- 25 % t1Wunt|Mn:
lMtu1uuLlutLnuu
uMnLM|tuM1lMtulu
uuMn1uu uu:ulvLMlv
uLtMvn1tt:uultun
u1uu 4 tlL1
401 Pregnancy
test
13 other unt alcohol
un:uMlMt1
lvWnnM1WDWMwnM
uLWnlvnMD:
M1WD|tu false positive lMun
Antiparkinson drugs ,
Anticonvulsant , Phenothiazine
nutuuLWnlMun D:
thyrotoxicosis, hematuria ,
proteinemia , manopause un:
soap :LWnlun interfere
reaction lM nu alcohol lLwt
LuLntnn1Wnlvn
MnM1WDWMwnM
402 Premarin 10 Therapeutic
use/
Efficacy/ndicati
on
w.n1unltuMlM
WLu1|luu
Premarin 0.625 mg
nLnltuulMn
ndication vlL
w.n1unlt Progynova WL
u1 1 mg uu Premarin 0.625
mg |u1n Premarin 0.625 lv
estradiol 40 pg/ml nu
Progynova 1 mg lv estradiol 50
pg/ml uM Progynova 2 mg lv
estradiol 60 pg/ml t1L estradiol
Ln|nult 1lt Progynova 1 mg
lnn|Wu1 Premarin 0.625 mg
LnnM nvt Premarin un:
Progynova :LMuulLu
|nlM|u |vLunu lMu
Progynova :|tu estradiol
valerate lMnwtWn|vn1
nu premarin W conjugated
equine estrogen lMnnM t1
ut1lt|vLunulunnL
nnLnnMuvLMt:|Mu
,ltnLnuMulLu|nlM
|u
403
Primaquine 9
Dosage/
Administration
M1ntuuMu1u
Primaquine lunnL
Malaria ( P.Virax)
uuMu Primaquine ltlun
nL Malaria W 15 mg/day
(base) once daily for 14 days or
45 mg base once weekly for 8
weeks
404 Progesterone
inj
05 nteraction WtulMt
progesterone inj un:
lMtunLnlWMu
:LWnMdrug interaction
vlL
|WuLu1unnn1Wtu
uuWLn|uM Lnt u
ttu: |tu Cefadroxil,
Penicillin, Macrolide uMu1ln
MLlLLvnnuuutM1
uWnMt:MtEstrogen
nMn1luWtulMtuttu:
uMlvuttu:|vnult
nM normal gut flora lv|wL
enterohepatic recirculation un:
|tuWnlv serum level u1u
nMn1 u1lnMunnL anti TB
|tu Rifampicin vunnL
barbiturate :n:Mu hepatic
enzyme production lv|wL
metabolism u1uWL nuunnL
anti fungal |tufluconazole:|wL
serum level u1uWLt1nnu
Wtult uWLtuM0M1lLL
WnMdrug interaction u1u
405 Progynova 10 Therapeutic
use/
Efficacy/ndicati
on
Progynova |uLuu
premarin nLnltuu
nulMvlLu1l un:
LltuMnM1n
Cycloprogynova u1l
Progynova un: premarin LMu
ulLu|nlM|u lMu
Progynova :|tu estradiol
valerate lMnwtWn|vn1
nu premarin W conjugated
equine estrogen lMnnM
un:LuuMnM1nulu|1uuM
nuttu un:nu1|Wu1
(un:|uMluutttunnlv
uLnu) nu Cycloprogynova
t:ntMu 11 |LMnu W
estradiol valerate 2 mg, 10 |LMn
uMn W estradiol valerate 2
mg,norgestrel 0.5 mg lMu
Progynova ltlunnMMLMnn
un nuCycloprogynova :ltlu
nnu1LLMnnu
406 Propylthioura
cil
4 pregnancy/nursi
ng
WtulvuLtM nLn
lvu propylthiouracil
un: Lugol solution lM
vlL
Lugol solution t:ntMu odine
un: potassium chloride WL
|uLuuL 130 mg/ml t1 odides
|tun|vMlv|nM abnormal
thyroid function v goiter in
neonate lM nu propylthiouracil
nLnutnlM1uuL t1
M1:LM:1nltluvu1lvuL
tM u1lnMLlLuu:ulvlt
uM1nn:v1lvuLtM
407 Propylthioura
cil
4 Pregnancy/
Nursing
PTU Mulu Cat.lM
uMuvlL
Propylthiouracil (PTU) |tuult
nL Hyperthyroidism Mulu
Pregnancy category D (Lu1u
n|nM teratogenic luWu)
408 Propylthioura
cil
4 pregnancy/nursi
ng
WtulvuLtM nLn
lvu propylthiouracil
lMvlL
propylthiouracil nLnutn
lM1uuL t1M1:LM:1n
ltluvu1lvuLtM u1lnML
lLuu:ulvltuM1nn:v1
lvuLtM
409 Propylthioura
cil (PTU)
7 ADR/Side effect WtulMtu PTU lu
uuM 300 mg/day un:L
nWnuln|uu lL
tnM1nn
|nMnnlMtutuMu
lMvlL
PTU lv|nMnWnuln
|uulM u1lnMLn
M1nnlLltuvLltu1Wtu
un:M1wnn1tuu
lvWtu|nMnM1nn
t1luWtuuuWtuLD:u1
lWn:|w:vLMu t1
|tun|vMu1n|nMn
Wnuln|uulM
410 Propylthioura
cil (PTU)
7 ADR/Side effect WtulMtu PTU unL
nMtL unt
|WuLu1un|nM
nMtLnu
M1nnvlL
nnntWuuLn wtL
u1un|nM Oedema
periorbital ( |tMtL ) uu 2
u lu:MtWLu:|tuu:
lt ( possible )
411 Pseudoephed
rine
7 ADR/side effect untn
u1|Wu1u1u
Pseudoephedrine
nu1|Wu1u1u
Pseudoephedrine lMun v
l|MuWM1v: tw|Mu| 11
tL tMv Wnuln |uu
u|wnu
412 Pseudoephed
rine
7 ADR/Side effect unt
Pseudoephedrine L
nlLw1t:n1W
lvvuuM1lMvlL
Pseudoephedrine LWnM:tt
vlun:vnM|nMW lvv
l|Mu| lnu lM lMuulv
WLMulnvM|wLuu u1ln
MLLu1uulv|nM
hypotension lM|tunu nn
ntWuuLnwt nvuuM1
wtlM|LlMtuluuuMn1
un:nu1u Spontaneous
report of ADR t 2004 wt
u1un|nMn flushing 1
u lu:Mt u:lt
413 Pyridoxin (
vitamin B6 )
9 p' dynamics /
efficacy
untuuMu1u
Vitamin B 6 ltlun
t1nuluWtulMtu
TB
uuMu1 Vitamin 6 lun
t1nun|nM neuritis n
soniazid W 25-100 mg/day
nuuuMltlunnLW
100-200 mg/ day
414
Rabies
vaccine
20 Others untM1n
lv rabies vaccine
nlv PCEC 1 M 1,2,3,4
1.Post-exposure,not
previously vaccinated lv 0.5
ml M u 0 3 7 14 28 un:
lv human rabies immune
globulin 20 nternational
Units/kg M 2.
Post-exposure, previously
vaccinated lv 0.5 ml M
u 0,3 3. Pre-
exposure, primary
immunization lv 0.5 ml M
u 0 ,7,21v 28 4.
Pre-exposure,booster
immunization 1 ml M lv
MLWL|tu|w
maintain serum titer lvL
n 1:5 (WtuLWL|nu1
test n 6 |Mu lLLWL
|nu1 test n 2 t )

415 Ranitidine 04 Pregnancy/
Nursing
Ranitidine 150 mg tab
nLnltluvu1M1WD
lMvlL
Ranitidine Mulu pregnancy cat
B lLLu1un|nM
teratogenicity nLnlvluvu1
M1WDlM
416 RDW 20 Others unt RDW luW
Lab CBC uLn:l
nMutnWLvLu
u1l
RDW uLn RBC Distribution
width (RDW) t1:|tunM|t1
tLnlMuMnWLuMnM1
u1uuM|LM|nMuM1t1:tu
u0uD: anemia
417 RG 10 Therapeutic
use/
Efficacy/ndicati
on
untn0M RG
lunnlLnLn0M
wLntnlvWtulu
W1unlM nLn0Mlu
uMLlMvlL
nlv RG nvuMlvun
Wtuvu1W1wLntnlv
WtuluuuMnvuMnlv
uuMn1nnvuM:LWnnM
DLWLnu|nMuulMu|0w:lu
u 10-14 lunnlLnLn
lv RG luuunwLntn
lvWtu Wwnlvluu
MLuMlLWlvvn1u 7
u1nlvWtu|w::LWnlu
nnMDLWLnu|nMuunn
lvWtu
418
Ritonavir 11
Compatibility/
Stability
Wtu:ltu: 1 u uM
M1tt:uu
Ritonavir |n 19.00 u.
1unntnL|tu
:M1uulnlunu:
MMuuu1vlL
u Ritonavir luuttuWttn
tnMunW|ntluM|uunvDL
2-8 1W vnunLnvDL
(uun 25 1W ) Wltu
Dulu 30 u un:lLlvulMu
un1vuluLWLun1
Wtu:uulttt:uun
tu lMu:nuuMu 1 L 1
nLnuunn
419 Roxithromyci
n
7 ADR/side effect Wtultu Roxithromycin
Lun 2 u unLWuWu
un:|nM|nMM uwu
n1 off ultun 4 u uM
Wtuu1LnWuu
un:u1L|nM|nMM
uwun1nuWtuuwu
Roxithromycin un
t|WuLu1un
|nM ADR M1nnvlL
nnntWu lLwtu1un
|nM|nM|nMMluWtuuwuu
uMwtu1un|nMnlL
w1t:n1W W |nM
gastrointestinal reaction , nausea
, vomitting , abdominal pain ,
diarrhoea un: allergic skin
reaction
420 Roxithromyci
n
10 Therapeutic
use/
Efficacy/ndicati
on
unt
Roxithromycin Lltlu
nnWtuLMnuvlL
Roxithromycin nLnltlun
nLvu1lu|uL
(Nongonococcal urethritis) lMu
lvluuuM 150 mg un:W1v
uuM 300 mg un:W1 |tu
:u:|n 10 u t1Wvu1MM
|tvu1lu|uLnuLn:lLL
nuMnuuu:LnMn
ulM
421
Roxithromy
cin
04 Pregnancy/
Nursing
u roxithromycin
nLnlvluvu1
M1WDun:lvuL
tMlMvlL
nnntWulLwtuLn
WLtnMDuu1nltu
roxithromycin luvu1
M1WDun:lvuLtM
M1uuWvnn|nu1nltu
uvnLWL|tuM1ltu
M1nn W|W:1u1
lnntM
422 Roxithromyci
n
10 Therapeutic use uwun1u
Roxithromycin (150) 2x2
luWtu otitis media lL
tlMvlL
uuMulMultu1
Roxithromycin luWtuWlvuW
300 mg/day lMulvutt single
dose vut1lvun: 2 W1 L
nWnLutt multicenter,RCT
|tut|utu Roxithromycin
(Rx) un: 300 mg nt
amoxy/clavulanic (Amx) 875+125
mg un: 2 W1 luWtu
ear-nose-throat infection wt
WtuMtnu1MnnLM
(82% lunnL Rx un: 78% lunnL
Amx) M1uuuuMu
Roxithromycin luuuM 600
mg/day u1lLwtnltlu1
Wnunun:uuMuun: 300
mg/day nlvWnnnLM
423 Roxithromyci
n , Sypjilis
10 Therapeutic
Use/ Efficacy/
ndication
Wtu|tu Sypjilis un:L
t:Muw Penicillin :
nLMu Roxithromycin
lMvlL u1l
nLnlt Roxithomycin lun
nL syphilis lM lMultulu
uuM 150 mg bid uu 14 u
424 Salbutamol 9 p' dynamics /
efficacy
nwuu salbutamol
Lnt Beradual vwu
nntnu lvWnuMnM1nu
vlL u1l
nnntWuuLn wtnlt
uwu Beradual t1|tuuWnLu1
beta -2 agonist ( Fenoterol )
LntnnL anticholinergic
(pratropium) lLlMuMnM1n
nlt Salbutamol |wu1M|Mu
u1LuunWu
425 Salbutamol
Beradual
11 Compatibility/
Stability
Salbutamol solution un:
Beraduol solution
vn1n|tMlt|ntllM
uu|l
Salbutamol solution vn1n|tM
lt|ntllMuu 1 |Mu nvDL
<= 25 1W|tn|tun un:t1nu
un1 nuBeraduol solution
vn1n|tMlt|ntllMuu 6
|Mu un:|ntluM|uulMulLM1
t1nuun1
426 Sandostatin 11 compatibility/St
ability
Sandostatin nLnWnL
ntnn:nu dextrose
lMvlL
nLnWnL sandostatin nt
nn:nu dextrose lM lMuu:
LWLW1M 24 tlL1 u1ln
ML|u1n sandostatin LWn
Mn|nM glucose hemostasis
M1uu1WWnLntnn:nu
normal saline Lnnnn:nu
dextrose
427 Sandostatin ,
Pantoprazole
11 Compatibility/
Stability
unt
Sandostatin un:
Controloc (
Pantoprazole ) inj
nLnlvu1|nu
|MunulMvlL
nnntWuwt Sandostatin
lLnLnWnLlMntnn:nu
|tu Fat emulsion un:lLwtuLn
incompatibility u1 Pantoprazole
ntuMu M1uu1nLnlv
u1nu|MunulM
428 Sermion ,
Nicergoline
10 Therapeutic
Use/ Efficacy/
ndication
Sermion L side effect
Mu cardiovascular
vlL
Sermion (nicergoline) L side
effect W G disturbance ( nnlL
ntulut11 ) L
Hypotension |nnuu lMulLlM
nnn1 side effect 1
cardiovascular u1u
429
Sermion ,
Nicergoline
10 Therapeutic
Use/
Efficacy/
ndication
Sermion L side effect
Mu cardiovascular
vlL
Sermion (nicergoline) L side
effect W G disturbance (
nnlLntulut11 )
L Hypotension |nnuu
lMulLlMnnn1 side effect
1 cardiovascular u1u
430 Shohl's
solution
6,14 Formulation
,Contraindicatio
n/ Precaution
M1nuLn Shohl's
solution ltu1l
t:ntMu:lt1un:
lvunM1:1:l
Shohl's solution |tuM1ulu
tutttt:ultlunnL
D: metabolic acidosis utt
|1lLnLnunlun|vMlM
|tuM1lMM1tM|tu|wnL
:Mt pH lu|nMlvLWt:Ln
7.35 v:Mt HCO3 t:Ln 20
mmol/l 1u|wlv:Mtn
1uM1 u11nuuluMn
tnML1t1nun|nM
osreopenia u1n:Mnun:tulv
|MnLn|u|MtlMtnM
lMul1wutnn1un:L 2
nMlMun nM 1 Na
0.51 mEq/ml K 0.46 meq/ml
HCO3 0.94 mEq/ml
Citrate 0.93 mEq/ml nM 2 Na
1.02 mEq/ml HCO3 0.94
mEq/ml Citrate 0.93 mEq/ml

lMu Chronic acidosis :wn
lv alkali 2 mE/kg/day un:
|wLu:Mt HCO3 tnM (22-23
mEq/l) nlvuM1:1luWtu
431 Silver
Sulfadiazine
13 Storage Silver sulfadiazine
nLn|ntluM|uulM
vlL
silver sulfadiazine nLn|ntlM
1luM|uuun:nvDLv1 ( 25
1W ) t1:nLn|ntlMuu 3
t ML0nn:t uMlunn|nt
lnvDLv1Lnn 25
1W :|ntlMuun 3 t |tu
nvDL 40 W nLn|ntlM
uu 2 t
432
Silver
Sulfadiazin
e
13 Storage Silver sulfadiazine
nLn|ntluM|uu
lMvlL
silver sulfadiazine nLn
|ntlM1luM|uuun:
nvDLv1 ( 25 1W ) t1
:nLn|ntlMuu 3 t
ML0nn:t uMlunn
|ntlnvDLv1
Lnn 25 1W :|ntlM
uun 3 t |tu nvDL 40
W nLn|ntlMuu 2
t
433 Silver nitrate 2 Availability Silver nitrate v1u
WnM|1vut1t
u1|Mu
50%Silver nitrate cream 1u
WnMult nnL1u|DntnL
|tuWWnMun:ut1tltDulu
l1wutnn1un
434 Silver nitrate 10 Therapeutic
Use/ Efficacy/
ndication
50% Silver nitrate
solution nLnlt
u:|wWlMvlL
nnntnL|DntnuWun
WnMu wt 50% Silver nitrate
solution nLnuLltt|n
u:|wWlM uMt|n:|tu
uM un:lLnnuntnlLL
uWnt|nuu
435 Simvastatin 9 P'dynamics/effic
acy
M1ntlLM1
tt:uu simvastatin
luMu|uuvnuuu
|u1nu simvastatin :L peak
plasma level u 4 tlL1un:
:nMn1u1M|u|vn|wu1
10% u1tLnn1nM vn1n
tt:uultun 12 tlL1
M1uunlvulut1Mu|uuv
nuuu:lv peak level u1
uu|n|vL:nLlun
n1|W:v cholesterol n1nMW
t1|n |u1Wun1M 2
436
smecta 7
ADR/ Side
Effects
smecta Lu1ulv
|nMnuwuvlL
smecta (Dioctahedral smectiee)
ltnL acute& chronic diarrhoea
MulunnLu non-systemic
antidiarrhealagent nnu|tu
mucoprotective un: absorbs
enterotoxins , rotavirus ltlM1lu
|Mnun:Wlvu nnWnLu1
DWtnLWnM w.
vn1nn
437 Sodium
bicarb inj
20 Others Sodium bicarb inj M|tu
High alert druglu
l1wutnn1unvlL
Sodium bicarb inj lLM|tu High
alert druglul1wutnn1un
438
Sodium
citrate
11
Compatibility/
Stability
Sodium citrate M1|nt
luM|uuvlL un:
nvuMlvLuvn1WnM
uu|lM un:vn1|tM
ltW1unnLn|ntl
lMuu|l
Sodium citrate nLn|ntllM
nvDLv1lMulLM1ut|uu
lMunvuMlvLuvn1nu
WnM|tu:u:|n 6 |Mu uMlLL
uLnlu|1u1:u:|nu1u
uvn1n|tMltW1un1u
uuuntLMuunvuMu1
uMn:l1wutnMLWL
|vL:nL
439 Sodium
hypochlorite
11 Compatibility/
Stability
untSodium
hypochloriteLWLW1M
vn1n|tMltuu|lv
nnntWulLwtuLnWLW1
MuutM uMnnntnLlt
u11uWnMu|MuLun:u
tWn|tu1w.n1un
nvuMllvLWLW1M
vn1nnn|tMlt|tu|n 3
|Mu t1n|MuLlvnn:nu
|tuutt freshly prepare n:M
nM
440 Sodium
valproate
6 Formulation l1wutnn1unL
Sodium valproate lu
tutt form :lt1
Sodium valproate lul1wutn
n1un L 2 dosage form W 1.
Sodium valproate 500 mg
control release tablet 2. Sodium
valproate 200 mg/ml syrup
441
Sodium
valproate
6 Formulation l1wutnn1unL
Sodium valproate
lututt form
:lt1
Sodium valproate lu
l1wutnn1un L 2
dosage form W 1. Sodium
valproate 500 mg control
release tablet 2. Sodium
valproate 200 mg/ml syrup
442 spiramycin 4 pregnancy/nursi
ng
u spiramycin nLnlt
luvu1M1WDlMvlL
nnltulu French un:
Europe n 15 t lLwtu1u
Wnu1|Wu1nnltu
spiramycin MnluWD t1
LnltuulMlunn|tu
443 Spiramycin 4 Pregnancy/
Nursing
Rovamycin nLnltlM
luvu1M1WDvlL
Rovamycin v Spiramycin |tu
macrolide antibiotics Mulu
Pregnancy category C uMu1l
nMLLuLnn French
investigation in 1974 wtlLL
u1un|nM Adverse event lu
fetus un:LnMMMLnlt
Spiramycin luultLuun 15
t lLwtn|nMuMuuu1
(harm) lu fetus
444 streptokinase 9 Dosage/
Administration
unt
streptokinase Lun
WnLuun:ntvu
u1l
unWnLuun:ntvuu1
streptokinase LWLuMnM1nu
MLut1lt M1u 1. acute
myocardial infarction : V 1.5
million units over 60 minutes.
lMu dilute 2 X 750,000 unit vials
lMult 5% dextrose 5 ml un:|
1lvlMnn:nu 1.5 million
units to 150 ml D5W lt|nlv
uuu 60 u 2. acute
pulmonary embolism ( APE) : V
3 million units over 24 hrs. lMu
dilute 4 X 750,000 unit vials lMu
lt 5% dextrose 5 ml un:|1
lvlMnn:nu 3 million units to
250 ml D5W lMulvu 250,000
unit ( 23 ml) lt|nuu 30 u
MLMu 100,000 units/hour ( 9
ml/ hours) for 24 hrs
445 streptomycin 9 p' dynamics /
efficacy
u streptomycin nLn
lv1 iv lMvlL (
uwun1ltluWtu HV )
un:nlv1 iv. Lu
W:1:lt1 un:L
WnMnnMwLMMt
u1WtuvlL
tnM streptomycin :lv1 M
|u1nMMtLlMMun:nLn
nMwL|nMnu uMnLnlv
1 iv. lM lMult|n 30 - 60
ulunlvu |u1nulv
|nMwLMvlMnlMtulu
M|n1|nult un:uW
:1u1nlt streptomycin
:M1LnttuuMn1luWtu
lWlM uMlLM1ttuuMulu
WtulWMt M1uunlvuutt
iv. 1lLu:LWnMnnMwLM
Mtu1WtulW|Mn
446 streptomycin 9 p' dynamics /
efficacy
untuuMu
streptomycin ltlun
nL TB
uuMu streptomycin ltnL
TB W WtuuvunM > 50
kg uuMult W 1 g/day nu
WtuuvunM < 50 kg uuM
ult W 0.75 g/day
447 Sucralfate 2 Availability untl1wutn
n1un Lu sucralfate
vlL un:LuuMn mg
l1wutnn1unL sucralfate
uuM 1000 mg ( 1G)
448
Sulfamethoxa
zole
3
Pharmacokineti
cs
Sulfamethoxazole L
half-life |l
Sulfamethoxazole L elimination
half-life = 9 hrs
449 sulfonylurea 9 Dosage/
Administration
unnL sulfonylurea
:M1tt:unu
vnu
unnL sulfonylurea lu
l1wutnn1unL 4 M W
glipizide , glibenclamide ,
glimiperide , gliclazide t1u
glipizide un: glibenclamide |L
tt:uwLv:
delayed nMMtLu M1uu1W
tt:uunuv|tu|n
30 u nu glimiperide un:
gliclazide lLLWnlun delayed
nMMtLu M1uu1tt:u
uwLvlM
450 Sulperazone
inj
09 Dosage/
Administration
unt
Sulperazone inj nLn
WnLnt0.9%NSSv
5%D5W lMvlL un:
nLn push ulvnt
WtulMvlL
uSulperazone inj nLnWnL
nt0.9%NSSv 5%D5W lM
un:untvuuunLnlv
ulMlMuu im lMun:nuu 1vial
luunnulvLWL|uLuuu1
uu 250mg/ml vlvlMuun
drip lMun:nuuMu 0.9%NSS
v 5%D5W vSWF lvlM
tLM 4ml (125+125mg/ml)un
|1 MlvlMtLM 20
ml(25+25mg/ml) lt|nlunlv
u 15-60 u lLuu:ulv0Mu
lMuu direct iv (vLu|vM WL
u1u1u11W Sulbactam
500 mg+Cefoperazone 500 mg)
451 Swiff 3 Pharmacokineti
cs
Swiff L onset uu|l Swiff t:ntMu monobasic
sodium phosphate 2.4 g un:
Dibasic sodium phosphate 0.9 g
lMult|tuu:tuun:|MuL
nln|wnWMMvn1nn1
lMuu:nnuDulu 2 -5 u
un::u:|nlunnnu 1 -
3 tlL1 lMu:u:|nlunlv
u:uuntuuMulv t1ulu
Mnuwuu1uwu
452 Syphilis ,
Guildline
10 Therapeutic
Use/ Efficacy/
ndication
Syphilis ltu:lnL
lMnunn Benzathine
Penicillin G
u|tu 1st choice lun Tx
Syphilis W parenteral penicillin G
vnWtuLt:MuwunnL
Penicillin uultlM lMun oral
tetracyclin 500 mg x 4 pc (14 day)
v doxycycline 100 mg x 2 pc
( 14 day)
453 Tamiflu 09 Dosage/
Administration
M1ntuuMu
Tamiflultlu|Mn
nltulu|Mnu1lLLuLn1
Wnun|wu1w lMuLnWnL
|DntnuWnMu1u wt |Mn
uuu:utuun:n
metabolite nnu:nMn1
M1uu|MnLu Lnn 12 t :
ltuluuuM|Mununtlv
Wlvult (uuMultluWlvu
W 75mg un:2W1 |tu|n 5
u)
454
Tamsulosin 10
Therapeutic
Use/ Efficacy/
ndication
untLu Harnal
lututunuu1
l1wutnn1unvlL
un:nlLLnLnltu
MlMMuulMt1
u Harnal vLtnLu1u
Tamsulosin Lut1ltlun
nL Bladder outlet disturbance
of lower Urinary tract symptoms
(LUTS) associated w/benigy
prostatic hyperplasia t1|WuLuu
ulututunuu1M1
wutnn1un MttulMMM
nltun l
455 TAT 20 Others TAT Lu skin test
u1l
n TAT skin test lvlt
tetanus antitoxi |1 1:10 0M
|ulMWvu1 0.2 ml vnlL|nM
WLWMtnMDulu 30 u
unM1WtunLnltulM
456 TAT 9 Dosage/
Administration
untuuMu TAT
ltlu|Mn
uuMu1u TAT lu|Mnun:
Wlvu:lvMLuvun W |Mn
LuvunMuun 30 kg :lv
uuMu 1500 unit nuWtuL
uvunMLnn 30 kg :lt
uuMu 3000-500 unit
457 TAT vaccine 9 p' dynamics /
efficacy
untuuMu1 TAT
lu|Mnuuun 2 t
nn Tetanus prophylaxis : lv
MLuvunM|Mn W < 30 kg.
lvuuM 1500 unit , |Mnun:
WlvuuvunM > 30 kg. lv
uuM 3000 - 5000 unit lMulv
lM1utt iv. un: sc. nunn
treatment 1|Mnun:Wlvulv
uuM 50,000 - 100,000 unit
lMuut1nuvu1lvutt iv.
|vnlvutt im nunnL
nun|nMMM|ttM:un
uu:ulv0M TAT 10,000 -
20,000 unit 1 iv.
458
Tatenus
toxoid
09 Dosage/
Administratio
n
WtulMttatenus
toxoid lMulMt
dose unluu 31
L W 52 un: dose 2
u 2 nw 52 un
t:Luunlu
u1l
u tatenus toxoid Lun
tvutt im lMulvu
uuM 0.5 ml lu dose un
un:lv dose 2 tlu
ntMv 4-8 vn1n0Mu
dose un un:lv dose 3
lu|Mu 6-12 vn1n dose
2 M1uuluWtuuu
wnlv0Mu dose
2 lvLluntMv 4-8 ut
nu 2 nw 52 un:uM0M
dose 3 MLlu|Mu
6-12 vn1nuu 1u
l1wutnn1unnvuMlv
0Mulu|Mu 0, 1, 7 M1uu
uuWtuuW0MuW1
Mltluu 2 LW 52 un: 2
nu 52 MLnMt
459 TB drug 10 Therapeutic use untun
desensitization u TB
luWtu TB/HV
|u1nWtuuwu NH,
Rifampicin ,
Streptomycin
luWtu TB/HV n
desensitization M1u1
:LM:1luWtunnLu|u1n
LWL|nu1n1:|nMtnu
uu1 nvt|WuWlun
desensitization W |LMuuuM
uuut:Ln 1/10 u1uuM
utnMun:1Wt 10 u
460 Terbutaline 9 P'dynamics/effic
acy
untuuMu
Terbutaline lu|Mnu 1
|Mu
uuMu Terbutaline lu|Mnu <
12 t lvutt SC W 0.005-0.01
mg/kg/dose ,maximum 0.3
mg/dose n 15-20 u (3 dose)
461 Tetanus
toxoid
4 pregnancy/nursi
ng
WtuM1WD nLn0M
Tetanus-Diptheria toxoid
lMtnMDuvlL
WtuM1WDnLn0M
Tetanus-Diptheria toxoid lMu1
tnMDu
462 Tetanus
toxoid
11 compatibility/sta
bility
Tetanus toxoid tuM
multiple dose vn1n
|tMltW1un:|ntllM
uu|l
lMultuu:ulv|ntllMuu
24 tlL1 lMu|nt 2-8
o
C
463 Tetanus
antitoxin
10 Therapeutic use untuuMu TAT
lu|Mnu 10 t u.u 26
kg nnlt|tu
Prophylaxis tetanus
|u1nuwulv 1500
U M
uuMuu1 tetanus antitoxin lu
|Mnun:Wlvu:lvMLuvunW
children < 30 kg lv 1500 unit
children and adults 30 kg :
3000-5000 units
464 Tetanus
antitoxin
(TAT)
10 Therapeutic
use/
Efficacy/ndicati
on
Wtut:nttM|vML
tMuWnu lMtn
0M Tetanus toxiod
(TT)luuun admit
uwun1 TAT LMu
uMwutnnL0Mlvnt
WtulMuWuL|tu
:u:|n 2 u un
t:LWn|nuM
WtuvlL un:
:u:|nlunlv TAT
lLW|nu:u:|n|l
nnntWulLwt:u:|n
:tltM|ulunlv TAT uM
nlv TAT :LWnlvLnlt
nu TT u1lLt:tt
t:n lMun:lv TAT
vlLuunttMuWnu1Wtu
lMu:lvluuuWnlvunntn
LnvlMWtuLuu|nu 10 t
un:LtMuWnLuu|nu 24
tlL1 M1uuWtuuu1Wlv
uunWtuu|L|vuWn1
uwu lMu:u:|nWuL 2
u:u1lLLWnn:tuu1
MWtuun:nlv TAT W
|MuL adrenalin 0.1 ml lMu
|wt1nunuwutt
anaphylaxis
465 Tetanus
toxiod
11 Compatibility/
Stability
Tetanus toxiod tuM
Multiple dose vn1|tMlt
unnLn|ntlltM
lMuu|l
tetanvs toxiod tuM muitiple dose
vn1|tMltunnLn|ntl
ltlMuu 24 tL. ( nvDL 2-4
1W)
466 Tetanus
toxoid
9 P'dynamics/effic
acy
Wtu|Wu0M vaccine
Tetanus toxoid Wt 1
course ( |uLnMu|Mu
L .u.2544 ) MLL
tMuWnMM|t
tM:unlM unt
WtuM1lMt vaccine
tvlL u1l
nnuWtu|WulMt vaccine L
Wt course un t1 vaccine |uL
nMuWtulMtWuLun
t:Ln 5 t uMMuuWtuL
tMuWn|nMnMM|t
tM:un M1uuWtuWlMt
vaccine utt booster tnW1 (
lMult vaccine t1nu
tM:un:M10Mtn 10 t )
467
tetanus
toxoid
9
Dosage/
Administration
Wtu0M tetanus toxoid
|uLun|Lu 6 n.w. 52
:nLn0M|uL 2
v1n|uLunlMuu
|l
Tetanus toxoid 0M|unnL|u
tLn 0.5 ml uu1vLM 3
|uL lMu0M|uL 2 v1n|uLun
4-8 ntMv un:|uL 3 v1n
|uL 2 6-12 |Mu Wtu0M|uL
un|L|MunLDwuu M1uuW
0M|LMu|uL 1 lvL
468 tetanus,
luvMlvu ,
vaccine
9 Dosage/
Administration
WtuWlvu 0M Tetanus
toxiod u 28/8/50 uu
Wu 20/8/50 un
t:nLn0M
vaccine luvMlvulM
vlL
vaccine Tetanus |tu vaccine
tuM toxoid t1|tunnnM|wL
u1 bac|teria LlvwLvLMlt
uMnLnn:Mu1nulvn1
antitoxin lM nu vaccine luvM
lvu|tuWtutuMMMut1nnM
||0w:nu|nuu1ntn
n1DLWLnuLlt|uu 1LWn
u1Wu1uu M1uuWtuuu1
nLn0M vaccin luvMlvulu
u 30/8/50 lM
469 Tetralogy of
Fallot
9 Dosage/
Administration
Wtu new born u
t:Ln 1 |Mu uwu
u0u|tu TOF n1M
ltw.L uwulvu
ASA 15 mg OD un
t maximum dose
|tu|l
TOF uLn Tetralogy of Fallot
|tu congenital heart defect lMu
LWLWMtnMlu 4 Muvu1
lMun ventricular septal defect
(VSD) , pulmonic stenosis,
overriding aorta and right
venticular hypertrophy WtuLnL
D: cyanosis nnuMoxygen
nLnnLMuuWMMun:
nltu nvtWtuuu
uwun1ltu ASA 15 mg OD
(uuMu ASA MuW 2-5
mg/kg) WtuuuLuvun
2.915 kg M1uu uuMu 15 mg
WtulMt|tuuuMun1nMlL
Lntt|wLlMn
470 Theophylline 10 Therapeutic use unt:lt
Theophylline (200) uuM
2*2 pc luWtu|tu
asthma un:LuvunM
65 kg lMvlL
uuMu Theophylline steady
state maintainance dose W 900
mg/24 hr u1lnMLuuMu
|wLuulvWtu|nMwLn
ulM 1M1uu:ulvWtut
n|tuwL|nMnu W
LnWnuln |uu tM1
uulLvnt un:lnu t1nL
nM1nnuu:ulvWtu
nntltwtuwu
471
thophylline 3
Pharmacokineti
cs
half - life , thophylline
|tu|l
half - life u1u theophylline L
WLvnuvnn MLt1u
lW|tuun:t:Mnnttv
|tu - lu
|Mnu 1-4 t :LW t1/2 |0nu
u 3.4 hr (1.2 -26.5 hr) - lu
|Mnu 6-17 t :LW t1/2 |0nu
u 3.7 h
472
ticlopidine 7
ADR/ Side
Effects
nuwuWvuM
tt:uu Ticlid nu
WvuMtt:uu Ticlopidine
nultnuwu 7 u
473 Tienam inj 11 Compatibility/
Stability
untnLnlv
Tienam inj nu|Munt
TPN lMvlL
Tienam inj WMu mipenem
500v mg +Cilastatin sodium 500
mg inj lLnLnlvLnt
Acyclovir, Amphotericin B,
Metronidazole,LRS.SW, Sodium
bicarbonate,un:TPN
M1uulLnLnlv Tienam inj
nu|Munt TPN lM
474 Tienem 11 Compatibility/
Stability
mipenem nLnWnL
nt Lactate Ringer 's
Solution lMvlL
n|nnnntu:t Tienem
|unulLlMnt lactate 1lLW
WnLuntuuL lactate |tu
nut:nt u1lnML
nLntvu Tienem lMu
Wu V system t1nn1vuMuu
lactate uuulM
475
Tolterodine 07 ADR/ Side
Effects
u tolterodine
nLnlv|nM
nu1|Wu1 v
l|MuWM1v: utt
fibrillation lMvlL
u tolterodine luuuMn1
nLnlv|nMn
u1|Wu1 lMunLnlv
|nMD:vl|MuWM1v:
LnnLn: QT prolong v
tachycardia lM (< 1%)
uu:ulv:1nltu
tolterodine luWtuLD:
congenital prolong QT v
WtulMtQT prolonging
drug (class a v
antiarrhythmics drugs) 1u
Wtu|nMnu1|Wu1
M1nnuu:ulv|tnuult
ltuMuuu
476 Tramadol 4 pregnancy/nursi
ng
uwun1ltu Tramadol
1 cap prn v n 8
tlL1 |wnLn
tMWL:lL|nulu
WtuM1WD 7 ntMv
untLWL
|vL:nLvlL
u Tramadol Mulu pregnancy
category C t1unLnWunlM
lLuu:ulvlt:v1nWnM
vlt|tut:lu:v1
M1WD |u1nlv|nM
physical dependence un:n
uLn post marketing survillance
wtlv|nM neonal
seizure , fatal death un: stillbirth
vnltu|tut: un:vn
|tuM1ltuu uu:ulvltlu
:u:nu |LLn|uu
477 Tramol 9 p' dynamics /
efficacy
Tramol inj. nLnlv
utt V lMvlL
nLnlvlM1utt M,V,SC
un: V infusion
478 Transamine
inj.
11 compatibility/St
ability
unt
Transamine inj. nLn
lvlMuu V push lM
vlLun:nLnWnL
ntnn:nuMlMlMt1
5%Transamine inj. L transamine
acid 250 mg/5 ml nLnlvlM
1 V v M ratelL|nu 1
ml/min un:nLnWnLnt
nn:nu D5W, NSS, D10W
un: RLS
479
Triflusal 10
Therapeutic
Use/ Efficacy/
ndication
Grendis Wu:l
Grendis LtnLu1u
Triflusal MulunnL Antipletelet
aggregation nnuutu1n
1uu1|ultL (do-oxygenase
(COX) |tnn|nM|nMLnn
vascular endolhellal all (1nM
cerebral henaorrhagie) Lut1lt
luWtuLWL|nu1Mn|nM
recurrent myocardial infarction
v stable or unstable angina
v stroke uuMtt:u 1x2
v 2x1 vn1vu
efficacy lLuMnM1u1L
uunWunt ASA uMLuMnW
|nM haemorrhagic risk Mn
480 Triple dye 10 Therapeutic
Use/ Efficacy/
ndication
untnlt triple
dye nt 70% alcohol
|tMn:M|Mnun|nM L
t:nuDwM1nuvlL
Alcohol Lt:nuDwlun
control umbilical colonization
un:nMM|tWvu1lMMn
nlt antimicrobial u |tu
triple dye v chlorhexidine un:
triple dye Lt:nuDwlunnM
umbilical colonization n|t
staphylococcal un: streptococcal
organisms lul1wutnlM
Mn alchohol , hexachlorphene
, bacitracin ointment un:
povidone iodine
481
Uralyte-U 2 Availability
lututuw.Lu
Uralyte-U vlL nlLL
ltMlM|tuunnuu
u Uralyte-U lMMMnntut
u w.n1un lLLMu|uLuu
Uralyte-U t:ntMu K Na
hydrogen Citrate ltnLu|nM
n uric acid , cystine stone , Ca
Oxalate, wnlvuMu
Llutt.w. uu |tu ult
nLu|nMn|nnuWn|tuL
|tu diuretic ,ultnLu|nM
n oxalate |tu B6,
cholestyramine, ultnLu
|nMn|nn uric acid |tu
allopurinol, sodium bicarbonate,
ultnLu|nMn cystine
stone |tu sodium bicarbonate
482 Vaccine 9 P'dynamics/effic
acy
Vaccine t1nulW
lwuMutt0MLu
tvuu1l
Vaccine utt0M 1 dose L 0.5 ml
lvlu|MnuLnn 2 t uult
lt0M|unnL|u nLnn:Mu
lMn 2 t nu1Llnn|nu1M
nnLWn|tlMuWtuL
t:nuDwun: 64-72
483 Valproic acid 11 Compatibility/
Stability
Valproic acid vn1WnL:
|ntllMuu|l
u Valproic acid lututtu0M
lLlM|ML preservative 1nLn
|ntnvDLv1lM|wu1 24
tlL1
484
Valproic
acid
11 Compatibility/
Stability
Valproic acid vn1
WnL:|ntllMuu
|l
u Valproic acid lututt
u0MlLlM|ML preservative
1nLn|ntnvDLv1
lM|wu1 24 tlL1
485 Vancomicin 11 compatibility/St
ability
Vancomicin |L|MuL
|tuuvuMM:LWL
Mu1l
|L|ntluM|uu:LWLW1M 14
u uMn|ntunM|uu:LWL
W1M 24 tlL1
486 Vancomycin 9 p' dynamics /
efficacy
M1lvu Vancomycin
luM||l|wnM
n|nM Red man
syndrome
nlv Vancomycin lMuu
infusion M1lt|nu1uu 60
u WL|uLuu 5 mg/ml vn
|nM red man syndrome tt
rate lunlvu|tu 1 1/2 - 2
tlL1un:|wL dilution volume
487 Vancomycin 9 Dosage/
Administration
uwun1u Vancomycin
lvWtuMM|t MRSA
un: Acetinobacter uuM
u 500 mg n 6 tlL1
untLWL
|vL:nLvlL un:n:
|tnuuu|tuutt switch
therapy :|tnuultltu
MlM1:|vL:nL
uuMu Vancomycin lun
nLWtuMM|t MRSA ,
MRSE , PRSP. uuMu
|vL:nL W 1G n 12 tlL1
lMult:u:|nlunnL 7-14
u un:nlvu:M1MW CrCl
u1Wtu|wttuuMulvL
WL|vL:nL lMunLW CrCl >
50-90 ml/min uuMu|vL:nL
W 1 G n 12 tlL1 , nLW
CrCl =10 - 50 ml/min uuMu
|vL:nL W 1 G n 24-96
tlL1 un:nLW CrCl < 10
ml/min uuMu|vL:nL W 1
G n 4 -7 u nun|tnuuu
switch therapy lvltu Sodium
fusidate uuM 250- 1,000 mg
un: 3 W1 |tu|n 7-14 u
488 Vancomycin 11 Compatibility/
Stability
uwun1ltu
Vancomycin lMuWu
heparin lock uMwtu
MnM:nu|LWnLnu:
nLnunlulMu1l
ulv|nMincompatibility nt
VancomycinlMun
Ampicilline,Cefazolin,Cefepime,C
efotaxime,Ceftazidime,Ceftriaxon
e,Cefuroxime,Chloramphenico,Co
-
trimoxazole,Dexamethazole,Hepa
rin,Hydrocortizone,PGs,Phenobar
bital,Phenytoin,Piperacillin,Sodiu
m bicarbonate un:nguideline
u1 The American Society of
Health System:tnlt
Heparin un:saline lock lLL
WLuMnM1nulunnMn|nM
phlebitis1uu:ulvlt 0.9%
sodium chloride injection uu
nlt heparin un:nlt saline
flush solution nLnnMWL
|nu1lun|nMnu1|Wu1n
heparin lM |tu n|nM induced
thrombocytopenia. Thrombosis,
hemorrhage. ncompatilbility
489 Ventolin 11 Compatibility/
Stability
Ventolin solution un:
Beradual solution
vn1n|tMltun|ntlM
uu|l
Salbutamol solution ( Ventolin )
vn1n|tMlt|ntlMuu 1 |Mu
nvDL <= 25 1W un:M1
|ntlvwuun1 nuBeradual
solution vn1n|tMlt|ntlMuu
6 |Mu un:uu:ulv|ntlu
M|uulMulL|tuM1t1nuun1
490
Ventolin 11 Compatibility/
Stability
Ventolin solution un:
Beradual solution
vn1n|tMltun
|ntlMuu|l
Salbutamol solution (
Ventolin ) vn1n|tMlt|nt
lMuu 1 |Mu nvDL <=
25 1W un:M1|ntlvwu
un1 nuBeradual solution
vn1n|tMlt|ntlMuu 6
|Mu un:uu:ulv|ntlu
M|uulMulL|tuM1
t1nuun1
491 Veraapmil 4 Pregnancy/
Nursing
Verapamil tuM
tt:unLnltlu
vu1M1WDlMvlL
Verapamil Mulu Pregnancy
category C W wt teratogenicity
lunMMn1uMlLwtvu1lLL
uLnnWnLuttWtWLlu
nMLWDun:nMMn1
u1lnML verapamil nLn
WunlM t1nnWnLutt
Retrospective lunMMn1 (vu
,n:Mu) lLwtn|nM
teratoginicity uMt1nWnL
wt|nM teratogenicity un:|nM
nMuluvuMn1 lMu|tu
WnLnwLnu |u1nlv
uuuMn1nltluLuLun1 6
| unnuLnWnLlunML
WDlut1 1 st trimester wt
|nM cardivascular defict 1.3%
uMuLnulLwtWLnLwuu
:v1untn|nM
cardiovascular defect M1uu
WWnMu1unLnltlunM
LWDt1 1 st trimester lMlMu
tWn fetal problem
492 Verapamil 10 Therapeutic use uwun1ltu Verapamil
inj lunnL SVT uM
uM1nnlLLlu
l1wutnnLnltu
lMuulM
ultlunlv SVT nnt|tu
sinus rhythm unn verapamil
W
1. Adenosine 6-12 mg 0M
|uvnM|nMM| un:M1t
lv intravenous fluid MLvn1
u1uu 20 ml
2.
Diltiazem 15-30 mg 0M V t
(lLLlu.w) 3. Digoxin
0.25-0.5 mg 0M|uvnM|nMM
uMlLWlt|tu first line of
treatment |w::nnuvn1
lvu 2 tlL1
493 Verorab 9 p' dynamics /
efficacy
Wtu|WulMt verorab
dose 1 - 3 luu 21
,24,28 n.W.2548 un:
lLlM0MuMlu dose
4 - 5 MLu 1 u.W. 48
WtulMuuLuu
uwun10M verorab |wL
n 2 dose W1n: 1 M
luu 1 u.W.48 un: 30
L.W. 49 lLt
nnM1vlL
n0M vaccine vn1nLWnnM n
W|WulMt vaccine Lnn 3
dose vMLDLWLnu > 0.5
U/ml |tuW|WulMt vaccine
Lnu nnnLWnnMn uu:u
lv0M vaccine 1 - 2 W1 lMun
lMt vaccine W1nMuuun
6 |Mu :0M|wu1W1|Mu un:
nLnn 6 |Mu :0M 2 W1
luu 0 , 3 lMu0M|unnL|u
MuuuMLMu v0M 0.1 -
0.2 ml |uluWvu1 unuMtuM
u1 vaccine lMulLM10M RG
M1uunuwun10M vaccine
n 2 W1uu 1W|tnuulv
WtuLt vaccine luu 0 , 3
|u1nnnuWtulMt
vaccine W1nMuLnn 6
|Mu un:uwulLlM:tu0M
1uu:ulvltu0Mutt id
494 verorab 9 p' dynamics /
efficacy
vaccine verorab lu dose
1 - 3 nLn delayed
n0MnltlMnu
nLntnntWLWnM|Wnu
lM 1 - 2 u
495 verorab 9 p' dynamics /
efficacy
Wtu|WulMt vaccine
Wt course Lun|L 5
tnu un:lMunuunM
uu untM1
|L0M vaccine lvL
1vLMvlL
vn|WulMt vaccine |uLnMu
uun 6 |Mu uu:ulv0M
|wu1 1 M uMnlMtn0M
vaccine W1nMuLLnn 6
|Mu :M10M vaccine luu 0
, 3 nulunnu|WulMt vaccine
W1nMuLuuun 1uu:u
lvnnLlvL1vLM
496 Verorab 9 p' dynamics /
efficacy
Wtu|WulMtu verorab
Lun 3 dose utt id
M1n|tnuuLltulv
uutt im :Lutt
nlvuu1l
WtulMtuLun 3 dose lMu
u id luu 0 ,3,7 nLn
|tnuuLlvulMuu im lu dose
4 un: 5 luu 14 un: 30
uunlvuutt id luu 14
un: 90 lMuuuMulvW 0.5 ml
497 Virkon 11 compatibility/St
ability
uuL|t Virkon
vn1nWnLun|ntllM
uu|l un:u1lL
WnLnLn|ntlMuu
|l un:nLnult
utlu|W1L tnn
tuMlMlMt1 lt|nlu
nutuu|l
uuL|t Virkon v Sodium
hypochlorite nWnLun|ntllM
uu 7 u vnnnn:nu
|tnuunnuLw|tunn:nuln
W|tnuuuu|u1n
t:nuDwu1uun1|nMlM
nnu1nn:nu un:u1lL
WnLulutW1uv1nLn|ntlM
uu 3 t nLnultltnt|W
L|nu1MnMM|t:Mtnn1
|tu tMlu lLnMnu |W1
n1nn1 nuu1nvtlvv
|vn :u:|nltutuu 10-30
u uMLu|nuW LnunM
nu nutnn|tunnu1
wnnMnlLuWLulv
nL|tlMultuu 1%virkon
uu 10 u
498 Vitamin B 12 3 Pharmacokineti
cs
Vitamin B12 inj utWu
1lM M1ttuuMu
luWtu dialysis
vlL
Vitamin B12 inj v|unnt
Mecobalamin v
Cyanocobalamin nnutn1
uMun:nn Convert |tuactive
enzyme lu|u|u Wu:tt
lvn|uu|nMMt (extemsive
enterohepatic recycling) L
t1nunnutn1lM 1lLL
uLnnttuuMuluWtu
lWlM
499 Vitamin B
complex
11 compatibility/St
ability
Potassium chloride inj.
nLnlvLnt Vitamin
B complex inj. un: 5%
D/N/2 lMvlL
nLnlvLnulM
500
Vitamin B1 9 Dosage/
Administratio
n
VitaminB1 v
Thiamine nLn
tvuutt iv push
v iv drip lMvlL
vn drip Wlt
|nuu|lv un:
nLnWnLlunu
lM
VitaminB1 v Thiamine
nLntvuutt im
v slow iv uut:Ln 30
min lMunultlMun
D5W v 0.9% NSS
501
Vitamin C 09 Dosage/
Administratio
n
uuMu1 Vitamin C
ltnvtt1nu
vM |nt|lv
uuMu1 Vitamin C ltn
|wvtt1nuvM |nt
1-3 g Mu uM|LMuLn
1|DntnuWnMu1u
wt nMMtLu1u:
|nMuuu1nMvn1lvlu
uuMn1 (|nu 1 g /u) t1
uuM 1.5 g /u wtn
MMtLu1MLut :nMn1
|vn 50% M1uuvnltn
|wvtt1nuvM uu:u
lvtt:uuuM 1g Mu
t1wtlvWnlunnM
WLuu1un::u:|n
|tuvM uMlLlMtunM
tMnnlun|nMvM
502
Vitamin E 20 Others Vitamin E 1 mg LnuuM
Vitamin E 1 mg |nt 1.5 U
(international unit)
503 Vitamin K 3 Pharmacokineti
cs
Vitamin K 10 mg V L
duration of action uu
|l (WtulMt vit K
u 30/5/51 un:lMt
u warfarin utt low
dose MLluu 3/6/51
uwuttuuMu
warfarin uu|tu high
dose |u1n NR u1M
u )
nlMt Vitamin K V :lv
prothombin time tnMlu:u:|n
12-14 hr. vn1lMtu un:L
duration lunnnut:Ln
24 tlL1 ( nn low dose vit. K 5
mg ) nunnlt high dose
wt duration of action u1 Vit
.K :uuuuu|tuntMvlM
M1uu1Wltu warfarin lu
uuM|MLltnu unuMWtuL
MMML NR u1lnntM
504
Vitamin K 3 Pharmacokin
etics
Vitamin K 10 mg V L
duration of action
uu|l (Wtu
lMt vit K u
30/5/51 un:lMtu
warfarin utt low
dose MLluu
3/6/51 uwutt
uuMu warfarin uu
|tu high dose
|u1n NR u1Mu
)
nlMt Vitamin K V :
lv prothombin time tnM
lu:u:|n 12-14 hr. vn1
lMtu un:L duration lu
nnnut:Ln 24
tlL1 ( nn low dose vit. K
5 mg ) nunnlt high
dose wt duration of
action u1 Vit .K :uuuu
u|tuntMvlM M1uu
1Wltu warfarin luuuM
|MLltnu unuMWtuL
MMML NR u1lnntM
505 Vitamin K inj. 9 Dosage/
Administration
Vitamin K inj. uuM 10
mg V OD lvuttlvu
Mn:v1 V push nt
drip un: rate |l (
l1wutn:u:LuuM
1 mg/0.5 ml M1lt 10
amp(5ml)
lv slow V infusion rate not
exceed 1 mg/min dilute D5W or
NSS or D5S
506 Vitrimix 11 Compatibility/
Stability
unt vitrimix
nLnlv1 cut down
lMvlLun:nLnlv
Lntu Meropenem
un: Omeprazole inj lM
vlL
Vitrimix nLnlvlM11
Central line un: Peripheral line
un:uu:ulvuunlvLntuM
u |u1n Vitrimix |tu
nvlv1vnM|nMM
un:Lnut:ntu1nv
vnutuM t1|nMtuvWL
lL|unuu1ulM
507
warfarin 9
Dosage/
Administration
untuuMu
warfarin un:u
tt:uu
uuMu|LMu W 5 mg/day |tu
|n 2-5 u vn1nuutt
uuMuML Prothrombin time
maintainance dose W 2-10 mg /
day utt:uu : lLW
tt:uuwLv un:
Wtt:uun:W1|n
|Munuu1nu
508 yasamin 7 ADR/ Side
Effects
Wtunuu yasmin un
LntMWL:Ln
unt:nLn
|tnuultltuMlMlMt1
Wtunuu yasmin t1|tuu
WLn|uM t:ntMu
Drospirenone 3 mg + Ethinyl
estradiol 30 mcg utt 21 |LM
t1ntMWL:|tun
u1|Wu1nulLu|nlM|u
t1nu|nMnnltuL
estrogen n1 nuLn:|nMlut1
2-3 |MuununWuvult
uMnlLnLnuMn
M1nnlM lv|tnuutuMu1u
|LMWLn|uM|tutuML|nlM
|utLnMn|ML |tu n 30
mcg |tu 20 mcg |tu Mercilon
|tuMu
509 tL|vM|W 07 ADR/ Side
Effects
unttL|vM|WL
nu1|Wu1:lt1 L
uunluu1lt1
tL|vM|WLn:nWuW
anthraquinone glycosides lMu
nnun:Mulvnln|nnttM
1uLltlunnLn
1Wn uuMuu:u-tt1
tL|vM|W t 3 nL/t1
(t:Ln12lt) W1n:1-2t1 t1
luu 120ml/t1 uu10u
tt:uun:1W1nuuu
nu1|Wu1 -Wnuln tMLu
1 LMnnttM 1|nu WnM
uuMn1vtt:uwLu
utnL |tu u1 nuwn n:u
|tuMu
uvLlt 1.lu|MnuMn
12t 2.vu1M1WD 3.WL
tuv|nunt:tt1|Muv
|tu nlnMMu
510 wuu Ascaris 10 Therapeutic
use/
Efficacy/ndicati
on
wtwuu Ascaris lu
:WtulLt
lvnLMuu:l
nMM|twuu Ascaris v
wuuln|Mu (Ascaris
lumbricoides) lMultLnu0u
lMunMwtluwuulu:
|tunWu uMutnML
t:nuDwun:uuLltlun
nLlMun 1) Parental Pamoate
dose 10 mg/kg uMlL|nu 1 gm
single dose uulLLltlu
l1wutnn1un
2)Mebendazole dose 100 mg bid
|tu|n 3 u 3)Albendazole
dose 400 mg single dose |Mn
uLnn 2 tun:Wlvultu
luuuM|Munu
511 u TB 9 P'dynamics/effic
acy
uwun1u TB nM A3
(H:300,
R:600,Z:2000,E:1200)
lMu HRE tlvnuL
|Munuuunu PZA
uunlvnu 1x4 pc lL
t|tu|w:|vMlM
unlWnM:uu:ulvnuW1
|Munuuu |wlvWtulLnL
nuuun:nMWnu1|Wu1u1u
|wWtuuuvntlunn
WtuLWnu1|Wu1nu |tu
Wnuln Lu1 :uu:ulvuun
nuu lMuuuMn:tuMlvnuW1
|Mu |tuu isoniazid un:
rifampicin nuW1|MuMu|t
nuu PZA un: ethambutol nu
nuuu t1nnuuW1|Mu:
lv:Mtulu|nMn1nn
uunnulvLt:nuDwlun
nLn1n uMlunnWtuu
uuwulvuunnuu|0w: PZA
|u1nM1nnMD:
Wnuln |uu u1Wtu
512
WtulW
luvMlvu
4
Pregnancy/
Nursing
WtulWluvMlvu
nLnltntvu1lvuL
tMlMvlL nlLlM
M1nlvuLtMnu
uvLnvtnltWulW
luvMlvu W -
WLt:Mnuwlulnwn
- Wu
nn1Llun1
|u1n
Wvu1lvuLtWlLlMuluuvL
lt1nLnlvlMlMulLM1vuM
lvuLtM
513 vMv1uln 10 Therapeutic
Use/ Efficacy/
ndication
vMv1ulnltuMlM
nL :u:|nuu
|lv
vMv1uln|nMn|t Human
papilloma virus(HPV) t1Lvnu type
un:nlv|nMvMu:u11nu
WuuMnM1nu vMu:|wW lMun
HPV-11,HPV-16,HPV18 |tuMu un:
|tu risk lv|nM cancer lu|n
ML ttuu1lLLnnL
tnMDuun:Lt:nuDw LultW
nMMvMnW cryotherapy ,
electrocautery, laser therapy or
surgical removal uMn:un
t:nuDwlLuMnM1nu uMM1nu
cost and side effect un:nWuWLn
nntL|tut nvtuuLlt:
|tu tropical agent |tu n|tuuL
u| :|tu topical salicylate n
u, flat warts lt topical tretinoin or
5-fluorouracil |tuMu un:M1ltLnt
|WunnWMMu1Mu **nvtWtu
nn|tu genital warts uMtnu1
W imiquimod 3 times/week nu
uu uu 16 wks nltLnt
interferon alfa : most effective un:
lowest recurrence rate unnuu1L
uuML 50-80% trichloroacetic acid
vun electrosurgery, excision,
laser ablation, vLlt Podophyllin
|u1nLn|tu t|tu 514
9,7
Dosage/
Administration,
ADR
WtuuMu1uLlvM
|wutuLnu
MlMuMu WnMWn|nu
u1u|wWLtnMDu
1MunuDw
ML|nnuutu
515
Acyclovir
tablet
4
Pregnancy/
Nursing
Acyclovir tab nLnlv
luvu1lvuLtMlM
vlL
Acyclovir nLnlvluvu1lv
uLtMlMtnMDuuWunuuL
uu
516
Antivenin
malayan pit
viper
7
ADR/ Side
Effects
Wtu skin test wt
uw Antivenin malayan pit
viper (|tL1n:t:) vn
uL|1lu D5W 100
v 200 ml :LWnM
nuw|tLvlL
tLnnult|1lLL
WnMtnuDLl|nu nlv
|tL1vnM|nMMt :
tunMtnunuwlM lMu
tnM:lvuu 30 un1 1 tlL1
517
Aspro 1 dentification Aspro Wu:l
Aspro W Aspirin Ltutt tablet
320 mg ,500 mg un:
effervescent tab 500 mg tL
Bayer Schering Pharma
518
BCG vaccine 9
Dosage/
Administration
Wtu0MWtu BCG vn1
0MlLLMLuu|nMuu:0M
tnM1v1n|uLun
uu|l
|L0MWtu BCG 1nu:
tnu|0w:|tu vn10M:
|nMMLvu1MLnnu|tuvu1
t1LnuMnnun:uv1lM|1
t1W1:nnu|tuvu1un:
uMntlMvnuW1nu:
nnu|tuuWnlunM t1tnu
|0w::|nMvn1n0M 2-3
ntMv Wtuuu0M|L 27
MnWL 52 0MLt:Ln 16 u
t1nn1ulut1|nMtnu
|0w:un:n0MWtunn|nult
lvlLtnDuuWn|tu
lM uM1nunLnn1
DLWLnulM 1WnuLulnn
uu:ulv0MWtuW1|Mu|uu
n0MWtuvnuW1lLlv
t:nuDwu1Wtu|wLuu
519
Benzathine
benzyl
penicillin
11
Compatibility/
Stability
Benzathine benzyl
penicillin 1.2 mu inj Lu
WnLu1l
Benzathine benzyl penicillin : im :
600,000 unit WnLnt SWF 1.5
ml M1uu uuMu Benz. pen G
1.2 mu WnLnt SWF 3 ml un:
W0MDulu 24 tlL1
520
Bromhexine,
Theodur ,
Roxithromyci
n
7
ADR/ Side
Effects
WtulMt Bromhexine,
Theodur , Roxithromycin
vn1ntt:uu
WtuLntnun1
uuuvunlLt
|nMnuMlM
nnntWulu Textbook of
ADR (Davies DM.) unLn
|nMntn seizures lM Wu
Theophylline un:uLnn
Handbook of Drug nformation
wt Theophylline :Mtulu
|nM>35 mcg/ml :lv|nM
nlnu (ventricular
tachycardia) , tn
(Seizure),frequent PVC nlvu
Theophylline LntunnL
macrolide (roxithromycin) :|nM
Drug interaction Mnu:Mt 2,
onset:delayed (uu|tuuv
ntMv ) WLuu1:Mttu
nn1 |nn11|tnW
unnL macrolide :ltutu1n
uttu1u theophylline lv
Lu theophylline lun:un|nM
|wLuuu|nMwLnulM un:
uLWnMnutunnnW
Wn1uutunn1nulM
tnuvuLn lvLWL
|nu1n|nMwLnuLnn
521
Budesonide
nhaler
9
Dosage/
Administration
Budesonide nhaler lv
uuM 1600 mcg/day lM
vlL
nnntWuwt Budesonide
nasal nhalation : 200-400 mcg
twice initially which may be
increase up to 800 mcg twice
daily M1uu budesonide nLn
|wLuuMlMun1 800 mcg un:
2 W1 |nt 1600 mcg/day 1
nLnlvlM
522
Calcium
carbonate
tablet
3
Pharmacokineti
cs
calcium carbonate WL
u1 350 mg , 100 mg L
equivalene to calcium
|l n|t|tuM
calcium carbonate 350 mg
equivalent to calcium 140 mg
calcium carbonate 1000 mg
equivalent to calcium 400 mg
calcium carbonate :L
elemental calcuim 40%
523
Cefoperazon
e inj.
7
ADR/ Side
Effects
lW1n1nulvuu1
cefoperazone lvM1
lv Vitamin K Muu
nnln:lWtun
un|tuM1lMt
vitamin k vlL
cefoperazone L N- methyl - thio -
retrazole (NMTT) side chain t1
:uMu1nn1|W:v vitamin k
- dependent clotting factors lMu
utu1 vitamin k epoxide
reductase 1t1nun activation
u1 prothrombin n1Wnlv|nM
hypoprothrombinemia nMn
n1 vitamin K lv|nM
|nMnlM nlv vitamin
MuuluWtulMt
cefoperazone lL|tuM1lvlu
Wtunu uMWt:|Lu
nnLn:Wtu WLtu|nu1W
poor nutritional status,
malabsorption, alcoholism,
prolonged hyperalimentation
regimens, Wn1u , WLn
1uu1MtvlMtnw1 lMu
lv vitamin K 5-15 mg/week
524
Ceftrixone,
Cefepime
7
ADR/ Side
Effects
ceftrixone un: cefepime
|nM cross reactivity
vlL
ceftriaxone un: cefepime L
lW1n1 R1- side chain
|vLunuM1uu1|nM cross
sensitivity lMvnWtuLt:M
uwMlMMvu1nlLWn1ltu
nM
525
Cefuroxime
suspension
9
Dosage/
Administration
cefuroxime susp LuuM
u|llunnL
pharygistis lu|Mn
uuMu cefuroxime susp lu|Mn
W 20 mg / kg /day ut1lvun: 2
W1 |tu|nuu 10 u
526
Chikungunya 10
Therapeutic
Use/ Efficacy/
ndication
Chikungunya lv|nM
exfoliative lMvlL
unnL chikungunya
u1l
nunM11Wvu1u1lW
chikungunya W LWuuM1uuML
1nu(nM uuuu)Wuutt MP
rash WuvlLWuwtWu
n:w1unL |wMutn MLWu
:nn|tuuu un:vulM|1
Dulu 7-10 u nnLlW
chikungunya : lLLnnL
|w:|:1nnL|tuutt
t:Wtt:W1|tu tMu lvu
w|tLn vLlvunlwu
|w::lv|nMnlM1u
|tMMMuun:M|wnMlu
L1lvWtuMLuun:uu
vntwnWulv|wu1w
527
Clindamycin 9
Dosage/
Administration
Clindamycin Lu
tt:uu1lltn
u:l|1
Clindamycin 600 mg/4ml nLn
|1Mu 0.9% NSS v D5W
tLn 50 ml tvuutt iv
infusion uu 10-60 mins
M|lL|nu 30 mg/min (lL|nu
1,200 mg/hr) WL|uLuuvn1|
1ulLW|nu 18 mg/ml vL
tvuutt V bolus unnu
nLntvutt im lM lMu
uuMulL|nu 600 mg Mn
u1|uL 1 W1 nn:nuun:
M|0MW uuMu 300 mg
nn:nu 50 ml |n0M 10
mins,uuMu 600 mg nn:nu
50 ml |n0M 20 mins,uuMu
900 mg nn:nu 50-100 ml
|n0M 30 mins,uuMu 1,200
mg nn:nu 100 ml |n0M
40 mins
528
Cloxacilline,C
eftriaxone
11
Compatibility/
Stability
cloxacilline lv V line
|Munu ceftriaxone lM
vlL
nnntWulLwtuLn
compatibility :v1 cloxacillin
un: ceftriaxone 1lLWlv1
nu|Munu
529

Dexamethaso
ne
7
ADR/ Side
Effects
Wtu0M dexamethasone
un|nMWuuM1uu
vn1n0MultlLuu
W1 untnLn
|tnuu|tu0M
hydrocortisone lMvlL
nlW1n11|WLu1
dexamethasone wtLWL
uMnM1n hydrocortisone un:
prednisolone W dexamethasone
L CH3 LMuvu1 16 |wLuuL
t1lLLlu hydrocortisone un:
prednisolone MLlW1n1u1
dexamethasone MulunnL
wutnunuw1Wvu1
uu un:LnuwuLnnLuun
hydrocortisone un: prednisolone
t1u1n1LlW1n1ulunnL
|Munu un:Lnwttnun
uwlMtu un:wtnuwuLlt
u1 hydrocortisone-17-butyrate
WtuuunLntt:u
prednisolone lMlMulL|nMn
WMtnMuu 1lv
hydrocortisone unWtuuulM
530
Diazepam
injection
9
Dosage/
Administration
Diazepam inj ltlun
nL alcohol withdrawal
symptom LuuMn1nM
nLnltlM|tu|l
uuMu|LMult W Diazepam
5-10 mg iv q 5 mis un:1
WtunntuMlLMuLuuMulv
n:nLLnnM (massive
cumulative dose)>500 mg lu
|nLnn 60-90 mins t1:
lv|nu1MnnMnvul
531
Diazepam
injection
9
Dosage/
Administration
Diazepam 10 mg drip
lvntnWnL|l rate
|lv
nlv diazepam drip W|1
luM > 1:40 v/v v 5
mg/50ml - 5 mg/100 ml lu
0.9%NaCl, 5% dextose in
Ringer's v Lactated Ringer's
injection M|lunlvulL
W|nu 5 mg/min
532
Digoxin 9
Dosage/
Administration
M1nlv digoxin 0.25
mg MWtulMuuM
utt V direct M1|MuL
uu1l
digoxin LluWL|uLuu 250
mcg/ml vnlv1 V nLnlv
direct V lMulv|tu|nu1uu
5 uuultlMu: diluted
v undiluted nlM lunn diluted
lv dilute lMult SWF v
dextrose 5% v NaCl0.9% lMu
lvWL|uLuunMuu1uu
M1|nt 4 |u1uuMult
t1luWtuuult 0.25 mg
M1uuW:ltulutLn 1 ml
ult dilute lMuMn:nu
u1MuulMtLM|nt 4 ml
un:lv direct V lMult|nu1
uu 5 u
533
Dobutamine,
Dopamine
11
Compatibility/
Stability
dobutamine nt
dopamine nLnlv V
line |MunulMuWu1
Y-site lMvlL
nnntWuuLnD:WL|u
nulMu1u1 2 Mwt
dobutamine un: dopamine
nLnlv V line |MunulMu
Wu1 Y-site lM
534
Dobutamine,
Dopamine
11
Compatibility/
Stability
dobutamine nt
dopamine nLnlv V
line |MunulMuWu1
Y-site lMvlL
nnntWuuLnD:WL|u
nulMu1u1 2 Mwt
dobutamine un: dopamine
nLnlv V line |MunulMu
Wu1 Y-site lM
535
Dobutamine,
Dopamine,
Sodium
bicarbonate
11
Compatibility/
Stability
dobutamine v
dopamine nLn drip
Wnt sodium bicarbonate
lMvlL
dobutamine incompat nt
sodium bicarbonate nu
dopamine incompat nt
nn:nuM1 M1uu1 2 M 1
lLnLn drip Wnt sodium
bicarbonate lM
536
Dopamine 11
Compatibility/
Stability
Dopamine nLnlv V
line |Munt Mg Su4 lM
vlL
nnntWulLwtuLnWL
|unulMvlL:v1 dopamine
un: MgSo4 M1uu |wWL
tnMDuu1Wtu1lLWlvu 2
tuM V line |Munu
537
Dopamine ,
Acetar
11
Compatibility/
Stability
WtulMt Dopimine
1vnM|nMM un:
uwulMn1nu W
Acetar lvWtu 1un
t Acetar nLn
lv flush nulvu
Dopamine un:nLnlv
Acetar Mn Dopimine
lM|nuvlL
Acetar solution t:ntMu Na
130 mEq , K 4 mEq , Ca 2.7 mEq
, Cl 108.7 mEq un: acetate 28
mEq nnntWu wtu
Dopimine nLn|unulMnnt
electrolyte nMlu Acetar
solution M1uu Acetar solution
1nLnlt flush nulvu
Dopamine un:nLnlv Acetar
solution MltlM
538
Dopamine,
Clindamycin
11
Compatibility/
Stability
Dopamine nLnlv
Lnu clindamycin
injection lMvlL
nnntWuuLnlLwtuLn
nMnt compatibility :v1
dopamine un: clindamycin
injection M1uu1uu:ulvu
uunnu
539
Dopamine,
Dobutamine
11
Compatibility/
Stability
Dopamine WnL|unulM
nt Dobutamine vlL
Dopamine nLnWnL|unulM
nt Dobutamine L1lvWu
Y-site lMuMlLLuLnnWnLlu
syringe |Munu
540
Doxazosin,
Alfuzosin
7
ADR/ Side
Effects
Wtuuw doxazosin
utt hypersensitivity
M1nt
Doxazosin un: alfuzosin
LlW1n1WnuWn1nu
vlL un:WltuM
lMuu
Doxazosin un: alfuzosin (Xatral)
LlW1n11|WLWnuWn1nu
lMu|tu quinazoline-derivative
Wtuuu|nM hypersensitivity
M Doxazosin M1uu1W
vnn|nu1u Alfuzosin Mu lMu
lt Tamsulosin t1|tu a1 -
adrenergic blocking agent
|tu|MunuuMLlW1n1M1n
doxazosin un: Alfuzosin lMu
Tamsulosin |tu
sulfamoylphenthylamine-derivativ
e uMM1:1nltluWtuL
t:Muw sulfa
541
dT vaccine 10
Therapeutic
Use/ Efficacy/
ndication
vu1M1WDWlMt
Wtu dt dose 2 v1n
dose unlMuu|l
un:uuuWlvu1M10M
lvL
vu1M1WDlMtWtu TT/dT 2
W1 :u:v1:v1W1lLuu
n 4 ntMv:u:v1:v1
W1 2 n1 uWnMlLuun 4
week un:lL|nu 3 t
542
endotracheal
drug
administratio
n
9
Dosage/
Administration
untLuM
lMt1nLntv1
endotracheal lM
unLntv1
endothacheal lM lMun
adrenaline , atropine , nalexone ,
lidocaine, vasopressin |tuMu
543
Flunarizine 7
ADR/ Side
Effects
Flunarizine nLnlv
|nMWnu1|Wu1M:tt
vlvnM|nMlMvlL
Flunarizine |tuulunnL
selective calcium channel blocker
LlW1n11|WLun:nu1
|DntuWnunt cinnarizine
nu1|Wu1wttu W 11
tL uvun|wL nnWuuLn
lLwt flunarizine nlv|nM
nu1|Wu11:ttvlun:
vnM|nM
544
Flunarizine 7
ADR/ Side
Effects
Flunarizine nLnlv
|nMWnu1|Wu1M:tt
vlvnM|nMlMvlL
flunarizine |tuulunnL selective
calcium channel blocker L
lW1n11|WL un:nu1
|DntuWnunt cinarizine
nu1|Wu1wttu W 11
tL uvun|wLnnWuuLn
lMwt flunarizine nlv|nM
nu1|Wu11:ttvlun:
vnM|nM uMLnWnL1
Pharmacodynamic :t
flunarizine LWnM negative
inotropic |wu1|nnuuM
nnL|uvl
545
Fosfomicin 9
Dosage/
Administration
Fosfomicin nLnlvlu
uuM 4 g q 8 hr lMvlL
uuMu fosfomycin t1|tuu
1utu1lLLuLnu0Mlu
|LnuuMu Adult dose W 2
g iv q 12 hr un|u menigitis 2 g iv
q 6-8 hr , Osteomyelitis 4 g iv q
12 hr , Maximun dose 16 g/day
nWnLWtulMtu 12g/day
t1u1lL|nu maximum dose
M1uunLnlvuluuuM 4 gm
iv q 8 hr
546
Gelofusine 9
Dosage/
Administration
Gelofusine nLn load
lMvlL
gelofusine 500 ml uMn: 1 ml
t:ntMu succineylsted gelatin
40 g , Na 154 mmol , Cl 120
mmol Lut1lt|w|wLtLM
luWtunu|nu|nMvulu
1nu nnu|nu|nMlu
tLn|ut| 1% of body
weight nLnlv V load lu 5-10
ulM un:1L sign u1
hypovolaemia Muuun:n
MM:Mt Hct lMuM1lLM
n 25% uuMun1nMlvW 20
ml/kg bodywt./day
547
Gentamicin 4
Pregnancy/
Nursing
u Gentamicin nLn
ltluvu1lvuLtMlM
vlL
u Gentamicin nLnWun
uuLlMuu un:MMtLn
1|Muvuu 1nLnlt
luvu1nn1lvuLtMlM uM
Wltu1:LM:1 |u1n
|nMWnu1|Wu1M1|Muv
u1nlM lMu|WuL case report
wtLMlMtu
Gentamicin Lnt Clindamycin
nLnnu:|tuLn
|nMuMn1|nuu1n
nLnvultlMvn1nvuMu
1 2 tuM
548
Griseofulvin 4
Pregnancy/
Nursing
Wtuvu1lvuLtM
tt:uu
Griseofulvin 500 mg 1*2
nLnlvuLtMlM
vlL
lLLuLnnutu Griseofulvin
n1uuL uMLu1uuu
nLnnlv|nML:|1lMlu
nMMn1 M1uu Wvnn|nu1
nltuulunMlvuLtM W
wn|nnltuu |tu
Ketoconazole v fluconazole
uu
549
Hemax 9
Dosage/
Administration
uwun1lt Hemax 4000
units sc t1M1|1W1
unt SWF 2 ml
nLnut10MlMvlL
nLn|1u Hemax 4000
units nt SWF 2 ml vn1ut10M
SC uuuu1n: 1 ml lMvn
uvu1 W |1 Hemax 4000
units nt SWF 1 ml un0M SC
550
Levophed 2 Availability
l1wutnn1unLu
levophed vlL WL
u1|l
Levophed (LtnLu1u W
Novepinephrine inj) tLWWnM
W hospin PL asia pacific t1lL
wn|ulututu w. uM
|nn Norpin tLWWnM W
Dalim biothech uuWLu1 8
mg/4ml ampule
551
Measles
vaccine
11
Compatibility/
Stability
Measles vaccine
unnlt diluent n
tLulvL nLn
reconstitute Mu
nn:nuulMvlL
Measles vaccine W reconstitute
Mu diluent tLuWnMLlv
|uu
552
Meropenem,
cloxacillin ,
TPN
11
Compatibility/
Stability
unt
Meropenem , cloxacillin ,
TPN nLnlv1nu
|MunulMvlL
nnntWuuLnlu Handbook
on njectable drug lLLuLn
compatibility :v1 Meropenem
, cloxacillin ,TPN 1uu:uW
lvuunnunu|wWLtnMDu
u1Wtu
553
Methimazole 9
Dosage/
Administration
uwuM1nu
Methimazole uu PTU
1*1luWtuM1WD
untnLnlv
lMvlL
PTU un: Methimazole Mulu
pregnancy category D 1W n
lvuluvu1LWD:lvn
|nu1Mn|nM hypothyrodism ,
goiter lMun:|nu1M aplasia cutis
, anal atresia , esophageal
atresia , development delay lM
vnn expose M
Methimazole 1uu:uu PTU
|tuuMun|nnltluvu1L
WD un::lt Methimazole lu
nnuw PTU vlLMtnu1
vMtnu1M PTU uu lMu
uuMultWltluuuMM
nMLt:nuDwlunnL
PTU lv 300 mg/day n 4-8
tlL1 nu Metimazole 15 mg/day
554
Methylergono
vine ,
methylergom
etrine
9
Dosage/
Administration
Methergin n10M im q 6 hr
x 2 dose lMvlL
methylergometrine 0.2 mg iv or
im nLn0MtlMlMuv1n
dose un 2-4 hrs M1uuuwun1
0M im Q 6 hr nLn0MlM
555
Methylprednis
olone
9
Dosage/
Administration
uwun1
Methylprednisolone 440
mg/h in 24 hr |Dntn
uuL 24 vials uM
wutnWunlM 22
vials wutnnLn
WnLulvvLMM|Mu
lMvlL vn1nWnL
un|ntlMuuuWlvu
Wlvuu1l
Methylprednisone 440 mg/hr in
24 hr W M1lM 10,560 mg in 24
h u 500 mg/bot M1ltu 22 bot
lMunlvulvWnLnt SWF
nLnWnLwLnulMnlvu
Wlv bolus 36-42 ml Dulu 15
u un: maintain V Mu NSS
lu 45 u vn1nuulv
maintemance dose 6.48-7.56
ml/hr |tu|n 23 hr uvn1WnL
nt SWF lv|ntnvDL 20-25
C lMlL|nu 48 tlL1
556
Metronidazol
e inj
11
Compatibility/
Stability
Metronidazole inj vn1n
|tMlt|ntlltMlMuu
|l
LuLnvn1nWnLlt W
Metronidazole inj vn1nWnL
Mununvt iv drip nLn
|ntlltlMuu 24 tlL1 uMlLL
uLnvn1n|tMuMlt
557
N-
acetylcystein
e (NAC)
nLnlv NAC luW
lMtwLnu
paracetamal Luu|nu
48 tL. lMvlLun:M1
lvltuu|l
NAC :lvt:lutun1nMlu
WtulMtu|nuuuMLunlL
|nu 8-10 tlL1uMuL:lv
NAC unWtulMtu|nuuuM
Lun 36 tlL1 nu1Lt:lutu
lunnMWLuu1u1n
nuMtn1lM lMuuuMulv
W NAC 150 mg/kg imfuse lu
|n 60 u nuuMLMu 50
mg/kg infuse lu|nLnn 4
tlL1MLMu 6.25 mg/kg/hr
un:lvuun:1|ultLMtun:
NR nMn1nntntnM un:n
1WnunMuu
558
Norfloxacin 9
Dosage/
Administration
Norfloxacin lvlu|Mnu
9 |Mu uu~9 kg M1lv
tt:uu1l
norfloxacin uuMu 15-20
mg/kg/day ut1lvun: 2 W1
|Mnuvun 9 kg M1lM
tt:uuMu = 15*9 = 135
mg/day uuMuML = 67.5 mg
nofloxacin 5 ml LMu 100 mg
M1uuWtuuutt:uu
W1n: 3/4 tut un: 2 W1
|t-|uu
559

Omeprazole,
methylcobalt,
Sermian
7
ADR/ Side
Effects
unt 1.
Omeprazole Ln
u1|Wu11lMvlL
2.methylcobalt :n:nL
lu1nulv|nM
uMulMvlL
3.Sermian Ln
u1|Wu1u1lt1 4.
un:uLnWnuln
|uu WLMuMnvM
MLu11 |tun
u1|Wu1nuvlL
1.Omeprazole Lnu1|Wu1
M1u tMWL: (3-7%) , Lu11
(2%),1|nu (3-4%), tM1
(2-5%), Wnuln (2-4%) , |uu
(2-3%) , 1Wn (1-2%) |tuMu
uuttMtutnL1
tnn:un:lLuu:ulvltlu
WtulWMtuMlLlMnnn1
WtulWlM1lLu:LWnMlM
2.methylcobalt v mecobalamin
v vitamin b12 M|tuMLu
n:nuluunMn1tnn:
lMlLn:nLlu1nu 3. sermian
v niceergoline Ln
u1|Wu1wtlMun WLMu
lnvMM Lu11 WLWMtnM
1|Muv (Wnuln 1|nu)
nuuM1Wvu1 11uu
un:uulLvnt 4.nunM1
WtutnW Wnuln|uu
|nMnlW GERD Wtu|tuu
vlL|nMnnu1|Wu1
nun1nuLnnM W sermion
1n1LW omeprazole nu
560
Oseltamivir 9
Dosage/
Administration
Wtu|Mnuvun 8
nlnnL u 8 |Mu :
lvu oseltamivir uuM
|l
uuMu oseltamivir u1|Mnu
uun 1 t lLuuntuvunM
t1LuuMuM1u 6-11 |Mu uuM
tt:u 25 mg bid MMMnu
uu 5 u
561
Oseltamivir
(Tamiflu)
9
Dosage/
Administration
Tamiflu uuMltnL
un:t1nuluWlvulv
tt:uu1l
Tamiflu v u Oseltamivir
WLu1 75 mg/cap uuMltlu
nLnMM|tlnluvMlvu
|Mn 10 t Wlvuun:|Mnu > 13
t W 75 mg un: 2 W1|tu
|nuu 5 u nuuuMt1nu
nMM|tlnluvMlvutuM|
un:t W 75 mg un: 1 W1 |tu
|nuu 7 u
562
Pethidine,
Meperidine
9
Dosage/
Administration
u pethidine lv1 V
push nLnlt SWF
lMvlLun:WL
|uLuultu 1:10
nnM1vlL
meperidine nLnWnL
(compatibility) lM1lu 0.9%NSS
, SWF un: D5W nvtnlv
u V push uuuu:ulvuu1
t lMuWL|uLuuuu:uW
10 mg/ml t1vn|MuL 1:10 (u
|uLuu 50 mg/ml) :lMWL
|uLuunMu|wu1 2.5 mg/ml
M1uuW: dilute u 50 mg/ml
lMult NSS,SWF v D5W |ML
n1ltluu 1 ml ulMtLM
nMu|nt 5 ml t1:lMWL
|uLuu|nt 10 mg/ml
563
Phenobarbital
inj
11
Compatibility/
Stability
Phenobarbital inj vn1|
1u|ntlltlMuu
|l
Phenobarbital inj vn1|1u
|ntlltuu 15 tlL1
nvDLv1 lLLuLn|L|ntlu
M|uu
564
Pseudoephed
rine
4
Pregnancy/
Nursing
u pseudoephedrine
nLnutWuuuLlM
vlL
pseudoephedrine utWuuuL
lMt:Ln 0.5% u1uuMu
tt:u|ultun:ulMuu 24
tL. The American Academy of
Pediatrics (AAP) :tnn
n1|nM uLtt:uu
pseudoephedrine lLwtWL
WMtnMlM lu|Mnnn1M
unLn compatible with
breast-feeding
565
Ranitidine,
Hyoscine inj.
11
Compatibility/
Stability
Ranitidine un: Hyoscine
injection |nM
incompatibility nuvlL
Ranitidine un: Hyoscine injection
lL|nM incompatibility lu syringe
nnMntwtu1n1L
physical compatibility 1
macroscopically un:
microscopically |tu|n 1
tlL1nvDL 25 C un:L
physical compatibility |tu
|nuu 4 tlL1 nvDLv1
DulMun1 Fluorescent
566
Rubella
vaccine
10
Therapeutic
Use/ Efficacy/
ndication
Rubella vaccine vn1lM
tWtu nLnL
DLWLnuulMnt
vn1lMtWtut1nulWvM
|uLu :MtDLMuuu
uun1 16 t unnu nn
ntWuluuuLn Drug Dex
wt Rubella vaccine (0M SC )
nLnn:MuDLWLnulMLnn
10 t uMnlvWtu MMR vn1
nLWnlWvM|uLu lLnLn
t1nun|nMlWvnMWL
uu1u1lWlM
567
Sandostatin,
Omeprazole
11
Compatibility/
Stability
Sandostatin nt
Omeprazole lvnu
|MunulMvlL
nnntWulLwtuLnn
Mnt|unu:v1 Sandostatin
un: Omeprazole 1lLt
u1n1M:WnL|unulMvlL
M1uu1uu:ulLWtv
u1n1MWu V line |Munu
568
Sertaline
(zoloft)
5 nteraction
untn
tt:ulnL nLun:
uWnLLWnMu
zoloft vlL
nnntWuwtu1un
ut1MwLwlu Journal of
Psychopharmacology , Feb 12,
2009 |1 recurrent relapses of
depression in a patrent
established on sertaline after
taking herbal medicinal mirtures
a herb - drug interaction t1
Dtun1WtunLnWL
ntL|WMuu sertaline lM
unvn1tt:u ayurvedic
herbal mixture nntLnnnt
|tutnt1|nuu1nt
pharmacokinetic herb-drug
interaction WnLulwltnM
t:nuDwu sertaline t1
nLulwnnn1|tu nL
(terminalia chebula v
commiphora wighteil) un:lLwt
u1uu:v1lnL uWnL
ntu sertaline
569
Snake bite 10
Therapeutic
Use/ Efficacy/
ndication
WtulMu1nM uMuwu
panicillin utt
anaphylaxis :wn
lvu Antibiotic Mlvu
lMuu
1nM :wtLn:L commonly
isolated pathogens W
P.areuginosa , Proteus spp.,
Bacteroides fragilis , clostridium
spp. u antibiotic uu:ulvlt
W ceftriaxone 1-2 g V q 12-24 h
v ampicillin/sulbactam 1.5-3.0
g V q 6 h uMluWtu
uuuwu penicillin unLn
|nnltlMW clindamycin
150-300 mg po qid+TMP/SMZ 1
double strength tab bid v
clindamycin 150-300 mg po
qid+fluoroquinolone (ciprofloxacin
500 mg bid)
570
streptokinase 9
Dosage/
Administration
n skin test u1u
streptokinase 1 D L
n|MuLuu1l
unMnt|wuu allergic
response nuu1lLLu
u|tnuuuulunnM1n
MntWtu W|tutut1u
uu:ulvltu skin test lMult
streptokinase lv1 D unu
Wnlu 15-20 u lunuun
|MuL|wlv1 D uunn
WuuLnlLLuuu:ulMult
1M1ltvnnn|1ulMu
uuunlv|1ulMult
0.9%NSS un: D5W 5 ml (u
streptokinase 1.5x10
6
units) lMu
Wu uWuu1uMlLW|uu
|w:lv|nMw1 nuu|
1MlMult 0.9%NSS v D5W
uLtLMWt 10 ml un1u
nn:nulMuL 0.1 ml t1:L
Muu 15,000 units uL|
1nW1uLtLM|nt 15
ml (lu 15 ml :LMu 15000
units) nuu1ut1nn:nu
lMuL 0.1 ml :lMnn:nuu
100 units |wultlt skin test
571
TPN 11
Compatibility/
Stability
untuMltu
nLnWnL|unulMnt
TPN vlL lMun
amikacin , Gentamicin
,furosemide , fentanyl ,
midazolam,
dexamethasone ,
aminophylline
nnntWulu Handbook on
njectable drug un:lM|utnM
TPN lnn|Wu1LnnMlu
handbook lLL Zn nMuL
|vLununMu1w. wt
Mntlu Y-site wtD:|unu
lMnvtu furosemide ,
amikacin , fentanyl ,
dexamethasone un:
aminophyline (uMnt:ntMu
Ca 600 mEq |nMnMnM:nu
u1M|) MntluvnM
Mn1|MunuwtD:|unulM
nvtu gentamicin t1nM TPN
L Ca 10 mEq un: K 20 mEq
:WnL|unulM uM|nMn
MnM:nulu TPN nML Ca 20
mEq,K 25 mEq nvt
Midazolam lLnLnWnL|unt
TPN nMlt|ut|Wu11lu
Y-site un: vnMMn1|Munu
(TPN nM|ut|Wu1t:ntMu
amino acid, dextrose, intralipid,
Na, K, Cl, PO4, Ca, Mg,
572
Tropper V 1 dentification Tropper V Wu:l
nnntWulLwtLtu
Tropper V
573
Vancomycin
, cefrom
9,10
Dosage/
Administration
WtuWMMvn1lMtu
vancomycin , cefrom |tu
|n 11 u Lunn:
|tnuu|tuunultMlM
lM
|u1nlLlMLnn1MWL
lM|tuwun1ltuutt
empirical therapy vnwn
nu0M|nnlt vancomycin
|wWtWnL|tMu MRSA u
tuMtt:u|nnltlM W
sodium fucidate (250) 2x3 pc
nvt Cefpirome (cefrom)
WtWnL|t Pseudomonas
aeuginosa,MSSA utuM
tt:u|nnltW
Ciprofloxacin (500) 1x2 pc
574
Venofer 11
Compatibility/
Stability
Venofer vn1n|tMlt
|ntluu|l
Venofer v ron sucrose
vn1n|tMltvvn1n|1
lu 0.9%NSS nLn|ntlltlM
Dulu 48 tlL1 nvDLlL|nu
25 C (uLnntL l|w )
qs
Drug nformation
Handbook 11
edition, 2003 -
2004, p.35
1. Drugs
nformation
Handbook
nterational 2.
AHFS drug
information, 2004
Departent of
Medical
Seiences ,
Ministry of Public
Health , TP
information on
Antidote , p.17
1.vnnnMun
WtulMtu
|nuuuM lu
WLnltu
nvttWnn
nunnu
2.JRMS,2006.11(
2),108-110
MM,102
edition.2006.309
Drug nformation
Handbook 11
edition, 2003 -
2004
WLnltu
nvttWnn
nunnu ,
2549,p.135-153
Drug nformation
Handbook.13th
edition.2006-
2007.45-47
WLuu1n
tvu0M|w
nMWL|nu1
nnL1u|Dnt
nL
l1wutnn1un
Handbook on
njectable drug ,
11 edition , p.494
Drug nformation
Handbook
nternational , 13
edition ,2005-
2006 , p.555-558
1.Drug
nformation
Handbook.13th
edition.2006-2007
.555-7 2.Drug
fact and
comparison,2006.
60th
edition.714-5
3.WL
uLWL|nu1
n1.nnL1u|Dnt
nL
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
Hanbook on
njectable Drug
website :
www.google.com
WLuLWL
|nu1n1 uLn
tWnn1
nuwuW
t|wWL
tnMDuWtu
l1wutnn1un
wut
n
Drug nformation
Handbook
Drugs in
Pregnancy and
Lactation 2
edition ,2002 , p.
510-516/e
AHFS: Drug
nformation
lnnnL
WnM .wLwW1
1.126-127
website :
www.pharmacy.p
su.ac.th
1.Drug
nformation
Handbook
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
website : www.
1. Spontaneous
report of ADR t
2000 , 2001 ,
2002 2. A
Practical Guoide
to
pharmacovigilanc
e vu 117 - 120
The sanford
guide to
antimicrobial
therapy ,2005
Drug nformation
Handbook
WLnltu
nvttWnn
nunnu 2549
, p.265-291
1. AHFS , Drug
nformation ,
2004 , p. 524
2. |nnt:tL
tn1u|Dnt
nLWnun W1
6 / 2546
Drug nformation
Handbook
MlWMM|t
|nn
t:ntnltu
u
WLuu1n
tvu0M|w
nMWL|nu1
1u$
1.nttn1
|DntnLlu
WtulWlM
2.Drug
nformation
Handbook
nternational ,11
edition, p.894-896
Hanbook on
njectable Drug
Medical
Dictionary,2547
Drug nformation
Handbook
Departent of
Medical
Seiences ,
Ministry of Public
Health , TP
information on
Antidote , p.21
,72
v}{
MM
annual.2006.p59
website :
www.google.com
1.The Sanford
Guide to
antimicrobial
therapy,2005.p51
-53 2.M
lWMM|t1.
2548,149-162
website : www.
Drug
nformation
Handbook
1.http://www.phar
m.chula.ac.th

2. u The pill
book.2547,117-
120
Drug nformation
Handbook , 13 th
edition ,p. 1480-
1482
nM1
v1ttMn.
2543.106-142
Wtuun:lWMM
|tt1nulM
MuWtu.2548.
38
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
uu1n
tvu0M|w
nMWL|nu1
Hanbook on
njectable Drug
Drug nformation
Handbook ,13th
edition.page 217.
wut
n
1.Drug
nformation
Handbook
nternational ,
p.259 -260
u
1.|nnnntu
2. WL
uu1n
tvu|wnM
WL|nu1
l1wutnn1un
wut
n
1.Drug in
Pregnancy and
Lactation.6th
edition,1485-
1489
2.www.uknicentra
l.nhs
website : www.
website : www.
1.Drug
nformation
Handbook 8
edition 2. Drug
Prescribing in
renal - failure 4
edition
M1t:|Mu|1
Adverse Drug
Reaction .2549.
60-61
Drug Facts and
Comparison
u
DWt|Dnt
nLWnun , t
n ( |nn
t:ntn|uu
nnu ) Wn:
|DntWnM
Lvunun1un
uWu ,2542
website : www.
AHFS: Drug
nformation
MM
uttt:|Lu
DUE u1u
Cefpirome
1.WLuu1
ntvu0M
|wnMWL|nu1
.w n1un,2549.
2.
|nnnntu
wut
n
WLuu1n
tvu0M|w
nMWL|nu1
nnL1u|Dnt
nL
l1wutnn1un
M1t:|Mu|1
Adverse Drug
Drug nformation
Handbook
Drug nformation
Handbook
uuLn up
to date
1.uu1n
tvu0M|w
nMWL|nu1 w.
n1un
2.Drug
nformation
Handbook.13th
edition.2006-
2007
3.MMs.2006.85
1.The Sanford
Guide to
antimicrobial
therapy,2005.p51
-53 2.
|nnnt:tL
|1u1l..
|Ln1nuuwu
website :
www.google.com
1.Drug
nformation
Handbook, 13th
edition , 2005

2.WuuMMML
nlLw1
t:n1Wnn
ltWnMDnv
nuDw ,
Spontaneous
Report of
Adverse Drug
Reaction, 2003.
|Dntn
www.askrx.net
|Dntn
1. Drug
nformation
Handbook.13th
edition.2006-
2007. 310 2.
Drug in
pregnancy and
lactation.3rd
edition. 222-223
unu
l1wutn
n1un0tt
ttt1 2549
uwu
website : www.
website : www.
website :
www.wikipedia.or
g
|DntMt
l1wutn t
2006 , 1u
|Dnt
nLnWnM
AHFS: Drug
nformation
Mc
Cormack.Drug
Therapy Decision
Making
Guide.Page 31-
32.
www.dms.moph.g
o.th/section3/315
015.htm.
|Dntn
Drug nformation
Handbook
Lawrence A.
Trissel,
Handbook on
injectable
drugs.11th
edition page 305.
|Dntn
u
Drug nteraction
Facts,2006.
|Dntn
M1t:|Mu|1
Adverse Drug
Reaction
.2549.63-65
Drug Therapy in
Pregnancy
WLuu1n
tvu0M|w
nMWL|nu1
nnL1u|Dnt
nL
l1wutnn1un
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
Drug
nformation
Handbook
WLnltu
0ttnLtn ,
2545
Hanbook on
njectable Drug
Drug
nformation
Handbook
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
Drug nformation
handbook 11
edition , 2003 -
2004
website : www.
v}{
Drug nformation
Handbook
Drug nformation
Handbook
Drug nformation
Handbook
Drug nformation
Handbook
AHFS: Drug
nformation
WLu0M w
n1un
website :
www.globalph.org
AHFS: Drug
nformation
MMs,2004. eph
website : www.
WLnltu
nvttWnn
nunnu
1.WLunvt
wutn 2547
2. |nn
nntu
WLnltu
nvttWnn
nunnu ,
2549,p.92-93
WLnltu
nvttWnn
nunnu 2549
, p.287
Spontaneous
report of adverse
drug reaction
1. Handbook of
njectable drugs,
11 edition, 2001:
p.402
2.Update in
Emergency
Medicine.2549.92
-104 3.WLn
tvu0M|w
nMWL|nu1 w.
n1un
u
Martindale 33 th
edition
u
1.WLntv
u0M|wnMWL
|nu1 w.n1un

2. CCS
Drug nformation
handbook 11
edition , 2003 -
2004
Drug nformation
handbook 11
edition , 2003 -
2004
v}{
Drug nformation
Handbook
Drug nteraction
Facts
Pocket Guide of
njectable drugs
Drug nformation
Handbook
Drug nformation
Handbook 11
edition, 2005
p.482
Spontaneous
report of adverse
drug reaction t
2003 Wuu
MMMLnu
lLw1t:n1Wn
nltWnMDnv
nuDw u.
2.WLMMML
nlLw1
t:n1WWL
WMtnM1:tt
Wvu1 0tt
ttt1 2548 ,
p.38-39
AHFS Drug
nformation.
2004.page 2786.
wut
n
1.Handbook of
njectable drugs,
11 edition, 2001:
p.420-432
wn 1WMu:
lu u The Pill
Book. wLwW1
2 ,2547.vu
33-36L49-52.
un
n-
un
nu
uuLn
WnL-WMt
Muu DS
u
WLuu1n
tvu0M|w
nMWL|nu1
nnL1u|Dnt
nL
l1wutnn1un
u
Handbook of
njectable drugs,
11 edition, 2001:
p.447-455
1. Handbook of
njectable drugs,
11 edition, 2001:
p.1129
2.WL
ntvu0M
|wnMWL|nu1
w.n1un
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
WLuu1n
tvu0M|w
nMWL|nu1.w.
n1un,2549.
4-5, 24.
|Dntn
Drug nformation
Handbook
Drug nformation
Handbook
MM
AHFS Drug
nformation.
2004.page
449,2624.
|Dntn
1.Drug
nformation
Handbook.13th
edition,2005-
2006. 2.
Clinical
Handbook of
Pedriatric.3th
edition,2003.
|Dntn
1.The Sanford
Guide to
antimicrobial
therapy,2005.p51
-53
2.Pedriatric
dosage
Handbook.8 th
edition.2001-
2002.p586-587
WLWtu,2548 :
31.
1.Drug
nformation
Handbook.11th
edition.2002-2003
.428 2. WL
Wtu.2548,31
3.Wtuun:
lWMM|t
t1nulMMu
Wtu.2548.554
Wtuun:lWMM
|tt1nulM
MuWtu
Drug nformation
Handbook
nternational ,13
edition , 2005 -
2006 , p.1734
MMs annual 16
th
edition,2004.p.23
0-231
1.|nnnntu
2. WL
uu1n
tvu|wnM
WL|nu1
l1wutnn1un
|Dntn
1.www.drug.phar
macy.psu.ac.th


2.www.cbh.moph.
go.th 3.M1
t:|Mu|1
Adverse Drug
Reaction
.2549.63-65
Drug nformation
Handbook , 2003
- 2004, p.820
AHFS, Drug
nformation,
2004.
Drug
nformation
Handbook.
wut
n
Drug nformation
Handbook
u
MM
MM
u
WL vaccine
1. Drug
monograph u
lvL
l1wutn
n1un 2.
|nnnntu
Drug nformation
Handbook , 11 th
edition ,2003-4 ,
p.1000
www.askrx.net
1. Antimicrobial
prophylaxis in
surgery (M
|DntttM) 2.
nt1nunMM
|t(MlWMM
|t 2)
website : www.
ntvu1
nu Nasogastric
tube MlMu
nnL1u|Dnt
nLl1wutn
n1un
|Dntn
Drug nformation
Handbook.13th
edition,2005-
2006.page 581.
|Dntn
AHFS , Drug
nformation ,
2004 , p.2832
u
WLntv
u0M|wnMWL
|nu1 w.n1un
1.Drug
Prescribing in
renal failure . 4
edition , p.56
2. |nnn
t:tL|t1
ttMn 1u
|DntnLWnun
W1 6/2546
vu Trends in
nfectious
disease. lMu .
tn nuunLtM
uLnnvuu
WnMu|MuL
un:utW
|t w.n1un
website :
www.wikipedia.or
g
1. WLnltu
nvttWnn
nunnu ,
2549,p.265-291
2. Drug
nformation
Handbook
Drug Facts and
Comparison
Pedriatric
dosage
handbook, 8th
edition, 2001-
2002:422-423.
wut
n
AHFS drug
information, 2004
Drug nformation
Handbook
Spontaneous
report of adverse
drug reaction ,
2001 ,2002
Spontaneous
report of adverse
drug reaction t
2003 Wuu
MMMLnu
lLw1t:n1Wn
nltWnMDnv
nuDw u.
Drug nformation
Handbook
1. J Med Assoc
Thai. 2003.
April;86(4):293-8
2. uu1
ttMnMun
nLlWMM|u
0ulnnluWMM
|t|tl /|Mn .
2547.75-83
u
Drug nformation
Handbook
spontaneous
ADR 2005
Drug nformation
Handbook
uuLn Up
to date
Drug
nformation
Handbook
WLnltu
nvt
tWnn
nunnu
MM
AHFS: Drug
nformation
uu1n
nLWtulW
|Mn , n:1
nunnu , 2545
Drug nformation
Handbook,2006.
|Dntn
Departent of
Medical
Seiences ,
Ministry of Public
Health , TP
information on
Antidote , p.55
Handbook of
njectable drugs,
11 edition, 2001
Website : www.
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
up to date
Textbook of
adverse drug
reaction , 4 th
edition,1991,
p.650
Drug nformation
Handbook
nternational , 13
edition , p 726-
727
Up to Date
database
Drug nformation
Handbook 11
edition , 2003 -
2004 p. 646
1.nttn1
|DntnLlu
WtulWlM
2. www.elib-
online.com
1.Drug
nformation
Handbook
nternational ,12
edition , 2003 -
2004
2.Spontaneous
Report of Averse
Drug Raction
2003.
Drug nformation
Handbook
nternational ,13
edition , 2005 -
2006 , p.742
http://members.tri
pad.com/dgholgat
e/sixteen.html
u
Spontaneous
report of adverse
drug reaction
Drug nformation
Handbook, 2005-
2006 edition,P
750.
Drug Prescribing
in renal failure,
Dosing
Guidelines for
adults ,forth
edition;83.
uwu
website :
www.wikipedia.or
g
Wikipedia ,
Micromedex
Drug nformation
Handbook 11
edition , 2003 -
2004 p. 1009-
1010
Drug nteraction
Facts
Drug nteraction
Facts
Advance in
Pharmaceutical
care and
Pharmacotherape
utics , 2549 ,
p.221
Wtuun:lWMM
|tt1nulM
MuWtu.
2548.83-90
1. Drugs facts
and comparison
2002 2. AHFS
drug
information, 2004
Drug nformation
Handbook
Drug nformation
Handbook
website : www.
1.uu1n
tvu0M|w
nMWL|nu1 w.
n1un

2.Drug
nformation
Handbook.13th
edition.2006-
2007
3.Handbook on
injectable drug
.11th edition.
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
website : www.
Drug nformation
Handbook
Evidence -
Based Clinical
Practice
Guideline , 2548
, p.370-371
WLWtu
General
Recommendation
s on
mmunization,
MMWR , Vol. 51
,RR 2 p. 1- 27
nLWLnL
uwuuv1
t:|Wlu ,
Wtuun:lWMM
|tt1nulM
MuWtu ,
p.47-59
MM
website : www.
Drug nformation
Handbook 11
edition, 2003 -
2004
v}{
CCS ;
Micromedex
Healthcare
series , 1974 -
2004
1.AHFS Drugs
nformation 2004
, p. 1667
2.Drug
nformation
Handbook , 11
edition
Handbook of
njectable drugs,
11 edition, 2001:
p.694-697
1.Handbook of
njectable drugs,
11 edition, 2001:
p.694-697

2.www.pharmacy.
psu.ac.th
Drug Facts and
Comparisons.
2002 page, 354
uwu
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
Drug nformation
Handbook 11
edition, 2003 -
2004
Drugs
nformation
Handbook 11 th
edition .
1.Drug
nformation
Handbook
nternational ,11
edition , p.725-
726 2.Drug in
pregnancy and
lactation,6th
edition.p693
WLnltu
nvttWnn
nunnu ,
2549,p.155-167
MvLuu|Mu
n.w. 48
lW1nWutM
lvwuL|wnn
uutnM|Mn
( MTCT-Plus )
WLWtu,vu 9
WL vaccine
u
WL vaccine
1.MMs.102nd
edition.2006.p309
-310 2. nMun
nLWtu
|tvuutt
1WL
Drugsfacts and
comparison ,
2005
1.uuttM
nvtn|nt
un:MunuM1
:1|tuw|WL
w.n1un
2.uLnn
tLnnLluu
ventolin un:
beraduol solution
AHFS : Drug
nformation , 2004
AHFS : Drug
nformation ,
2004 : p. 544 -
560
|nn
t:ntn
t:tL|t1
ttMn1u
|DntnLWnun
W1 5/2548
vu|1
Tuberculosis
lMuutn
nuunLtM
Drug nformation
Handbook
1.
Cardiovascular
Pharmacotherape
utics,2nd edition

2.http://www.rx
list.com 3.unt
lWvlun:
vnM|nM
uu1nMun
nLnMM|t
HV un:Wtu
lW|Mn|Mnun:
Wlvulut:|W
lu t w.W. 2545
Drug nteraction
Facts
u
u
u
Hanbook on
njectable Drug
1.WLWu
w.n1un 0tt
ttt1 1 nw. 50
nLnu t
Mu .Advance
in Management
of Complications
in Patients with
Chronic Kidney
Disease.|Dnt
ttMLnLu.
|Dntn
Hanbook on
njectable Drug
u
u
Drug nformation
handbook 11
edition , 2003 -
2004
Drug nformation
Handbook
|nn
t:ntn
t:tL|t1
ttMn1u
|DntnLWnun
W1 5/2548
vu|1
Antiretroviral
therapy in adult
lMuutn
nuunLtM
WuuMMML
nlLw1
t:n1Wnn
ltWnMDnv
nuDw ,
Spontaneous
Report of
Adverse Drug
Reaction, 2003.
|Dntn
Drug nformation
Handbook
website : www.
Drug nformation
Handbook 13th
edition, page 905.
|Dntn
www.google.com
uttwL|nu
u|u
l1wutnn1un
Drug nformation
Handbook
Drug nformation
Handbook
Drug nformation
Handbook
Am J Hosp
Pharm. 1981.
Nov;38(11):1745-
7. uL
luuwnL .
Dtu:tu
un:n|ntnL
u lu WLn
ltunvt
tWnn
nunnu.
134-153.
|Dntn
AHFS : Drug
nformation ,
2004 : p. 477
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
1. Drug
nformation
Handbook.13th
edition.2006-
2007. 2.
Drug therapy in
pregnancy.3rd
edition.40,50-52
MM
Spontaneous
Report of Averse
Drug Raction
2003.p143
uu1|t
tDtMnMun
nLlWMM|t
0ulnnlu
WtuMM|t
HV/ADS. nun
lW|Mn nlW
un:lWMMM1
|wWnLwuu nL
WtWLlW
n:1
nunnu.2547
|Dntn
WLuu1n
tvu0M|w
nMWL|nu1
nnL1u|Dnt
nL
l1wutnn1un
AHFS, Drug
nformation,
2004., Page
2142.
wut
n
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
www.globalrph.com/dilm
#MANNTOL
gqq
j
www.google.com
,
www.mcramerica
n.com/product
Drug nformation
Handbook
Drugs
nformation
Handbook 11 th
edition .
Drugsfacts and
comparison ,
2005 , p 828 -
831
AHFS : Drug
nformation , 2004
Hanbook on
njectable Drug
1.Handbook on
injectable drug .
11th edition.835

2.WLnltu
nvttWnn
nunnu.2549
3.|nnnntu
1.Handbook on
njectable drug
11 edition , p
835-841 2.
|nnnntu
meropenem
WLnltu
nvttWnn
nunnu ,
2549,p.135-153
AHFS: Drug
nformation
Drug nformation
Handbook
Drug nformation
Handbook
1. Tatro DS. ,
Drug nteraction
Facts,2006 ,
p.1004 2.
M|DntttM ,
2546 , p.20
|Dntn
Drug nformation
Handbook
nternational ,
2003-2004 ,
p.914-916
uuLn up
to date
Drug nformation
Handbook
Drugs
nformation
Handbook 11 th
edition .
1.AHFS Drug
nformation, 2004
2. MlW
MM|t , nLWL
lWMM|tuv1
t:|Wlu |nL 2
1.Drug
nformation
Handbook
nternational ,11
edition , p.922-
924 2. Drugs in
Pregnancy and
lactation , 6
edition , p.920-
927
uu |LL:nn
ML , tt Lu
nuMnn ,
vLn nun1u ,
n|nuM t
uuDw ,
Pharmacotherapy
M|DntttM
,2546 ,p.339-342
uwu
|0w:
1
Drug nformation
Handbook
Drug nformation
Handbook
nternational ,13
edition , 2005 -
2006 , p.394-395
WuuuSingulair
tL MSD
www.rxlist.com
Drug nformation
handbook 11
edition , 2003 -
2004
Spontaneous
report of adverse
drug reaction ,
2002
Drug nformation
Hanbook , 11 th
edition p.974 -
975
1. Drug
nformation
Handbook
nternational ,13
edition , 2005 -
2006 ,
p.1085-1086 2.
WLntv
u0M|wnMWL
|nu1 l1wutn
n1un
1. Handbook on
injectable drug
.11th edition.919-
921
2.http://www.rx
list.com
Drug nformation
Handbook
Pedriatric
Dose.2547.144-
145
1.http://dermnetnz
.org
2.Spontaneous
Report of Averse
Drug Raction
2001.
website : www.
Drug nformation
Handbook
nternational
2005-2006.
eph
Hanbook on
njectable Drug
Drug
nformation
Handbook
www.kkh.go.th/ph
armacy/phnews.h
tm.
www.google.co.th
Drug Facts and
Comparison
WLuLWL
|nu1n1 uLn
tWnn1
nuwuW
t|wWL
tnMDuWtu
l1wutnn1un
|Dntn
Hanbook on
njectable Drug
1.Drug
nformation
Handbook 10
edition, 2002 -
2003 2.
|nnnntu
Drug nformation
Handbook 10
edition, 2002 -
2003
u
Drug nformation
Handbook
1.Lacy CF et al.,
Drug nformation
Handbook ,13th
edition
2005-2006. 2.
uu |LL:nn
ML . nfectious
Diarrhea. lu
Textbook of
Pharmacotherapy
2546. 111-125.

3. AHFS Drug
nformation
2004.,page 398-
399.
t:t
tu
u
website : www.
WLnltu
nvt
tWnn1
nuwu
Drug in
Pregnancy and
Lactation , 6 th
edition
ntvu1
nu NG tube
Drug nformation
Handbook 11
edition, 2003 -
2004,p.1029 -
1030
Handbook on
njectable drug ,
11 edition ,
p.1359
u
Drug nformation
Handbook
Drug
nformation
Handbook
u ( tL
u)
Drug nformation
Handbook
1. Handbook on
njectable drug.,
11th edition.
2.
|nnnntu
|Dntn
|nnnntu
1.Drug
nformation
Handbook
nternational ,
2003-2004 ,
p.1171 2.
Textbook of
Pharmacotherapy
, Nausea and
vomitting , p.94-
110
Drug nformation
Handbook
nternational ,13
edition , 2005 -
2006 , p.1173
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
AHFS: Drug
nformation
poison 2000
u:w1L Mnv
|tu. Wtu
t1nuMWwL
nuut.nLWL
nLuwuuv1
t:|Wlu
2548. 171-189.
|Dntn
lWwLnuut.
nuLw Wuu
un:WDLM tnv
nuMu
tnun.
vu 8.
wut
n
u:w1L Mnv
|tu. Wtuun:
lWMM|t
t1nulMMu
Wtu.WnM ltM
|nWnMun:Wn:
(tnun)
vu 171-189.
uu1n
tvu0M|w
nMWL|nu1
Drug nformation
Handbook
AHFS: Drug
nformation
WLuu1
ntvu
0M|wnM
WL|nu1
1uDS
uM u1nuu ,
uL luu
wnL , M1
t:|Mu|1
Adverse Drug
Reaction , 2549 ,
p.71
wut
n
Drug nformation
Handbook
Drug nformation
Handbook
www.pumed.com
1.Drug
nformation
Handbook 11
edition, 2003 -
2004, 2.AHFS
Drug nformation,
2004
Drug nformation
Handbook 11
edition, 2003 -
2004, p.1102
www.
vhpharmsci.com
WLnt:|Lu
un:MMML ADR
uLnntLu
Drug nformation
Handbook
Drug nformation
Handbook
nternational ,
2003-2004 ,
p.1102-1106
WLuu1n
tvu0M|w
nMWL|nu1
nnL1u|Dnt
nL
l1wutnn1un
www.google.com
,
www.pubmed.co
m
website : www.
v}{
Drug nformation
Handbook
Drug nformation
Handbook
Hanbook on
njectable Drug
tLWWnM
Drug nformation
Handbook
Drug nformation
Handbook
Spontaneous
report of adverse
drug reaction
|nn1u
t:tLtn "
nMnuL
WL|nu1n1 "
lMu .L1n
t:wuuMu:
wut
n
uuLn up
to date
Handbook of
njectable drugs,
11 edition, 2001:
p. 1165 - 1177
Pedriatric
dosage
handbook, 8th
edition, 2001-
2002:1109.
|Dntn
Drugs in
Pregnancy and
Lactation 6
edition , 2002 , p.
1152
1.Kirtly
P.jones,Estrogen
s and
Progestine:What
to use and how
to use,Clinical
obstertrics and
gynecology,1992
Dec,vol
35,No4,871-883
2.MMs,106th
edition, 2007,203-
204
up to date
website : www.
1.Clinical
practice
condition |1
nMunnL
nMu1.w.
n1un
2.
|nnnntu
Progynova
3.
MMs.100th
edition. 2005
1.Drug
nformation
Handbook ,
2005, p.1304
2.AHFS , Drug
nformation,
2004,p.3096
1. Drug
nformation
Handbook.13th
edition.2006-
2007. 1340 2.
Drug in
pregnancy and
lactation.6th
edition.
2002.1180
1.Drug
nformation
Handbook ,
2005, p.1304
2.AHFS , Drug
nformation,
2004,p.3096
Drug nformation
Handbook 11 th
edition ; p.1175-
176
eph
Spontaneous
Report of Averse
Drug Raction
2002,2003.
eph
Drug nformation
Handbook 11
edition, 2003 -
2004, p.1179
1. Drug
nformation
Handbook
nternational ,13
edition , 2005 -
2006
2.Spontaneous
report of adverse
drug reaction
,2004, p.182
Drug nformation
Handbook
nternational , 13
edition ,2005-
2006 , p.1353
u
Drug nformation
Handbook
www.google.co.th
Wtuun:lWMM
|tt1nulM
MuWtu.
2548.171-189.
Drug nformation
Handbook
1.Spontaneous
report of adverse
drug reaction
,2002, p.191 -
193 2. Mims
Annual 16 th
edition ,2004,
p.730
1.MicromedexH
ealth care series
vol.127
exp.3/2006

2.www.thailabonli
ne.com
MM
J Chemother.
2001. Dec;
13(6):621-7.
Drug
information
Handbook 13th
edition.page
1416.
eph
website :
www.thailabonline
.com
Ziebach R. et al ,
Bronchodilatotory
effect of
salbutamol ,
pratopium Br nd
their compatibility
, Peadiaty
Pulmonol , 2001,
June , 31 (6) :
431 -5
AHFS: Drug
nformation
1.Handbook on
njectable drugs ,
11 edition ,
2001, p.980 -
981 2.
|nnnntu
Hanbook on
njectable Drug
u
u
1. M|nnlM
lnMlu|Mn.
2548,221-239
2. tuv
wttulu|Mn
un:uu1n
MunnL.
2546,236-240
website : www.
website : www.
1.WLWu
w.n1un 0tt
ttt1 1 nw.
50 2.
lWw 1502
1uWnMu w.
n1un
http://se-
ed.net/belotte/nacha/freq
uency.html
|Dntn
MM
u
Drug nformation
Handbook
u
u
v}{
Drug in
Pregnancy and
Lactation
Drug in
pregnancy and
lactation.6th
edition.
2002.1268-9
Up to Date :
database
1.Clinical
Pharmacy and
Therapeutics , 3
rd edition ,2003 ,
p.588,591
2. Drugs
nformation
handbook , 11 th
edition , 2003 p.
1290
|nnt:tL
tn|Dnt
nLWnunW1
6/2546 |1
tuberculosis
tutunu
l1wutn
n1un 0tt
ttt1 2549
Drug nformation
Handbook
Drug Facts and
Comparison
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
CCS ;
Micromedex
Healthcare series
website :
www.wikipedia.or
g
u
MM
WLunvt
wutn 1uDS
uuLn
WnL-WMt
Muu DS
Drug nformation
Handbook
nternational
website : www.
Management of
TB. n1nlW
nLWtWL
lWMMM.0tt
unlu wLwW1
1. w.W. 2544.
|Dntn
Drug nformation
Handbook ,13th
edition.page
1513.
uwu
www.drspock.co
m
|nnnntu
Drug nformation
Handbook
nternational
2005-2006.
page.1518.
|Dntn
1.http://nonthaburi
.moph.go.th

2.http://thaigcd.dd
c.moph.go.th
|nnnntu
Wtuulu
uWunn1
|nLDLWLnu
lWu1n:1
nunnu
t:t
tu
Drug nformation
Handbook
website : www.
website :
www.wikipedia.or
g
Drug nformation
Handbook , 13 th
edition ,p. 1525-
1528
v}{
WLuu1n
tvu0M|w
nMWL|nu1
1uDS
1.LA. Trissel.
Handbook on
njectable Drugs.,
11th
edition.,2001.
2.
|nnnntu
Tienem
wut
n
uuLn up
to date
1. AHFS , Drug
nformation ,
2004 , p. 2067
|nn
t:ntnltu
WLuu1n
tvu0M|w
nMWL|nu1
w.n1un .
2549,64
MM
Website : www.
MM
WLWtu,2548 :
113-117.
wut
n
AHFS: Drug
nformation
AHFS: Drug
nformation
1.Drug
nformation
Handbook
Drug nformation
Handbook
nternational ,13
edition , 2005 -
2006 , p.1625
Website : www.
website : www.
AHFS: Drug
nformation
AHFS: Drug
nformation
Drugs in
Pregnancy and
Lactation , 6 th
edition
1lu nnMu
w1L lu vl|Mu
|WM1v:tuM
Supraventricular
un: Atrial
Flutter. vu
150-237.
|Dntn
WLWtu ,2548 ,
p. 108
Update in Rabies
Control and
Prophylaxis in
Thailand (
Symposium X ,
December 13 -
14 , 2001
nuLw Wuu ,
WDLM tnv
nuMu , lW
wLnuut , p 8-9
1.www.si.mahidol.
ac.th
2.http://drug.phar
macy.ac.th
Drug nformation
Handbook
Handbook of
njectable drugs,
11 edition, 2001:
p. 1079 - 1084
Hanbook on
njectable Drug
website : www.
website : www.
AHFS: Drug
nformation
AHFS: Drug
nformation
Drug nformation
Handbook.13th
edition.2006-
2007.1264-1265
|nnnntu
Vitrimix
wut
n
Drug nformation
Handbook
MM
website : www.
MlWMM|t.
887-889
|u tltMn.
nlWluWlvu .
MlWMM|t 1.
nLWLlWMM
|tuv1t:|W
lu. wLwW1 1
MnWL
2548.683-719.
|Dntn
WL vaccine
u
ML
|nnuutu
Advances in
Pharmacotherape
ntics and
pharmacy
WuuwLu
w.LutMl
.1347
website :
www.google.com
Wtuun:lWMM
|tt1nulM
MuWtu
WLu0M
Drug nteraction
Facts
Drug nformation
Handbook
WLtutuw.
n1un
WLnM
lW1n1unt
nuwuuLnnL
Drug nformation
Handbook,15th
ed.
website :
www.moph.go.th
Drug nformation
Handbook
Hanbook on
njectable Drug
uptodate 2007
uptodate 2007
AHFS: Drug
nformation
Drug nformation
Handbook
Hanbook on
njectable
Drug,11th ed.
Hanbook on
njectable
Drug,11th ed.
Drug nformation
Handbook
Hanbook on
njectable Drug
Hanbook on
njectable Drug
Hanbook on
njectable Drug
uptodate
AHFS: Drug
nformation
|nn
t:ntn
t:tL |1n
tvWtu.
nLn
Drug nformation
Handbook
Drug nformation
Handbook
Drug nformation
Handbook
micromedex
MM,112th
ed.2008
v}{
WLnltu
tWnn
nunnu ,2549
u
AHFS: Drug
nformation
Drug nformation
Handbook
Drug nteraction
Facts
Hanbook on
njectable Drug
WLu0M
WLnltu
nvttWnn
nunnu
u
Drug nformation
Handbook
uu1
ttMnMun
WtuMM|t
vMM|t
luvMlvunu
wuulvLtuM|
(H1N1)
pack insert
Drug nformation
Handbook
tLu gardinal
AHFS , Drug in
Pregnancy and
lactation
Hanbook on
njectable Drug
fvvaccine
Hanbook on
njectable Drug
website :
www.medworm.c
om
Harrison volume
1
Drug nformation
Handbook
Hanbook on
njectable Drug
website : www.
uLnntL
l|w